




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :	A1	(11) International Publication Number:	WO 99/15672
C12N 15/45, C07K 14/135, C12N 7/08, A61K 39/155		(43) International Publication Date:	1 April 1999 (01.04.99)
(21) International Application Number:	PCT/US98/19145	(81) Designated States:	AL, AM, AT, AU, AZ, BA, BB, BG, BR,
(22) International Filing Date:	15 September 1998 (15.09.98)		BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,
(30) Priority Data:			GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ,
60/059,552	19 September 1997 (19.09.97)		LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
	US		MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
(71) Applicant (for all designated States except US):	AMERICAN		TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO
CYANAMID COMPANY [US/US];	Five Giralda Farms,		patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian
Madison, NJ 07940 (US).			patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
(72) Inventors; and			patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
(75) Inventors/Applicants (for US only):	UDEM, Stephen, A.		IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF,
[US/US];	Apartment 6F/G, 155 West 70th Street, New		CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
York, NY 10023 (US).	SIDHU, Mohinderjit, S. [US/US];		
35 Lowell Drive, New City, NY 10956 (US).	RANDOLPH,		
Valerie, B. [US/US];	535 PineBrook Road, Lincoln Park,		
NJ 07035 (US).			
(74) Agents:	GORDON, Alan, M. et al.;		
American Home Products	Corporation, Patent Law Dept. - 2B2, One Campus Drive,		
Parsippany, NJ 07054 (US).			

(54) Title: ATTENUATED RESPIRATORY SYNCYTIAL VIRUSES



(57) Abstract

Isolated, recombinantly-generated, attenuated, respiratory syncytial viruses of subgroup B having at least one attenuating mutation in the RNA polymerase gene are described. Vaccines are formulated comprising such viruses and a physiologically acceptable carrier. The vaccines are used for immunizing an individual to induce protection against respiratory syncytial virus.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

ATTENUATED RESPIRATORY SYNCYTIAL VIRUSES

Field Of The Invention

5 This invention relates to respiratory
syncytial viruses of subgroup B having at least one
attenuating mutation in the RNA polymerase gene. This
invention was made with Government support under a
grant awarded by the Public Health Service. The
10 Government has certain rights in the invention.

Background Of The Invention

15 Respiratory syncytial virus (RSV) is a
nonsegmented, negative-sense, single stranded enveloped
RNA virus. RSV belongs to the Family Paramyxoviridae,
the Subfamily Pneumovirinae and the genus *Pneumovirus*.
Pneumoviruses have 10 protein-encoding cistrons. These
proteins in RSV are the nucleocapsid protein N, the
20 phosphoprotein P, the nonglycosylated virion matrix
protein M, the attachment protein G, the fusion protein
F, the polymerase protein L, the nonstructural proteins
NS1 and NS2, the small hydrophobic protein SH, and the
transcription elongation factor protein M2.

25 The genomic RNA of RSV serves two template
functions in the context of a nucleocapsid: as a
template for the synthesis of messenger RNAs (mRNAs)
and as a template for the synthesis of the antigenome
(+) strand. RSV encodes and packages its own RNA
30 dependent RNA Polymerase. Messenger RNAs are only
synthesized once the virus has been uncoated in the
infected cell. Viral replication occurs after
synthesis of the mRNAs and requires the continuous
synthesis of viral proteins. The newly synthesized
35 antigenome (+) strand serves as the template for

- 2 -

generating further copies of the (-) strand genomic RNA.

5 The polymerase complex actuates and achieves transcription and replication by engaging the *cis*-
acting signals at the 3' end of the genome, in particular, the promoter region. Viral genes are then transcribed from the genome template unidirectionally from its 3' to its 5' end. There is always less mRNA made from the downstream genes (e.g., the polymerase
10 gene (L)) relative to their upstream neighbors (i.e., the nucleoprotein gene (N)). Therefore, there is always a gradient of mRNA abundance according to the position of the genes relative to the 3'-end of the genome.

15 RSV is the leading cause of viral pneumonia and bronchiolitis in infants and young children and is responsible for an estimated 95,000 hospitalizations and 4,500 deaths per year in the United States (Bibliography entries 1,2,3). Serious disease is most prevalent in infants 6 weeks to 6 months of age and in
20 children with certain underlying illnesses (e.g. immunodeficiencies, congenital heart disease and bronchopulmonary dysplasia).

 Two major subgroups of RSV have been identified, A and B, as well as antigenic variants
25 within each subgroup (4). Multiple variants of each subgroup have been found to cocirculate in epidemics which occur annually during late fall, winter, and spring months (5). Most children are infected by two years of age. Complete immunity to RSV, however, does
30 not develop and reinfections occur throughout life (6,7). These reinfections often are symptomatic, though generally confined to mild upper respiratory tract disease. A decrease in severity of disease is associated with two or more prior infections and, in
35 some studies, with high levels of serum antibody,

- 3 -

suggesting that protective immunity to RSV disease will accumulate following repeated infections (2,6,8,9,10,11). There is also evidence that children infected with one of the two major RSV subgroups may be somewhat protected against reinfection with the homologous subgroup (12). These observations suggest that it is both possible and worthwhile to develop an RSV vaccination regimen for infants and young children which would provide sufficient temporary immunity to protect against severe disease and death.

The identification of the two major subgroups of RSV has been based on reactivities of the F and G surface glycoproteins with monoclonal antibodies (4,13) and further delineated by sequence analysis (14,15). Both F and G proteins elicit neutralizing antibodies and immunization with these proteins provides protection against reinfection in mouse and cotton rat models (16,17,18). Most neutralizing antibodies are directed against the F protein. Beeler and Coelingh reported that out of 16 neutralization epitopes mapped to the F protein, 8 epitopes were conserved in all or all but one of 23 virus isolates tested (19). A high degree of sequence homology exists between the F protein of subgroups A and B (approximately 90% amino acid and approximately 80% nucleotide) whereas a much lower degree of homology exists between the G proteins (approximately 50-60% amino acid and approximately 60-70% nucleotide) (14). Correspondingly, immunity elicited by the F protein is more crossprotective between subgroups than is immunity elicited by the G protein (16,17). In mice, humoral immunity induced by both the F and G proteins is thought to be responsible for protection against reinfection with virus (20) whereas the CTL response is thought to be more important in resolution of primary infections

- 4 -

(21,22,23). The M2 (or 22K) protein has been shown to be a potent inducer of cytotoxic lymphocytes (CTL) in mice, with lesser CTL recognition of F, N, and P proteins (24,25). Human CTL's have been shown to
5 recognize the F, M2, N, M, SH, and NS2 (or 1b) proteins (26). These data suggest that the F protein of either virus subgroup is a crucial immunogen in any RSV vaccine and that the G, M2, N, M, SH, and NS2 proteins should also be considered potential vaccine components.

10 For RSV, no vaccines of any kind are currently available. Thus, there is a need to develop vaccines against this human pathogen. Such vaccines would have to elicit an immune response in the recipient which will prevent serious RSV disease, i.e.,
15 LRD. The qualitative and quantitative features of such a favorable response are extrapolated from those seen in survivors of natural virus infection, who, though not protected from reinfection by the same or highly related viruses, are protected from serious or fatal
20 disease.

A variety of approaches can be considered in seeking to develop such vaccines, including the use of:
(1) purified individual viral protein vaccines (subunit vaccines); (2) inactivated whole virus preparations;
25 and (3) live, attenuated viruses.

Subunit vaccines have the desirable feature of being pure, definable and relatively easily produced in abundance by various means, including recombinant DNA expression methods. To date, with the notable
30 exception of hepatitis B surface antigen, viral subunit vaccines have generally only elicited short-lived and/or inadequate immunity, particularly in naive recipients.

Formalin inactivated whole virus preparations
35 of polio (IPV) and hepatitis A have proven safe and

- 5 -

efficacious. In contrast, immunization with similarly inactivated whole RSV elicited unfavorable immune responses and/or response profiles which predisposed vaccinees to exaggerated or aberrant disease when subsequently confronted with the natural or "wild-type" virus.

Early attempts (1966) to vaccinate young children used a parenterally administered formalin-inactivated RSV vaccine. Unfortunately, several field trials of this vaccine revealed serious adverse reactions - the development of a severe illness with unusual features following subsequent natural infection with RSV (27,28). It has been suggested that this exposure to formalinized RSV antigen elicited an abnormal or unbalanced immune response profile, predisposing the vaccinee to RSV disease potentiation (29,30).

Several different live, attenuated viruses have proven remarkably effective as a means of achieving immunoprophylaxis. Pursuit of such vaccine candidates for RSV has been intense and long-standing.

RSV temperature sensitive (*ts*) mutants derived by chemical mutagenesis (31) were shown to be attenuated in rodent and non-human primate models (32,33).

Cold adaptation, a process by which virus is adapted to growth at temperatures colder than those at which it normally optimally grows, has been used to develop attenuated *ts* virus mutants for use as vaccines (for review see (34)). This method generally results in the accumulation of multiple genetic lesions which may help to confer phenotypic stability by reducing the probability that reversion of any one lesion will result in reversion of the relevant phenotype. Maassab has used stepwise cold adaptation to successfully

- 6 -

develop several *ts* influenza vaccine candidates currently in clinical trials (35,36,37). These mutants, which bear attenuating mutations in at least four different genes, appear to be attenuated, immunogenic, and phenotypically stable.

Belshe and co-workers have used cold adaptation to develop attenuated, *ts* strains of a paramyxovirus, parainfluenza virus type 3 (38,39). In this case, cold adaptation was carried out in primary African green monkey kidney cells by reducing temperatures to 20°C. Analysis of several virus variants cloned from this cold adapted population demonstrated that the level of attenuation and temperature sensitivity increased as the length of cold adaptation increased. These variants were shown to have reduced potential for virulence in humans, however the temperature sensitive phenotype was somewhat unstable in clinical trials (40).

RSV was successfully cold adapted to 25-26°C in several laboratories in the mid 1960's, but was found to be under-attenuated in vaccine trials (34,41,42). Maassab and DeBorde (34) have suggested this may be because cold adaptation was not carried out at low enough temperatures, or clones of adequately attenuated virus were not isolated from a genetically mixed population of cold-adapted virus.

Nevertheless, this means for generating attenuated live RSV vaccine candidates is lengthy and, at best, unpredictable, relying largely on the selective outgrowth of those randomly occurring genomic mutants with desirable attenuation characteristics. The resulting viruses may have the desired phenotype *in vitro*, and even appear to be attenuated in animal models. However, all too often they remain either under- or overattenuated in the human or animal host

- 7 -

for whom they are intended as vaccine candidates.

Thereafter, two live, attenuated RSV mutants were generated by cold passage or chemical mutagenesis.

5 These RSV strains were found to have reduced virulence in seropositive adults. Unfortunately, they proved either over- or underattenuated when given to seronegative infants; in some cases they were also found to lack genetic stability (43,44). Another vaccination approach using parenteral administration of
10 live virus was found ineffective and efforts along this line were discontinued (45). Notably, these live RSV vaccines were never associated with disease enhancement as observed with the formalin-inactivated RSV vaccine described above.

15 Currently, there are no RSV vaccines approved for administration to humans, although clinical trials are now in progress with cold-passaged, chemically mutagenized strains of RSV designated A2 and B-1.

20 Appropriately attenuated live derivatives of wild-type viruses offer a distinct advantage as vaccine candidates. As live, replicating agents, they initiate infection in recipients during which viral gene products are expressed, processed and presented in the context of the vaccinee's specific MHC class I and II
25 molecules, eliciting humoral and cell-mediated immune responses, as well as the coordinate cytokine patterns, which parallel the protective immune profile of survivors of natural infection.

30 This favorable immune response pattern is contrasted with the delimited responses elicited by inactivated or subunit vaccines, which typically are largely restricted to the humoral immune surveillance arm. Further, the immune response profile elicited by some formalin inactivated whole virus vaccines, e.g.,
35 measles and respiratory syncytial virus vaccines

- 8 -

developed in the 1960's, have not only failed to provide sustained protection, but in fact have led to a predisposition to aberrant, exaggerated, and even fatal illness, when the vaccine recipient later confronted the wild-type virus.

While live, attenuated viruses have highly desirable characteristics as vaccine candidates, they have proven to be difficult to develop. The crux of the difficulty lies in the need to isolate a derivative of the wild-type virus which has lost its disease-producing potential (i.e., virulence), while retaining sufficient replication competence to infect the recipient and elicit the desired immune response profile in adequate abundance.

Historically, this delicate balance between virulence and attenuation has been achieved by serial passage of a wild-type viral isolate through different host tissues or cells under varying growth conditions (such as temperature). This process presumably favors the growth of viral variants (mutants), some of which have the favorable characteristic of attenuation. Occasionally, further attenuation is achieved through chemical mutagenesis as well.

This propagation/passage scheme typically leads to the emergence of virus derivatives which are temperature sensitive, cold-adapted and/or altered in their host range -- one or all of which are changes from the wild-type, disease-causing viruses -- i.e., changes that are associated with attenuation.

Rational vaccine design would be assisted by a better understanding of RSV, in particular, by the identification of the virally encoded determinants of virulence as well as those genomic changes which are responsible for attenuation.

- 9 -

Summary Of The Invention

Accordingly, it is an object of this invention to identify those regions of the polymerase gene of RSV subgroup B where mutations result in attenuation of those viruses.

It is a further object of this invention to produce recombinantly-generated RSV subgroup B which incorporate such attenuating mutations in their genomes.

It is still a further object of this invention to formulate vaccines containing such attenuated viruses.

These and other objects of the invention as discussed below are achieved by the generation and isolation of recombinantly-generated, attenuated, RSV subgroup B having at least one attenuating mutation in the RNA polymerase gene.

The at least one attenuating mutation in the RNA polymerase gene is selected from the group consisting of nucleotide changes which produce changes in an amino acid selected from the group consisting of residues 353 (arginine → lysine), 451 (lysine → arginine), 1229 (aspartic acid → asparagine), 2029 (threonine → isoleucine) and 2050 (asparagine → aspartic acid).

In another embodiment of this invention, attenuated virus is used to prepare vaccines which elicit a protective immune response against the wild-type form of the virus.

In yet another embodiment of this invention, an isolated, positive strand, antigenomic message sense nucleic acid molecule (or an isolated, negative strand genomic sense nucleic acid molecule) having the

- 10 -

complete viral nucleotide sequence (whether of wild-type virus or virus attenuated by non-recombinant means) is manipulated by introducing one or more of the attenuating mutations described in this application to generate an isolated, recombinantly-generated attenuated virus. This virus is then used to prepare vaccines which elicit a protective immune response against the wild-type form of the virus.

In still another embodiment of this invention, such a complete wild-type or vaccine viral nucleotide sequence (as well as a revertant sequence) is used: (1) to design PCR primers for use in a PCR assay to detect the presence of the corresponding virus in a sample; or (2) to design and select peptides for use in an ELISA to detect the presence of the corresponding virus in a sample.

Brief Description Of The Figures

Figure 1 shows a flow chart detailing the propagation of RSV 2B working seed MK7V14b and RSV 3A working seed MK8V17b.

Figure 2 shows growth and cytopathic effect of RSV 2B at temperatures from 26°C to 36°C in Vero cells.

Figure 3 shows growth and cytopathic effect of RSV 3A at temperatures from 26°C to 36°C in Vero cells.

Figure 4 graphically shows titration results obtained at each passage of RSV 2B and RSV 3A.

Figure 5 shows the growth curves of RSV 2B, RSV 2Bp24G, RSV 2Bp20L, RSV 3A, RSV 3Ap20E and RSV 3Ap20F in Vero cells at temperatures from 20°C to 40°C.

Figure 6 compares graphically the growth of

- 11 -

RSV 2B and RSV 2Bp20L in cotton rats from 3 to 7 days post-infection.

Figure 7 compares the relative growth and pathogenicity of RSV 2B and RSV 2Bp20L in four (4) year old seropositive chimps.

Figure 8 is a diagram showing virus titrations for monkeys infected with the RSV 2B ts mutants and subsequently challenged with the parental strain.

Figure 9 is a diagram showing virus growth in African green monkey cells infected with the RSV 3A ts mutants and challenged with the parental 3A strain.

Figure 10 is a diagram showing a growth study in African green monkeys comparing TS-1 with RSV 2Bp33F and 3Ap28F.

Figure 11 depicts a genetic map of the RSV subgroup B wild-type strains designated 2B and 18537 (top portion), the intergenic sequences of those strains (middle portion) and the 68 nucleotide overlap between the M2 and L genes (bottom portion). The RSV 2B strain has six fewer nucleotides in the G gene, encoding two fewer amino acid residues in the G protein, as compared to the 18537 strain. The 2B strain has 145 nucleotides in the 5' trailer region, as compared to 149 nucleotides in the 18537 strain. The 2B strain has one more nucleotide in each of the NS-1, NS-2 and N genes, and one fewer nucleotide in each of the M and F genes, as compared to the 18537 strain.

Detailed Description Of The Invention

The first step in the identification of attenuating mutations in the L gene of RSV subgroup B vaccine strains was the generation of those strains from wild-type strains. The original RSV subgroup B

- 12 -

vaccine strains (as well as subgroup A vaccine strains) were generated by cold adaptation of the wild type virus. Cold adaptation comprises obtaining live virulent virus derived from clinical isolates that have been isolated in primary rhesus monkey kidney cells. These are then passed in Vero cells at 35-36°C and plaque purified. Preferably, the Vero cells are passage 133 to 148 of the Vero cell line CCL81, obtained from the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland, U.S.A. 20852. The maintenance medium is preferably MEM with 2% FBS, L-glutamine, non-essential amino acids and 20mM Hepes pH 7.5, and the freezing medium is MEM with 10% FBS and 20mM Hepes pH 7.5.

A confluent monolayer of Vero cells is inoculated with about 1.0 ml of virus inoculum, and virus is allowed to absorb for about one to two hours (preferably, 70 to 120 minutes, and most preferably 90 minutes) at ambient temperature (about 18°C to about 25°C).

The virus flask is incubated at about 18°C to about 26°C, preferably about 20°C, for about two to fifteen days. Virus is harvested by removing the medium and replacing it with freezing medium. The flask is then frozen directly at -70°C, then thawed in a 32°C water bath.

A portion (about 1 ml) is removed from the freeze-thaw lysate and is used to inoculate Vero cells; the process is then repeated. The remaining freeze-thaw lysate is stored at -70°C. It can be used to perform virus titrations and plaque purify virus.

To plaque purify virus, the freeze-thaw lysate is thawed in a 32°C water bath. About three to five serial dilutions of the lysate are made in the maintenance medium. Six-well, twenty-four well, or

- 13 -

ninety-six well plates containing confluent Vero cells are rinsed with a phosphate buffered saline solution. Wells are inoculated with virus dilution, using only enough volume to cover the bottom of the well. Virus inoculum is adsorbed for 90 minutes at ambient temperature. Wells are overlaid with 1% methylcellulose in MEM-maintenance medium. Plates are incubated at 32°C for five days. Isolated plaques are identified microscopically by looking for typical syncytial plaques, and wells are marked. Plaques are picked at marked sites using small bore pipette or pipette tip and are emulsified in 0.5 ml maintenance medium for 1-3 hours at 4°C. Picked plaques are used to inoculate duplicates of 25 cm² flask or 96-well plates containing Vero cell monolayers as described above. Duplicate inoculated flasks or plates are overlaid with maintenance medium. One duplicate is incubated at 32°C and the other at 39°C for 5-10 days. Flasks or plates incubated at 32°C are examined microscopically for virus cytopathic effect (CPE). Flasks or plates incubated at 39°C are stained by immunoperoxidase assay for RSV specific antigen. Flasks or plates which demonstrate easily detectable CPE at 32°C and little or no detectable RSV antigen by immunoperoxidase staining are selected as containing temperature sensitive (*ts*) mutants. Virus from the selected flask or plate described above are harvested by freeze-thaw technique. This virus represents a plaque purified mutant.

Cold adaptation as just described was used to develop attenuated strains of RSV from two parental strains derived from clinical isolates. Seven *ts* mutants were isolated, four from a subgroup B virus (RSV 2B) and three from a subgroup A virus (RSV 3A). All seven mutants displayed a temperature sensitive

- 14 -

phenotype in Vero cell culture, each with unique characteristics. All mutants were attenuated in growth in cotton rats, but displayed different phenotypes. Growth of one of the ts mutants, RSV 2Bp20L, was shown to be attenuated in seropositive chimpanzees. All seven mutants retained two major neutralization epitopes.

Cold adaptation of RSV had previously been done in primary or diploid cell lines (bovine embryonic kidney, WI38, and cercopithecus monkey kidney) at temperatures beginning at 34°C-37°C and decreasing to 25°C-26°C. No attempt had been made to isolate multiple individual mutant phenotypes from the cold-adapted virus (37,46,47).

The approach described herein to cold-adapting RSV differed in several significant ways from these previous attempts. This procedure started with a subgroup A and subgroup B virus of different strains than those used previously. These strains bore distinct phenotypic differences from the reference strains and each other. These strains were passed several times to adapt virus to Vero cells and to plaque purify virus. Virus was passaged in a continuous cell line, Vero cells, rather than a diploid or primary cell line. Several strategies of temperature change were used, to provide a greater potential for isolation of a variety of mutant phenotypes.

Unlike previous RSV cold adaptation strategies where cold adaptation had started at 34-37°C and gone down to 25-26°C, cold adaptation started at either 26°C (since it was found that the parental strains grew well at this temperature) or 22°C, and gradually reduced the growth temperature to 20°C. Passage strategies attempted to cover both the

- 15 -

recommendation of "slow" adaptation to very low temperatures as proposed by Massab and DeBorde (37), as well as efforts to try a faster and more aggressive approach. RNA viruses mutate at such a high frequency that any population of virus will contain a number of individual virus variants (48). Therefore, a variety of virus mutants were isolated from individual flasks at various virus passage levels and from different cold adaptation strategies.

The results were interesting and somewhat unexpected. The rate at which virus became adapted (i.e., grew to consistently high titers at the 20°C temperature), was most affected by the strain of virus used, implying a significant host-related factor in adaptation. RSV 2B easily adapted to the cold temperatures, even using a rapid adaptation scheme. In contrast, RSV 3A grew poorly at the low temperatures. RSV 3A was eventually cold-adapted using the slow passage scheme, but the more rapid adaptation approaches did not appear promising and were discontinued. Based on cold adaptation experiences reported by other researchers, it was expected *ts* mutants would arise and eventually become the predominant virus variants in the cold-adapted populations. For example, Belshe and Hissom (41) reported that with parainfluenza virus type 3 adapted to grow at 20°C, 80% of plaque purified virus clones were *ts* by passage 18 and 100% were *ts* by passage 45. In this study, even after 38-40 low temperature passages, including up to 32 passages done at 20°C, RSV *ts* mutants remained a minor population. This would suggest that *ts* and cold-adapted phenotypes may not be as strongly linked in RSV as they are in other viruses.

The level of attenuation is a critical factor in developing vaccines for any target population and is

- 16 -

of particular importance for vaccines intended for infants and young children. Virus must be sufficiently attenuated to not cause disease, yet grow well enough in the vaccine to elicit protective immunity.

5 Widely accepted markers for attenuation are *ts* phenotype and reduced growth in animal models. However, these markers are only approximate and testing must eventually be done in the target population. The RSV 3A *ts* mutants could be distinguished from the RSV
10 3A parental virus by reduced replication in both the nose and lungs. Also of note, although the RSV 3A parental virus grew much better in the nose than the lungs of cotton rats, virus recovery was similar in both nose and lungs of BALB/c mice. These data suggest
15 that the attenuation seen in cotton rats is due to more than one factor, and that this factor is not directly related to temperature sensitivity as measured in *vitro*. The cotton rat is relatively nonpermissive for growth of RSV and disease does not develop, suggesting
20 that this model is an unreliable indicator of level of attenuation in humans.

 In contrast, chimpanzees are highly susceptible to RSV infection and develop an upper and lower respiratory tract disease that is very similar to
25 that seen in humans. In seropositive chimps, it was found that the RSV 2B parental strain caused mild upper respiratory tract disease similar to that caused by natural RSV infections in adult humans. The RSV 2Bp20L mutant did not grow, clearly demonstrating that this *ts*
30 mutant was attenuated in a permissive host as well as the non-permissive cotton rat. The level of attenuation is best assessed in a seronegative chimp, as prior virus exposure will affect the host response to virus challenge. Unfortunately, testing in
35 seronegative chimps is severely hampered by the limited

- 17 -

availability of these animals.

The mutants described herein bear the desirable traits of an attenuated, phenotypically stable, and immunogenic RSV vaccine virus in the human target population.

The immunopotency of the recombinantly-generated RSV subgroup B vaccine is determined by monitoring the immune response of test animals following immunization with the vaccine. Test animals include, but are not limited to, mice, rats (e.g., cotton rats), rabbits, primates, e.g., African green monkeys, chimps, and human subjects. Methods of introduction of the immunogen may include oral, parenteral, topical, intranasal or any other standard routes of immunizations. The immune response of the test subjects is analyzed by four approaches: (a) the reactivity of the resultant immune serum to authentic RSV antigens, as assayed by known techniques, e.g., enzyme linked immunosorbant assay (ELISA), immunoblots, radioimmunoprecipitations, etc.; (b) the ability of the immune serum to neutralize RSV infectivity *in vitro*; (c) the ability of the immune serum to inhibit virus fusion *in vitro*; and (d) protection from RSV infection or significant disease.

The cold-adapted RSV mutants are capable of eliciting an immune response when administered to a subject without causing significant disease, such as respiratory distress or otitis media. As used herein, the term "cold-adapted mutant" means an attenuated virus that has been attenuated by propagation at lower than optimal temperatures. Examples of cold-adapted mutant viruses have been provided as described above. The cold-adapted mutant RSV may be a mutant of subgroup A, such as the group consisting of 3Ap20E, 3Ap20F and 3Ap28F. The cold-adapted mutant RSV may also be a

- 18 -

mutant of the subgroup B, such as the group consisting of 2Bp33F, 2Bp24G, 2Bp20L and 2Bp34L. The subgroup B viruses are then sequenced and differences between wild-type and mutant strains are identified. Those mutations which contribute to the attenuated phenotype are then assessed.

Transcription and replication of negative-sense, single stranded RNA viral genomes such as RSV subgroup B are achieved through the enzymatic activity of a multimeric protein acting on the ribonucleoprotein core (nucleocapsid). Naked genomic RNA cannot serve as a template. Instead, these genomic sequences are recognized only when they are entirely encapsidated by the N protein into the nucleocapsid structure. It is only in that context that the genomic and antigenomic terminal promoter sequences are recognized to initiate the transcriptional or replication pathways.

All paramyxoviruses require the two viral proteins, L and P, for these polymerase pathways to proceed. The pneumoviruses, including RSV, also require the transcription elongation factor M2 for the transcriptional pathway to proceed efficiently. Additional cofactors may also play a role, including perhaps the virus-encoded NS1 and NS2 proteins, as well as perhaps host-cell encoded proteins.

However, considerable evidence indicates that it is the L protein which performs most if not all the enzymatic processes associated with transcription and replication, including initiation, and termination of ribonucleotide polymerization, capping and polyadenylation of mRNA transcripts, methylation and perhaps specific phosphorylation of P proteins. The L protein's central role in genomic transcription and replication is supported by its large size, sensitivity to mutations, and its catalytic level of abundance in

- 19 -

the transcriptionally active viral complex (49).

These considerations led to the proposal that L proteins consist of a linear array of domains whose concatenated structure integrates discrete functions (50). Indeed, three such delimited, discrete elements within the negative-sense virus L protein have been identified based on their relatedness to defined functional domains of other well-characterized proteins. These include: (1) a putative RNA template recognition and/or phosphodiester bond formation domain; (2) an RNA binding element; and (3) an ATP binding domain. All prior studies of L proteins of nonsegmented negative-sense, single stranded RNA viruses have revealed these putative functional elements (50).

In summary, the invention comprises the identification of changes in the polymerase gene (L) which result in attenuation of the virus while retaining sufficient ability of the virus to replicate. Attenuation is optimized by rational mutations of the polymerase gene, which provide the desired balance of replication efficiency: so that the virus vaccine is no longer able to produce disease, yet retains its capacity to infect the vaccinee's cells, to express sufficiently abundant gene products to elicit the full spectrum and profile of desirable immune responses, and to reproduce and disseminate sufficiently to maximize the abundance of the immune response elicited.

Animal studies have demonstrated a decrease in viral replication sufficient to avoid illness but adequate to elicit the desired immune response. This likely represents a decrease in transcription, a decrease in gene expression of virally encoded proteins, a decrease in antisense templates and, therefore, the production of fewer new genomes. The

- 20 -

resulting attenuated viruses are significantly less virulent than the wild-type.

The attenuating mutations described herein may be introduced into viral strains by two methods:

5 (1) Conventional means such as chemical mutagenesis during virus growth in cell cultures to which a chemical mutagen has been added, selection of virus that has been subjected to passage at suboptimal temperature in order to select temperature sensitive
10 and/or cold-adapted mutations, identification of mutant virus that produce small plaques in cell culture, and passage through heterologous hosts to select for host range mutations. These viruses are then screened for attenuation of their biological activity in an animal
15 model. Attenuated viruses are subjected to nucleotide sequencing of their polymerase genes to locate the sites of attenuating mutations. Once this has been done, method (2) is then carried out.

20 (2) A preferred means of introducing attenuating mutations comprises making predetermined mutations using site-directed mutagenesis. These mutations are identified either by method (1) or by reference to closely-related viruses whose attenuating mutations are already known. One or more mutations are
25 introduced into the polymerase gene. Cumulative effects of different combinations of coding and non-coding changes can also be assessed.

 The mutations to the polymerase gene are introduced by standard recombinant DNA methods into a
30 DNA copy of the viral genome. This may be a wild-type or a modified viral genome background (such as viruses modified by method (1)), thereby generating a new virus. Infectious clones or particles containing these attenuating mutations are generated using the cDNA
35 "rescue" system, which has been applied to a variety of

- 21 -

viruses, including Sendai virus (51); measles virus (52); respiratory syncytial virus (53); rabies (54); vesicular stomatitis virus (VSV) (55); and rinderpest virus (56); these references are hereby incorporated by reference. See, for RSV rescue, published International patent application WO 97/12032, designating the United States (57); this application is hereby incorporated by reference.

Briefly, all Mononegavirales rescue systems can be summarized as follows: Each requires a cloned DNA equivalent of the entire viral genome placed between a suitable DNA-dependent RNA polymerase promoter (e.g., the T7 RNA polymerase promoter) and a self-cleaving ribozyme sequence (e.g., the hepatitis delta ribozyme) which is inserted into a propagatable bacterial plasmid. This transcription vector provides the readily manipulable DNA template from which the RNA polymerase (e.g., T7 RNA polymerase) can faithfully transcribe a single-stranded RNA copy of the viral antigenome (or genome) with the precise, or nearly precise, 5' and 3' termini. The orientation of the viral genomic DNA copy and the flanking promoter and ribozyme sequences determine whether antigenome or genome RNA equivalents are transcribed. Also required for rescue of new virus progeny are the virus-specific trans-acting proteins needed to encapsidate the naked, single-stranded viral antigenome or genome RNA transcripts into functional nucleocapsid templates: the viral nucleocapsid (N or NP) protein, the polymerase-associated phosphoprotein (P) and the polymerase (L) protein. These proteins comprise the active viral RNA-dependent RNA polymerase which must engage this nucleocapsid template to achieve transcription and replication.

The trans-acting proteins required for RSV

- 22 -

rescue are the encapsidating protein N, the polymerase complex proteins, P and L, and an additional protein, M2, the RSV-encoded transcription elongation factor.

Typically, these viral trans-acting proteins
5 are generated from one or more plasmid expression
vectors encoding the required proteins, although some
or all of the required trans-acting proteins may be
produced within mammalian cells engineered to contain
and express these virus-specific genes and gene
10 products as stable transformants.

The typical (although not necessarily
exclusive) circumstances for rescue include an
appropriate mammalian cell milieu in which T7
polymerase is present to drive transcription of the
15 antigenomic (or genomic) single-stranded RNA from the
viral genomic cDNA-containing transcription vector.
Either cotranscriptionally or shortly thereafter, this
viral antigenome (or genome) RNA transcript is
encapsidated into functional templates by the
20 nucleocapsid protein and engaged by the required
polymerase components produced concurrently from co-
transfected expression plasmids encoding the required
virus-specific trans-acting proteins. These events and
processes lead to the prerequisite transcription of
25 viral mRNAs, the replication and amplification of new
genomes and, thereby, the production of novel viral
progeny, i.e., rescue.

For the rescue of rabies, VSV and Sendai, T7
polymerase is provided by recombinant vaccinia virus
30 VTF7-3. This system, however, requires that the
rescued virus be separated from the vaccinia virus by
physical or biochemical means or by repeated passaging
in cells or tissues that are not a good host for
poxvirus. For measles virus (MV) cDNA rescue, this
35 requirement is avoided by creating a cell line that

- 23 -

expresses T7 polymerase, as well as viral N and P proteins. Rescue is achieved by transfecting the genome expression vector and the L gene expression vector into the helper cell line. Advantages of the host-range mutant of the vaccinia virus, MVA-T7, which expresses the T7 RNA polymerase, but does not replicate in mammalian cells, are exploited to rescue RSV, Rinderpest virus and MV. After simultaneous expression of the necessary encapsidating proteins, synthetic full length antigenomic viral RNA are encapsidated, replicated and transcribed by viral polymerase proteins and replicated genomes are packaged into infectious virions. In addition to such antigenomes, genome analogs have now been successfully rescued for Sendai and PIV-3 (58,59).

The rescue system thus provides a composition which comprises a transcription vector comprising an isolated nucleic acid molecule encoding a genome or antigenome of RSV subgroup B having at least one attenuating mutation in the RNA polymerase gene, together with at least one expression vector which comprises at least one isolated nucleic acid molecule encoding the trans-acting N, P, L and M2 proteins necessary for encapsidation, transcription and replication. Host cells are then transformed or transfected with the at least two vectors just described. The host cells are cultured under conditions which permit the co-expression of these vectors so as to produce the infectious attenuated virus.

The rescued infectious RSV is then tested for its desired phenotype (temperature sensitivity, cold adaptation, plaque morphology, and transcription and replication attenuation), first by *in vitro* means.

If the attenuated phenotype of the rescued

- 24 -

virus is present, challenge experiments are conducted with an appropriate animal model. Non-human primates provide the preferred animal model for the pathogenesis of human disease. These primates are first immunized
5 with the attenuated, recombinantly-generated virus, then challenged with the wild-type form of the virus. Monkeys are infected by various routes, including but not limited to intranasal or intratracheal routes of inoculation (60). Protection in non-human primates is
10 measured by such criteria as disease signs and symptoms, virus shedding and antibody titers. If the desired criteria are met, the attenuated, recombinantly-generated virus is considered a viable vaccine candidate for testing in humans. The "rescued"
15 virus is considered to be "recombinantly-generated", as are the progeny and later generations of the virus, which also incorporate the attenuating mutations.

Even if a "rescued" virus is underattenuated or overattenuated relative to optimum levels for
20 vaccine use, this is information which is valuable for developing such optimum strains.

Optimally, a codon containing an attenuating point mutation may be stabilized by introducing a second or a second plus a third mutation in the codon
25 without changing the amino acid encoded by the codon bearing only the attenuating point mutation. Infectious virus clones containing the attenuating and stabilizing mutations are also generated using the cDNA "rescue" system described above.

30 Two major subgroups of human RSV, designated A and B, have been identified based on reactivities of the F and G surface glycoproteins with monoclonal antibodies (4). More recently, the A and B lineages of RSV strains have been confirmed by sequence analysis
35 (14,15). Bovine, ovine, and caprine strains of this

- 25 -

virus have also been isolated. The host specificity of the virus is most clearly associated with the G attachment protein, which is highly divergent between the human and the bovine/ovine strains (61,62), and may be influenced, at least in part, by receptor binding.

RSV is the primary cause of serious viral pneumonia and bronchiolitis in infants and young children. Serious disease, i.e., lower respiratory tract disease (LRD), is most prevalent in infants less than six months of age. It most commonly occurs in the nonimmune infant's first exposure to RSV. RSV additionally is associated with asthma and hyperreactive airways and it is a significant cause of mortality in "high risk" children with bronchopulmonary dysplasia and congenital heart disease (CHD). It is also one of the common viral respiratory infections predisposing to otitis media in children. In adults, RSV generally presents as uncomplicated upper respiratory illness; however, in the elderly it rivals influenza as a predisposing factor in the development of serious LRD, particularly bacterial bronchitis and pneumonia. Disease is always confined to the respiratory tract, except in the severely immunocompromised, where dissemination to other organs can occur. Virus is spread to others by fomites contaminated with virus-containing respiratory secretions, and infection initiates through the nasal, oral, or conjunctival mucosa.

RSV disease is seasonal and virus is usually isolated only in the winter months, e.g., from November to April in northern latitudes. The virus is ubiquitous, and over 90% of children have been infected at least once by 2 years of age. Multiple strains cocirculate. There is no direct evidence of antigenic drift (such as that seen with influenza A viruses), but

- 26 -

sequence studies demonstrating accumulation of amino acid changes in the hypervariable regions of the G protein and SH proteins suggest that immune pressure may drive virus evolution.

5 In mouse and cotton rat models, both the F and G proteins of RSV elicit neutralizing antibodies and immunization with these proteins alone provides longterm protection against reinfection (16,17).

10 In humans, complete immunity to RSV does not develop and reinfections occur throughout life (6,7); however, there is evidence that immune factors will protect against severe disease. A decrease in severity of disease is associated with two or more prior
15 infections and there is evidence that children infected with one of the two major RSV subgroups may be somewhat protected against reinfection with the homologous subgroup (13), observations which suggest that a live attenuated virus vaccine may provide protection
20 sufficient to prevent serious morbidity and mortality. Infection with RSV elicits both antibody and cell mediated immunity. Serum neutralizing antibody to the F and G proteins has been associated, in some studies, with protection from LRD, although reduction in upper
25 respiratory disease (URD) has not been demonstrated. High levels of serum antibody in infants is associated with protection against LRD, and administration of intravenous immunoglobulin with high RSV neutralizing
30 antibody titers has been shown to protect against severe disease in high risk children (7,10,63). The role of local immunity, and nasal antibody in particular, is being investigated.

 The RSV virion consists of a ribonucleoprotein core contained within a lipoprotein envelope. The virions of pneumoviruses are similar in
35 size and shape to those of all other paramyxoviruses.

- 27 -

When visualized by negative staining and electron microscopy, virions are irregular in shape and range in diameter from 150-300 nm (64). The nucleocapsid of this virus is a symmetrical helix similar to that of other paramyxoviruses, except that the helical diameter is 12-15 nm rather than 18nm. The envelope consists of a lipid bilayer that is derived from the host membrane and contains virally coded transmembrane surface glycoproteins. The viral glycoproteins mediate attachment and penetration and are organized separately into virion spikes. All members of paramyxovirus subfamily have hemagglutinating activity, but this function is not a defining feature for pneumoviruses, being absent in RSV but present in PVM (65).

Neuraminidase activity is present in members of the genera Paramyxovirus, Rubulavirus, and is absent in Morbillivirus and Pneumovirus of mice (PVM) (65).

RSV possesses two subgroups, designated A and B. The wild-type RSV (strain 2B) genome is a single strand of negative-sense RNA of 15,218 nucleotides (SEQ ID NO:1) that are transcribed into ten major subgenomic mRNAs. Each of the ten mRNAs encodes a major polypeptide chain: Three are transmembrane surface proteins (G, F and SH); three are the proteins associated with genomic RNA to form the viral nucleocapsid (N, P and L); two are nonstructural proteins (NS1 and NS2) which accumulate in the infected cells but are also present in the virion in trace amounts and may play a role in regulating transcription and replication; one is the nonglycosylated virion matrix protein (M); and the last is M2, another nonglycosylated protein recently shown to be an RSV-specified transcription elongation factor (see Figure 11). These ten viral proteins account for nearly all of the viral coding capacity.

- 28 -

The viral genome is encapsidated with the major nucleocapsid protein (N), and is associated with the phosphoprotein (P), and the large (L) polymerase protein. These three proteins have been shown to be
5 necessary and sufficient for directing RNA replication of cDNA encoded RSV minigenomes (66). Further studies have shown that for transcription to proceed with full processing, the M2 protein (ORF 1) is required (64). When the M2 protein is missing, truncated transcripts
10 predominate, and rescue of the full length genome does not occur (64).

Both the M (matrix protein) and the M2 proteins are internal virion-associated proteins that are not present in the nucleocapsid structure. By
15 analogy with other nonsegmented negative-stranded RNA viruses, the M protein is thought to render the nucleocapsid transcriptionally inactive before packaging and to mediate its association with the viral envelope. The NS1 and NS2 proteins have only been
20 detected in very small amounts in purified virions, and at this time are considered non-structural. Their functions are uncertain, though they may be regulators of transcription and replication. Three transmembrane surface glycoproteins are present in virions: G, F, and
25 SH. G and F (fusion) are envelope glycoproteins that are known to mediate attachment and penetration of the virus into the host cell. In addition, these glycoproteins represent major independent immunogens (3). The function of the SH protein is unknown,
30 although a recent report has implicated its involvement in the fusion function of the virus (67).

The genomes of two wild-type RSV subgroup B strains (2B and 18537) have now been sequenced in their entirety (see SEQ ID NOS:1 and 3, discussed below).
35 Genomic RNA is neither capped nor polyadenylated (68).

- 29 -

In both the virion and intracellularly, genomic RNA is tightly associated with the N protein.

The 3' end of the genomic RNA consists of a 44-nucleotide extragenic leader region that is presumed to contain the major viral promoter (68; Fig. 11). The 3' genomic promoter region is followed by ten viral genes in the order 3'-NS1-NS2-N-P-M-SH-G-F-M2-L-5' (Fig. 11). The L gene is followed by a 145-149 nucleotide extragenic trailer region (see Figure 11). Each gene begins with a conserved nine-nucleotide gene start signal 3'-GGGGCAAAU (except for the ten-nucleotide gene start signal of the L gene, which is 3'-GGGACAAAAU; differences underlined). For each gene, transcription begins at the first nucleotide of the signal. Each gene terminates with a semi-conserved 12-14 nucleotide gene end (3'-A G U/G U/A ANNN U/A A₃₋₅) (where N can be any of the four bases) that directs transcription termination and polyadenylation (Fig. 11). The first nine genes are non-overlapping and are separated by intergenic regions that range in size from 3 to 56 nucleotides for RSV B strains (Fig. 11). The intergenic regions do not contain any conserved motifs or any obvious features of secondary structure and have been shown to have no influence on the preceding and succeeding gene expression in a minreplicon system (Fig. 11). The last two RSV genes overlap by 68 nucleotides (Fig. 11). The gene-start signal of the L gene is located inside of, rather than after, the M2 gene. This 68 nucleotide overlap sequence encodes the last 68 nucleotides of the M2 mRNA (exclusive of the Poly-A tail), as well as the first 68 nucleotides of the L mRNA.

Ten different species of subgenomic polyadenylated mRNAs and a number of polycistronic polyadenylated read-through transcripts are the

- 30 -

products of genomic transcription (64).

Transcriptional mapping studies using UV light mediated genomic inactivation showed that RSV genes are transcribed in their 3' to 5' order from a single promoter near the 3' end (69). Thus, RSV synthesis appears to follow the single entry, sequential transcription model proposed for all Mononegavirales (70,71). According to this model, the polymerase (L) contacts genomic RNA in the nucleocapsid form at the 3' genomic promoter region and begins transcription at the first nucleotide. RSV mRNAs are co-linear copies of the genes, with no evidence of mRNA editing or splicing.

Sequence analysis of intracellular RSV mRNAs showed that synthesis of each transcript begins at the first nucleotide of the gene start signal (64). The 5' end of the mRNAs are capped with the structure m7G(5')ppp(5')Gp (where the underlined G is the first template nucleotide of the mRNA) and the mRNAs are polyadenylated at their 3' ends (72). Both of these modifications are thought to be made co-transcriptionally by the viral polymerase. Three regions of the RSV 3' genomic promoter have been found to be important as cis acting elements (73). These regions are the first ten nucleotides (presumably acting as a promoter), nucleotides 21-25, and the gene start signal located at nucleotides 45-53 (73). Unlike other Paramyxovirinae, such as measles, Sendai and PIV-3, the remainder of the leader and non-coding region of NS1 gene of RSV was found to be highly tolerant of insertions, deletions and substitutions (73).

Additionally, by saturation mutagenesis (wherein each base is replaced independently by each of the other three bases and compared for translation and replication efficiencies) within the first 12

- 31 -

nucleotides of the 3' genomic promoter region, a U-tract located at nucleotides 6-10 was shown to be highly inhibitory to substitutions (73). In contrast, the first five nucleotides were relatively tolerant of a number of substitutions and two of them at position four were up-regulatory mutations, resulting in a four- to 20-fold increase in RSV-CAT RNA replication and transcription. Using a bi-cistronic minireplicon system, gene-start and gene-end motifs were shown to be signals for mRNA synthesis and appear to be self contained and largely independent of the nature of adjoining sequence (74).

The L gene start signal lies 68 nucleotides upstream of the M2 gene-end signal, resulting in gene overlap (Fig. 11) (64). The presence of the M2 gene-end signal within the L gene results in a high frequency of premature termination of L gene transcripts. Full length L mRNA is much less abundant and is made when the polymerase fails to recognize the M2 gene-end motif. This results in much lower transcription of L mRNA. The gene overlap seems incompatible with a model of linear sequential transcription. It is not known whether the polymerase that exits the M2 gene jumps backward to the L gene-start signal or whether there is a second, internal promoter for L gene transcription (64). It is also possible that the L gene is accessible by a small fraction of polymerases that fail to start transcription at the M2 gene-start signal and slide down the M2 gene to the L gene-start signal.

The relative abundance of each RSV mRNA decreases with the distance of its gene from the promoter, presumably due to polymerase fall-off during sequential transcription (69). Gene overlap is a second mechanism that reduces the synthesis of full

- 32 -

length L mRNA. Also, certain mRNAs have features that might reduce the efficiency of translation. The initiation codon for SH mRNA is in a suboptimal Kozak sequence context, while the G ORF begins at the second methionyl codon in the mRNA.

RSV RNA replication is thought (64) to follow the model proposed from studies with vesicular stomatitis virus and Sendai virus (70,71). This involves a switch from the stop-start mode of mRNA synthesis to an antiterminator read-through mode. This results in synthesis of positive sense replication-intermediate (RI) RNA that is an exact complementary copy of genomic RNA. This serves in turn as the template for the synthesis of progeny genomes. The mechanism involved in the switch to the antiterminator mode is proposed to involve cotranscriptional encapsidation of the nascent RNA by N protein (70,71). RNA replication in RSV like other nonsegmented negative-strand RNA viruses is dependent on ongoing protein synthesis (75). Predicted RI RNA has been detected for the standard virus as well as RSV-CAT minigenome (64,75). RI RNA was 10-20 fold less abundant intracellularly than was the progeny genome both for the standard and the minigenome system. The nucleotide sequences (in positive strand, antigenomic, message sense) of various wild-type, vaccine and revertant RSV strains, as well as the deduced amino acid sequences of the RNA polymerase (L protein) of these RSV viruses, are set forth as follows with reference to the appropriate SEQ ID NOS. contained herein:

- 33 -

<u>Virus</u>	<u>Nucleotide Sequence</u>	<u>L Protein Sequence</u>
--------------	----------------------------	---------------------------

Wild-Type

2B	SEQ ID NO:1	SEQ ID NO:2
18537	SEQ ID NO:3	SEQ ID NO:4

5

Vaccine

2B33F	SEQ ID NO:5	SEQ ID NO:6
2B20L	SEQ ID NO:7	SEQ ID NO:8

10

Revertant

2B33F TS(+)	SEQ ID NO:9	SEQ ID NO:10
2B20L TS(+)	SEQ ID NO:11	SEQ ID NO:12

15

It is noted that the Sequence Listings recite "DNA"; this is necessary for the antigenomic message sense RNA to be provided in full (reciting sequences as "RNA" causes each "T" to be deleted from the sequence).

20

Each RSV virus genome encodes an L protein that is 2,166 amino acids long. Genome length and other nucleotide information is as follows:

<u>Virus</u>	<u>Genome</u>		
<u>Wild-Type</u>	<u>Length</u>	<u>L Start Codon</u>	<u>L Stop Codon</u>

25

2B	15218	8502-8504	15000-15002
18537	15229	8509-8511	15007-15009

Vaccine

2B33F	15219	8503-8505	15001-15003
2B20L	15219	8503-8505	15001-15003

30

Revertant

2B33F TS(+)	15219	8503-8505	15001-15003
2B20L TS(+)	15219	8503-8505	15001-15003

35

As detailed in Example 8 (especially Tables

- 34 -

21 and 22) below, the key potentially attenuating sites for the L protein of RSV subgroup B are as follows:

amino acid residues 353 (arginine → lysine), 451

(lysine → arginine), 1229 (aspartic acid →

5 asparagine), 2029 (threonine → isoleucine) and 2050

(asparagine → aspartic acid). It is understood that the nucleotide changes responsible for these amino acid changes are not limited to those set forth in Example 8

10 below; all changes in nucleotides which result in codons which are translated into these amino acids are within the scope of this invention.

The attenuated RSV subgroup B viruses of this invention exhibit a substantial reduction of virulence compared to wild-type viruses which infect human and
15 animal hosts. The extent of attenuation is such that symptoms of infection will not arise in most immunized individuals, but the virus will retain sufficient replication competence to be infectious in and elicit the desired immune response profile in the vaccinee.

20 The attenuated RSV subgroup B viruses of this invention may be used to formulate a vaccine. To do so, the attenuated virus is adjusted to an appropriate concentration and formulated with any suitable vaccine adjuvant, diluent or carrier. Physiologically
25 acceptable media may be used as carriers. These include, but are not limited to: an appropriate isotonic medium, phosphate buffered saline and the like. Suitable adjuvants include, but are not limited to MPL™ (3-O-deacylated monophosphoryl lipid A; RIBI
30 ImmunoChem Research, Inc., Hamilton, MT) and IL-12 (Genetics Institute, Cambridge, MA).

In one embodiment of this invention, the formulation including the attenuated virus is intended for use as a vaccine. The attenuated virus may be mixed

- 35 -

with cryoprotective additives or stabilizers such as proteins (e.g., albumin, gelatin), sugars (e.g., sucrose, lactose, sorbitol), amino acids (e.g., sodium glutamate), saline, or other protective agents. This mixture is maintained in a liquid state, or is then
5 dessicated or lyophilized for transport and storage and mixed with water immediately prior to administration.

Formulations comprising the attenuated viruses of this invention are useful to immunize a human or animal subject to induce protection against
10 infection by the wild-type counterpart of the attenuated virus. Thus, this invention further provides a method of immunizing a subject to induce protection against infection by an RSV subgroup B virus by administering to the subject an effective immunizing
15 amount of a vaccine formulation incorporating an attenuated version of that virus as described hereinabove.

A sufficient amount of the vaccine in an appropriate number of doses must be administered to the
20 subject to elicit an immune response. Persons skilled in the art will readily be able to determine such amounts and dosages. Administration may be by any conventional effective form, such as intranasally, parenterally, orally, or topically applied to any
25 mucosal surface such as intranasal, oral, eye, vaginal or rectal surface, such as by an aerosol spray. The preferred means of administration is by intranasal administration.

In another embodiment of this invention, an isolated nucleic acid molecule having the complete viral nucleotide sequence of the wild-type viruses, the vaccine viruses or the revertant viruses described
30 herein is used to generate oligonucleotide probes (from either positive strand antigenomic message sense or
35

- 36 -

negative strand complementary genomic sense) and to express peptides (from positive strand antigenomic message sense only), which are used to detect the presence of those wild-type viruses, vaccine strains and/or revertant strains in samples of body fluids and tissues. The nucleotide sequences are used to design highly specific and sensitive diagnostic tests to detect the presence of the virus in a sample.

Polymerase chain reaction (PCR) primers are synthesized with sequences based on the viral wild-type, vaccine or revertant sequences described herein. The test sample is subjected to reverse transcription of RNA, followed by PCR amplification of selected cDNA regions corresponding to the nucleotide sequence described herein which have nucleotides which are distinct for a defined strain of virus. Amplified PCR products are identified on gels and their specificity confirmed by hybridization with specific nucleotide probes.

ELISA tests are used to detect the presence of antigens of the wild-type, vaccine or revertant viral strains. Peptides are designed and selected to contain one or more distinct residues based on the wild-type, vaccine or revertant sequences described herein. These peptides are then coupled to a hapten (e.g., keyhole limpet hemocyanin (KLH) and used to immunize animals (e.g., rabbits) for the production of monospecific polyclonal antibody. A selection of these polyclonal antibodies, or a combination of polyclonal and monoclonal antibodies can then be used in a "capture ELISA" to detect antigens produced by those viruses.

Samples of mutant RSV described herein have been deposited by Applicants' assignee on March 19, 1992 with the American Type Culture Collection (ATCC)

- 37 -

12301 Parklawn Drive, Rockville, Maryland, U.S.A.
20852, under the provisions of the Budapest Treaty for
the Deposit of Microorganisms for the Purposes of
Patent Procedures ("Budapest Treaty"). The viruses were
5 accorded the following ATCC designation numbers:
2Bp33F(VR 2364), 2Bp24G(VR 2370), 2Bp20L(VR 2368),
2Bp34L(VR 2365), 3Ap20E(VR 2369), 3Ap20F(VR 2367), and
3Ap28F(VR 2366). In addition, samples of the 2B wild-
type RSV virus were deposited by Applicants on August
10 21, 1997 with the American Type Culture Collection,
12301 Parklawn Drive, Rockville, Maryland 20852,
U.S.A., under the provisions of the Budapest Treaty and
have been assigned ATCC accession number VR2586.

Given these deposited subgroup B strains and
15 the sequence information for these and other strains
provided herein, one can use site-directed mutagenesis
and rescue techniques described above to introduce
mutations (or restore a wild-type genotype) of all the
subgroup B strains described herein, as well as taking
20 these strains and making additional mutations from the
panel of mutations set forth in Tables 21 and 22 below.

In order that this invention may be better
understood, the following examples are set forth. The
examples are for the purpose of illustration only and
25 are not to be construed as limiting the scope of the
invention.

Examples

30 Standard molecular biology techniques are
utilized according to the protocols described in
Sambrook et al. (76).

- 38 -

Example 1Passage and Characterization of RSV 2B
and RSV 3A Parental Strains

5 RSV 2B and RSV 3A parental strains were isolated and passed in qualified cell lines and under conditions consistent with use as clinical study material.

10 Two RSV strains, 20648 and 23095, were isolated by Dr. Robert Belshe (St. Louis University Health Science Center, St. Louis, MO) from nasal swab samples taken from ill children. These viruses were later recovered from the original frozen nasal swab samples, passed two to three times in primary rhesus
15 monkey kidney (PRMK) cells, and then sent to applicants.

Isolate 20648 (subgroup B) was renamed RSV 2B. Virus was passed seven times in PRMK cells at 35°C, two times in Vero cells at 35°C and plaque
20 purified and amplified three times (six passages) in Vero cells at 36°C. Virus was further amplified an additional two times in Vero (36°C), stocks were filtered with a 0.2 m filter and amplified another two times in Vero cells. This was followed by production
25 of a Master Seed (RSV 2B, MK7 V12b), Intermediate working seed (RSV 2B, MK7 V13b) and Working seed (RSV 2B, MK7 V14b). See Figure 1.

Isolate 23095 (subgroup A) was renamed RSV 3A. RSV 3A was passed eight times in PRMK cells at
30 35°C. This was followed by two passages in Vero at 35°C and six passages in Vero cells at 36°C, including three plaque purification steps. Virus was further passaged six times in Vero cells at 36°C including a 0.2 m filtration step. This was followed by production
35 of a Master seed (RSV 3A, MK8 V15b), Intermediate

- 39 -

working seed (RSV 3A, MK8 V16b), and Working seed (RSV 3A, MK8 V17b). See Figure 1.

Subgroup specificities of RSV 2B and RSV 3A Master seeds were confirmed using subgroup specific monoclonal antibodies. Virus stocks were shown to be free of microbial contaminants and adventitious agents.

The F, N, and G proteins of RSV 2B and RSV 3A stocks and reference RSV strains A2, Long, and 18537 were analyzed by radioimmunoprecipitation (RIP) and western blotting procedures using monoclonal antibodies. The F1 subunits of the RSV subgroup B strains, 2B and 18537, migrated faster on SDS-polyacrylamide gels than did the F1 subunits of the RSV subgroup A strains, 3A and Long. No difference in migration of the N proteins of the RSV 2B and 3A strains and the reference strains was seen. In RIP gels, the G protein was visible as two bands at approximately 80-90 kD and approximately 45 kD. The 80-90 kD bands of RSV 3A and Long comigrated; however, the 80-90 kD band of RSV 2B also appeared to comigrate with the subgroup A species rather than with the faster RSV 18537 (subgroup B1). This suggests that RSV 2B may be a member of the B2 subgroup as described by Akerlind (77). In western blots, the relative proportions of 80-90 kD and 45 kD bands were roughly equal for RSV Long, A2, 2B, and 18537 grown in Vero cells, but staining of the 80-90 kD band of RSV 3A was significantly greater, suggesting a difference in processing of the G protein for this strain when grown in Vero cells. These data demonstrate that the apparent M_r for the RSV 2B and RSV 3A strains are consistent with current subgroup classifications of RSV, but confirm that these strains are not identical to the prototype RSV reference strains.

Growth of RSV 2B, RSV 3A and RSV A2 in mice

- 40 -

and in cotton rats was compared. Both RSV 2B and RSV 3A replicated poorly in Balb/c mice compared to the RSV A2 reference strain. Consistent recovery of RSV 2B and RSV 3A could only be obtained at the highest inoculum dose used ($10^{6.0-6.2}$ PFU), and was similar in magnitude to recovery of RSV A2 at a 100-fold lower inoculum ($10^{4.3}$ PFU). In contrast, growth of RSV 2B in cotton rat nose and lungs was similar to growth of RSV A2. Growth of RSV 3A in the nose was similar to the other strains; however growth in lungs was significantly poorer. Both mouse and cotton rat growth data indicate that RSV 2B and RSV 3A have significantly different in vivo growth characteristics than the RSV A2 reference strain, as well as differing from each other.

Example 2

Cold Adaptation of RSV

In order to select an appropriate starting temperature for cold adaptation of RSV, growth of the RSV 2B and RSV 3A parental strains in Vero cells at temperatures ranging from 26°C to 36°C was compared. Cells were infected at an MOI of 0.4 and virus yield and CPE was monitored for four days. The results, shown in Figures 2 and 3, demonstrated that for both virus strains, growth at 30°C, 32°C, and 36°C was similar in kinetics and yield. At 26°C, virus growth lagged behind growth at the higher temperatures by about 24 hours. The limiting factor in achieving optimum titers appeared to be the viral CPE, which occurred earlier at higher temperatures. For both RSV 2B and RSV 3A, optimum titers were achieved by maintaining cultures at 30°C. At this temperature, a lower level of CPE allowed growth and spread of virus to continue over a longer time period. The results

- 41 -

suggested that these strains of RSV were already well adapted to growth at 30°C to 36°C. A maximum temperature of 26°C was selected as a starting temperature for cold adaptation, as virus growth at this temperature was suboptimal and therefore some selective pressure for cold adaptation would be exerted.

Cold adaptation was initiated on virus stocks RSV 2B (passage MK7 V14) and RSV 3A (passage MK8 V14). To maximize the chance of recovering appropriately attenuated mutants from these cold-adapted populations, two flasks of virus were independently passed using each of three different cold adaptation strategies. This provided a total of six cold-adapted populations for RSV 2B and six for RSV 3A. Virus was passaged in 25 cm² flasks containing confluent Vero cell monolayers. At each passage, virus was harvested by replacing the maintenance medium (10 mls of MEM/2%FBS/20mmHepes) in the infected flask with a reduced volume of freezing medium (3 mls of MEM/10%FBS/20mmHepes) and performing a quick freeze at -70°C followed by a thaw at 32°C. To infect the next passage, one ml of the freeze-thaw lysate was transferred to a fresh flask of confluent Vero cells, virus was allowed to adsorb at room temperature (20°C-22°C), and then flasks were overlaid with maintenance medium (MEM/2%FBS/20mmHepes) and incubated at the appropriate temperature in water baths (i.e., 26°C, 22°C, 20°C).

Titration were performed at 32°C on each freeze-thaw lysate and the remainder of the material was stored at -70°C for future isolation of virus variants. Three passaging strategies were used. Flasks E and F were "slowly" adapted, beginning at 26°C with four passages every two days, followed by passage once every week until titers appeared to be relatively

- 42 -

stable or were increasing. Virus was then passaged weekly at 22°C until consistently high titers were achieved, and finally maintained by passage every 1-2 weeks at 20°C. Flasks G, H, and I were adapted by a more moderate strategy. Virus was passaged two times at 26°C at three day intervals, then passaged weekly at 22°C five times, and finally maintained by passage every 1-2 weeks at 20°C. Flasks J and L were "rapidly" adapted, starting with five weekly passages at 22°C, followed by passage at 1-2 week intervals at 20°C. Actual passage conditions and titration results are shown in Tables 1 and 2, and are summarized in Table 3. Titration results obtained at each passage are graphically displayed in Figure 4. The titration results demonstrated an influence of strain on rate of adaptation. For RSV 2B, all three cold adaptation strategies eventually yielded high virus titers when flasks were maintained at 20°C. In contrast, RSV 3A was adapted to growth at 20°C using a "slow" strategy (E,F), but efforts to force a more rapid adaptation resulted in a precipitous decline in virus growth. Passage of these cultures (3A:H,I,J,L) was discontinued.

To screen the cold-adapted virus populations for accumulation of *ts* variants, virus taken from each flask following 5 and 17 weeks of cold adaptation was tested for efficiency of plaquing (EOP) at 39°C vs. 32°C. As seen in Table 4, in most cases plaquing efficiency of the cold passage virus was relatively high at 39°C (≥ 0.2) and was similar to values obtained with the parental virus control (≥ 0.6). The results showed that the cold-adapted virus populations, with the possible exception of flask RSV 3A-F, had not become predominantly *ts* over a period of up to 17 low temperature passages.

- 43 -

Following further cold passaging, attempts were made to isolate temperature sensitive mutants by plaque purifying virus from each cold-adapted flask. Plaque purified mutants were initially identified by
5 relatively poor growth (lower titers or smaller plaque size) at 39°C vs 32°C. In these assays, shown in Table 5, the percentage of plaque purified virus that could be clearly identified as temperature sensitive ranged from 0% to 40% of plaques picked. Several individual
10 flasks (2B-H, 2B-L, 3A-E, 3A-F) appeared to contain a relatively higher percent of *ts* phenotypes, and in some cases the percentage of *ts* mutants increased over time. However, *ts* mutants did not appear to become a predominant variant over a period of up to 42 weeks of
15 cold passaging.

To summarize, cold passaging of RSV 2B and RSV 3A resulted in cold adaptation of virus based on the ability of virus to grow stably at 20°C with consistently high yields. Analysis of EOP assays and
20 the rate of isolation of *ts* mutants indicated that although *ts* mutants did arise in the cold-adapted virus populations, they did not become a predominant species.

Example 3

Screening for Vaccine Candidates in In Vitro Studies

The *ts* mutants were further screened and selected for vaccine candidates based on degree of temperature sensitivity in vitro, attenuation in animal
30 models (including mice, cotton rats, and chimps), and retention of neutralizing epitopes.

Over a period of 39 weeks of cold adaptation, a total of 13 RSV 2B and six RSV 3A *ts* mutants were plaque purified a second time and further
35 characterized. Comparison of EOP's at 37/32°C,

- 44 -

39/32°C, and/or 40/32°C confirmed that these mutants had reduced plaquing efficiency at the higher temperatures and represented a range of temperature sensitivity (see Table 6).

5 Prior to completing the isolation of all 19 mutants described above, a group of four mutants, RSV 2Bp24G, RSV 2Bp20L, RSV 3Ap20E, and RSV 3Ap20F, were selected from the first set of plaque purified viruses for preliminary characterization. To look at actual
10 virus growth curves, Vero cells were infected with these four mutants at an MOI of 2, and incubated at 20°C, 32°C, 37°C, and 40°C for seven days. The results, shown in Figure 5, indicated that all four mutants were cold-adapted and temperature sensitive, as evidenced by
15 earlier and higher rises in titer in cultures incubated at 20°C, and reduced or absent growth of virus in cultures incubated at 37°C, 39°C, and 40°C. Based on the degree of temperature sensitivity seen in EOP and growth studies, one subgroup A and one subgroup B
20 mutant, RSV 2Bp20L and RSV 3Ap20E, were selected to perform additional preliminary experiments on phenotypic stability and growth in mice.

 The infectivity and immunogenicity of RSV 2Bp20L and RSV 3Ap20E were evaluated in Balb/c mice.
25 Virus growth was measured in nasal wash and lung samples harvested four and five days post-infection and serum neutralizing antibody titers were determined 32 days post-infection. Results are shown in Table 7. Growth and immunogenicity of the parental virus was
30 very low, but detectable. In contrast, no virus was recovered and no neutralizing antibody was detected following inoculation of the ts strains, indicating that these strains were highly attenuated in mice.

 Of the 19 ts mutants which were eventually
35 isolated, four RSV 2B and three RSV 3A mutants were

- 45 -

selected for further *in vitro* and *in vivo* characterization. These mutants included the original four mutants described above, as well as three mutants isolated at later time points. Selection criteria
5 included demonstration of definite *ts* phenotype at both 37°C and 39°C and representation of both subgroups and varying passage strategies and passage numbers. These seven *ts* mutants were plaque purified a third time and amplified to make small working stocks. Their passage
10 histories are summarized in Table 8. The initial analysis of these mutant strains included comparison of plaquing efficiencies and plaque morphologies at 32°C, 37°C, and 39°C in Vero cells (Table 9), and growth at 32°C, 37°C, 39°C, and 40°C in Vero cells (Table 10). At
15 37°C and 39°C, EOP was reduced and small and intermediate plaque sizes predominated, indicating that mutants were *ts*. Some breakthrough of "wt" plaque size revertants was seen with all variants except RSV 2Bp34L and RSV 3Ap20F.

20 In growth studies, Vero cells were infected with the virus strains at an MOI of 0.2 and virus yield was determined four days post-infection. Comparison of virus yields in Vero cells at the various temperatures demonstrated that virus yield, expressed as PFU per
25 cell, decreased significantly at the higher temperatures (37°C, 39°C, 40°C). In some cases, virus yield was also somewhat reduced at 32°C relative to the parental strain, indicating attenuation in growth at 32°C. This is consistent with the smaller plaque sizes
30 observed in the 32°C EOP assays (Table 9). For all strains, at least one plaque was detected in cells incubated at 39°C or 40°C, suggesting that some revertants were present. Both EOP and virus yield studies demonstrate that these seven isolates possess
35 varying levels of temperature sensitivity and may

- 46 -

represent a range of levels of attenuation.

Retention of neutralizing epitopes was examined by comparing reactivities of the seven mutants and parental strains with two neutralizing monoclonal antibodies representing antigenic sites A and C on the F protein described by 19-Beeler and Coelingh (1989) (Table 11). Both antibodies were able to neutralize all the virus strains at similarly high dilutions, indicating that the neutralizing epitopes were intact.

Example 4

Growth of Mutant Strains in Animal Models

Growth and immunogenicity of the seven *ts* mutant strains was evaluated in cotton rats. Groups of rats were inoculated intranasally with each mutant and lungs and nasal turbinates were harvested four days post-infection for virus titrations. Sera were collected from an identical set of rats 20 days post-infection to test for neutralizing and EIA antibody responses. A summary of virus titration and immunogenicity results are shown in Table 12. RSV 2B grew well in the nose and lungs, whereas growth of all four RSV 2B *ts* mutants was very poor. Two of the mutants, RSV 2Bp33F and RSV 2Bp24G, displayed a less attenuated phenotype than did RSV 2Bp20L and RSV 2Bp34L, as indicated by a slightly higher level of replication, as well as a 100% infection rate. The RSV 3A parental and *ts* mutant strains grew well in the nasal turbinates, but poorly in the lungs. Titers of the RSV 3A *ts* mutants were lower than that of the parental strain, indicating that the *ts* mutants were somewhat more attenuated than the parent virus. Neutralizing and EIA-F antibody titers on sera from rats infected with the RSV 2B and RSV 3A parental and *ts*

- 47 -

mutant strains were also measured. The level of neutralizing and EIA F antibody titer was low for the RSV 2B ts mutants, consistent with the low level of viral replication seen. Interestingly, titers from animals infected with RSV 2Bp33F were higher than would be expected in view of the low titration values, and may indicate an intermediate level of attenuation for this virus. Neutralizing and EIA-F antibody titrations on all 3 RSV 3A ts mutants demonstrated that these mutants were quite immunogenic, consistent with their high level of replication in nasal tissue.

Growth of RSV 2Bp20L was further evaluated in cotton rats from three to seven days post-infection to determine if failure to recover virus was due to a shift in timing of peak titers. RSV 2B was used as a positive control (see Figure 6). The growth kinetics of RSV 2B were typical of other strains of RSV; peak titers occurred on days 4 and 5 in nasal turbinates and on day 4 in lungs. These results substantiate the use of day 4 as the optimal harvest day for the parental strain. RSV 2Bp20L was not detected in lungs and rare plaques were seen in nasal turbinate titrations on days 3, 5, 6, and 7, demonstrating that attenuation of this virus was not simply due to an early or late growth peak.

Relative growth and immunogenicity of RSV 2B and RSV 2Bp20L were also compared in four year old seropositive chimps. Two chimps were infected intranasally with $10^{4.0}$ and $10^{5.0}$ PFU of RSV 2B, and two chimps were similarly infected with RSV 2Bp20L. The results are shown in Figure 7 and Table 13. Both chimps infected with RSV 2B developed a mild upper respiratory infection, consisting of nasal discharge and cough. Both chimps shed virus from three through seven days post-infection. The amount of virus shed

- 48 -

was higher and shedding occurred earlier in the chimp infected with the higher dose of RSV 2B. Neither chimp inoculated with RSV 2Bp20L showed clinical signs of disease or shed virus. Chemistry and hematology workups on all four chimps revealed no significant findings. Serum neutralizing and EIA-F, Ga, and Gb antibody titers were substantially increased 14 and 21 days post-infection with RSV 2B. No rises in antibody titers were seen in chimps inoculated with RSV 2Bp20L. The results indicated that, in seropositive chimps, the parental RSV 2B strain was infectious and immunogenic, whereas the RSV 2Bp20L mutant was highly attenuated.

15

Example 5

Challenge Experiments in Cotton Rat Model

Additional experiments were done in cotton rats to evaluate the efficacy of the RSV 2B and 3A ts mutants in preventing infection when challenged with a reference strain of the homologous subgroup (RSV 18537/subgroup B and RSV A2/subgroup A). Cotton rats (eight per group) were inoculated intranasally with each RSV ts mutant. Nasal turbinates and lungs were harvested four days post-infection, from four rats per group, for virus titrations. Six weeks post-infection, the remaining rats were bled for neutralizing and EIA-F titers, then challenged with the appropriate reference RSV strain. Four days post-challenge, nasal turbinates and lungs were removed for virus titration. Results are shown in Tables 14 and 15.

As discussed previously and shown in Table 12, growth of all four RSV 2B TS mutants was very poor compared to the parental RSV 2B strain. Neutralizing

35

- 49 -

and EIA antibody titers elicited by RSV 2Bp33F and RSV 2Bp24G were relatively high despite poor virus recovery, possibly indicating an intermediate level of attenuation for both mutants. Level of protection against virus challenge reflected the level of neutralizing antibody response and was high for RSV 2Bp33F and 2Bp24G, moderate for RSV 2Bp20L, and ineffective for RSV 2Bp34L. All RSV 3A strains grew in the nasal turbinates but demonstrated a high level of attenuation in growth in the lungs. Titers of neutralizing and EIA antibodies were high and all rats were completely protected against virus challenge.

The results demonstrate that growth of the attenuated strains elicited protective immunity against virus challenge, suggesting that these strains may be useful as vaccine. Failure of vaccination with the RSV 2Bp34L strain to protect was most likely due to failure of virus to grow due to its high level of attenuation. Since cotton rats are a less susceptible host than humans, failure of this strain to protect does not imply that 2Bp34L would be an ineffective vaccine in humans.

Example 6

Challenge Experiments in African Green Monkey Model

Growth, immunogenicity, and efficacy of ts mutant strains RSV 2Bp33F, 2Bp24G, 2Bp20L, 3Ap20E, 3Ap20F, and 3Ap28F were evaluated in African green monkeys (AGMs). AGMs are more susceptible to infection with human RSV than are the cotton rats, and characteristics of infection may be more relevant to that seen in humans because of the closer phylogenetic relationship. Two AGMs each were inoculated with 10^6 PFU of each mutant virus by combined intranasal and

- 50 -

intratracheal route. Virus growth was evaluated by nasal wash and bronchial lavage. Neutralizing and EIA antibody responses were tested at approximately 0, 1, 2, 3, 4, 6, and 8 weeks post-infection. Eight weeks post-infection, animals were challenged with 10^6 PFU of the parental strain by intranasal and intratracheal route. Virus growth and antibody response was evaluated as described above.

Growth of the parental RSV 2B and 3A strains can be seen in Figures 8 and 9: vaccine controls. Both virus strains grew to high titers in both the nose and lung. Nasal discharge and radiographic evidence of viral pneumonia was seen in one control monkey (032B) infected with RSV 2B, demonstrating that RSV is capable of causing disease in AGMs. These results confirm differences in these characteristics of infection in AGMs vs the cotton rat model, in which disease was not observed and RSV 3A was unable to replicate in the lung. Failure of the parental strains of RSV to cause disease in three of four monkeys suggests that the AGMs are not as susceptible a host as are humans.

Virus titrations for each monkey infected with the RSV 2B ts mutants and then challenged with the parental strain are shown in Figure 8. RSV 2Bp33F grew to low levels in the nasal wash in one of two monkeys, RSV 2Bp24G grew to low levels in nasal wash or in lungs in both monkeys. RSV 2Bp20L failed to grow. In those AGMs where the RSV 2B ts mutants grew, monkeys were partially to fully protected against challenge with parental strain. Tables 16 and 17 give antibody titration results obtained for each monkey post-vaccination (Table 16) and post-virus challenge (Table 17). Results show that in monkeys where virus grew, low levels of neutralizing and EIA antibody titers were seen by 2.5 weeks post-infection. Following challenge

- 51 -

with the parental strain, antibody titers boosted one full week earlier in vaccinated monkeys with antibody titers prior to challenge, than in vaccinated animals which failed to seroconvert or in unvaccinated controls. This demonstrated that vaccination with these ts mutants was sufficient to both prime the immune system and to elicit protection against virus challenge. Because these monkeys are not as susceptible to infection as humans, failure of attenuated virus to grow and to effectively immunize does not imply that virus would not be effective in a fully susceptible host (i.e. seronegative human infant).

Virus growth in AGMs infected with the RSV 3A ts mutants and challenged with the parental 3A strain are shown in Figure 9. All three RSV 3A ts mutant strains were attenuated in growth, in the order of most to least attenuated: 3Ap28F>3Ap20E>3Ap20F. Vaccination with all three ts mutants afforded excellent protection against virus challenge. Antibody response for monkeys vaccinated with RSV 3A ts mutants is shown in Table 18, and response following virus challenge is shown in Table 19. In all vaccinated AGMs, with the exception of one monkey given RSV 3Ap28F, low levels of neutralizing and EIA antibody titers were detected beginning three weeks post-vaccination. Following challenge with the parental strain, all vaccinated monkeys boosted a full week earlier than the unvaccinated controls and were protected either fully or partially from infection, demonstrating that vaccination primed the immune response and was protective. This included the one AGM in which antibody response was not detected following vaccination, indicating that measure of serum antibody response may not be fully representative of level of

- 52 -

protective immunity.

The results from the AGM studies again demonstrate that all six *ts* mutants tested were attenuated. Vaccination with those mutants which were able to replicate in these monkeys was efficacious in preventing infection with challenge virus.

Example 7

Degree of Attenuation

An RSV *ts* mutant, TS-1, was obtained from Dr. Brian Murphy, NIH. This *ts* mutant was originally derived from the RSV A2 strain by chemical mutagenesis and was tested in clinical trials in seronegative human infants in the 1970's. The outcome of these trials suggested that TS-1 was underattenuated and caused an unacceptable level of disease (rhinitis and otitis media) in infants. In addition, the *ts* phenotype of TS-1 partially reverted following growth in humans. Experiments have been carried out which compare growth of the RSV 2B and 3A *ts* mutants with that of the TS-1 mutant in an attempt to assess the relative *in vivo* attenuation level of the RSV 2A and 3B mutants, and to demonstrate differences between these mutants and what had been used by others in previous clinical trials. The results of the cotton rat study are shown in Table 20, and may be compared directly with the cotton rat data shown in Tables 14 and 15. The TS-1 mutant was less attenuated than the RSV 2B and 3A *ts* mutants, as can most clearly be seen by comparing growth in the lung.

A growth study in African green monkeys (AGMs) comparing TS-1 with RSV 2Bp33F and 3Ap28F was carried out and the results are shown in Figure 10. Monkeys were infected with virus either intranasally

- 53 -

(TS-1 and 2Bp33F) or intranasally plus intratracheally (3Ap28F). Virus was recovered in one of four monkeys infected with 2Bp33F and two of four monkeys infected with 3Ap28F. Titers were relatively low in both cases, indicating that virus was attenuated. In contrast, relatively high titers of virus were recovered in all four monkeys inoculated with TS-1. In two of four monkeys, the levels of TS-1 titers were equivalent to those seen in monkeys infected with wild type virus. TS-1 did not spread to the lungs, as would be expected for wild type virus, indicating that TS-1 was somewhat attenuated. The results clearly show that RSV 2Bp33F and 3Ap28F have different phenotypic characteristics than TS-1 and are significantly more attenuated. This higher level of attenuation is a property that is desirable for a vaccine to be administered to human infants.

Example 8

Sequence Analyses of RSV Subgroup B Strains

The temperature-sensitive (*ts*) phenotype is strongly associated with attenuation *in vivo*; in addition, some non-*ts* mutations may also be attenuating. Identification of *ts* and non-*ts* attenuating mutations was achieved by sequence analysis and evaluation of *ts*, cold-adapted (*ca*), and *in vivo* growth phenotypes of RSV mutants and revertants.

The genomes of the following five RSV 2B strains have now been completely sequenced: 2B parent, 2B33F, one revertant designated 2B33F TS(+), 2B20L and one revertant designated 2B20L TS(+). The 2B33F and 2B20L strains are *ts* and *ca* and are described in U.S. Serial No. 08/059,444 (78), which is hereby incorporated by reference. After identifying regions

- 54 -

where mutations in 2B33F and 2B20L are located, nine additional isolates of 2B33F "revertants" obtained following in vitro passaging at 39°C and in vivo passaging in African Green Monkeys or chimpanzees, and
5 nine additional isolates of 2B20L "revertants" obtained following in vitro passaging at 39°C have been sequenced in those regions. The *ts*, *ca*, and attenuation phenotypes of many of these revertants have now been characterized and assessed. Correlations
10 between phenotype *ts*, vaccine attenuation and sequence changes have been identified.

A summary of results is presented in Tables 21-26.

15 Several significant observations can be drawn from these data:

a. As shown in Tables 21 (for 2B33F) and 22 (for 2B20L), there are relatively few sequence changes identified in the two mutant strains: RSV 2B33F
20 differs from parental RSV 2B by two changes at the 3' genomic promoter region, two changes at the non-coding 5'-end of the M gene, and four coding changes plus one non-coding (poly(A) motif) change in the RNA dependent RNA polymerase coding L gene. In addition, 14 changes
25 mapped to the SH gene alone. RSV 2B20L differs from its RSV 2B parent only at seven nucleotide positions, of which three are common with 2B33F virus, including two changes at the 3' genomic promoter and one coding change in the L gene. Two additional unique changes of
30 2B20L virus mapped to the coding region of the L gene. Potentially attenuating mutations at the RNA dependent RNA polymerase gene have been identified.

b. Two *ts* mutations can be identified in the L
35 gene of the attenuated virus strains 2B33F and 2B20L:

- 55 -

(i) In 2B33F, a mutation at nucleotide position 9853 (A → G) leading to a coding change in L protein at amino acid 451 (Lys → Arg) is clearly associated with the *ts* and attenuation phenotypes. Reversion at this site alone in the 2B33F TS(+) 5a strain is responsible for complete restoration of growth at 39°C (Table 23) and partial reversion in attenuation in animals. This association of *ts* was also supported by partial sequence analyses of six additional "full *ts* revertants" (designated 4a, 3b, pp2, 3A, 5a, 5A) isolated from cell culture and from chimps, in which only the nucleotide 9853 mutation reverted (Tables 24-26) (note that one AGM (African Green Monkey) isolate which reverted at 9853 only partially reverted in *ts* phenotype). This amino acid 451 mutation (Lys → Arg) is amenable to stabilization in cDNA infectious clone constructs, by inserting a second mutation to stabilize the codon, thereby lessening the likelihood that it will revert back to Lys.

(ii) In 2B20L, a mutation at base 14,649 (A → G) leading to a coding change in the L protein (amino acid position 2,050, Asn → Asp) appears to be associated with the *ts* and attenuation phenotypes. This aspartic acid at the amino acid 2050 invariably reverts back (Asp → Asn) in TS(+) revertants or changes to a different amino acid (Asp → Val) by nucleotide substitution at position 14,650 (A → T) (Tables 22, 25). The above observation is based on complete sequence analysis on the TS(+) revertant R1 and partial sequence of several additional TS(+) revertants (R2, R4A, R7A, R8A) at selected regions (Table 25). An

- 56 -

additional mutation is seen in the R1 revertant at nucleotide position 13,347 (amino acid 1616, Asn → Asp) associated with the above reversion. However, the effect of this mutation on the ts phenotype is not known; the L gene of other revertants has not been sequenced completely.

c. Three base changes are common to 2B33F and 2B20L strains of virus:

(i) A change at position 14,587 (C → T) with a corresponding change (Thr → Ile) at amino acid 2029 is present in both 2B33F and 2B20L (Tables 21,22). This nucleotide "T" substitution was found to be present in 10% of the population of the progenitor RSV2B strain and may have been preferred during the attenuation process. No wildtype base "C" was found in the 2B33F and 2B20L virus.

(ii) Two mutations are seen in the 2B33F and 2B20L 3' genomic promoter region: nucleotide 4 (C → G) and the insertion of an extra A in the stretch of A's at positions 6-11 (in antigenomic, message sense). When the sequences of selected TS(+) revertants were analyzed, these mutations were seen to have been retained in the 2B33F TS(+)5a (Table 21) and the 2B20L TS(+)R1 (Table 22) revertants. These non-coding, cis-acting mutations remained associated with partial viral attenuation.

Expression using the minireplicon RSV-CAT system for the analysis of these cis-acting changes has shown the 3' genomic promoter nucleotide 4 (C → G) change to be an upregulation of transcription/replication in this in vitro system when

- 57 -

the 2B progenitor virus or either of the 2B33F or 2B33F TS(+) provided helper L gene functions (the N, P and M2 genes are identical in these viruses).

5 Complementation analysis of the 2B33F 3' genomic promoter and the helper functions provided by the progenitor RSV2B virus or the 2B33F and 2B33F TS(+) viruses by this RSV-CAT minireplicon system has also been conducted. All three viruses supported both the 2B and 2B33F 3' genomic promoter mediated
10 transcription/replication functions. However, the 2B33F and 2B33F TS(+) viruses preferred their 2B33F 3' genomic promoters. This analysis clearly shows co-evolution of 3' genomic promoter changes during the vaccine attenuation process, along with the RNA
15 dependent RNA polymerase gene. Reversion of *ts* phenotype in the 2B33F mutant 5a by reversion of the single L protein amino acid 451 (Arg → Lys) by sequence analysis was clearly demonstrated by support of transcription/replication functions of RSV-CAT
20 minireplicon at 37°C. The 2B33F virus did not provide helper functions to the RSV-CAT minireplicon (with 2B or 2B33F 3' genomic promoters) at 37°C.

d. A biased hypermutation of SH seen in 2B33F is
25 present in all 2B33F revertants, regardless of phenotype, and is not seen in 2B20L, which is *ts*, *ca*, and attenuated. Thus, there are no data at this time that associate this mutation with any biological phenotype.

30 Another wild-type RSV designated 18537 was also sequenced and compared to the sequence of the wild-type RSV 2B strain. With one exception, at all the critical residues described above, the two wild-type strains were identical. For 2B, the codon ACA at
35 nucleotides 14586-14588 encodes a Thr at amino acid

- 58 -

2029 of the L protein, while for 18537, the codon ATT at nucleotides 14593-14595 encodes an Ile at amino acid 2029 (the L gene start codon is at nucleotides 8509-8511 in 18537, compared to 8502-8504 in 2B).

5

Example 9PCR Assay to Detect RSV

10 A PCR assay is used to detect the presence of RSV. PCR primers are designed and selected based on homologies to the RSV sequences described herein to be specific for all subgroup B strains, or for the individual wild-type, vaccine or revertant RSV subgroup B strains described herein. The assay is conducted by
15 subjecting the sample to reverse transcription of RNA, followed by PCR amplification of selected cDNA regions corresponding to RSV nucleotide sequence. Amplified PCR products are identified on gels and their specificity confirmed by hybridization with specific
20 RSV nucleotide probes.

Example 10ELISA to Detect RSV

25 An ELISA test is used to detect the presence of RSV. Peptides are designed and selected based on homologies to the RSV sequences described herein to be specific for all subgroup B strains, or for individual wild-type, vaccine or revertant RSV subgroup B strains
30 described herein. These peptides are then coupled to KLH and used to immunize rabbits for the production of monospecific polyclonal antibody. A selection of these polyclonal antibodies, or a combination of polyclonal and monoclonal antibodies is then used in a "capture
35 ELISA" to detect the presence of an RSV antigen.

- 59 -

Table 1
RSV 2B Cold Adaptation

E, F					
Passage #	Cumm. Time Passage Weeks	Incubation		Virus Yield	
		Temp °C	Time Days	log ₁₀ PFU	
				E	F
1	0.2	26	2	6.9	6.7
2	0.4	26	2	6.0	6.1
3	0.6	26	2	5.5	5.6
4	0.8	26	2	4.5	4.7
5	1.0	26	7	4.9	5.0
6	2.0	26	7	6.2	6.3
7	3.0	26	7	7.9*	7.6*
8	4.0	22	7	7.5	7.6
9	5.0	22	7	7.3	7.3
10	6.0	22	7	7.2*	7.2*
11	7.0	22	7	7.5*	7.7*
12	8.0	22	7	8.0*	7.9*
13	9.0	22	7	8.0*	7.9*
14	10.0	20	7	7.6	7.7
15	11.0	20	7	7.0	5.9
16	12.0	20	7	7.2	7.1
17	13.0	20	7	6.7	6.3
18	15.0	20	14	5.5	5.2
19	17.0	20	14	6.3	6.0
20	18.0	20	7	6.1	5.8
21	19.0	20	7	5.4	5.7
22	20.0	20	7	5.9	5.7
23	21.0	20	7	6.3	5.5
24	22.0	20	7	6.9	6.3
25	23.0	20	7	6.8	6.6
26	24.0	20	8	6.6	6.2
27	25.0	20	7	6.3	6.0
28	26.0	20	6	6.5	6.2
29	27.0	20	7	6.2	6.3
30	28.0	20	7	7.0	7.2
31	29.0	20	7	7.3	7.1
32	30.0	20	7	6.8	6.5
33	31.0	20	7	6.9	6.7
34	32.0	20	7	6.9	7.0
35	33.0	20	7	7.4	7.0
36	34.0	20	7	7.2	7.1
37	35.0	20	7	7.4	7.0
38	36.0	20	7	7.4	7.1
39	37.0	20	7	7.5	7.0
40	38.0	20	7	7.2	6.7

*Syncytial CPE seen at harvest

SUBSTITUTE SHEET (RULE 26)

- 60 -

Table 1b
RSV 2B Cold Adaptation

Passage #	Cumm. Time Passage Weeks	G,H		Virus Yield	
		Incubation		\log_{10} PFU	
		Temp °C	Time Days	G	H
1	0.3	26	3	7.1	7.1
2	0.7	26	3	6.9	6.9
3	1.0	22	7	6.4	6.4
4	2.0	22	7	6.4	6.3
5	3.0	22	7	6.6	6.4
6	4.0	22	7	6.9	6.8
7	5.0	20	7	6.9	6.7
8	6.0	20	7	6.3	6.3
9	7.0	20	7	6.2	6.3
10	8.0	20	7	6.6	6.9
11	9.0	20	7	7.0	7.0
12	10.0	20	7	7.0	7.4
13	11.0	20	7	6.3	7.3
14	12.0	20	7	7.7	7.9
15	13.0	20	7	7.2	7.4
16	15.0	20	14	6.4	6.3
17	16.0	20	8	6.8	6.9
18	17.0	20	6	6.9	7.0
19	18.0	20	7	6.9	7.1
20	19.0	20	7	6.7	7.0
21	20.0	20	7	6.4	6.8
22	21.0	20	7	6.5	7.0
23	22.0	20	7	6.9	7.1
24	23.0	20	7	6.8	6.7
25	24.0	20	8	6.4	6.2
26	25.0	20	7	6.0	5.5
27	26.0	20	6	6.3	5.5
28	27.0	20	7	6.5	5.9
29	28.0	20	7	7.1	6.4
30	29.0	20	7	6.1	7.1
31	30.0	20	7	6.4	5.5
32	31.0	20	7	6.2	5.9
33	32.0	20	7	6.4	6.2
34	33.0	20	7	6.4	6.9
35	34.0	20	7	6.9	6.5
36	35.0	20	7	7.0	6.7
38	37.0	20	7	7.1	7.2

- 61 -

Table 1c
RSV 2B Cold Adaptation

Passage #	Cumm. Time Passage Weeks	J, L		Virus Yield	
		Incubation		log ₁₀ PFU	
		Temp °C	Time Days	J	L
1	1.0	22	7	6.8	
2	2.0	22	7	7.1	
3	3.0	22	7	6.7	
4	4.0	22	7	5.9	6.1
5	5.0	22	7	4.8	5.7
6	6.0	20	7	4.9	5.0
7	7.0	20	7	4.8	4.9
8	9.0	20	14	6.0	6.0
9	11.0	20	14	6.6	6.3
10	12.0	20	7	6.9	6.9
11	13.0	20	7	6.6	6.7
12	15.0	20	14	6.0	6.0
13	16.0	20	8	6.3	6.2
14	17.0	20	6	6.2	6.5
15	18.0	20	7	6.6	6.7
16	19.0	20	7	6.4	6.9
17	20.0	20	7	6.5	6.9
18	21.0	20	7	6.9	7.0
19	22.0	20	7	7.4	7.4
20	23.0	20	7	7.2	7.4
21	24.0	20	8	7.0	7.1
22	25.0	20	7	6.8	6.9
23	26.0	20	6	6.9	7.0
24	27.0	20	7	7.0	7.0
25	28.0	20	7	7.8	7.4
26	29.0	20	7	7.5	7.3
27	30.0	20	7	6.8	6.7
28	31.0	20	7	6.9	6.8
29	32.0	20	7	7.0	6.9
30	33.0	20	7	7.4	7.2
31	34.0	20	7	7.3	6.7
32	35.0	20	7	7.3	6.9
33	36.0	20	7	7.3	7.0
34	37.0	20	7	7.2	6.9
35	38.0	20	7	6.6	6.3

- 62 -

Table 2a
RSV 3A Cold Adaptation

E				
	Cumm. Time	Incubation		Virus Yield
Passage	Passage	Temp	Time	\log_{10} PFU
#	Weeks	°C	Days	E
1	0.2	26	2	6.2
2	0.4	26	2	5.1
3	0.6	26	2	4.7
4	0.8	26	2	3.8
5	1.0	26	7	4.0
6	2.0	26	7	5.0
7	3.0	26	7	6.1
8	4.0	22	7	6.0
9	5.0	22	7	5.6
10	6.0	22	7	5.8
11	7.0	22	7	5.7
12	8.0	22	7	5.9
13	9.0	22	7	5.9
14	11.0	20	14	5.8
15	13.0	20	14	6.1
16	15.0	20	14	4.8
17	17.0	20	14	4.9
18	19.0	20	14	4.8
19	20.0	20	7	4.3
20	22.0	20	14	4.9
21	24.0	20	14	5.2
22	26.0	20	15	5.6
23	28.0	20	13	6.3
24	30.0	20	14	6.3
25	32.0	20	14	7.3
26	34.0	20	14	7.8
27	36.0	20	14	7.2
28	38.0	20	14	7.4
29	40.0	20	14	6.8
30	42.0	20	14	7.3

- 63 -

Table 2b
RSV 3A Cold Adaptation

F				
	Cumm. Time	Incubation		Virus Yield
Passage	Passage	Temp	Time	\log_{10} PFU
#	Weeks	°C	Days	F
1	0.2	26	2	6.1
2	0.4	26	2	5.1
3	0.6	26	2	4.7
4	0.8	26	2	3.6
5	1.0	26	7	4.3
6	2.0	26	7	5.3
7	3.0	26	7	6.4
8	4.0	22	7	6.3
9	5.0	22	7	5.2
10	6.0	22	7	5.8
11	7.0	22	7	5.7
12	8.0	22	7	6.0
13	9.0	22	7	5.6
14	11.0	20	14	5.5
15	13.0	20	14	5.4
16	15.0	20	14	3.9
17	17.0	20	14	3.7
18	19.0	20	14	3.5
19	21.0	20	14	3.8
20	23.0	20	14	4.2
21	25.0	20	15	3.2
22	27.0	20	13	3.9
23	29.0	20	14	4.5
24	31.0	20	14	4.7
25	33.0	20	14	4.8
26	35.0	20	14	5.3
27	37.0	20	14	5.5
28	39.0	20	14	5.8

- 64 -

Table 2c
RSV 3A Cold Adaptation

<u>Passage</u> <u>#</u>	<u>Cumm. Time</u> <u>Passage</u> <u>Weeks</u>	<u>H, I</u>		<u>Virus Yield</u>	
		<u>Incubation</u>		<u>log₁₀PFU</u>	
		<u>Temp</u> <u>°C</u>	<u>Time</u> <u>Days</u>	<u>H</u>	<u>I</u>
1	0.3	26	3	6.9	7.0
2	0.7	26	3	6.1	6.4
3	1.0	22	7	5.8	5.8
4	2.0	22	7	5.8	5.9
5	3.0	22	7	5.9	5.7
6	4.0	22	7	5.6	5.5
7	5.0	22	7	5.1	5.1
8	6.0	20	7	4.0	3.8
9	7.0	20	7	3.3	2.8
10	9.0	20	14	3.9	3.2
11	11.0	20	14	3.9	3.1
12	13.0	20	14	4.0	3.0

<u>Passage</u> <u>#</u>	<u>Cumm. Time</u> <u>Passage</u> <u>Weeks</u>	<u>J, L</u>		<u>Virus Yield</u>	
		<u>Incubation</u>		<u>log₁₀PFU</u>	
		<u>Temp</u> <u>°C</u>	<u>Time</u> <u>Days</u>	<u>J</u>	<u>L</u>
1	1.0	22	7	6.7	
2	2.0	22	7	6.7	
3	3.0	22	7	6.0	
4	4.0	22	7	5.7	5.6
5	5.0	22	7	4.2	4.9
6	6.0	20	7	3.7	3.7
7	7.0	20	7	3.1	3.0
8	9.0	20	14	2.8	3.2
9	11.0	20	14	2.3	3.3
10	13.0	20	14	3.0	2.8

- 65 -

Table 3
Summary of Cold Adaptation Passage History

	#Parental Virus Passage				# Cold Adaptation Passage				
	<u>PRMK</u>	<u>Vero</u>				<u>Vero</u>			
<u>Virus</u>	<u>35°C</u>	<u>35°C</u>	<u>36°C</u>	<u>Total</u>	<u>Flask</u>	<u>26°C</u>	<u>22°C</u>	<u>20°C</u>	<u>Total</u>
2B	7	2	12	21	E,F	7	6	27	40
					G,H	2	5	32	39
					J,L	0	5	30	35
3A	8	2	12	22	E	7	6	17	30
					F	7	6	15	28
					H,I	2	5	5	12
					J,L	0	5	5	10

- 66 -

Table 4
Efficiency of Plaquing of Cold Passaged Virus

<u>Virus</u>	<u>Week 5</u>	<u>Week 17</u>
2B	0.8	0.6
2B-E	0.6	0.6
2B-F	0.8	0.7
2B-G	0.6	0.8
2B-H	0.7	0.4
2B-J	ND	0.9
2B-L	0.7	0.6
3A	0.6	0.6
3A-E	0.6	0.4
3A-F	0.8	0.2
3A-H	0.6	ND
3A-I	0.9	ND
3A-J	0.6	ND
3A-L	0.6	ND

- 67 -

Table 5

TS Mutants Plaque Purified from Cold Adapted Virus

#TS/#Total		#TS/#Total		
Cumm./Passage	Plaques	Cumm./Passage	Plaques	
<u>Weeks</u>	<u>#</u>	<u>Weeks</u>	<u>#</u>	
	<u>Isolated</u>		<u>Isolated</u>	
	<u>E</u>	<u>F</u>	<u>E</u>	
wk23/p25	0/10	1/10	wk22/p20	2/10
wk31/p33	0/10	1/10	wk32/p25	1/10
wk38/p40	0/10	1/10	wk42/p30	3/9
	<u>G</u>	<u>H</u>	<u>F</u>	
wk23/p24	1/10	2/10	wk23/p20	1/9
wk31/p32	0/10	2/10	wk31/p24	0/10
wk38/p39	1/10	4/10	wk37/P27	1/10
	<u>J</u>	<u>L</u>	wk39/p28	2/5
wk23/p20	0/9	1/10		
wk31/p28	0/10	0/10		
wk37/p34	0/8	2/9		
wk38/p35	1/20	3/8		

- 68 -

Table 6

Summary of EOP Data on Twice
Plaque Purified RSV TS Mutants

<u>RSV Isolate</u>	<u>EOP</u>		
	<u>37/32°C</u>	<u>39/32°C</u>	<u>40/32°C</u>
2B (parent)	0.7-1.0	0.6-0.8	0.4
2Bp33F (pp10-1)	0.5	0.002	ND
2Bp40F (pp7-2)		0.0008	ND
2Bp24G (pp2-1)	0.2	0.00001	<0.00001
2Bp39G (pp7-3)	1.0	0.009	ND
2Bp24H (pp3-2)	ND	0.003	0.001
2Bp32H (pp6-2)	0.9	0.03	ND
2Bp39H (pp6-5)	1.0	0.04	ND
2Bp35J (pp2-1)	0.4	0.2	ND
2Bp20L (pp5-1)	0.02	ND	<0.00001
2Bp34L (pp2-2)	0.005	0.0005	ND
2Bp35L (pp1-1)	0.3	0.02	ND
2Bp35L (pp2-1)	0.5	0.1	ND
2Bp35L (pp8-3)	0.2	0.05	ND

<u>RSV Isolate</u>	<u>EOP</u>		
	<u>37/32°C</u>	<u>39/32°C</u>	<u>40/32°C</u>
3B (parent)	1.0	0.5-0.9	0.6
3Ap20E (pp3-1)	0.6	0.006	0.000009
3Ap25E (pp7-5)	0.5	0.2	ND
3Ap30E (pp3-1)	0.4	0.08	
3Ap20F (pp4-3)	0.8	>0.1	0.000004
3Ap27F (pp1-2)	0.3	0.003	ND
3Ap28F (pp10-1)	0.2	0.002	ND

ND = Not Done

Table 7
RSV Infection of BALB/c Mice: Attenuation and Immunogenicity

Virus Strain	Dose \log_{10} PFU	Infection Rate	Nasal Wash		Lung Tissue		Antibody Titers*		
			\log_{10} PFU/ml	day 4	\log_{10} PFU/g	day 4	2B	3A	A2
2B (parental) 2B-CAP20L	6.2	8/8+	2.0	1.9	2.8	2.0*	17	21	<8
	6.3	0/8	N.P.	N.P.	N.P.	N.P.	<8	<8	<8
3A (parental) 3A-Cap-20E	6.0	8/8	1.4	0.5*	2.3*	2.6	19	57	11
	6.5	0/8	N.P.	N.P.	N.P.	N.P.	<8	<8	<8
Vero	---	0/8	N.P.	N.P.	N.P.	N.P.	<8	<8	<8

N.P. = No plaques

* = Values are below optimal detection limits of assay based on a minimum of 1 plaque per well.

+ = Sera was taken 32 days post-infection.

Neutralization results are expressed as the reciprocal of the dilution giving 60% plaque reduction neutralization, again RSV 2B, 3A, and A2

F = Infection rate = # of mice positive for RSV/Total # of mice inoculated.

- 70 -

Table 8
Summary of RSV TS Mutant Passage History

Virus	# Vero Passage									
	Adaptation and Plaque Purification (x3)				Cold Adaptation			Plaque Purification (x3) + expansion		
	PRMK 35°C	35°C	36°C	(parental virus)	26°C	22°C	20°C	32°C		
2Bp33F pp10-1-2	7	2	12	12	7	6	20	6		
2Bp24G pp2-1-1	7	2	12	12	2	5	17	5		
2Bp20L pp5-1-1	7	2	12	12	-	5	15	5		
2Bp34L pp2-2-2	7	2	12	12	-	5	29	5		
3Ap20E pp3-1-1	8	2	12	12	7	6	7	5		
3Ap20F pp4-3-1	8	2	12	12	7	6	7	5		
3Ap28F pp10-1-2	8	2	12	12	7	6	15	5		

- 71 -

Table 9
EOP and Plaque Morphology of RSV 2B and RSV 3A TS Mutants in Vero Cells

<u>VIRUS</u>	<u>TEMPERATURE</u> (°C)	<u>EOP</u>	<u>PLAQUE MORPHOLOGY</u> <u>OBSERVATIONS</u>
2B	32°	1.0	99% WT
	37°	0.9	H, Most WT
	39°	0.6	99% WT
2Bp33F	32°	1.0	1/3 SP, I, WT
pp10-1-2, V+3	37°	0.01	Mostly SP, F
	39°	0.00005	95% SP, D, Few WT
2BP24G	32°	1.0	1/3 SP, I, WT
pp2-1-1, V+3	37°	0.09	H, SP and I
	39°	0.004	1/3 SP, I, WT
2Bp20L	32°	1.0	H, 1/3 WT
pp5-1-1, V+4	37°	0.01	1/3, SP, I, WT
0.0002	39°	0.0002	1/3 SP, I, WT
2Bp34L	32°	1.0	H, Mostly I
pp2-2-2, V+3	37°	0.002	Mostly SP, F
	39°	0.0001	Very SP, No WT

Table 9 (continued)
EOP and Plaque Morphology of RSV 2B and RSV 3A TS Mutants in Vero Cells

<u>VIRUS</u>	<u>TEMPERATURE</u> (°C)	<u>EOP</u>	<u>PLAQUE MORPHOLOGY</u> <u>OBSERVATIONS</u>
3A	32°	1.0	99% WT
	37°	0.9	Mostly WT
	39°	0.5	Mostly WT
3Ap20E	32°	1.0	Mostly I
pp3-1-1, V+4	37°	0.8	Mostly I, 1/3 SP
	39°	0.04	95% SP, I, F, Few WT
3Ap20F	32°	1.0	Mostly I and WT
pp4-3-1, V+3	37°	0.7	Mostly I and WT
	39°	0.1	Mostly SP, I, No WT
3Ap28F	32°	1.0	Mostly SP and I
pp10-1-2, V+3	37°	0.4	Mostly I, F, Few WT
	39°	0.01	90% SP, I, F, Few WT

Abbreviations: SP Small Plaque
I Intermediate
WT Wild Type
D Dark Stained
F Faint Stained
H Heterogeneous

- 73 -

Table 10
Temperature-Related Growth of RSV 2B and 3A strains
in Vero Cells: Four Day Virus Yields

Virus	Virus Yield			
	PFU/Cell 32°C	37°C	39°C	40°C
2B	0.8	0.6	0.4	0.1
2BP33F pp10-1-2, V+3	0.5	0.01	≤0.00008	<0.000005
2BP24G pp2-1-1, V+3	1.0	0.08	0.0003	0.00001
2BP20L pp5-1-1, V+4	0.5	0.01	0.00003	0.000007
2BP34L pp2-2-2, V+3	0.008	<0.000005	<0.000005	≤0.000007
3A	1.6	0.3	0.08	0.05
3Ap20E pp3-1-1, V+4	0.2	0.02	≤0.000006	<0.000006
3Ap20F pp4-3-1, V+3	0.5	0.05	0.00005	<0.000006
3Ap28F pp10-1-2, V+3	0.2	0.006	≤0.000006	<0.000006

SUBSTITUTE SHEET (RULE 26)

- 74 -

Table 11
Monoclonal Antibody Neutralization of
RSV 2B and RSV 3A Parental and TS Mutants

<u>Challenge Strains</u>	<u>Neutralization Titers</u>	
	<u>143-6C</u>	<u>133-1H</u>
2B	15,091	46,775
2Bp33F	23,364	32,690
2Bp24G	>25,600	32,571
2Bp20L	25,972	32,790
2Bp34L	16,757	77,172
3A	99,814	46,493
3Ap20E	76,203	>25,600
3Ap20F	69,513	13,743
3Ap28F	80,436	34,136

Neutralizations were done by a standard 60% plaque reduction neutralization assay on Vero cell monolayers in 96-well microtiter plates. Challenge with a 1:400 dilution of non-neutralizing monoclonal antibody 131-2G showed no reduction in titer in any of the nine strains.

Table 12
RSV TS Mutant Infection of Cotton Rats - 4 Days Post-Infection

Virus Strain	Dose Log ₁₀ PFU	Infection Rate	Log ₁₀ Nasal	GMT+ PFU/gm Lung	Sero(+) Rate	Challenge Virus			EIA-F	EIA-Ga	EIA-Gb
						RSV 28	RSV A2	RSV 3A			
2B	6.5	4/4	5.48 (0.19)	5.00 (0.42)	4/4	2.80 (0.36)	2.26 (.052)	3.42 (0.40)	3.43 (0.14)	≤1.95 (0.30)	3.23 (0.13)
2Bp33F	7.3	4/4	1.88 (.028)	<1.30 (0.12)	4/4	2.24 (0.22)	1.86 (0.48)	2.95 (0.25)	2.76 (0.26)	<1.70	2.33 (0.25)
2Bp24G	6.9	4/4	1.73 (0.33)	≤1.30 (0.08)	4/4	1.58 (0.23)	≤1.05 (0.05)	2.33 (0.24)	2.62 (0.34)	≤1.71 (0.01)	2.10 (0.32)
2Bp20L	7.0	0/4	<1.92 (0.11)	<1.30 (0.12)	2/3	≤1.26 (0.24)	≤1.01 (0.02)	≤1.25 (0.31)	≤2.05 (0.32)	<1.70	<1.70
2Bp34L	5.6	1/4	≤1.73 (0.05)	<1.33 (0.10)	1/3	≤1.03 (0.06)	<1.00	≤1.08 (0.08)	<1.70	<1.70	<1.70
3A	6.3	4/4	5.70 (0.23)	2.00 (0.42)	4/4	2.31 (0.13)	2.28 (0.28)	3.12 (0.31)	3.55 (0.18)	2.28 (0.29)	≤1.93 (0.46)
3Ap20E	6.5	4/4	4.97 (0.22)	≤1.40 (0.22)	4/4	2.09 (0.05)	1.74 (0.09)	2.59 (0.16)	3.40 (0.18)	2.61 (0.58)	2.18 (0.32)
3Ap20F	6.7	4/4	4.95 (0.13)	≤1.70 (0.29)	4/4	2.40 (0.41)	2.59 (0.26)	3.32 (0.39)	3.62 (0.12)	2.88 (0.33)	2.57 (0.47)
3Ap28F	6.4	4/4	3.98 (0.86)	≤1.40 (0.05)	4/4	2.12 (0.64)	1.90 (0.44)	2.73 (0.36)	3.28 (0.36)	2.45 (0.16)	≤1.83 (0.22)

+ GMT = geometric mean titer

* Sera obtained from animals three weeks post-infection.

PRINT is a 60% plaque reduction neutralization test.

EIA-F, Ga, Gb are enzyme immunoassays testing reactivity of sera with purified F protein (from RSV A2), purified Ga (from RSV A2, and purified Gb (from RSV 18537).

Table 13
RSV Infection of Seropositive Chimps

<u>VIRUS</u>	<u>DOSE</u>	<u>DAY</u>	<u>NEUTRALIZATION TITERS¹</u> (LOG ₁₀)				<u>EIA TITERS²</u> (LOG ₁₀)			
			<u>2B</u>	<u>3A</u>	<u>A2</u>	<u>ETA-F</u>	<u>EIA-Ga</u>	<u>EIA-Gb</u>		
RSV 2B	4.0 PFU	-1	2.0	2.1	2.0	4.1	3.6	2.9		
		7	2.7	2.4	2.4	4.2	3.4	3.1		
		14	5.0	5.1	5.0	6.6	5.4	5.2		
		21	4.9	5.0	4.9	6.5	5.3	5.2		
		D21/D-1*	2.9	2.9	2.9	2.4	1.7	2.3		
RSV2B	5.0 PFU	-1	2.4	2.8	2.8	4.6	4.3	3.5		
		7	2.9	3.2	3.0	4.9	4.3	3.5		
		14	5.0	5.1	>5.1	6.5	5.5	4.7		
		21	4.8	5.4	4.9	6.4	5.8	5.3		
		D21/D-1	2.4	2.6	2.1	1.8	1.5	1.8		
RSV 2Bp20L	4.0 PFU	-1	2.1	2.7	2.1	4.2	3.7	2.7		
		7	2.2	2.4	2.0	4.2	3.8	2.6		
		14	2.0	2.4	1.9	4.1	3.8	2.6		
		21	2.2	2.8	2.4	4.1	3.7	2.8		
		D21/D-1	0.1	0.1	0.3	-0.1	0.0	0.1		
RSV 2Bp20L	5.0 PFU	-1	1.8	2.6	2.3	3.8	4.0	3.0		
		7	1.8	2.2	2.2	3.7	3.9	2.8		
		14	2.2	2.5	1.9	3.8	3.9	2.7		
		21	2.4	2.5	2.1	3.9	4.0	3.0		
		D21/D-1	0.6	-0.1	-0.2	0.1	0.0	0.0		

SUBSTITUTE SHEET (RULE 26)

1 = 60% plaque reduction neutralization assay performed against RSV strain 2B, 3A, + A2.

2 = Enzyme immunoassay testing reactivity purified RSV.

Source of protein = F(RSV A2), Ga(RSV A2), Gb(RSV 18537).

* Rise in titer day - 1 to day 21.

- 77 -

Table 14
Growth, Immunogenicity, and Efficacy of RSV 2B ts Mutants in Cotton Rats¹

Virus	Dose	Virus Titer (log ₁₀ PFU/gm)		Immunogenicity ²				Challenge Virus Titer (log ₁₀ PFU/gm)		
				Neutralization ²				#RSV+	Nose	Lung
		#RSV+	Nose	A2	3A	2B	EIA-F ²			
2B	6.1	4/4	≤3.1	174	502	521	1911	1/3	≤2.0	≤1.8
2Bp33F	5.8	2/4	≤1.2	35	115	145	1041	1/4	<1.8	≤1.8
2Bp24G	6.4	2/4	≤1.3	92	201	377	2432	0/4	<1.7	<1.4
2Bp20L	6.2	0/4	<1.3	41	123	75	482	3/4	≤2.6	3.1
2Bp34L	5.2	0/4	<1.3	<10	<10	<10	≤77	4/4	4.8	5.4
PBS				<10	<10	<10	<50	4/4	4.9	5.5

1 = Cotton rats were inoculated with virus by intranasal route. Four days post-infection, lungs and nasal turbinates were harvested for virus titrations. Six weeks post-infection, blood was taken for neutralization and EIA titrations and rats were challenged intranasally with 10⁶ PFU of RSV 18537. Lungs and nasal turbinates were harvested 4 days post-challenge. Virus and antibody titers are reported as geometric mean titers.

2 = 60% plaque reduction neutralization test.

3 = Source of coating protein is RSV A2 F protein.

Table 15
Growth, Immunogenicity, and Efficacy of RSV 3A ts Mutants in Cotton Rats¹

Virus	Dose	#RSV+	Virus Titer		Immunogenicity				Challenge Virus Titer			
			(log ₁₀ PFU/gm)		Neutralization ²				(log ₁₀ PFU/gm)			
			Nose	Lung	A2	3A	2B	EIA-F ²	#RSV+	Nose	Lung	
3A	6.0	4/4	3.2	<4.1	35	141	35	1202	0/3	<1.6	<1.4	
3Ap20E	6.0	4/4	≤3.2	≤1.4	≤17	85	66	646	0/4	<1.6	<1.3	
3Ap20F	6.0	4/4	3.7	<1.3	≤23	87	55	708	0/4	<1.8	<1.2	
3Ap28F	6.0	3/4	≤2.3	<1.4	47	282	123	2188	0/4	<1.6	<1.4	
PBS					<10	<10	<10	<50	4/4	5.6	5.6	

1 = Cotton rats were inoculated with virus by intranasal route. Four days post-infection, lungs and nasal turbinates were harvested for virus titrations. Six weeks post-infection, blood was taken for neutralization and EIA titrations and rats were challenged intranasally with 10⁶ PFU of RSV A2.

Lungs and nasal turbinates were harvested 4 days post-challenge. Virus and antibody titers are reported as geometric mean titers.

2 = 60% plaque reduction neutralization test.

3 = Source of coating protein is RSV A2 F protein.

- 79 -

Table 16
RSV Growth and Immunogenicity in African Green Monkeys:
RSV 2B ts Mutants¹

		<u>ts Mutant Virus Growth</u>		<u>Immunogenicity</u>				
		<u>Peak Virus Titer (log10 PFU/ml)</u>			<u>Neutralization Titers²</u>			<u>EIA Titers³ (x10³)</u>
<u>Virus</u>	<u>AGM</u>	<u>Nasal</u>	<u>Lung</u>	<u>Day</u>	<u>2B</u>	<u>A2</u>	<u>3A</u>	<u>anti-F</u>
2Bp33F	SK034	<0.7	<0.7	0	<10	<10	<10	<0.15
				7	<10	<10	<10	<0.15
				14	<10	<10	<10	0.88
				24	<10	<10	<10	0.49
				27	<10	<10	<10	0.92
				41	<10	<10	<10	0.26
2Bp33F	SK028	2.9	<0.7	0	<10	<10	<10	<0.15
				7	<10	<10	<10	<0.15
				14	<10	<10	<10	<0.15
				24	28	<10	<10	2.92
				27	33	<10	<10	3.56
				41	19	<10	11	1.74
2Bp24G	SK012	<0.7	1.9	0	<10	<10	<10	<0.15
				7	<10	<10	<10	<0.15
				14	<10	<10	<10	<0.15
				24	12	<10	<10	14.91
				27	10	<10	<10	13.18
				41	<10	<10	<10	11.05

1 = All monkeys were inoculated with 10⁶ PFU of RSV 2B ts virus, IN+IT.

2 = 60% plaque reduction neutralization test.

3 = Source of coating protein is RSV A2 F protein.

- 80 -

Table 16 (continued)
 RSV Growth and Immunogenicity in African Green Monkeys:
 RSV 2B ts Mutants¹

		<u>ts Mutant Virus Growth</u>		<u>Immunogenicity</u>				
		<u>Peak Virus Titer</u> (log10 PFU/ml)		<u>Day</u>	<u>Neutralization Titers²</u>			<u>EIA Titers³</u> (x10 ³)
<u>Virus</u>	<u>AGM</u>	<u>Nasal</u>	<u>Lung</u>		<u>2B</u>	<u>A2</u>	<u>3A</u>	<u>anti-F</u>
2Bp24G	SK030	3.2	<0.7	0	<10	<10	<10	<0.15
				7	<10	<10	<10	<0.15
				14	<10	<10	<10	<0.15
				24	440	10	204	34.13
				27	404	21	190	37.64
				41	256	<10	98	17.74
2Bp20L	SK033	<0.7	<0.7	0	<10	<10	<10	0.24
				7	<10	<10	<10	0.30
				14	<10	<10	<10	1.48
				24	<10	<10	<10	1.64
				27	<10	<10	<10	1.24
				41	<10	<10	<10	0.34
2Bp20L	SK042	<0.7	<0.7	0	<10	<10	<10	<0.15
				7	<10	<10	<10	<0.15
				14	<10	<10	<10	<0.15
				24	<10	<10	<10	1.64
				27	<10	<10	<10	0.20
				41	<10	<10	<10	0.15

1 = All monkeys were inoculated with 10⁶ PFU of RSV 2B ts virus, IN+IT.

2 = 60% plaque reduction neutralization test.

3 = Source of coating protein is RSV A2 F protein.

- 81 -

Table 17
 RSV Growth and Immunogenicity in African Green Monkeys:
 RSV 2B Challenge of Monkeys 8 Weeks Post-Vaccinated with
 RSV 2B *ts* Mutants¹

		Challenge		Immunogenicity				
		<u>Virus Growth</u>			<u>Neutralization</u>			<u>EIA</u>
		<u>Peak Virus</u>			<u>Titers²</u>			<u>Titers³</u>
		<u>Titer</u>						
<u>Vaccine</u>		(log10 PFU/ml)		<u>Day</u>				(x10 ³)
<u>Virus</u>	<u>AGM</u>	<u>Nasal</u>	<u>Lung</u>		<u>2B</u>	<u>A2</u>	<u>3A</u>	<u>anti-F</u>
2Bp33F	SK034	5.7	5.0	0	<10	<10	<10	0.52
				7	<10	<10	<10	0.91
				14	451	10	472	303.84
				21	6797	33	829	592.61
				28	4353	50	815	135.85
				42	1978	44	264	52.76
2Bp33F	SK028	<0.8	3.8	0	13	<10	<10	2.50
				7	208	65	576	43.64
				14	2868	443	2051	131.70
				21	1883	404	2344	144.39
				28	1127	227	2797	53.22
				42	941	79	729	43.30
2Bp24G	SK012	3.9	3.2	0	<10	<10	<10	21.58
				7	281	111	323	258.89
				14	604	431	731	551.49
				21	698	298	692	668.50
				28	357	325	985	189.81
				42	272	82	895	104.16

1 = AGMs were previously vaccinated with RSV 2B *ts* strains.

All monkeys were challenged 8 weeks post-vaccination with
 10⁶ PFU of RSV 2B, IN+IT.

2 = 60% plaque reduction neutralization test.

3 = Source of coating protein is RSV A2 F protein.

- 82 -

Table 17 (continued)
 RSV Growth and Immunogenicity in African Green Monkeys:
 RSV 2B Challenge of Monkeys 8 Weeks Post-Vaccinated with
 RSV 2B ts Mutants¹

		<u>Challenge</u>				<u>Immunogenicity</u>			
		<u>Virus Growth</u>				<u>Neutralization</u>			<u>EIA</u>
		<u>Peak Virus</u>				<u>Titers²</u>			<u>Titers³</u>
		<u>Titer</u>							(x10 ³)
<u>Vaccine</u>	<u>AGM</u>	<u>Nasal</u>	<u>Lung</u>	<u>Day</u>	<u>2B</u>	<u>A2</u>	<u>3A</u>	<u>anti-F</u>	
2Bp24G	SK030	<0.8	<0.7	0	91	<10	69	34.55	
				7	628	322	1120	174.07	
				14	1617	397	1953	203.58	
				21	1184	256	968	145.71	
				28	851	276	1313	49.28	
				42	637	48	329	27.36	
2Bp20L	SK033	5.3	4.5	0	<10	<10	<10	1.78	
				7	<10	<10	<10	1.88	
				14	516	<10	325	289.94	
				21	500	22	550	418.91	
				28	783	56	525	148.25	
				42	518	48	442	91.39	
2Bp20L	SK042	5.4	3.3	0	<10	<10	<10	0.21	
				7	<10	<10	<10	0.32	
				14	36	<10	116	135.80	
				21	213	21	284	116.99	
				28	256	30	300	30.06	
				42	516	40	289	19.30	

1 = AGMs were previously vaccinated with RSV 2B ts strains.
 All monkeys were challenged 8 weeks post-vaccination with
 10⁶ PFU of RSV 2B, IN+IT.

2 = 60% plaque reduction neutralization test.

3 = Source of coating protein is RSV A2 F protein.

- 83 -

Table 17 (continued)

RSV Growth and Immunogenicity in African Green Monkeys:
 RSV 2B Challenge of Monkeys 8 Weeks Post-Vaccinated with
 RSV 2B ts Mutants¹

		Challenge		Immunogenicity				
		<u>Virus Growth</u>						
		<u>Peak Virus</u>						
		<u>Titer</u>						
		(log10 PFU/ml)						
<u>Vaccine</u>	<u>AGM</u>	<u>Nasal</u>	<u>Lung</u>	<u>Day</u>	<u>Neutralization</u>			<u>EIA</u>
<u>Virus</u>					<u>Titers²</u>			<u>Titers³</u>
								(x10 ³)
Control	SK046	5.9	4.7	0	<10	<10	<10	0.10
				7	<10	<10	<10	0.13
				14	272	50	594	275.33
				21	488	98	1140	587.93
				28	1377	75	1393	190.49
				42	1659	47	573	183.97
Control	032B	5.5	3.9	0	<10	<10	<10	0.25
				7	<10	<10	<10	0.24
				14	2462	201	3458	626.57
				21	1546	303	1279	482.31
				28	1162	104	1729	164.53
				42	1044	83	689	75.1

1 = AGMs were previously vaccinated with RSV 2B ts strains.

All monkeys were challenged 8 weeks post-vaccination with
 10⁶ PFU of RSV 2B, IN+IT.

2 = 60% plaque reduction neutralization test.

3 = Source of coating protein is RSV A2 F protein.

- 84 -

Table 18
 RSV Growth and Immunogenicity in African Green Monkeys:
 RSV 3A ts Mutants¹

		<u>ts Mutant Virus Growth</u>		<u>Immunogenicity</u>				
		<u>Peak Virus Titer</u> (log10 PFU/ml)		<u>Day</u>	<u>Neutralization Titers²</u>			<u>EIA Titers³</u> (x10 ³) <u>anti-F</u>
<u>Virus</u>	<u>AGM</u>	<u>Nasal</u>	<u>Lung</u>		<u>2B</u>	<u>A2</u>	<u>3A</u>	
3Ap20E	01128	1.7	1.3	0	<10	<10	<10	<0.05
				7	<10	<10	<10	<0.05
				14	<10	<10	<10	3.72
				21	38	<10	39	23.12
				28	21	<10	13	27.42
				40	14	<10	<10	31.11
3Ap20E	0L1161	2.3	2.9	0	<10	<10	<10	<0.05
				7	<10	<10	<10	<0.05
				14	<10	<10	30	5.84
				21	14	12	57	19.51
				28	56	18	126	27.53
				40	44	31	108	38.90
3Ap20F	90B037	3.2	<1.0	0	<10	<10	<10	<0.05
				7	<10	<10	<10	<0.05
				14	<10	<10	11	1.17
				21	12	<10	47	34.32
				28	20	17	86	31.58
				40	49	26	123	35.05

1 = All monkeys were inoculated with 10⁶ PFU of RSV 3A ts virus, IN+IT.

2 = 60% plaque reduction neutralization test.

3 = Source of coating protein is RSV A2 F protein.

- 85 -

Table 18 (continued)
 RSV Growth and Immunogenicity in African Green Monkeys:
 RSV 3A *ts* Mutants¹

		<u><i>ts</i> Mutant Virus Growth</u>		<u>Immunogenicity</u>				
		<u>Peak Virus Titer</u> (log10 PFU/ml)		<u>Day</u>	<u>Neutralization Titers²</u>			<u>EIA Titers³</u> (x10 ³) <u>anti-F</u>
<u>Virus</u>	<u>AGM</u>	<u>Nasal</u>	<u>Lung</u>		<u>2B</u>	<u>A2</u>	<u>3A</u>	
3Ap20F	90B045	3.9	1.0	0	<10	<10	<10	0.35
				7	<10	<10	<10	0.30
				14	<10	<10	19	3.16
				21	11	11	22	12.61
				28	12	13	24	16.82
				40	24	<10	39	14.92
3Ap28F	91B027	2.0	<0.8	0	<10	<10	<10	<0.05
				7	<10	<10	<10	<0.05
				14	<10	<10	<10	0.18
				21	<10	<10	<10	1.29
				28	<10	<10	<10	2.63
				40	<10	11	27	3.83
3Ap28F	91B043 ⁴	2.9	<0.9	0	<10	<10	<10	<0.05
				7	<10	<10	<10	<0.05
				14	<10	11	27	3.83

1 = All monkeys were inoculated with 10⁶ PFU of RSV 3A *ts* virus, IN+IT.

2 = 60% plaque reduction neutralization test.

3 = Source of coating protein is RSV A2 F protein.

4 = Monkey died on day 15. Cause of death unrelated to RSV infection.

- 86 -

Table 19
 RSV Growth and Immunogenicity in African Green Monkeys:
 RSV 3A Challenge of Monkeys 8 Weeks Post-Vaccinated with
 RSV 3A ts Mutants¹

		Challenge		Immunogenicity				
		<u>Virus Growth</u>						
		<u>Peak Virus</u>						
		<u>Titer</u>						
		(log ₁₀ PFU/ml)						
<u>Vaccine</u>	<u>AGM</u>	<u>Nasal</u>	<u>Lung</u>	<u>Day</u>	<u>Neutralization</u>			<u>EIA</u>
<u>Virus</u>					<u>Titers²</u>			<u>Titers³</u>
								(x10 ³)
								<u>anti-F</u>
3Ap20E	01128	1.4	0.7	0	14	12	<10	35.75
				7	216	281	602	699.10
				14	417	265	784	611.24
				21	289	307	573	247.16
				28	263	289	731	463.57
				42	145	141	426	285.47
3Ap20E	0L1161	2.2	<0.8	0	21	<10	56	25.37
				7	526	412	2735	535.05
				14	516	521	2382	252.93
				21	581	473	1840	275.32
				28	478	437	1651	244.01
				42	250	239	753	141.33
3Ap20F	90B03	<1.1	<0.8	0	84	56	221	41.17
				7	2374	2093	6051	435.25
				14	3701	2916	8652	450.55
				21	2933	2224	6561	481.99
				28	1849	1588	4031	287.28
				42	3086	967	3950	207.98

1 = AGMs were previously vaccinated with RSV 3A ts strains. All monkeys were challenged 8 weeks post-vaccination with 10⁶ PFU of RSV 3A, IN+IT.

2 = 60% plaque reduction neutralization test.

3 = Source of coating protein is RSV A2 F protein.

- 87 -

Table 19 (continued)
 RSV Growth and Immunogenicity in African Green Monkeys:
 RSV 3A Challenge of Monkeys 8 Weeks Post-Vaccinated with
 RSV 3A *ts* Mutants¹

		Challenge		Immunogenicity				
		<u>Virus Growth</u>			<u>Neutralization</u>			<u>EIA</u>
		<u>Peak Virus</u>			<u>Titers²</u>			<u>Titers³</u>
		<u>Titer</u>						(x10 ³)
<u>Vaccine</u>	<u>AGM</u>	<u>Nasal</u>	<u>Lung</u>	<u>Day</u>	<u>2B</u>	<u>A2</u>	<u>3A</u>	<u>anti-F</u>
3Ap20F	90B045	<1.0	<0.8	0	24	12	56	13.44
				7	644	627	1381	182.99
				14	1024	549	2174	223.70
				21	1835	699	2130	273.87
				28	831	318	1499	177.21
				42	534	258	1073	127.80
3Ap28F	91B027	<1.0	0.8	0	<10	<10	<10	5.50
				7	408	229	521	150.97
				14	585	560	2016	234.25
				21	449	311	1161	359.53
				28	316	400	714	184.91
				42	242	217	436	142.67
Control	91K041	5.0	4.7	0	<10	<10	<10	<0.05
				7	<10	<10	<10	0.13
				14	19	<10	205	213.29
				21	106	33	423	602.54
				28	123	99	278	562.05
				42	107	80	277	252.99

1 = AGMs were previously vaccinated with RSV 3A *ts* strains. All monkeys were challenged 8 weeks post-vaccination with 10⁶ PFU of RSV 3A, IN+IT.

2 = 60% plaque reduction neutralization test.

3 = Source of coating protein is RSV A2 F protein.

- 88 -

Table 19 (continued)

RSV Growth and Immunogenicity in African Green Monkeys:
 RSV 3A Challenge of Monkeys 8 Weeks Post-Vaccinated with
 RSV 3A ts Mutants¹

		<u>Challenge</u>		<u>Immunogenicity</u>				
		<u>Virus Growth</u>			<u>Neutralization</u>			<u>EIA</u>
		<u>Peak Virus</u>			<u>Titers²</u>			<u>Titers³</u>
		<u>Titer</u>						(x10 ³)
<u>Vaccine</u>	<u>AGM</u>	<u>Nasal</u>	<u>Lung</u>	<u>Day</u>	<u>2B</u>	<u>A2</u>	<u>3A</u>	<u>anti-F</u>
Control	91K059	5.1	4.6	0	<10	<10	<10	<0.05
				7	<10	<10	<10	0.09
				14	97	34	384	166.59
				21	288	158	1259	268.47
				28	<160	<160	575	286.52
				42	290	178	1448	218.74

1 = AGMs were previously vaccinated with RSV 3A ts strains. All monkeys were challenged 8 weeks post-vaccination with 10⁶ PFU of RSV 3A, IN+IT.

2 = 60% plaque reduction neutralization test.

3 = Source of coating protein is RSV A2 F protein.

Table 20
Growth, Immunogenicity, and Efficacy of RSV TS-1 Cotton Rats¹

Virus	Virus Titer			Immunogenicity					Challenge Virus Titer		
	Dose	(log ₁₀ PFU/gm)			Neutralization			(log ₁₀ PFU/gm)			
		#RSV+	Nose	Lung	A2	3A	2B	EIA-F ²	#RSV+	Nose	Lung
A2	5.5	4/4	3.6	4.0	234	367	188	1259	0/4	<1.8	<1.3
TS-1	5.9	4/4	≤2.7	2.3	100	385	181	2071	0/3	<1.9	<1.3
PBS					<10	<10	<10	<50	4/4	4.5	4.8

1 = Cotton rats were inoculated with virus by intranasal route. Four days post-infection, lungs and nasal turbinates were harvested for virus titrations. Six weeks post-infection, blood was taken for neutralization and EIA titrations and rats were challenged intranasally with 10⁶ PFU of RSV A2.

Lungs and nasal turbinates were harvested 4 days post-challenge. Virus and antibody titers are reported as geometric mean titers.

2 = 60% plaque reduction neutralization test.

3 = Source of coating protein is RSV A2 F protein.

- 90 -

Table 21
Sequence comparison between RSV 2B and 2B33F strains

Gene/ region	Nucl. pos.†	Nucleotide changes			Amino acid changes
	3' end of vRNA	RSV 2B	RSV 2B33F	RSV 2B33F TS(+), 5a revertant	
Genomic Promoter	4 6	C -	G extra A	G extra A	non-coding non-coding
M	4175 4199	T T	C C	C C	non-coding non-coding
SH	4329 4409 4420 4442 4454 4484 4497 4505 4525 4526 4542 4561 4575 4598	T T T T T T T T T T T T T T	C C C C C C C C C C C C C C	C C C C C C C C C C C C C C	Phe-Leu (10) none Ile (36) Ile-Thr (40) none His (47) none Cys (51) none Tyr (61) Stop-Gln (66) none Ser (68) Ile-Thr (75) Ile-Thr (75) Stop-Gln (81) Leu-Pro (87) Trp-Arg (92) none Thr (99)
L	9559 9853* 12186 14587 15071	G A G C A	A G A T G	A A A T G	Arg-Lys (353) Lys-Arg (451)* Asp-Asn (1229) Thr-Ile (2029) non-coding

† For 2B33F and 2B33F TS(+), nucl. pos. numbers
are one larger than for 2B for M, SH & L genes

* At pos. 9853, the Lys-Arg change has reverted
back to Lys in the 2B33F TS(+) strain

- 91 -

Table 22
Sequence comparison between RSV 2B and 2B20L strains

Gene/ region	Nucl. pos.†	Nucleotide changes			Amino acid changes
		RSV 2B	RSV 2B20L	RSV 2B20L TS(+), R1 revertant	
Genomic Promoter	4 6	C -	G extra A	G extra A	non-coding* non-coding*
L	8963 13347 14587 14649 14650	C A C A A	T A T G A	T G T G T	none Thr (154) Asn-Asp (1616) Thr-Ile (2029)* Asn-Asp (2050) Asn-Asp-Val (2050)**

† For 2B20L and 2B20L TS(+), nucl. pos. numbers
are one larger than for 2B for L gene

* Mutation is common in 2B33F and 2B20L strains

** At pos. 14650, the mutation suppresses the ts
phenotype in 2B20L TS(+) revertant

Table 23
RSV 2B, ts and Revertant Strains

Sample	Source	In Vitro Phenotype ts		In Vivo Growth* Cotton Rat				AGM
		39/32°C EOP plaque morph	20/32°C Yield	Nasal turbينات	Lungs	Nasal Wash	Bronchial Lavage	
RSV 2B	Wild-type Parent Strain	0.7 (WT)	0.0001	5.5 ^a 3.9 ^b (4/4)	5.8 ^a 5.2 ^b (4/4)	5.8 ^a (4/4)	4.7 ^a (4/4)	
RSV 2B33F	ca, ts mutant isolated from 2B cold-passaged x 33	0.00007 (sp/int/wt)	0.04	≤1.6 ^a <1.9 ^b (1/4)	<1.5 ^a <1.2 ^b (0/4)	3.0 ^a (4/4)	<0.9 ^a (0/4)	
RSV 2B33F - 5a TS(+)	2B33F spinner passage, plaque picked at 39°C	0.5 (WT)	0.03	≤1.7 ^a (1/4)	3.5 ^a (4/4)	4.2 ^a (4/4)	4.0 ^a (4/4)	
RSV 2B33F - 4a TS(+)	2B33F spinner passage, plaque picked at 39°C	0.7 (WT)	0.01	≤1.7 ^a (3/4)	3.8 ^a (4/4)	ND	ND	
RSV 2B33F - 3b TS(+)	2B33F spinner passage, plaque picked at 39°C	0.5 (WT)	0.04	≤2.5 ^a (3/4)	2.9 ^a (4/4)	ND	ND	
AGM pp2	2B33F-infected AGM #A2,d7 nasal wash plaque picked at 32°C	0.3 (sp,int)	0.00002	≤2.0 ^b (1/4)	1.6 ^b (4/4)	ND	ND	

Table 23 (continued)
RSV 2B, ts and Revertant Strains

Sample	Source	In Vitro Phenotype ts		In Vivo Growth* Cotton Rat			
		39/32°C EOP plaque morph	20/32°C yield	Nasal turbينات	Lungs	Nasal Wash	Bronchial Lavage
AGM pp4	2B33F-infected AGM #A2,d7 nasal wash plaque picked at 32°C	0.1 (sp,int)	0.008	<1.6 ^b (0/4)	1.2 ^b (4/4)	ND	ND
AGM pp6	2B33F-infected AGM #A4,d12 nasal wash plaque picked at 32°C	0.000004 (wt)	≤0.00005	≤1.5 ^b (1/4)	<1.1 ^b (0/4)	ND	ND
AGM pp7	2B33F-infected AGM #A4,d12 nasal wash plaque picked at 32°C	0.000004 (sp/int/wt)	0.007	≤1.4 ^b (1/4)	<1.0 ^b (0/4)	ND	ND
Chimp pp1A	2B33F-infected Chimp #1552, d4 tracheal lavage plaque picked at 32°C	0.5 (WT)	ND	ND	ND	ND	ND
Chimp pp3A	2B33F-infected Chimp #1560, d6 tracheal lavage plaque picked at 32°C	0.7 (WT)	ND	2.4 ^c (4/4)	≤3.0 ^c (3/4)	ND	ND
Chimp pp5A	2B33F-infected Chimp #1563, d10 nasal swab plaque picked at 32°C	0.7 (WT)	ND	≤2.3 ^c (3/4)	3.0 ^c (4/4)	ND	ND

Table 23 (continued)
RSV 2B, ts and Revertant Strains

Sample	Source	In Vitro Phenotype ts		In Vivo Growth* Cotton Rat			AGM
		39/32°C EOP plaque morph	20/32°C Yield	Nasal turbinate	Lungs	Nasal Wash	
RSV 2B20L	ca, ts mutant isolated from 2B cold-passaged x 20	0.0002 (int/wt)	0.02	<1.9 ^d (0/4)	<1.3 ^d (0/4)	<0.7 ^f (0/2)	<0.7 ^f (0/2)
RSV 2B20L R1 TS(+)	2B20L spinner passage, plaque picked at 39°C	0.6 (WT)	ND	2.3 ^c (4/4)	3.5 ^c (4/4)	ND	ND
RSV 2B20L R2 TS(+)	2B20L spinner passage, plaque picked at 39°C	0.6 (WT)	ND	≤2.5 ^c (3/4)	2.7 ^c (4/4)	ND	ND
RSV 2B20L R9 TS(+)	2B20L spinner passage, plaque picked at 39°C	0.8 (WT)	ND	≤2.2 ^c (3/4)	4.0 ^c (4/4)	ND	ND
RSV 2B20L R10 TS(+)	2B20L spinner passage, plaque picked at 39°C	0.7 (WT)	ND	2.6 ^c (4/4)	3.2 ^c (4/4)	ND	ND

* In Vivo growth measured in log₁₀ mean virus titer (# infected/# total)
ND = not done WT = wild-type plaque size sp = small plaque size int = intermediate
plaque size

• Dose = 10^{5.6} PFU IN ^b Dose = 10^{5.3} PFU IN

• Dose = 10^{6.7} PFU IN ^c Dose = 10^{6.0} PFU IN+IT

- 95 -

Table 24
2B33F Revertants

	<i>ts</i> (+) <i>In vitro</i>			AGM				Chimp		
	5a	4a	3b	pp2	pp4	pp6	pp7	1A	3A	5A
base no.†										
<u>M</u>										
4176,4200	S	S	S	S	S	S	S	S	S	S
<u>SH</u>										
14 bases*	S	S	S	S	S	S	S	S	S	S
<u>L</u>										
9560	S	S	S	S	S	S	S	S	S	S
9854	2B	2B	2B	S	S	S	S	2B	2B	2B
12187	S	S	S	S	S	S	S	S	S	S
14588	S	S	S	S	S	S	S	S	S	S
15072	S	S	S	S	S	S	S	S	S	S
Phenotype										
<i>ts</i>	2B	2B	2B	r	r	S	S	2B	2B	2B
<i>ca</i>	S	S	S	2B	S	2B	S	ND	ND	ND
Attenuated	r	r	r	(r)	(r)	S	S	ND	r	r

† These 2B33F revertant base nos. are one larger than for 2B for M, SH and L genes

* bases 4330,4410,4421,4443,4455,4485,4498,4506,4526,4527,4543, 4562,4576,4599

S = same base as 2B33F

2B = reversion to 2B base or complete reversion in phenotype

r = moderate reversion in phenotype

(r) = slight reversion in phenotype

ND = not done

- 96 -

Table 25
2B20L Revertants

	TS(+) In vitro Isolates									
base no.†	R1	R2	R3A	R4A	R5A	R6A	R7A	R8A	R9A	R10A
<u>L</u>										
8964	S	S	S	S	S	S	S	S	S	S
13348	C*	S	ND	S	S	ND	S	S	S	S
14588	S	S	S	S	S	S	S	S	S	S
14650	S	S	2B	S	2B	2B	S	S	2B	2B
14651	A*	A*	S	A*	S	S	A*	A*	S	S
Phenotype										
ts	2B	2B	ND	ND	ND	ND	ND	ND	2B	2B
Attenuated	r	r	ND	ND	ND	ND	ND	ND	r	r

† These 2B20L revertant base nos. are one larger than for 2B for L genes

S = same base as 2B20L

2B = reversion to 2B base

r = moderate reversion in phenotype

* = base change, different from 2B or 2B20L

ND = not done

- 97 -

Table 26
RSV 2B, *ts* and Revertant Strains: Phenotype Summary

Virus Isolate	Source	In Vitro Phenotype		In Vivo Attenuation	
		<i>ts</i>	<i>ca</i>	Cotton Rat	AGM
RSV 2B	Wild-type Parent Strain	-	-	-	-
RSV 2B33F	<i>ca</i> , <i>ts</i> mutant isolated from 2B, cold-passaged x 33	++++	++	++++	+++
RSV 2B33F - 5a TS(+)	2B33F spinner passage plaque picked at 39°C	-	++	++	+
RSV 2B33F - 4a TS(+)	2B33F spinner passage plaque picked at 39°C	-	++	++	ND
RSV 2B33F - 3b TS(+)	2B33F spinner passage plaque picked at 39°C	-	++	++	ND
AGM pp2	2B33F-infected AGM A2, d7 nasal wash plaque picked at 32°C	+	-	+++	ND
AGM pp4	2B33F-infected AGM A2, d7 nasal wash plaque picked at 32°C	+	++	+++	ND
AGM pp6	2B33F-infected AGM A4, d12 nasal wash plaque picked at 32°C	++++	-	++++	ND
AGM pp7	2B33F-infected AGM A4, d12 nasal wash plaque picked at 32°C	++++	++	++++	ND
Chimp pp1A	2B33F-infected chimp #1552, d4 tracheal lavage, plaque picked at 32°C	-	ND	ND	ND
Chimp pp3A	2B33F-infected chimp #1560, d6 tracheal lavage, plaque picked at 32°C	-	ND	++	ND
Chimp pp5A	2B33F-infected chimp #1563, d10 tracheal lavage, plaque picked at 32°C	-	ND	++	ND

- 98 -

Table 26 (continued)
 RSV 2B, *ts* and Revertant Strains: Phenotype Summary

Virus Isolate	Source	In Vitro Phenotype		In Vivo Attenuation	
		<i>ts</i>	<i>ca</i>	Cotton Rat	AGM
RSV 2B20L	<i>ca</i> , <i>ts</i> mutant isolated from 2B, cold-passaged x 20	++++	++	++++	++++
RSV 2B20L R1 TS(+)	2B20L spinner passage plaque picked at 39°C	-	ND	++	ND
RSV 2B20L R2 TS(+)	2B20L spinner passage plaque picked at 39°C	-	ND	++	ND
RSV 2B20L R9 TS(+)	2B20L spinner passage plaque picked at 39°C	-	ND	++	ND
RSV 2B20L R10 TS(+)	2B20L spinner passage plaque picked at 39°C	-	ND	++	ND

ND = not done

- = wild-type phenotype, i.e., not temperature sensitive, not cold-adapted, not attenuated

+ to ++++ = increasing levels of temperature sensitivity, cold-adaptation or attenuation

- 99 -

Bibliography

1. Institute of Medicine, Committee on Issues and Priorities for New Vaccine Development, pages 397-409 of Volume 1, Diseases of importance in the United States (National Academy Press, Washington, D.C. (1985)).
2. Hall, C.B., and McBride, J.T., New Eng. J. Med., 325, 57-58 (1991).
3. McIntosh, K., and Chanock, R.M., pages 1045-1072 of Virology, B.N. Fields, et al., Eds. (2nd ed., Raven Press, 1990).
4. Anderson, L.J., et al., J. Inf. Dis., 151, 626-633 (1985).
5. Anderson, L.J., et al., J. Inf. Dis., 163, 687-692 (1991).
6. Henderson, F.W., et al., N. Engl. J. Med., 300, 530-534 (1979).
7. Hall, S.L., et al., J. Infect. Dis., 163, 693-698 (1991).
8. Lamprecht, C.L., et al., J. Infect. Dis., 134, 211-217 (1976).
9. Glezen, W.P., et al., J. Ped., 98, 706-715 (1981).
10. Glezen, W.P., et al., Am. J. Dis. Child., 140, 543-546 (1986).
11. Kasel, J.A., et al., Viral Immunology, 1, 199-205 (1987/1988).
12. Mufson, M.A., et al., J. Clin. Microbiol., 25, 1535-1539 (1987).
13. Mufson, M.A., et al., J. Gen. Virol., 66, 2111-2124 (1985).
14. Collins, P.L., pages 103-162 of The Paramyxoviruses, D.W. Kingsbury, Ed. (Plenum Press, NY and London, 1991).

- 100 -

15. Sullender, W.M., J. Virology, 65, 5425-5434 (1991).
16. Johnson, P.R., et al., J. Virology, 61, 3163-3166 (1987).
17. Stott, E.J., et al., J. Virology, 61, 3855-3861 (1987).
18. Walsh, E.E., et al., J. Inf. Dis., 155, 1198-1204 (1987).
19. Beeler, J.A., and Coelingh, K.W., J. Virology, 63, 2941-2950 (1989).
20. Connors, M., et al., J. Virology, 65, 1634-1637 (1991).
21. Sun, C.S., et al., Am. Rev. Resp. Dis., 128, 668-672 (1983).
22. Anderson, J.J., et al., J. Gen. Virology, 71, 1561-1570 (1990).
23. Graham, B.S., et al., J. Clin. Invest., 88, 1026-1033 (1991).
24. Oppenshaw, P.J.M., et al., J. Virology, 64, 1683-1689 (1990).
25. Nicholas, J.A., et al., J. Virology, 64, 4232-4241 (1990).
26. Cherrie, A.H., et al., J. Virology, 66, 2102-2110 (1992).
27. Kapikian, A.Z., et al., Am. J. Epidemiology, 89, 405-421 (1969).
28. Chin, J., et al., Am. J. Epidemiology, 89, 449-463 (1969).
29. Fulginiti, V.A., et al., Am. J. Epidemiology, 89, 435-448 (1969).
30. Prince, G.A., et al., J. Virology, 57, 721-728 (1986).
31. Gharpure, M.A., et al., J. Virology, 3, 414-421 (1969).
32. Wright, P.F., et al., J. Inf. Dis., 122,

- 101 -

501-512 (1970).

33. Richardson, L.S., et al., J. Med. Virology, 3, 91-100 (1978).

34. Maassab, H.F., and DeBorde, D.C., Vaccine, 3, 355-369 (1985).

35. Maassab, H.F., et al., "Cold-adapted influenza viruses for use as live vaccines for man", in Viral Vaccines (Wiley-Liss, Inc. (1990)).

36. Obrosova-Serova, N.P., et al., Vaccine, 8, 57-60 (1990).

37. Edwards, K.M., et al., J. Inf. Dis., 163, 740-745 (1991).

38. Belshe, R.B., and Hissom, F.K., J. Med. Virology, 10, 235-242 (1982).

39. Murphy, B.R., et al., pages 91-95 of Vaccines 90 (Cold Spring Harbor Laboratory Press (1990)).

40. Clements, M.L., et al., J. Clin. Microbiol., 29, 1175-1182 (1991).

41. Kim, H.W., et al., Pediatrics, 48, 745-755 (1971).

42. Forsyth, B.R., and Phillips, C.A., "Laboratory and antigenic studies of respiratory syncytial virus; evaluation of respiratory syncytial, meningococcal, and pneumococcal polysaccharide vaccines", NIH contract report number IDB-VDP-07-067 (1973).

43. Kim, H.W., et al., Pediatrics, 52, 56-63 (1973).

44. Hodes, D.S., et al., Proc. Soc. Exp. Biol. Med., 145, 1158-1164 (1974).

45. Belshe, R.B., et al., J. Inf. Dis., 145, 311-319 (1982).

46. Friedewald, W.T., et al., J. Amer. Med. Assn., 204, 690-694 (1968).

- 102 -

47. Frickey, P.H., "Markers differentiating a 'cold' variant of respiratory syncytial virus from its parent line" (Internal report - Lederle Laboratories, Pearl River, NY (1969)).
48. Holland, J., et al., Science, 215, 1577-1585 (1982).
49. Lamb, R.A., and Kolakosky, D., pages 1177-1204 of Volume 1, Fields Virology, B.N. Fields, et al., Eds. (3rd ed., Raven Press, 1996).
50. Sidhu, M.S., et al., Virology, 193, 50-65 (1993).
51. Garcin, D., et al., EMBO J., 14, 6087-6094 (1995).
52. Radecke, F., et al., EMBO J., 14, 5773-5783 (1995).
53. Collins, P.L., et al., Proc. Natl. Acad. Sci., USA, 92, 11563-11567 (1995).
54. Published European Patent Application No. 702,085.
55. Rota, J.S., et al., Virus Res., 31, 317-330 (1994).
56. Baron, M.D., and Barrett, T., J. Virology, 71, 1265-1271 (1997).
57. Published International Application No. WO 97/12032.
58. Kato, A., et al., Genes to Cells, 1, 569-579 (1996).
59. U.S. Provisional Patent Application No. 60/047575.
60. Shaffer, M.F., et al., J. Immunol., 41, 241-256 (1941).
61. Lerch, R.A., et al., J. Virology, 64, 5559-5569 (1990).
62. Mallipeddi, S.K., and Samal, S.K., J. Gen Virol., 74, 2787-2791 (1993).

- 103 -

63. Hemming, V.G., et al., Clin. Microbiol. Res., 8, 22-33 (1995).
64. Collins, P. L. et. al., pages 1313-1351 of volume 1, Fields Virology, B. N. Fields, et al., Eds. (3rd ed., Raven Press, 1996).
65. Ling, R., and Pringle, C.R., J. Gen. Virol., 70, 1427-1440 (1989).
66. Yu, Q., et al., J. Virology, 69, 2412-2419 (1995).
67. Heminway, B.R., et al., page 167 of Abstracts of the IX International Congress of Virology, P17-2, (1993).
68. Mink, M.A., et al., Virology, 185, 615-624 (1991).
69. Dickens, L.E., et al., J. Virology., 52, 364-369 (1990).
70. Lamb, R.A., and Kolakofsky, D., pages 1177-1204 of volume 1, Fields Virology, B.N. Fields, et al., Eds. (3rd ed., Raven Press, 1996).
71. Wagner, R.R., and Rose, J.K., pages 1121-1135 of volume 1, Fields Virology, B.N. Fields, et al., Eds. (3rd ed., Raven Press, 1996).
72. Barik, S., J. Gen. Virol., 74, 485-490 (1993).
73. Collins, P.L., et al., pages 259-264 of Vaccines 93: modern approaches to new vaccines including prevention of AIDS, F. Brown et al., Eds. (Cold Spring Harbor Laboratory Press, NY, 1993).
74. Kuo, L., et al., J. Virology., 70, 6892-6901 (1996).
75. Huang, Y.T., and Wertz, G.W., J. Virology, 43, 150-157 (1982).
76. Sambrook, J., et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

- 104 -

77. Akerlind, B., et al., J. Gen. Virology,
69, 2145-2154 (1988).

78. U.S. Patent Application No. 08/059,444.

- 105 -

What is claimed is:

1. An isolated, recombinantly-generated, attenuated, human respiratory syncytial virus (RSV) subgroup B having at least one attenuating mutation in the RNA polymerase gene.
2. The virus of Claim 1 wherein the at least one attenuating mutation in the RNA polymerase gene is selected from the group consisting of nucleotide changes which produce changes in an amino acid selected from the group consisting of residues 353 (arginine → lysine), 451 (lysine → arginine), 1229 (aspartic acid → asparagine), 2029 (threonine → isoleucine) and 2050 (asparagine → aspartic acid).
3. A vaccine comprising an isolated, recombinantly-generated, attenuated RSV subgroup B according to Claim 1 and a physiologically acceptable carrier.
4. A vaccine comprising an isolated, recombinantly-generated, attenuated RSV subgroup B according to Claim 2 and a physiologically acceptable carrier.
5. A method for immunizing an individual to induce protection against RSV subgroup B which comprises administering to the individual the vaccine of Claim 3.
6. A method for immunizing an individual to induce protection against RSV subgroup B which comprises administering to the individual the vaccine of Claim 4.
7. A composition which comprises a transcription vector comprising an isolated nucleic acid molecule encoding a genome or antigenome of an RSV subgroup B having at least one attenuating mutation in

- 106 -

the RNA polymerase gene, together with at least one expression vector which comprises at least one isolated nucleic acid molecule encoding the trans-acting N, P, L and M2 proteins of the virus necessary for encapsidation, transcription and replication, whereby upon expression an infectious attenuated virus is produced.

8. The composition of Claim 7 wherein the transcription vector comprises an isolated nucleic acid molecule which encodes an RSV subgroup B according to Claim 2.

9. A method for producing infectious attenuated RSV subgroup B which comprises transforming or transfecting host cells with the at least two vectors of Claim 7 and culturing the host cells under conditions which permit the co-expression of these vectors so as to produce the infectious attenuated virus.

10. The method of Claim 9 wherein the virus is the RSV subgroup B of Claim 2.

11. An isolated nucleic acid molecule comprising a RSV subgroup B sequence in positive strand, antigenomic message sense selected from the group consisting of 2B wild-type strain (SEQ ID NO:1), 18537 wild-type strain (SEQ ID NO:3), 2B33F vaccine strain (SEQ ID NO:5), 2B20L vaccine strain (SEQ ID NO:7), 2B33F TS(+) revertant strain (SEQ ID NO:9), and 2B20L TS(+) revertant strain (SEQ ID NO:11), and the complementary genomic sequences thereof.

1/15




FIG.1

SUBSTITUTE SHEET (RULE 26)

2/15




FIG.2

3/15




FIG.3

FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F




FIG.5A




FIG.5B




FIG.5C




FIG.5D




FIG.5E





FIG.5F



8/15




FIG.6A





FIG.6B





9/15











DAT	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
86A003																					
RSV 2B	4.0	PFU																			
NASAL DISCHARGE	0	0	0	0	0	0	2	2	0/+0/+	2	2	2	2	1	0/+	0	0	0	0	0	0
COUGH	0	0	0	0	0	0	0	2	1	0	1	1	1	0	1	1	1	0	0	0	0
86A004																					
RSV 2B	5.0	PFU																			
NASAL DISCHARGE	0	0	0	0	0	0	1	1	0	0	1	1	0	0	0/+	0	0	0	0	0	0
COUGH	0	0	0	0	0	0	0	0	0	0	1	2	2	1	1	1	1	1	0	0	0
86A001																					
RSV 2Bp20L	4.0	PFU																			
NASAL DISCHARGE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
COUGH	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
86A002																					
RSV 2Bp20L	5.0	PFU																			
NASAL DISCHARGE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
COUGH	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0





FIG.7

SUBSTITUTE SHEET (RULE 26)









14/15

COMPARATIVE GROWTH OF RSV 2Bp33F, RSV 3Ap28F AND RSV TS-1
IN AFRICAN GREEN MONKEY

FIG.10A


COMPARATIVE GROWTH OF RSV 2Bp33F, RSV 3Ap28F AND RSV TS-1
IN AFRICAN GREEN MONKEY

FIG.10B



COMPARATIVE GROWTH OF RSV 2Bp33F, RSV 3Ap28F AND RSV TS-1
IN AFRICAN GREEN MONKEY

FIG.10C






FIG. 11

SEQUENCE LISTING

<110> American Cyanamid Company

<120> Attenuated Respiratory Syncytial Viruses

<130> 33359-00PCT

<140>

<141>

<150> US60/059552

<151> 1997-09-19

<160> 12

<170> PatentIn Ver. 2.0

<210> 1

<211> 15218

<212> DNA

<213> respiratory syncytial virus

<400> 1

acgcgaaaaa atgcgtacta caaacttgca cattcgaaaa aaatggggca aataagaact 60
tgataagtgc tattaagtc taaccttttc aatcagaaat ggggtgcaat tctactgagca 120
tgataaagggt tagattacaa aatttatttg acaatgacga agtagcattg ttaaaaataa 180
catgtttatc tgataaatta attcttctga ccaatgcatt agccaaagca gcaatacata 240
caattaaatt aaacggcata gtttttatac atgtttataa aagcagtga gtgtgccctg 300
ataacaatat tgtagtgaat tctaacttta caacaatgcc aatactacaa aatggaggat 360
acatatggga attgattgag ttgacacact gctctcaatt aaacggttta atggatgata 420
attgtgaaat caaattttct aaaagactaa gtgactcagt aatgactaat tatatgaatc 480
aaatatctga cttacttggg cttgatctca attcatgaat tatgtttagt ctaattcaat 540
agacatgtgt ttattaccat tttagttaat ataaaaactc atcaaaggga aatggggcaa 600
ataaactcac ctaatcaatc aaaccatgag cactacaaat gacaacacta ctatgcaaag 660
attgatgatc acagacatga gaccctgtc aatggattca ataataacat ctcttaccaa 720
agaaatcatc acacacaaat tcatatactt gataaacaat gaatgtattg taagaaaact 780
tgatgaaaga caagctacat ttacattctt agtcaattat gagatgaagc tactgcacaa 840
agtagggagt accaaatata aaaaatacac tgaatataat acaaaatatg gcactttccc 900
catgcctata tttatcaatc acggcggggt tctagaatgt attggcatta agcctacaaa 960
acacactcct ataataatac aatatgacct caaccctga attccaacaa aaaaaccaac 1020
ccaaccaaac caaactattc ctcaaacaac agtgctcaat agttaagaag gagctaatac 1080
attttagtaa ttaaaaataa aagtaaagcc aataacataa attggggcaa atacaaagat 1140
ggctcttagc aaagtcaagt tgaatgatac attaaataag gatcagctgc tgtcatccag 1200
caaatacact attcaacgta gtacaggaga taatattgac actcccaatt atgatgtgca 1260
aaaacaccta aacaaactat gtggtatgct attaatcact gaagatgcaa atcataaatt 1320
cacaggatta ataggtatgt tatatgctat gtccagggtta ggaaggggaag acactataaa 1380
gatacttaaa gatgctggat atcatgttaa agctaattga gtagatataa caacatatcg 1440


```

tcaagatata aatggaaagg aaatgaaatt cgaagtatta acattatcaa gcttgacatc 1500
agaaatacaa gtcaatattg agatagaatc tagaaagtcc tacaaaaaaa tgctaaaaga 1560
gatgggagaa gtggctccag aatataggca tgattctcca gactgtggga tgataatact 1620
gtgtatagct gcacttgtga taaccaaatt agcagcagga gacagatcag gtcttacagc 1680
agtaattagg agggcaaaca atgtcttaaa aaacgaaata aaacgataca agggcctcat 1740
accaaaggat atagctaaca gtttttatga agtgtttgaa aaacaccctc atcttataga 1800
tgttttcgtg cactttggca ttgcacaatc atccacaaga gggggtagta gagttgaagg 1860
aatctttgra ggattgttta tgaatgccta tqtttcaggg caagtaatgc taagatgggg 1920
agtttttagcc aaatctgtaa aaaatatcat gctaggacat gctagtgtcc aggcagaaat 1980
ggagcaagtt gtggaagtct atgagtatgc acagaagttg ggaggagaag ctggattcta 2040
ccatatattg aacaatccaa aagcatcatt gctgtcatta actcaatttc ccaacttctc 2100
aagtgtggtc ctaggcaatg cagcaggtct aggcataatg ggagagtata gaggtacacc 2160
aagaaaccag gatctttatg atgcagctaa agcatatgca gagcaactca aagaaaatgg 2220
agtaataaac tacagtgtat tagacttaac agcagaagaa ttggaagcca taaagcatca 2280
actcaacccc aaagaagatg atgtagagct ttaagttaac aaaaaatacg gggcaaataa 2340
gtcaacatgg agaagtttgc acctgaattt catggagaag atgcaaataa caaagctacc 2400
aaattcctag aatcaataaa gggcaagttc gcatcatcca aagatcctaa gaagaaagat 2460
agcataatat ctgttaactc aatagatata gaagtaacta aagagagccc gataacatct 2520
ggcaccaaca tcatcaatcc aacaagtga gccgacagta cccagaaaac aaaagccaac 2580
taccacaaga aacccttagt aagcttcaaa gaagatctca cccaagtga caaccctttt 2640
tctaagttgt acaaggaaac aatagaaaca ttgtataaca atgaagaaga atctagctac 2700
tcatatgaag agataaatga tcaaacaaat gacaacatta cagcaagact agatagaatt 2760
gatgaaaaat taagtgaat attaggaatg ctccatacat tagtagttgc aagtgcagga 2820
cccacttcag ctgcgcatgg aataagagat gctatggttg gtctaagaga agagatgata 2880
gaaaaaataa gagcgggaagc attaatgacc aatgataggt tagaggctat ggcaagactt 2940
aggaatgagg aaagcgaaaa aatggcaaaa gacacctcag atgaagtgtc tcttaatcca 3000
acttccaaaa aattgagtga cttgttgga a gacaacgata gtgacaatga tctatcactt 3060
gatgatTTTT gatcagcgat caactcactc agcaatcaac aacatcaata aaacagacat 3120
caatccattg aatcaactgc cagaccgaac aaacaaacgt ccatcagtag aaccaccaac 3180
caatcaatca accaattgat caatcagcaa cccgacaaaa ttaacaatat agtaacaaaa 3240
aaagaacaag atggggcaaa tatggaaaca tacgtgaaca agcttcacga agggctccaca 3300
tacacagcag ctgttcagta caatgttcta gaaaaagatg atgacctgc atcactaaca 3360
atatgggtgc ctatgttcca gtcactctgt ccagcagact tgctcataaa agaacttgca 3420
agcatcaata tactagtga gcatctctc acgccccaaag gaccttcact acgagtcacg 3480
attaactcaa gaagtgtgt gctggctcaa atgcctagta atttcatcat aagcgcaaat 3540
gtatcattag atgaaagaag caaattagca tatgatgtaa ctacacctg tgaaatcaaa 3600
gcatgcagtc taacatgctt aaaagtaaaa agtatgttaa ctacagtcaa agatcttacc 3660
atgaagacat tcaacccac tcattgagatc attgtcttat gtgaatttga aaatattatg 3720
acatcaaaaa gagtaataat accaacctat ctaagatcaa ttagtgtcaa gaacaaggat 3780
ctgaactcac tagaaaatat agcaaccacc gaattcaaaa atgctatcac caatgcaaaa 3840
attattcctt atgcaggatt agtgttagtt atcacagtta ctgacaataa aggagcattc 3900
aaatatatca aaccacagag tcaatttata gtagatcttg gtgcctacct agaaaaagag 3960
agcatatatt atgtgactac taattggaag catacagcta cacgtttttc aatcaaacca 4020
ctagaggatt aaacttaatt atcaacactg aatgacaggt ccacatatat cctcaacta 4080
cacactatat ccaaacatca taaacatcta cactacacac ttcatcacac aaaccaatcc 4140
cactcaaaat ccaaaatcac taccagccac tatctgctag acctagagtg cgaataggta 4200
aataaaacca aaatatgggg taaatagaca ttagttagag ttcaatcaat cttacaacc 4260
atttataccg ccaattcaac acatatacta taaatcttaa aatgggaaat acatccatca 4320

```

caatagaatt cacaagcaaa ttttggccct attttact aatacatatg atcttaactc 4380
 taatcttttt actaattata atcactatta tgattgcaat actaaataag ctaagtgaac 4440
 ataaagcatt ctgtaacaaa actcttgaac taggacagat gtatcaaate aacacataga 4500
 gttctacatg tatgctgtgt caaattataa tctgtatat ataaacaaaac aaatccaatc 4560
 ttctcacaga gtcattgtgt cgcaaaacca cgctaactat catggtagca tagagtagtt 4620
 atttaaaaat taacataatg atgaattgtt agtatgagat caaaaacaac attggggcaa 4680
 atgcaacatg gtccaaacac aagaatcaac gcaatgccag gactctagaa aagacctggg 4740
 atactctttaa tcatctaatg gtaatatctt cttgtttata caqattaaat ttaaaatcta 4800
 tagcacaatg agcactatca gttttggcaa tgataatctc aacctctctc ataattgcag 4860
 ccataatatt catcatctct gccaatcaca aagttactac aacaacgggc acagttcaaa 4920
 caataaaaaa ccacactgaa aaaaacatca ccacctacc taccagagtc tcaccagaaa 4980
 gggtagtttc atccaagcaa cccacaacca catcaccaat ccacacaagt tcagctacaa 5040
 catcacccaa tacaataatca gaaacacacc atacaacagc acaaaccaaa ggcagaacca 5100
 ccacttcaac acagaccaac aagccaagca caaaaccacg tccaaaaaat ccaccaaaaa 5160
 aagatgatta ccattttgaa gtgttcaact tctgtccctg cagtatatgt ggcaacaatc 5220
 aactttgcaa atccatctgc aaaacaatac caagcaacaa accaaagaag aaaccaacca 5280
 tcaaacccac aaacaaacca accaccaaaa ccacaaacaa aagagacca aaaacaccag 5340
 ccaaaacgac gaaaaaagaa actaccacca acccaacaaa aaaactaacc ctcaagacca 5400
 cagaagagaa caccagcacc tcacaatcca ctgcaatcca cacaaccaca ttaaaacaca 5460
 cagtccaaca gcaatccctc ctctcaacca ccccgaaaa cacaccaac tccacacaaa 5520
 caccacagc atccgagccc tccacaccaa actccacca aaaaaccag ccacatgctt 5580
 agttattcaa aaactacatc ttagcagaga accgtgatct atcaagcaag aacgaaatta 5640
 aacctggggc aaataacatg ggagttgatg atccacaagt caagtgcatt cttcctaact 5700
 cttgtatta atgcattgta cctcacctca agtcagaaca taactgagga gttttacca 5760
 tgcacatgta gtgcagttag cagaggttat tttagtgtt taagaacagg ttggtatact 5820
 agtgatcata caatagaatt aagtaataa aaagaaacca aatgcaatgg aactgacact 5880
 aaagtaaac ttatgaaaca agaattagat aagtataaga atgcagtaac agaattacag 5940
 ctacttatgc aaaacacacc agctgtcaac aaccgggcca gaagagaagc accacagtat 6000
 atgaactaca caatcaatac cactaaaaac ctaaatgtat caataagcaa gaagaggaaa 6060
 cgaagatttc taggtctctt gttaggtgtg ggatctgcaa tagcaagtgg tatagctgta 6120
 tcaaaagttc tacaccttga aggagaagtg aacaagatca aaaatgcttt gttgtctaca 6180
 aacaaagctg tagtcagttt atcaaatggg gtcagtgttt taaccagcaa agtgtagtat 6240
 ctcaagaatt acataataa ccaattatta cccatagtaa atcaacagag ctgtcgcac 6300
 tccaacattg aaacagttat agaattccag cagaagaaca gcagattgtt ggaaatcacc 6360
 agagaattta gtgtcaatgc aggtgtaaca acacctttaa gcacttacat gttgacaaa 6420
 agtgagttac tatcattaat caatgatatg cctataacaa atgatcagaa aaaattaatg 6480
 tcaagcaatg ttcagatagt aaggcaacaa agttattcca tcatgtctat aataaaggaa 6540
 gaagtcttg catatgttgt acagctgcct atctatgggt taatagatac accttgctgg 6600
 aaattgcaca catcgctct atgcactacc aacatcaaag aaggatcaaa tatttgttta 6660
 acaaggactg atagaggatg gtattgtgat aatgcaggat cagtatcctt ctttcacag 6720
 gctgacactt gtaaaagta gtccaatcga gtattttgtg aactatgaa cagtttgaca 6780
 ttaccaagtg aagtcagcct ttgtaacact gacatattca attccaagta tgactgcaa 6840
 attatgacat caaaaacaga cataagcagc tcagtaatta cttctcttgg agctatagt 6900
 tcatgctatg gtaaaactaa atgcactgca tccaacaaaa atcgtgggat tataaagaca 6960
 ttttctaagt gttgtgacta tgtgtcaaac aaaggagtag atactgtgtc agtgggcaac 7020
 actttatact atgtaaacaa gctggaaggc aagaaccttt atgtaaaagg ggaacctata 7080
 ataaattact atgacctct agtgtttcct tctgatgagt ttgatgcac aatatctcaa 7140
 gtcaatgaaa aaatcaatca aagtttagct tttattcgta gatctgatg attactacat 7200

aatgtaaata ctggcaaatc tactacaaat attatgataa ctacaattat tatagtaate 7260
 attgtagtat tgttatcatt aatagctatt ggtttactgt tgtattgtaa agccaaaaac 7320
 acaccagtta cactaagcaa agaccaacta agtggaaatca ataattattgc attcagcaaa 7380
 tagacaaaaa accacctgat catgttttcaa caacaatctg ctgaccacca atcccaaatc 7440
 aacttacaac aaatatattca acatcacagt acaggctgaa tcatttcctc acatcatgct 7500
 acccacataa ctaagctaga tccttaactt atagttacat aaaaacctca agtatcacia 7560
 tcaaccacta aatcaacaca tcattcacia aattaacagc tggggcaaat atgtcgcgaa 7620
 gaaatccctg taatatttgag attagaggrr attgcttgaa tqtaqaaga tgtcactaca 7680
 gtcataatta ctttgaatgg cctcctcatg cttactagt gaggcaaaac ttcattgttaa 7740
 acaagatact caagtcaatg gacaaaagca tagacacttt gtctgaaata agtggagctg 7800
 ctgaactgga tagaacagaa gaatatgctc ttggtatagt tggagtgcta gagagttaca 7860
 taggatctat aaacaacata acaaaacaat cagcatgtgt tgctatgagt aaacttctta 7920
 ttgagatcaa tagtgatgac attaaaaagc tttagagataa tgaagaacct aattcaccta 7980
 agataagagt gtacaatact gttatatcat acattgagag caatagaaaa aacaacaagc 8040
 aaaccatcca tctgtcctag agactaccag cagacgtgct gaagaagaca ataaagaaca 8100
 cattagatat ccacaaaagc ataaccataa gcaatccaaa agagtcaact gtgaatgatc 8160
 aaaatgacca aacaaaaaat aatgatatta ccggataaat atcctttagt tatatcatcc 8220
 atattgatct caagtgaag catggttgct acattcaatc ataaaaacat attacaattt 8280
 aaccataact atttggataa ccaccagcgt ttattaaatc atatatattga tgaatttcac 8340
 tggacaccta aaaacttatt agatgccact caacaatttc tccaacatct taacatccct 8400
 gaagatata atacagtata tatattagt tcataatgct tgaccataac gactctatgt 8460
 catccaacca taaaactatt ttgataaggc tatgggacaa aatggatccc attattaatg 8520
 gaaactctgc taatgtgtat ctaactgata gttatttaaa aggtgttatc tctttttcag 8580
 agtghtaatgc tttagggagt tatcttttta acggccctta tcttaaaaat gattacacca 8640
 acttaattag tagacaaagc ccactactag agcatatgaa tcttaaaaaa ctaactataa 8700
 cacagtcatt aatatctaga tatcataaag gtgaactgaa attagaagaa ccaacttatt 8760
 tccagtcatt acttatgaca tataaaagta tgcctcctgc tgaacaaatt gctacaacta 8820
 acttacttaa aaaaaataata cgaagagcca tagaaataag tgatgtaaag gtgtacgcca 8880
 tcttgaataa actaggatta aaggaaaagg acagagttaa gcccaacaat aattcaggtg 8940
 atgaaaactc agtacttaca accataatta aagatgatat actttcggct gtggaaaaca 9000
 atcaatcata tacaatttca gacaaaagtc actcagtaaa tcaaaatatc actatcaaaa 9060
 caacactctt gaaaaaattg atgtgttcaa tgcaacatcc tccatcatgg ttaatacact 9120
 ggttcaattt atatacaaaa ttaaataaca tattaacaca atatcgatca aatgaggtaa 9180
 aaagtcatgg gtttatatta atagataatc aaactttaag tggttttcag tttattttta 9240
 atcaatatgg ttgtatcgtt tatcataaag gactcaaaaa aatcacaact actacttaca 9300
 atcaattttt gacatggaaa gacatcagcc ttagcagatt aaatgtttgc ttaattactt 9360
 ggataagtaa ttgttttaaat acattaaaca aaagcttagg gctgagatgt ggattcaata 9420
 atgttgtgtt atcacaatta tttctttatg gagattgtat actgaaatta tttcataatg 9480
 aaggcttcta cataataaaa gaagtagagg gatttattat gtctttaatt ctaaacataa 9540
 cagaagaaga tcaatttagg aaacgatttt ataatagcac gctaaataac atcacagatg 9600
 cagctattaa ggtcaaaaag gacctactat caagagtatg tcacacttta ttagacaaga 9660
 cagtgtctga taatatcata aatggtaaat ggataatcct attaaagtaa tttcttaaat 9720
 tgattaagct tgcaggtgat aataatctca ataacttgag tgagctatat tttctcttca 9780
 gaatcttttg acatccaatg gtcgatgaaa gacaagcaat ggattctgta agaattaaact 9840
 gtaatgaaac taagttctac ttattaagta gtctaagtac attaaagggt gctttcattt 9900
 atagaatcat aaaagggttt gtaaatacct acaacagatg gccacctta aggaatgcta 9960
 ttgtcctacc tctaagatgg ttaaactact ataaacttaa tacttatcca tctctacttg 10020
 aatcacaga aaatgatttg attattttat caggattgct gttctatcgt gagtttcac 10080

tgcctaaaaa agtggatctt gaaatgataa taaatgacaa agccatttca cctccaaaag 10140
 atctaataatg gactagtttt cctagaaatt acatgccatc acatatacaa aattatatag 10200
 aacatgaaaa gttgaagtcc tctgaaagcg acagatcgag aagagtacta gagtattact 10260
 tgagagataa taaattcaat gaatgcgac tatacaattg ttagtcaat caaagctatc 10320
 tcaacaactc taatcacgtg gtatcactaa ctggtaaaga aagagagctc agtgtaggta 10380
 gaatgtttgc tatgcaacca ggtatgttta ggcaaatcca aatcttagca gagaaaatga 10440
 tagctgaaaa tattttacaa ttcttccctg agagtgtgac aagatatggg gatctagagc 10500
 ttcaaaaagat atttgaattt aaagcaggaa raagcaacaa gtcaaatcqt tataatgata 10560
 actacaacaa ttatatcagt aaatgttcta tcattacaga tcttagcaaa ttcaatcagg 10620
 catttagata tgaaacatca tgtatctgca gtgatgtatt agatgaactg catggagtag 10680
 aatctctgtt ctcttggttg catttaacaa tacctcttgt cacaataata tgtacatata 10740
 gacatgcacc tcttttcata aaggatcatg ttgttaatct taatgagggt gatgaacaaa 10800
 gtggattata cagatatcat atgggtggta ttgagggtg gtgtcaaaaa ctgtggacca 10860
 ttgaagctat atcattatta gatctaatat ctctcaaagg gaaattctct atcacagctc 10920
 tgataaatgg tgataatcag tcaattgata taagcaaac agttagactt atagagggtc 10980
 agacccatgc acaagcagat tatttgttag cattaaatag ccttaaattg ttatataaag 11040
 agtatgcagg tataggccat aagcttaagg gaacagagac ctatatatcc cgagatatgc 11100
 agttcatgag caaaacaatc cagcacaatg gagtgtacta tccagccagt atcaaaaaag 11160
 tcttgagagt aggtccatgg ataaacacga tacttgatga ttttaaagtt agtttagaat 11220
 ctataggcag cttaacacag gagttagaat acagaggaga aagcttatta tgcagtttaa 11280
 tatttaggaa catttggtta tacaatcaaa ttgctttgca actccgaaat catgcattat 11340
 gtaacaataa gctatattta gatatatgta aagtattaaa acacttaaaa acttttttta 11400
 atcttgatag cattgatatg gctttatcat tgtatatgaa tttgcctatg ctgtttggtg 11460
 gtggtgatcc taatttggtta tatcgaagct tttataggag aactccagac ttccttacag 11520
 aagctatagt acattcagtg tttgtgttga gctattatac tggtcacgat ttacaagata 11580
 agctccagga tcttcagat gatagactga acaaatctt gacatgtgtc atcacatttg 11640
 ataaaaatcc caatgccgag tttgtaacat tgatgaggga tccacaggct ttagggctcg 11700
 aaaggcaagc taaaattact agtgagatta atagattagc agtaacagaa gtcttaagta 11760
 tagcccaaaa caaaatattt tctaaaagt cacaacatta tactaccact gagattgatc 11820
 taaatgacat tatgcaaaat atagaaccaa cttaccctca tggattaaga gttgtttatg 11880
 aaagtttacc tttttataaa gcagaaaaaa tagttaatct tatatcagga acaaaatcca 11940
 taactaatat acttgaaaaa acatcagcaa tagatacaac tgatattaat aggggtactg 12000
 atatgatgag gaaaaatata actttactta taaggatact tccactagat tgtaacaaag 12060
 acaaaagaga gttattaagt ttagaaaatc ttagtataac tgaattaagc aagtatgtaa 12120
 gagaaagatc ttggtcatta tccaatatag taggagtaac atcgccaagt attatgttca 12180
 caatggacat taaatataca actagcacta tagccagtgg tataataata gaaaaatata 12240
 atgttaatatg ttaactcgt ggtgaaagag gacccaccaa gccatgggta ggctcatcca 12300
 cgcaggagaa aaaaacaatg ccagtgtaca acagacaagt tttaacaaa aagcaaagag 12360
 accaaataga ttatttagca aaattagact gggatatatg atccatagac aacaaagatg 12420
 aattcatgga agaactgagt actggaacac ttggactgtc atatgaaaa gccaaaaagt 12480
 tgtttccaca atatctaagt gtcaattatt tacaccgttt aacagtcagt agtagaccat 12540
 gtgaattccc tgcacataa ccagcttata gaacaacaaa ttatcatttt gatactagtc 12600
 ctatcaatca tgtattaaca gaaaagtatg gagatgaaga tategacatt gtgtttcaaa 12660
 attgcataag ttttggtctt agcctgatgt cggttgtgga acaattcaca aacatatgtc 12720
 ctaatagaat tattctcata ccgaagctga atgagataca tttgatgaaa cctcctatat 12780
 ttacaggaga tgttgatatc atcaagttga agcaagtgat acaaaagcag cacatgttcc 12840
 taccagataa aataagttta acccaatatg tagaattatt cttaagtaac aaagcactta 12900
 aatctggatc tcacatcaac tctaatttaa tattagtaca taaaatgtct gattattttc 12960

ataatgctta tattttaagt actaatatag ctggacattg gattctgatt attcaactta 13020
 tgaagaattc aaaagggtatt ttgaaaaag attggggaga ggggtacata actgacata 13080
 tgttcattaa ttgaaatgtt ttctttaatg cttataagac ttatttgcta tgttttcata 13140
 aagggttatgg taaagcaaaa ttagaatgtg atatgaacac ttcagatctt ctttgtgttt 13200
 tggagttaat agacagtagc tactggaaat ctatgtctaa agttttccta gaacaaaaag 13260
 tcataaaata catagtcaat caagacacaa gtttgcgtag aataaaaggc tgtcacagtt 13320
 ttaagttgtg gtttttaaaa cgccttaata atgctaaatt taccgtatgc ccttgggttg 13380
 ttaacataga ttaacaccca acacacatga aagctatatt atcttacata gatttaqtta 13440
 gaatgggggtt aataaatgta gataaattaa ccattaaaaa taaaaacaaa ttcaatgatg 13500
 aattttacac atcaaatctc ttttacatta gttataactt ttcagacaac actcatttgc 13560
 taacaaaaa aataagaatt gctaattcag aattagaaga taattataac aaactatatc 13620
 acccaacccc agaaacttta gaaaatatgt cattaattcc tgttaaaagt aataatagta 13680
 acaaacctaa attttgata agtggaaata ccgaatctat gatgatgtca acattctcta 13740
 gtaaaatgca tattaatctt tccactgtta ccacaagatt caattatagc aaacaagact 13800
 tgtacaattt atttccaatt gttgtgatag acaagattat agatcattca ggtaatacag 13860
 caaaatctaa ccaactttac accaccactt cacatcagac atcttttagta aggaatagt 13920
 catcacttta ttgcatgctt ccttggcatc atgtcaatag atttaacttt gtatttagtt 13980
 ccacaggatg caagatcagt atagagtata ttttaaaaga tcttaagatt aaggaccca 14040
 gttgtatagc attcataggt gaaggagctg gtaacttatt attacgtacg gtagtagaac 14100
 ttcatccaga cataagatac atttacagaa gtttaaaaga ttgcaatgat catagtttac 14160
 ctattgaatt tctaaggtta tacaacgggc atataaacat agattatggt gagaatttaa 14220
 ccattcctgc tacagatgca actaataaca ttcattggtc ttatttacat ataaaatttg 14280
 cagaacctat tagcatcttt gtctgcgatg ctgaattacc tgttacagcc aattggagta 14340
 aaattataat tgaatggagt aagcatgtaa gaaagtgcaa gtactgttct tctgtaaata 14400
 gatgcatttt aattgcaaaa tatcatgctc aagatgacat tgatttcaa ttagataaca 14460
 ttactatatt aaaaacttac gtgtgcctag gtagcaagtt aaaaggatct gaagtttact 14520
 taatccttac aataggccct gcaaatatac ttctgtttt tgatgttcta caaatgcta 14580
 aattgacact ttcaagaact aaaaatttca ttatgcctaa aaaaactgac aaggaatcta 14640
 tcgatgcaaa tattaagaagc ttaatacctt tcttttgta ccctataaca aaaaaaggaa 14700
 ttaagacttc attgtcaaaa ttgaagagt tagttaatgg agatatatta tcatattcta 14760
 tagctggacg taatgaagta ttcagcaaca agcttataaa ccacaagcat atgaatatcc 14820
 taaaatggct agatcatggt ttaaatttta gatcagctga acttaattac aatcatttat 14880
 acatgataga gtccacatat ccttacttaa gtgaattgtt aaatagttta acaaccaatg 14940
 agctcaagaa gctgattaaa ataacaggta gtgtgctata caacctccc aacgaacagt 15000
 agtttaaaat atcataaaca agtttggtca aatttagatg ctaacacatc attatattat 15060
 agttattaaa aaatatacaa acttttcaat aatttagcat attgattcca aaattatcat 15120
 tttagtctta aggggttaaa taaaagtcta aaactaaca ttatacatgt gcattcaca 15180
 cacaacgaga cattagtttt tgacactttt tttctcgt 15218

<210> 2

<211> 2166

<212> PRT

<213> respiratory syncytial virus

<400> 2

Met Asp Pro Ile Ile Asn Gly Asn Ser Ala Asn Val Tyr Leu Thr Asp

1

5

10

15

Ser Tyr Leu Lys Gly Val Ile Ser Phe Ser Glu Cys Asn Ala Leu Gly
 20 25 30
 Ser Tyr Leu Phe Asn Gly Pro Tyr Leu Lys Asn Asp Tyr Thr Asn Leu
 35 40 45
 Ile Ser Arg Gln Ser Pro Leu Leu Glu His Met Asn Leu Lys Lys Leu
 50 55 60
 Thr Ile Thr Gln Ser Leu Ile Ser Arg Tyr His Lys Gly Glu Leu Lys
 65 70 75 80
 Leu Glu Glu Pro Thr Tyr Phe Gln Ser Leu Leu Met Thr Tyr Lys Ser
 85 90 95
 Met Ser Ser Ser Glu Gln Ile Ala Thr Thr Asn Leu Leu Lys Lys Ile
 100 105 110
 Ile Arg Arg Ala Ile Glu Ile Ser Asp Val Lys Val Tyr Ala Ile Leu
 115 120 125
 Asn Lys Leu Gly Leu Lys Glu Lys Asp Arg Val Lys Pro Asn Asn Asn
 130 135 140
 Ser Gly Asp Glu Asn Ser Val Leu Thr Thr Ile Ile Lys Asp Asp Ile
 145 150 155 160
 Leu Ser Ala Val Glu Asn Asn Gln Ser Tyr Thr Asn Ser Asp Lys Ser
 165 170 175
 His Ser Val Asn Gln Asn Ile Thr Ile Lys Thr Thr Leu Leu Lys Lys
 180 185 190
 Leu Met Cys Ser Met Gln His Pro Pro Ser Trp Leu Ile His Trp Phe
 195 200 205
 Asn Leu Tyr Thr Lys Leu Asn Asn Ile Leu Thr Gln Tyr Arg Ser Asn
 210 215 220
 Glu Val Lys Ser His Gly Phe Ile Leu Ile Asp Asn Gln Thr Leu Ser
 225 230 235 240
 Gly Phe Gln Phe Ile Leu Asn Gln Tyr Gly Cys Ile Val Tyr His Lys
 245 250 255
 Gly Leu Lys Lys Ile Thr Thr Thr Tyr Asn Gln Phe Leu Thr Trp
 260 265 270

Lys Asp Ile Ser Leu Ser Arg Leu Asn Val Cys Leu Ile Thr Trp Ile
 275 280 285
 Ser Asn Cys Leu Asn Thr Leu Asn Lys Ser Leu Gly Leu Arg Cys Gly
 290 295 300
 Phe Asn Asn Val Val Leu Ser Gln Leu Phe Leu Tyr Gly Asp Cys Ile
 305 310 315 320
 Leu Lys Leu Phe His Asn Glu Gly Phe Tyr Ile Ile Lys Glu Val Glu
 325 330 335
 Gly Phe Ile Met Ser Leu Ile Leu Asn Ile Thr Glu Glu Asp Gln Phe
 340 345 350
 Arg Lys Arg Phe Tyr Asn Ser Met Leu Asn Asn Ile Thr Asp Ala Ala
 355 360 365
 Ile Lys Ala Gln Lys Asp Leu Leu Ser Arg Val Cys His Thr Leu Leu
 370 375 380
 Asp Lys Thr Val Ser Asp Asn Ile Ile Asn Gly Lys Trp Ile Ile Leu
 385 390 395 400
 Leu Ser Lys Phe Leu Lys Leu Ile Lys Leu Ala Gly Asp Asn Asn Leu
 405 410 415
 Asn Asn Leu Ser Glu Leu Tyr Phe Leu Phe Arg Ile Phe Gly His Pro
 420 425 430
 Met Val Asp Glu Arg Gln Ala Met Asp Ser Val Arg Ile Asn Cys Asn
 435 440 445
 Glu Thr Lys Phe Tyr Leu Leu Ser Ser Leu Ser Thr Leu Arg Gly Ala
 450 455 460
 Phe Ile Tyr Arg Ile Ile Lys Gly Phe Val Asn Thr Tyr Asn Arg Trp
 465 470 475 480
 Pro Thr Leu Arg Asn Ala Ile Val Leu Pro Leu Arg Trp Leu Asn Tyr
 485 490 495
 Tyr Lys Leu Asn Thr Tyr Pro Ser Leu Leu Glu Ile Thr Glu Asn Asp
 500 505 510
 Leu Ile Ile Leu Ser Gly Leu Arg Phe Tyr Arg Glu Phe His Leu Pro
 515 520 525

Lys Lys Val Asp Leu Glu Met Ile Ile Asn Asp Lys Ala Ile Ser Pro
 530 535 540

Pro Lys Asp Leu Ile Trp Thr Ser Phe Pro Arg Asn Tyr Met Pro Ser
 545 550 555 560

His Ile Gln Asn Tyr Ile Glu His Glu Lys Leu Lys Phe Ser Glu Ser
 565 570 575

Asp Arg Ser Arg Arg Val Leu Glu Tyr Tyr Leu Arg Asp Asn Lys Phe
 580 585 590

Asn Glu Cys Asp Leu Tyr Asn Cys Val Val Asn Gln Ser Tyr Leu Asn
 595 600 605

Asn Ser Asn His Val Val Ser Leu Thr Gly Lys Glu Arg Glu Leu Ser
 610 615 620

Val Gly Arg Met Phe Ala Met Gln Pro Gly Met Phe Arg Gln Ile Gln
 625 630 635 640

Ile Leu Ala Glu Lys Met Ile Ala Glu Asn Ile Leu Gln Phe Phe Pro
 645 650 655

Glu Ser Leu Thr Arg Tyr Gly Asp Leu Glu Leu Gln Lys Ile Leu Glu
 660 665 670

Leu Lys Ala Gly Ile Ser Asn Lys Ser Asn Arg Tyr Asn Asp Asn Tyr
 675 680 685

Asn Asn Tyr Ile Ser Lys Cys Ser Ile Ile Thr Asp Leu Ser Lys Phe
 690 695 700

Asn Gln Ala Phe Arg Tyr Glu Thr Ser Cys Ile Cys Ser Asp Val Leu
 705 710 715 720

Asp Glu Leu His Gly Val Gln Ser Leu Phe Ser Trp Leu His Leu Thr
 725 730 735

Ile Pro Leu Val Thr Ile Ile Cys Thr Tyr Arg His Ala Pro Pro Phe
 740 745 750

Ile Lys Asp His Val Val Asn Leu Asn Glu Val Asp Glu Gln Ser Gly
 755 760 765

Leu Tyr Arg Tyr His Met Gly Gly Ile Glu Gly Trp Cys Gln Lys Leu
 770 775 780

Trp Thr Ile Glu Ala Ile Ser Leu Leu Asp Leu Ile Ser Leu Lys Gly
 785 790 795 800
 Lys Phe Ser Ile Thr Ala Leu Ile Asn Gly Asp Asn Gln Ser Ile Asp
 805 810 815
 Ile Ser Lys Pro Val Arg Leu Ile Glu Gly Gln Thr His Ala Gln Ala
 820 825 830
 Asp Tyr Leu Leu Ala Leu Asn Ser Leu Lys Leu Leu Tyr Lys Glu Tyr
 835 840 845
 Ala Gly Ile Gly His Lys Leu Lys Gly Thr Glu Thr Tyr Ile Ser Arg
 850 855 860
 Asp Met Gln Phe Met Ser Lys Thr Ile Gln His Asn Gly Val Tyr Tyr
 865 870 875 880
 Pro Ala Ser Ile Lys Lys Val Leu Arg Val Gly Pro Trp Ile Asn Thr
 885 890 895
 Ile Leu Asp Asp Phe Lys Val Ser Leu Glu Ser Ile Gly Ser Leu Thr
 900 905 910
 Gln Glu Leu Glu Tyr Arg Gly Glu Ser Leu Leu Cys Ser Leu Ile Phe
 915 920 925
 Arg Asn Ile Trp Leu Tyr Asn Gln Ile Ala Leu Gln Leu Arg Asn His
 930 935 940
 Ala Leu Cys Asn Asn Lys Leu Tyr Leu Asp Ile Leu Lys Val Leu Lys
 945 950 955 960
 His Leu Lys Thr Phe Phe Asn Leu Asp Ser Ile Asp Met Ala Leu Ser
 965 970 975
 Leu Tyr Met Asn Leu Pro Met Leu Phe Gly Gly Gly Asp Pro Asn Leu
 980 985 990
 Leu Tyr Arg Ser Phe Tyr Arg Arg Thr Pro Asp Phe Leu Thr Glu Ala
 995 1000 1005
 Ile Val His Ser Val Phe Val Leu Ser Tyr Tyr Thr Gly His Asp Leu
 1010 1015 1020
 Gln Asp Lys Leu Gln Asp Leu Pro Asp Asp Arg Leu Asn Lys Phe Leu
 1025 1030 1035 1040

Thr Cys Val Ile Thr Phe Asp Lys Asn Pro Asn Ala Glu Phe Val Thr
 1045 1050 1055
 Leu Met Arg Asp Pro Gln Ala Leu Gly Ser Glu Arg Gln Ala Lys Ile
 1060 1065 1070
 Thr Ser Glu Ile Asn Arg Leu Ala Val Thr Glu Val Leu Ser Ile Ala
 1075 1080 1085
 Pro Asn Lys Ile Phe Ser Lys Ser Ala Gln His Tyr Thr Thr Thr Glu
 1090 1095 1100
 Ile Asp Leu Asn Asp Ile Met Gln Asn Ile Glu Pro Thr Tyr Pro His
 1105 1110 1115 1120
 Gly Leu Arg Val Val Tyr Glu Ser Leu Pro Phe Tyr Lys Ala Glu Lys
 1125 1130 1135
 Ile Val Asn Leu Ile Ser Gly Thr Lys Ser Ile Thr Asn Ile Leu Glu
 1140 1145 1150
 Lys Thr Ser Ala Ile Asp Thr Thr Asp Ile Asn Arg Ala Thr Asp Met
 1155 1160 1165
 Met Arg Lys Asn Ile Thr Leu Leu Ile Arg Ile Leu Pro Leu Asp Cys
 1170 1175 1180
 Asn Lys Asp Lys Arg Glu Leu Leu Ser Leu Glu Asn Leu Ser Ile Thr
 1185 1190 1195 1200
 Glu Leu Ser Lys Tyr Val Arg Glu Arg Ser Trp Ser Leu Ser Asn Ile
 1205 1210 1215
 Val Gly Val Thr Ser Pro Ser Ile Met Phe Thr Met Asp Ile Lys Tyr
 1220 1225 1230
 Thr Thr Ser Thr Ile Ala Ser Gly Ile Ile Ile Glu Lys Tyr Asn Val
 1235 1240 1245
 Asn Ser Leu Thr Arg Gly Glu Arg Gly Pro Thr Lys Pro Trp Val Gly
 1250 1255 1260
 Ser Ser Thr Gln Glu Lys Lys Thr Met Pro Val Tyr Asn Arg Gln Val
 1265 1270 1275 1280
 Leu Thr Lys Lys Gln Arg Asp Gln Ile Asp Leu Leu Ala Lys Leu Asp
 1285 1290 1295

Trp Val Tyr Ala Ser Ile Asp Asn Lys Asp Glu Phe Met Glu Glu Leu
 1300 1305 1310
 Ser Thr Gly Thr Leu Gly Leu Ser Tyr Glu Lys Ala Lys Lys Leu Phe
 1315 1320 1325
 Pro Gln Tyr Leu Ser Val Asn Tyr Leu His Arg Leu Thr Val Ser Ser
 1330 1335 1340
 Arg Pro Cys Glu Phe Pro Ala Ser Ile Pro Ala Tyr Arg Thr Thr Asn
 1345 1350 1355 1360
 Tyr His Phe Asp Thr Ser Pro Ile Asn His Val Leu Thr Glu Lys Tyr
 1365 1370 1375
 Gly Asp Glu Asp Ile Asp Ile Val Phe Gln Asn Cys Ile Ser Phe Gly
 1380 1385 1390
 Leu Ser Leu Met Ser Val Val Glu Gln Phe Thr Asn Ile Cys Pro Asn
 1395 1400 1405
 Arg Ile Ile Leu Ile Pro Lys Leu Asn Glu Ile His Leu Met Lys Pro
 1410 1415 1420
 Pro Ile Phe Thr Gly Asp Val Asp Ile Ile Lys Leu Lys Gln Val Ile
 1425 1430 1435 1440
 Gln Lys Gln His Met Phe Leu Pro Asp Lys Ile Ser Leu Thr Gln Tyr
 1445 1450 1455
 Val Glu Leu Phe Leu Ser Asn Lys Ala Leu Lys Ser Gly Ser His Ile
 1460 1465 1470
 Asn Ser Asn Leu Ile Leu Val His Lys Met Ser Asp Tyr Phe His Asn
 1475 1480 1485
 Ala Tyr Ile Leu Ser Thr Asn Leu Ala Gly His Trp Ile Leu Ile Ile
 1490 1495 1500
 Gln Leu Met Lys Asp Ser Lys Gly Ile Phe Glu Lys Asp Trp Gly Glu
 1505 1510 1515 1520
 Gly Tyr Ile Thr Asp His Met Phe Ile Asn Leu Asn Val Phe Phe Asn
 1525 1530 1535
 Ala Tyr Lys Thr Tyr Leu Leu Cys Phe His Lys Gly Tyr Gly Lys Ala
 1540 1545 1550

Lys Leu Glu Cys Asp Met Asn Thr Ser Asp Leu Leu Cys Val Leu Glu
 1555 1560 1565

Leu Ile Asp Ser Ser Tyr Trp Lys Ser Met Ser Lys Val Phe Leu Glu
 1570 1575 1580

Gln Lys Val Ile Lys Tyr Ile Val Asn Gln Asp Thr Ser Leu Arg Arg
 1585 1590 1595 1600

Ile Lys Gly Cys His Ser Phe Lys Leu Trp Phe Leu Lys Arg Leu Asn
 1605 1610 1615

Asn Ala Lys Phe Thr Val Cys Pro Trp Val Val Asn Ile Asp Tyr His
 1620 1625 1630

Pro Thr His Met Lys Ala Ile Leu Ser Tyr Ile Asp Leu Val Arg Met
 1635 1640 1645

Gly Leu Ile Asn Val Asp Lys Leu Thr Ile Lys Asn Lys Asn Lys Phe
 1650 1655 1660

Asn Asp Glu Phe Tyr Thr Ser Asn Leu Phe Tyr Ile Ser Tyr Asn Phe
 1665 1670 1675 1680

Ser Asp Asn Thr His Leu Leu Thr Lys Gln Ile Arg Ile Ala Asn Ser
 1685 1690 1695

Glu Leu Glu Asp Asn Tyr Asn Lys Leu Tyr His Pro Thr Pro Glu Thr
 1700 1705 1710

Leu Glu Asn Met Ser Leu Ile Pro Val Lys Ser Asn Asn Ser Asn Lys
 1715 1720 1725

Pro Lys Phe Cys Ile Ser Gly Asn Thr Glu Ser Met Met Met Ser Thr
 1730 1735 1740

Phe Ser Ser Lys Met His Ile Lys Ser Ser Thr Val Thr Thr Arg Phe
 1745 1750 1755 1760

Asn Tyr Ser Lys Gln Asp Leu Tyr Asn Leu Phe Pro Ile Val Val Ile
 1765 1770 1775

Asp Lys Ile Ile Asp His Ser Gly Asn Thr Ala Lys Ser Asn Gln Leu
 1780 1785 1790

Tyr Thr Thr Thr Ser His Gln Thr Ser Leu Val Arg Asn Ser Ala Ser
 1795 1800 1805

Leu Tyr Cys Met Leu Pro Trp His His Val Asn Arg Phe Asn Phe Val
 1810 1815 1820
 Phe Ser Ser Thr Gly Cys Lys Ile Ser Ile Glu Tyr Ile Leu Lys Asp
 1825 1830 1835 1840
 Leu Lys Ile Lys Asp Pro Ser Cys Ile Ala Phe Ile Gly Glu Gly Ala
 1845 1850 1855
 Gly Asn Leu Leu Leu Arg Thr Val Val Glu Leu His Pro Asp Ile Arg
 1860 1865 1870
 Tyr Ile Tyr Arg Ser Leu Lys Asp Cys Asn Asp His Ser Leu Pro Ile
 1875 1880 1885
 Glu Phe Leu Arg Leu Tyr Asn Gly His Ile Asn Ile Asp Tyr Gly Glu
 1890 1895 1900
 Asn Leu Thr Ile Pro Ala Thr Asp Ala Thr Asn Asn Ile His Trp Ser
 1905 1910 1915 1920
 Tyr Leu His Ile Lys Phe Ala Glu Pro Ile Ser Ile Phe Val Cys Asp
 1925 1930 1935
 Ala Glu Leu Pro Val Thr Ala Asn Trp Ser Lys Ile Ile Ile Glu Trp
 1940 1945 1950
 Ser Lys His Val Arg Lys Cys Lys Tyr Cys Ser Ser Val Asn Arg Cys
 1955 1960 1965
 Ile Leu Ile Ala Lys Tyr His Ala Gln Asp Asp Ile Asp Phe Lys Leu
 1970 1975 1980
 Asp Asn Ile Thr Ile Leu Lys Thr Tyr Val Cys Leu Gly Ser Lys Leu
 1985 1990 1995 2000
 Lys Gly Ser Glu Val Tyr Leu Ile Leu Thr Ile Gly Pro Ala Asn Ile
 2005 2010 2015
 Leu Pro Val Phe Asp Val Val Gln Asn Ala Lys Leu Thr Leu Ser Arg
 2020 2025 2030
 Thr Lys Asn Phe Ile Met Pro Lys Lys Thr Asp Lys Glu Ser Ile Asp
 2035 2040 2045
 Ala Asn Ile Lys Ser Leu Ile Pro Phe Leu Cys Tyr Pro Ile Thr Lys
 2050 2055 2060

Lys Gly Ile Lys Thr Ser Leu Ser Lys Leu Lys Ser Val Val Asn Gly
 2065 2070 2075 2080

Asp Ile Leu Ser Tyr Ser Ile Ala Gly Arg Asn Glu Val Phe Ser Asn
 2085 2090 2095

Lys Leu Ile Asn His Lys His Met Asn Ile Leu Lys Trp Leu Asp His
 2100 2105 2110

Val Leu Asn Phe Arg Ser Ala Glu Leu Asn Tyr Asn His Leu Tyr Met
 2115 2120 2125

Ile Glu Ser Thr Tyr Pro Tyr Leu Ser Glu Leu Leu Asn Ser Leu Thr
 2130 2135 2140

Thr Asn Glu Leu Lys Lys Leu Ile Lys Ile Thr Gly Ser Val Leu Tyr
 2145 2150 2155 2160

Asn Leu Pro Asn Glu Gln
 2165

<210> 3

<211> 15229

<212> DNA

<213> respiratory syncytial virus

<400> 3

acgcgaaaa atgcgtacta caaacttgca cattcggaaa aaatggggca aataagaatt 60
 tgataagtgc tatttaaadc taaccttttc aatcagaaat ggggtgcaat tcactgagca 120
 tgataaaggc tagattacaa aatttatttg acaatgacga agtagcattg ttaaaaaataa 180
 catgttatac tgacaaatta attcttctga ccaatgcatt agccaaagca gtaatacata 240
 caattaaatt aaacggcata gtttttatac atgttataac aagcagtga gttgtccctg 300
 acaacaatat tgtagtgaat tctaacttta caacaatgcc aatattacaa aacggaggat 360
 acatatggga attgattgag ttgacacact gctctcaatc aaatgggtcta atggatgata 420
 attgtgaaat caaattttct aaaagactaa gtgactcagt aatgactaat tatatgaatc 480
 aaatatctga ttacttggg cttgatctca attcatgaat tatgtttagt ctaatttaata 540
 agacatgtgt ttatcaccat tttagttaat ataaaacctc atcaaaggga aatgggggcaa 600
 ataaactcac ctaatcagtc aaaccatgag cactacaaat gacaacacta ctatgcaaag 660
 attgatgatc acagacatga gaccctgtc gatggaatca ataataacat ctctcaccaa 720
 agaaatcata acacacaaat tcatatactt gataaacaat gaatgtattg taagaaaact 780
 tgatgaaaga caagctacat ttacattctt agtcaattat gagatgaagc tattgcacaa 840
 agtagggagt accaaataca agaaatacac tgaatataat acaaaatatg gcactttccc 900
 catgcctata tttatcaatc atgacgggtt tctagaatgt attggcatta agcctacaaa 960
 acacactcct ataataataca aatatgacct caaccgtaa attccaacaa aaaactaacc 1020
 catccaaact aagctattcc tcaaacaaca gtgctcaaca gtttaagaagg agctaatacca 1080
 ttttagtaat taaaaataaaa ggcagagcca ataacataaa ttgggggcaa tacaagatg 1140
 gctcttagca aagtcaagtt aaatgataca ttaaataagg atcagctgct gtcattccagc 1200

```

aaatacacta ttcaäcgtag tacaggagat aatattgaca ctcccaatta tgatgtgcaa 1260
aaacacctaa acaactatg tggatatgcta ttaatcactg aagatgcaaa tcataaattc 1320
acaggattaa taggtatgtt atatgctatg tccagggttag gaagggaaga cactataaag 1380
atacttaaag atgctggata tcatgttaaa gctaattggag tagatataac aacatatcgt 1440
caagatataa acggaagga aatgaaattc gaagtattaa cattatcaag cttgacatca 1500
gaaatacaag tcaatattga gatagaatct agaaagtcct acaaaaaaat gctaaaagag 1560
atgggagaag tggctccaga atataggcat gattctccag actgtgggat gataatactg 1620
tgtatagctg cacttgraar aaccaagtta gcaqcaqqag atagatcagg tcttacagca 1680
gtaattagga gggcaaacaa tgtcttaaaa aacgaaataa aacgctacaa gggcctcata 1740
ccaaaggata tagctaacag tttttatgaa gtgtttgaaa aacaccctca tcttatagat 1800
gtttttgtgc actttggcat tgcacaatca tccacaagag ggggtagtag agttgaagga 1860
atctttgcag gattatttat gaatgcctat ggttcagggc aagtaatgct aagatgggga 1920
gttctagcca aatctgtaaa aaatatcatg ctaggacatg ctagtgtcca ggcagaaatg 1980
gaacaagtgt tgggaagtta tgagtatgca cagaagtgtg gaggagaagc tggattctac 2040
catatattga acaatccaaa agcatcattg ctgtcattaa ctcaatttcc taacttctca 2100
agtgtggtcc taggcaatgc agcaggtcta ggcataatgg gagagtatag aggtacacca 2160
agaaaccaag atctatatga tgcagccaaa gcatatgcag agcaactcaa agaaaaatgga 2220
gtaataaact acagtgtatt agacttaaca gcagaagaat tgggaagccat aaagcatcaa 2280
ctcaacccca aagaagatga tgtagagctt taagttaaca aaaaatacgg ggcaataaag 2340
tcaacatgga gaagtttgca cctgaatttc atggagaaga tgcaaacac aaagctacca 2400
aattcctaga atcaataaag ggcaagtgtg catcatcaa agatcctaag aagaaagata 2460
gcataatc tgtaactca atagatatag aagtaactaa agagagcccg ataacatctg 2520
gcaccaacat catcaatcca ataagtgaag ctgatagtac ccagaagct aaagcgaact 2580
acccaagaaa acccctagta agcttcaaag aagatctcac cccaagtgc aaccctttt 2640
ctaagtgtga caaagaaaca atagaaacat ttgataacaa tgaagaagaa tctagctact 2700
catatgaaga aataaatgat caaacaatg acaacattac agcaagacta gatagaattg 2760
atgaaaaatt aagtgaata ttaggaatgc tccatacatt agtagttgca agtgcaggag 2820
ccacctcagc tcgcgatgga ataagagatg ctatgggttg tctaagagaa gaaatgatag 2880
aaaaaataag agcggaagca ttaatgacca atgatagggt agaggctatg gcaagacta 2940
ggaatgagga aagcgaaaaa atggcaaaa acacctcaga tgaagtgtct cttaatcaa 3000
cttccaaaaa attgagtaat ttgttggaa acaacgatag tgacaatgat ctatcacttg 3060
atgatttttg atcagtgatc aactcactca gcaatcaaca acatcaatga aacagacatc 3120
aatccattga atcaactgcc agactgaaca cacaacgctc catcagcaga actaccaacc 3180
aatcaatcaa ccaattgatc aatcagcgac ctaacaaaat taacaatata gtaacaaaaa 3240
aagaacaaga tggggcaaat atggaaacat acgtgaacaa gcttcacgag ggctccacat 3300
acacagcagc tgttcagtac aatgttctag aaaaagatga tgatcctgca tcaactaaca 3360
tatgggtgcc tatgttccag tcatctgtgc cagcagactt gtcataaaa gaacttgcaa 3420
gcatcaacat actagtgaag cagatctcca cgcccaaagg accttcacta cgagtcacga 3480
ttaactcaag aagtgtgtg ctggcacaaa tgcctagtag ttttatcata agtgcaaatg 3540
tatcattaga tgaaagaagc aaattagcat atgatgtaac tacaccttgt gaaatcaaag 3600
catgcagtct aacatgctta aaagtaaaaa gtatgttaac tacagtcaaa gatcttacca 3660
tgaaaacatt caatcccact catgagatta ttgctctatg tgaatttgaa aatattatga 3720
catcaaaaag agtaataata ccaacctatc taagatcaat tagtgtcaaa aacaaggacc 3780
tgaactcact agaaaatata gcaaccaccg aattcaaaaa tgctatcacc aatgcaaaaa 3840
ttattcccta tgcaggatta gtattagtta tcacagttac tgacaataaa ggagcattca 3900
aatatatcaa gccacagagt caatttatag tagatcttgg ggcctaccta gaaaaagaga 3960
gcatatatta tgtgactaca aattggaagc atacagctac acgtttttca atcaaaccac 4020
tagaggatta aacttaatta tcaacactaa atgacaggtc cacatatatc ttcaaactat 4080

```

acatttatatc caaacatcat gagcattttac actacacact tttaccatat aaatcaatct 4140
 cattttaaatt ccaaaattac ttccagctat catctgttag acctagagtg cgaataggta 4200
 aataaaacca aaatatgggg taaatagaca ttagtttagag ttcaatcaat ctcaacaacc 4260
 atttataaccg ccaattcagt acatatacta taaatctcaa aatgggaaat acatccatca 4320
 caatagaatt cacaagcaaa ttttggcctt attttacact aatacatatg atcttaactc 4380
 taatctcttt actaattata atcactatta tgattgcaat actaaataag ctaagtgaac 4440
 ataaaacatt ctgcaacaaa actcttgaac taggacagat gtatcaaate aacacatagt 4500
 gttctaccar targetgtgt caaattataa tcttgtatat ataaacaaac aaatccaate 4560
 ttctcacaga gtcattggtg cgcaaaacca cgccaaccat catgatagca tagagtagtt 4620
 atttaaaaat taacataatg atgaattatt ggtatgagat caggaacaac attggggcaa 4680
 atgcagccat gtccaagcac aagaatcggc gactgcccgg gactctagaa aggacctggg 4740
 atactcttaa tcatctaatt gtaatatcct cttgtttata cagattaaat ttaaaatcta 4800
 tagcacaaat agcactgtca gttttggcaa tgataatctc aacctctctc ataattgcag 4860
 ccataatatt catcatctct gccaatcaca aggttacact aacaacgggt acagttcaaa 4920
 caataaaaaa ccacactgaa aaaaacatct ccacctacct tactcaagtc ccaccagaaa 4980
 ggggtcaactc atccaaacaa cccacaacca catcaccaat ccacacaaat tcagccacaa 5040
 tatcaccaaa taaaaaatca gaaacacacc atacaacagc acaaaccaaa ggcagaatca 5100
 ccacttcaac acagaccaac aagccaagca caaaatcacg ttcaaaaaat ccaccaaaaa 5160
 aaccaaaga tgattaccat ttggaagtgt tcaattttgt tccctgtagt atatgtggta 5220
 ataatcaact ctgcaaatcc atctgcaaaa caataccaag caacaaacca aagaaaaaac 5280
 caaccatcaa acccacaac aaaccaacca ccaaaaccac aaacaaaaga gaccccaaaa 5340
 caccagccaa aatgccaaaa aaagaaatca tcaccaaccc agcaaaaaaa ccaaccctca 5400
 agaccacaga aagagacacc agcatttcac aatccaccgt gctcgacaca atcactccaa 5460
 aatacacaa ccaacagcaa tccctccact caaccacctc cgaaaacaca ccagctcca 5520
 caaaaatacc cacagcatcc gagccctcca cattaaatcc taattaaaaa acctagtcac 5580
 atgcttagtt attcaaaaac tacatcttag cagagaaccg tgatctatca agcaagaaca 5640
 aaattaaacc tggggcaaat aaccatggag ttgctgatcc acaggtcaag tgcaatcttc 5700
 ctaactcttg ctgttaatgc attgtacctc acctcaagtc agaacataac tgaggagttt 5760
 taccaatcga catgtagtgc agtttagcaga ggttatttta gtgctttaag aacagggttg 5820
 tataccagtg tcataacaat agaattaaat aatataaaag aaaccaaag caatggaact 5880
 gacactaaag taaaacttat aaaacaagaa ttagataagt ataagaatgc agtaacagaa 5940
 ttacagctac ttatgcaaaa cagccagct gccacaacc gggccagaag agaagcacca 6000
 cagtacatga actacacaat caataccaca aaaaacctaa atgtatcaat aagcaagaaa 6060
 aggaacgaa gatttctggg cttcttggtt ggtgtaggat ctgcaatagc aagtggata 6120
 gctgtatcca aagttttaca cttgaagga gaagtgaaca aaatcaaaaa tgctttgttg 6180
 tctacaaaca aagctgtagt cagtctatca aatggggtca gtgttttaac cagcaaagt 6240
 ttagatctca agaattacat aaataaccga atattacca tagtaaatca acagagctgt 6300
 cgcattctca acattgaaac agttatagaa ttccagcaga agaatagcag attgttgga 6360
 atcaccagag aatttagtgt taatgcaggt gtaacaacac ctttaagcac ttacatgta 6420
 acaaacagtg agttactatc attgatcaat gatatgccta taacaaatga ccagaaaaa 6480
 ttaatgtcaa gcaatgttca gatagtaagg caacaaagt attctatcat gtctataata 6540
 aaggaagaag tccttgcata tgtgtacag ctacctatct atggtgtaat agatacacct 6600
 tgctggaaat tacacacatc acctctatgc accaccaaca tcaaagaagg atcaaatatt 6660
 tgtttaacaa ggactgatag aggatgggtat tgtgataatg caggatcagt atcttcttc 6720
 ccacaggctg atacttgcaa agtacagtc aatcgagtat tttgtgacac tatgaacagt 6780
 ttaacattac caagtgaagt cagcctttgt aacactgaca tattcaattc caagtatgac 6840
 tgcaaaatta tgacatcaaa aacagacata agcagctcag taattacttc tcttgagct 6900
 atagtgtcat gctatggaaa aactaaatgc actgcatcca ataaaaatcg tgggattata 6960

aagacatttt ctaatggttg tgactatgtg tcaaacaaag gagtagatac tgtgtcagtg 7020
ggcaacacct tatactatgt aaacaagctg gaaggcaaaa acctttatgt aaaaggggaa 7080
cctataataa attactatga tctcttagtg tttccttctg atgagtttga tgcatacata 7140
tctcaagtca atgaaaaaat caatcaaagt ttagctttta ttcgtagatc tgatgaatta 7200
ctacataatg taaatactgg caaatctact acaaatatta tgataactac aattattata 7260
gtaatcattg tagtattggt atcattaata gctattggtt tactgttgta ttgcaaagcc 7320
aaaaacacac cagttacact aagcaaagac caactaagtg gaatcaataa tattgcatcc 7380
agcaaaalaga caaaaaacta ctttaactatg tttcaaacac aatctgctga ccaccaatcc 7440
caaatcaact taacaacaaa tatttcaaca tcatagcaca ggctgaatca tttcctcata 7500
tcatgctacc tacacaacta agctagatct tcaactcata gttacataaa aaccccaagt 7560
atcacaaatca aacactaaat cgacacatca ttcacaaaat taacaactgg ggcaaatatg 7620
tcgcgaagaa atccttgtaa atttgagatt agaggtcatt gcttgaatgg tagaagatgt 7680
cactacagtc ataattattt tgaatggcct cctcatgcat tactagttag gcaaaaacttc 7740
atgttaaaca agatacttaa gtcaatggac aaaagcatag acactttgtc ggaaataagt 7800
ggagctgctg aactggatag aacagaagaa tatgctcttg gtatagttgg agtgctagag 7860
agttacatag gatcaataaa caacataaca aaacaatcag catgtgttgc tatgagtaaa 7920
cttcttattg agatcaacag tgatgacatt aaaaaactga gagataacga agaaccat 7980
tcgcctaaga taagagtgtg caatactggt atatcataca ttgagagcaa tagaaaaaac 8040
aacaagcaaa ccatccatct gctcaaaaga ctaccagcag acgtgctgaa gaagacaata 8100
aagaacacat tagatatcca caaaagcata accataagca actcaaaaga gtcaaccgtg 8160
aatgatcaaa atgaccaaac caaaaataat gatattaccg gataaatac cttgtagtat 8220
atcatccata ttgatttcaa gtgaaagcat gattgctaca ttcaatcata aaaacatatt 8280
acaatttaac cataaccatt tggataacca ccagtgttta ttaaatcata tatttgatga 8340
aattcattgg acacctaaaa acttattaga tggcactcaa caatttctcc aacatcttaa 8400
catccttgaa gatatatata cagtatatat attagtgtca taatgcttga ccataacaat 8460
tttatatcat tcaaccataa aacaacctta ataaggttat gggacaaaat ggatcccatt 8520
attaatggaa actctgcca tgtgtatcta actgatagtt atctaaaagg tgttatctct 8580
ttttcagaat gtaatgcttt agggagtta ctttttaacg gccctatct taaaaatgat 8640
tacaccaact taattagtag acaaagccca ctactagagc atatgaatct aaaaaacta 8700
actataacac agtcattaat atctagatat cataaagggt aactgaagtt agaagaacca 8760
acttatttcc agtcattact tatgacatat aaaagtatgt cctcgtctga acaaatgtct 8820
acaactaatt tacttaaaaa aataatacga agagctatag aaataagtga tgtaaagggt 8880
tacgccatct tgaataaact gggactaaag gaaaaggaca gagttaagcc caacaataat 8940
tcaggtgatg aaaactcagt tcttacaacc ataatcaaag atgatatact ttcagctgtg 9000
gaaaacaatc aatcatatac aaattcagac aaaaatcatt cagtaaatca aaatatcact 9060
atcaaaaaca cactcttgaa aaaattgatg tgttcaatgc aacatcctcc atcatgggtta 9120
atacactggg tcaatttata tacaaaatta aataacatat taacacaata tcgatcaaat 9180
gaggtaaaaa gtcattgggt tatattaata gataatcaaa ctttaagtga ttttcagttt 9240
attttaaatc aatatgggtg tatcgtttat cataaaggac tcaaaaaaat cacaactact 9300
acttacaatc aatttttgac atggaaagac atcagcctta gcagattaaa tgtttgctta 9360
attacttggg taagtaattg tttaaatata ttaaataaaa gcttaggggt gagatgtgga 9420
ttcaataatg ttgtgttatc acaactattt ctttatggag attgtatact gaaattattc 9480
cataatgaag gcttctacat aataaaaaga gtagagggat ttattatgtc ttttaattcta 9540
aacataacag aagaagatca atttaggaaa cgattttata atagcatgct aaataacatc 9600
acagatgcag ctattaaggc tcaaaaaaac ctactatcaa gagtatgtca cactttatta 9660
gacaagacag tgtctgataa tatcataaat ggtaaatgga taatcctatt aagtaaat 9720
cttaaatgga ttaagcttgc aggtgataat aatctcaata acttgagtga gctttatttt 9780
ctcttcagaa tctttggaca tccaatgggt gatgaaagac aagcaatgga tgctgtaaga 9840

attaactgta atgaaaccaa gttctactta ttaagtaatc taagtacgtt aagaggtgct 9900
 ttcatTTata gaatacataa ggggttttga aatacctaca acagatggcc cactttaagg 9960
 aatgctattg ttctacctct aagatgggtg aactattata aacttaatac ttatccatct 10020
 ctacttgaaa tcacagagaa agatttgatt attttatcag gattgCGgtt ctatcgtgag 10080
 ttcatctgc ctaaaaaagt ggatcttgaa atgataataa atgacaaaag catttcacct 10140
 ccaaaagatt taatatggac tagtttttcc agaaattaca tgccatcaca tatacaaaat 10200
 tatatagaac atgaaaagt gaagttctct gaaagtgaca gatcaagaag agtactagag 10260
 tattacilya yagataataa attcaatgaa tgcgatacat acaatttgtt ggtcaatcaa 10320
 agtatctca acaactctaa ccatgtggta tcaactaactg gtaaagaaag agagctcagt 10380
 gtaggtagaa tgtttgctat gcaaccaggt atgttttaggc aaattcaaat cttagcagag 10440
 aaaatgatag ccgaaaatat ttacaattc ttccctgaga gtttgacaag atatggtgat 10500
 ctagagcttc aaaagatatt agaattaaaa gcaggaataa gcaacaagtc aaatcgttat 10560
 aatgataact acaacaatta ttcagtaaa tgttctatca ttacagacct tagcaaatc 10620
 aatcaagcat ttgatatga aacatcatgt atctgcagt atgtattaga tgaactgcat 10680
 ggagtacaat ctctgttctc ttggttgcat ttaacaatac ctcttgctac aataatatgt 10740
 acatatagac atgcacctcc tttataaaag gatcatgttg ttaatcttaa taaagttgat 10800
 gaacaaagt gattatacag atatcatatg ggtggtattg aaggctgggt tcaaaaactg 10860
 tggaccattg aagctatatc attattagat ctaatatctc tcaagggaag attctctatc 10920
 acagctctaa taaatggtga taatcagtca attgatataa gtaaaccagt tagacttata 10980
 gagggtcaga cccatgctca agcagattat ttgttagcat taaatagcct taaattgcta 11040
 tataaagagt atgcgggcat aggccacaag ctcaagggaag cagagaccta tatatccca 11100
 gatatgcaat tcatgagcaa aacaatccag cacaatggag tgtactatcc agccagtatc 11160
 aaaaaagtc tgagagtagg tccatggata aatacaatac ttgatgattt taaagttagt 11220
 ttagaatcta taggtagctt aacacaggag ttagaatata gaggagagag cttattatgc 11280
 agtttaatat ttaggaacat ttggttatac aatcaaatg ctttgcaact ccgaaatcat 11340
 gcattatgtc acaataagct atatttagat atattgaaag tattaaaaca cttaaaaact 11400
 ttttttaate ttgatagtat tgatattggt ttaacattgt atatgaattt gcctatgctg 11460
 ttggtggtg gtgatcctaa tttgttatat cgaagctttt ataggagaac tccagacttc 11520
 cttacagaag ctatagtaca ttcagtgtt gtgttgagct attatactgg tcacgattta 11580
 caagataagc tccaggatct tccagatgat agactgaaca aattcttgac atgtatcatc 11640
 acgtttgata aaaatcccaa tgccgagttt gtaacattga tgagagatcc acaggcttta 11700
 gggctctgaaa ggcaagcaaa aattactagt gagattaata gattagcagt gacagaagtc 11760
 ttaagtatag ctccaaacaa aatattttct aaaagtgcac aacattatac taccactgag 11820
 attgatctaa atgatattat gcaaaatata gaaccaactt accctcatgg attaagagtt 11880
 gtttatgaaa gtttaccttt ttataaaagca gaaaaaatag ttaatcttat atcaggaaca 11940
 aaatccataa ctaatatact tgaaaaaaca tcagcaatag attcaactga tattaatagg 12000
 gctactgata tgatgaggaa aaatataact ttacttataa ggatacttcc actagattgt 12060
 aacaaagaca aaagagagtt attaagttta gaaaatctta gtataactga attaagcaag 12120
 tatgtaagag aaagatcttg gtcgttatcc aatatagtag gagtaacatc gccagattt 12180
 atgttcacaa tggacattaa atatacaact agcactatag ccagtgggtat aattatagaa 12240
 aaatataatg ttaatagttt aactcgtggt gaaagaggac ctactaagcc atgggtagggt 12300
 tcatctacgc aggagaaaaa acaaatgcca gtgtacaata gacaagtttt aacaaaaaag 12360
 caaagagacc aaatagattt attagcaaaa ttagactggg tatatgcatc catagacaac 12420
 aaagatgaat tcatggaaga actgagtact ggaacacttg gactgtcata tgagaaagcc 12480
 aaaaaattgt ttccacaata tctaagtgtc aattatttac accgcttaac agtcagtagt 12540
 agaccatgtg aattccctgc atcaatacca gcttatagaa caacaaatta tcatttcgat 12600
 actagtccta tcaacctgtt attaacagaa aagtatggag atgaagatat cgacattgtg 12660
 tttcaaaatt gcataagttt tggctcttagc ttaatgtcgg ttgtggaaca attcacaac 12720

```

atatgtccta atagaattat tctcataccg aagctgaatg agatacattt gatgaaacct 12780
cctatattta caggagatgt tgatatcatc aagttgaagc aagtataca aaaacagcac 12840
atgttcctac cagataaaaat aagtttaacc caatatgtag aattattcct aagtaacaaa 12900
gcacttaaat ctggatctca catcaactct aatttaatat tagtacataa aatgtctgat 12960
tattttcata atgcttatat ttttaagtact aatttagctg gacattggat tctgattatt 13020
caacttatga aggattcaaa aggtatTTTT gaaaaagatt ggggagaggg gtatataact 13080
gatcatatgt tcattaattt gaatgttttc tttaatgctt ataagactta tttgctatgt 13140
tttcaiaaag gttatggtaa agcaaaatTA gaargtgata tgaacacttc agatcttctt 13200
tgtgttttgg agctaataga cagtagctac tggaaatcta tgtctaaagt tttcctagaa 13260
caaaaagtca taaaatacat aatcaatcaa gacacaagtt tgcatagaat aaaagggtgt 13320
catagtttta agttatgggt tttaaaacgc ctttaaatatg cttaaatttac cgtatgccct 13380
tgggttgtaa acatagatta tcaccaaca cacatgaaag ctatattatc ttacatagat 13440
ttagttagaa tggggttaat aaatgtagat aaattaacca ttaaaaaataa aaataaattc 13500
aatgatgaat tttacacatc aaatctcttt tacattagtt ataacttttc agataaact 13560
catttgctaa caaaacaaat aagaattgct aattcagaat tagaaaaataa ttataacaaa 13620
ctatatcacc caacccaga aactttagaa aatatgtcat taattcctgt caaaagtaat 13680
aatagtaata aacctaattt tgggtataagt ggaataaccg aatctatgat gacgtcaaca 13740
ttctccaata aaacgcatat taaatcttcc gctgttatta caagattcaa ttatagtaaa 13800
caagacttgt acaatttatt tccaattgtc gtgatagaca ggattataga tcattcaggt 13860
aatacagcaa aatctaacca actctacact accacttcac atcagacatc tttagtaagg 13920
aatagtgcac cactttattg catgcttctt tggcatcatg tcaatagatt taactttgta 13980
tttagttcca caggatgcaa gatcagtata gagtatattt taaaagatct taagattaaa 14040
gacccagtt gtatagcatt cataggtgaa ggagctggta acttattatt acgtacagta 14100
gtagaacttc atccagacat aagatacatt tacagaagtt taaaagattg caatgatcat 14160
agtttaccta ttgaatttct aagggtatata aacgggcata taaacataga ttatggtgag 14220
aatttaacca ttcttgctac agatgcaact aataacattc attggtctta tttacatata 14280
aaatttgtag aacctattag catttttgtc tgcgatgctg aattacctgt tacagccaat 14340
tggagtataa ttataattga atggagtaag catgtaagaa agtgcaagta ctgttctct 14400
gtaaatagat gcattttaat tgcaaaatat catgcccaag atgatattga tttcaaatta 14460
gataacatta ctatattaaa aacttacgtg tgcctaggta gcaagttaa aggatctgaa 14520
gtttacttag tccttacaat aggccttgca aatatacttc ctgtttttaa tgttggtgaa 14580
aatgctaaat tgattctttc aaggactaaa aatttcatta tgcctaaaaa aactgacaaa 14640
gaatctatcg atgcaaatat taaaagctta ataccttcc tttgttacc tataacaaa 14700
aaaggaatta agacttcatt gtcaaaattg aagagtgtag ttagtggaga tatattatca 14760
tattctatag ctggacgtaa tgaagtattc agcaacaagc ttataaacca caagcatatg 14820
aatatcctaa aatggctaga tcatgtttta aacttttagat cagctgaact taattacaat 14880
catttatata tgatagagtc cacatctctt tacttaagtg aattgttaa cagtttaaca 14940
accaatgagc tcaagaagct gattaaaata acaggtagtg tactatacaa cttcccaac 15000
gaacagtaac ttaaaacatc attaacaagt ttgatcaaat ttagatgcta acacatcata 15060
atattatagt tattaaaaaa tatatatgca aacttttcaa taatttagca tattgattcc 15120
aaagttatca ttttggctct aaggggttga ataaaaatct aaaactaaca attatacatg 15180
tgcatttaca acacaacgag acattagttt ttgacacttt ttttctcgt 15229

```

<210> 4

<211> 2166

<212> PRT

<213> respiratory syncytial virus

<400> 4

```

Met Asp Pro Ile Ile Asn Gly Asn Ser Ala Asn Val Tyr Leu Thr Asp
 1             5             10             15

Ser Tyr Leu Lys Gly Val Ile Ser Phe Ser Glu Cys Asn Ala Leu Gly
      20             25             30

Ser Tyr Leu Phe Asn Gly Pro Tyr Leu Lys Asn Asp Tyr Thr Asn Leu
      35             40             45

Ile Ser Arg Gln Ser Pro Leu Leu Glu His Met Asn Leu Lys Lys Leu
      50             55             60

Thr Ile Thr Gln Ser Leu Ile Ser Arg Tyr His Lys Gly Glu Leu Lys
      65             70             75             80

Leu Glu Glu Pro Thr Tyr Phe Gln Ser Leu Leu Met Thr Tyr Lys Ser
      85             90             95

Met Ser Ser Ser Glu Gln Ile Ala Thr Thr Asn Leu Leu Lys Lys Ile
      100            105            110

Ile Arg Arg Ala Ile Glu Ile Ser Asp Val Lys Val Tyr Ala Ile Leu
      115            120            125

Asn Lys Leu Gly Leu Lys Glu Lys Asp Arg Val Lys Pro Asn Asn Asn
      130            135            140

Ser Gly Asp Glu Asn Ser Val Leu Thr Thr Ile Ile Lys Asp Asp Ile
      145            150            155            160

Leu Ser Ala Val Glu Asn Asn Gln Ser Tyr Thr Asn Ser Asp Lys Asn
      165            170            175

His Ser Val Asn Gln Asn Ile Thr Ile Lys Thr Thr Leu Leu Lys Lys
      180            185            190

Leu Met Cys Ser Met Gln His Pro Pro Ser Trp Leu Ile His Trp Phe
      195            200            205

Asn Leu Tyr Thr Lys Leu Asn Asn Ile Leu Thr Gln Tyr Arg Ser Asn
      210            215            220

Glu Val Lys Ser His Gly Phe Ile Leu Ile Asp Asn Gln Thr Leu Ser
      225            230            235            240

Asp Phe Gln Phe Ile Leu Asn Gln Tyr Gly Cys Ile Val Tyr His Lys
      245            250            255

```

Gly Leu Lys Lys Ile Thr Thr Thr Tyr Asn Gln Phe Leu Thr Trp
 260 265 270

Lys Asp Ile Ser Leu Ser Arg Leu Asn Val Cys Leu Ile Thr Trp Ile
 275 280 285

Ser Asn Cys Leu Asn Thr Leu Asn Lys Ser Leu Gly Leu Arg Cys Gly
 290 295 300

Phe Asn Asn Val Val Leu Ser Gln Leu Phe Leu Tyr Gly Asp Cys Ile
 305 310 315 320

Leu Lys Leu Phe His Asn Glu Gly Phe Tyr Ile Ile Lys Glu Val Glu
 325 330 335

Gly Phe Ile Met Ser Leu Ile Leu Asn Ile Thr Glu Glu Asp Gln Phe
 340 345 350

Arg Lys Arg Phe Tyr Asn Ser Met Leu Asn Asn Ile Thr Asp Ala Ala
 355 360 365

Ile Lys Ala Gln Lys Asn Leu Leu Ser Arg Val Cys His Thr Leu Leu
 370 375 380

Asp Lys Thr Val Ser Asp Asn Ile Ile Asn Gly Lys Trp Ile Ile Leu
 385 390 395 400

Leu Ser Lys Phe Leu Lys Leu Ile Lys Leu Ala Gly Asp Asn Asn Leu
 405 410 415

Asn Asn Leu Ser Glu Leu Tyr Phe Leu Phe Arg Ile Phe Gly His Pro
 420 425 430

Met Val Asp Glu Arg Gln Ala Met Asp Ala Val Arg Ile Asn Cys Asn
 435 440 445

Glu Thr Lys Phe Tyr Leu Leu Ser Asn Leu Ser Thr Leu Arg Gly Ala
 450 455 460

Phe Ile Tyr Arg Ile Ile Lys Gly Phe Val Asn Thr Tyr Asn Arg Trp
 465 470 475 480

Pro Thr Leu Arg Asn Ala Ile Val Leu Pro Leu Arg Trp Leu Asn Tyr
 485 490 495

Tyr Lys Leu Asn Thr Tyr Pro Ser Leu Leu Glu Ile Thr Glu Lys Asp
 500 505 510

Leu Ile Ile Leu Ser Gly Leu Arg Phe Tyr Arg Glu Phe His Leu Pro
 515 520 525
 Lys Lys Val Asp Leu Glu Met Ile Ile Asn Asp Lys Ala Ile Ser Pro
 530 535 540
 Pro Lys Asp Leu Ile Trp Thr Ser Phe Pro Arg Asn Tyr Met Pro Ser
 545 550 555 560
 His Ile Gln Asn Tyr Ile Glu His Glu Lys Leu Lys Phe Ser Glu Ser
 565 570 575
 Asp Arg Ser Arg Arg Val Leu Glu Tyr Tyr Leu Arg Asp Asn Lys Phe
 580 585 590
 Asn Glu Cys Asp Leu Tyr Asn Cys Val Val Asn Gln Ser Tyr Leu Asn
 595 600 605
 Asn Ser Asn His Val Val Ser Leu Thr Gly Lys Glu Arg Glu Leu Ser
 610 615 620
 Val Gly Arg Met Phe Ala Met Gln Pro Gly Met Phe Arg Gln Ile Gln
 625 630 635 640
 Ile Leu Ala Glu Lys Met Ile Ala Glu Asn Ile Leu Gln Phe Phe Pro
 645 650 655
 Glu Ser Leu Thr Arg Tyr Gly Asp Leu Glu Leu Gln Lys Ile Leu Glu
 660 665 670
 Leu Lys Ala Gly Ile Ser Asn Lys Ser Asn Arg Tyr Asn Asp Asn Tyr
 675 680 685
 Asn Asn Tyr Ile Ser Lys Cys Ser Ile Ile Thr Asp Leu Ser Lys Phe
 690 695 700
 Asn Gln Ala Phe Arg Tyr Glu Thr Ser Cys Ile Cys Ser Asp Val Leu
 705 710 715 720
 Asp Glu Leu His Gly Val Gln Ser Leu Phe Ser Trp Leu His Leu Thr
 725 730 735
 Ile Pro Leu Val Thr Ile Ile Cys Thr Tyr Arg His Ala Pro Pro Phe
 740 745 750
 Ile Lys Asp His Val Val Asn Leu Asn Lys Val Asp Glu Gln Ser Gly
 755 760 765

Leu Tyr Arg Tyr His Met Gly Gly Ile Glu Gly Trp Cys Gln Lys Leu
 770 775 780
 Trp Thr Ile Glu Ala Ile Ser Leu Leu Asp Leu Ile Ser Leu Lys Gly
 785 790 795 800
 Lys Phe Ser Ile Thr Ala Leu Ile Asn Gly Asp Asn Gln Ser Ile Asp
 805 810 815
 Ile Ser Lys Pro Val Arg Leu Ile Glu Gly Gln Thr His Ala Gln Ala
 820 825 830
 Asp Tyr Leu Leu Ala Leu Asn Ser Leu Lys Leu Leu Tyr Lys Glu Tyr
 835 840 845
 Ala Gly Ile Gly His Lys Leu Lys Gly Thr Glu Thr Tyr Ile Ser Arg
 850 855 860
 Asp Met Gln Phe Met Ser Lys Thr Ile Gln His Asn Gly Val Tyr Tyr
 865 870 875 880
 Pro Ala Ser Ile Lys Lys Val Leu Arg Val Gly Pro Trp Ile Asn Thr
 885 890 895
 Ile Leu Asp Asp Phe Lys Val Ser Leu Glu Ser Ile Gly Ser Leu Thr
 900 905 910
 Gln Glu Leu Glu Tyr Arg Gly Glu Ser Leu Leu Cys Ser Leu Ile Phe
 915 920 925
 Arg Asn Ile Trp Leu Tyr Asn Gln Ile Ala Leu Gln Leu Arg Asn His
 930 935 940
 Ala Leu Cys His Asn Lys Leu Tyr Leu Asp Ile Leu Lys Val Leu Lys
 945 950 955 960
 His Leu Lys Thr Phe Phe Asn Leu Asp Ser Ile Asp Met Ala Leu Thr
 965 970 975
 Leu Tyr Met Asn Leu Pro Met Leu Phe Gly Gly Gly Asp Pro Asn Leu
 980 985 990
 Leu Tyr Arg Ser Phe Tyr Arg Arg Thr Pro Asp Phe Leu Thr Glu Ala
 995 1000 1005
 Ile Val His Ser Val Phe Val Leu Ser Tyr Tyr Thr Gly His Asp Leu
 1010 1015 1020

Gln Asp Lys Leu Gln Asp Leu Pro Asp Asp Arg Leu Asn Lys Phe Leu
 1025 1030 1035 1040

Thr Cys Ile Ile Thr Phe Asp Lys Asn Pro Asn Ala Glu Phe Val Thr
 1045 1050 1055

Leu Met Arg Asp Pro Gln Ala Leu Gly Ser Glu Arg Gln Ala Lys Ile
 1060 1065 1070

Thr Ser Glu Ile Asn Arg Leu Ala Val Thr Glu Val Leu Ser Ile Ala
 1075 1080 1085

Pro Asn Lys Ile Phe Ser Lys Ser Ala Gln His Tyr Thr Thr Thr Glu
 1090 1095 1100

Ile Asp Leu Asn Asp Ile Met Gln Asn Ile Glu Pro Thr Tyr Pro His
 1105 1110 1115 1120

Gly Leu Arg Val Val Tyr Glu Ser Leu Pro Phe Tyr Lys Ala Glu Lys
 1125 1130 1135

Ile Val Asn Leu Ile Ser Gly Thr Lys Ser Ile Thr Asn Ile Leu Glu
 1140 1145 1150

Lys Thr Ser Ala Ile Asp Ser Thr Asp Ile Asn Arg Ala Thr Asp Met
 1155 1160 1165

Met Arg Lys Asn Ile Thr Leu Leu Ile Arg Ile Leu Pro Leu Asp Cys
 1170 1175 1180

Asn Lys Asp Lys Arg Glu Leu Leu Ser Leu Glu Asn Leu Ser Ile Thr
 1185 1190 1195 1200

Glu Leu Ser Lys Tyr Val Arg Glu Arg Ser Trp Ser Leu Ser Asn Ile
 1205 1210 1215

Val Gly Val Thr Ser Pro Ser Ile Met Phe Thr Met Asp Ile Lys Tyr
 1220 1225 1230

Thr Thr Ser Thr Ile Ala Ser Gly Ile Ile Ile Glu Lys Tyr Asn Val
 1235 1240 1245

Asn Ser Leu Thr Arg Gly Glu Arg Gly Pro Thr Lys Pro Trp Val Gly
 1250 1255 1260

Ser Ser Thr Gln Glu Lys Lys Thr Met Pro Val Tyr Asn Arg Gln Val
 1265 1270 1275 1280

Leu Thr Lys Lys Gln Arg Asp Gln Ile Asp Leu Leu Ala Lys Leu Asp
 1285 1290 1295
 Trp Val Tyr Ala Ser Ile Asp Asn Lys Asp Glu Phe Met Glu Glu Leu
 1300 1305 1310
 Ser Thr Gly Thr Leu Gly Leu Ser Tyr Glu Lys Ala Lys Lys Leu Phe
 1315 1320 1325
 Pro Gln Tyr Leu Ser Val Asn Tyr Leu His Arg Leu Thr Val Ser Ser
 1330 1335 1340
 Arg Pro Cys Glu Phe Pro Ala Ser Ile Pro Ala Tyr Arg Thr Thr Asn
 1345 1350 1355 1360
 Tyr His Phe Asp Thr Ser Pro Ile Asn His Val Leu Thr Glu Lys Tyr
 1365 1370 1375
 Gly Asp Glu Asp Ile Asp Ile Val Phe Gln Asn Cys Ile Ser Phe Gly
 1380 1385 1390
 Leu Ser Leu Met Ser Val Val Glu Gln Phe Thr Asn Ile Cys Pro Asn
 1395 1400 1405
 Arg Ile Ile Leu Ile Pro Lys Leu Asn Glu Ile His Leu Met Lys Pro
 1410 1415 1420
 Pro Ile Phe Thr Gly Asp Val Asp Ile Ile Lys Leu Lys Gln Val Ile
 1425 1430 1435 1440
 Gln Lys Gln His Met Phe Leu Pro Asp Lys Ile Ser Leu Thr Gln Tyr
 1445 1450 1455
 Val Glu Leu Phe Leu Ser Asn Lys Ala Leu Lys Ser Gly Ser His Ile
 1460 1465 1470
 Asn Ser Asn Leu Ile Leu Val His Lys Met Ser Asp Tyr Phe His Asn
 1475 1480 1485
 Ala Tyr Ile Leu Ser Thr Asn Leu Ala Gly His Trp Ile Leu Ile Ile
 1490 1495 1500
 Gln Leu Met Lys Asp Ser Lys Gly Ile Phe Glu Lys Asp Trp Gly Glu
 1505 1510 1515 1520
 Gly Tyr Ile Thr Asp His Met Phe Ile Asn Leu Asn Val Phe Phe Asn
 1525 1530 1535

Ala Tyr Lys Thr Tyr Leu Leu Cys Phe His Lys Gly Tyr Gly Lys Ala
 1540 1545 1550
 Lys Leu Glu Cys Asp Met Asn Thr Ser Asp Leu Leu Cys Val Leu Glu
 1555 1560 1565
 Leu Ile Asp Ser Ser Tyr Trp Lys Ser Met Ser Lys Val Phe Leu Glu
 1570 1575 1580
 Gln Lys Val Ile Lys Tyr Ile Ile Asn Gln Asp Thr Ser Leu His Arg
 1585 1590 1595 1600
 Ile Lys Gly Cys His Ser Phe Lys Leu Trp Phe Leu Lys Arg Leu Asn
 1605 1610 1615
 Asn Ala Lys Phe Thr Val Cys Pro Trp Val Val Asn Ile Asp Tyr His
 1620 1625 1630
 Pro Thr His Met Lys Ala Ile Leu Ser Tyr Ile Asp Leu Val Arg Met
 1635 1640 1645
 Gly Leu Ile Asn Val Asp Lys Leu Thr Ile Lys Asn Lys Asn Lys Phe
 1650 1655 1660
 Asn Asp Glu Phe Tyr Thr Ser Asn Leu Phe Tyr Ile Ser Tyr Asn Phe
 1665 1670 1675 1680
 Ser Asp Asn Thr His Leu Leu Thr Lys Gln Ile Arg Ile Ala Asn Ser
 1685 1690 1695
 Glu Leu Glu Asn Asn Tyr Asn Lys Leu Tyr His Pro Thr Pro Glu Thr
 1700 1705 1710
 Leu Glu Asn Met Ser Leu Ile Pro Val Lys Ser Asn Asn Ser Asn Lys
 1715 1720 1725
 Pro Lys Phe Gly Ile Ser Gly Asn Thr Glu Ser Met Met Thr Ser Thr
 1730 1735 1740
 Phe Ser Asn Lys Thr His Ile Lys Ser Ser Ala Val Ile Thr Arg Phe
 1745 1750 1755 1760
 Asn Tyr Ser Lys Gln Asp Leu Tyr Asn Leu Phe Pro Ile Val Val Ile
 1765 1770 1775
 Asp Arg Ile Ile Asp His Ser Gly Asn Thr Ala Lys Ser Asn Gln Leu
 1780 1785 1790

Tyr Thr Thr Thr Ser His Gln Thr Ser Leu Val Arg Asn Ser Ala Ser
 1795 1800 1805
 Leu Tyr Cys Met Leu Pro Trp His His Val Asn Arg Phe Asn Phe Val
 1810 1815 1820
 Phe Ser Ser Thr Gly Cys Lys Ile Ser Ile Glu Tyr Ile Leu Lys Asp
 1825 1830 1835 1840
 Leu Lys Ile Lys Asp Pro Ser Cys Ile Ala Phe Ile Gly Glu Gly Ala
 1845 1850 1855
 Gly Asn Leu Leu Leu Arg Thr Val Val Glu Leu His Pro Asp Ile Arg
 1860 1865 1870
 Tyr Ile Tyr Arg Ser Leu Lys Asp Cys Asn Asp His Ser Leu Pro Ile
 1875 1880 1885
 Glu Phe Leu Arg Leu Tyr Asn Gly His Ile Asn Ile Asp Tyr Gly Glu
 1890 1895 1900
 Asn Leu Thr Ile Pro Ala Thr Asp Ala Thr Asn Asn Ile His Trp Ser
 1905 1910 1915 1920
 Tyr Leu His Ile Lys Phe Ala Glu Pro Ile Ser Ile Phe Val Cys Asp
 1925 1930 1935
 Ala Glu Leu Pro Val Thr Ala Asn Trp Ser Lys Ile Ile Ile Glu Trp
 1940 1945 1950
 Ser Lys His Val Arg Lys Cys Lys Tyr Cys Ser Ser Val Asn Arg Cys
 1955 1960 1965
 Ile Leu Ile Ala Lys Tyr His Ala Gln Asp Asp Ile Asp Phe Lys Leu
 1970 1975 1980
 Asp Asn Ile Thr Ile Leu Lys Thr Tyr Val Cys Leu Gly Ser Lys Leu
 1985 1990 1995 2000
 Lys Gly Ser Glu Val Tyr Leu Val Leu Thr Ile Gly Pro Ala Asn Ile
 2005 2010 2015
 Leu Pro Val Phe Asn Val Val Gln Asn Ala Lys Leu Ile Leu Ser Arg
 2020 2025 2030
 Thr Lys Asn Phe Ile Met Pro Lys Lys Thr Asp Lys Glu Ser Ile Asp
 2035 2040 2045

Ala Asn Ile Lys Ser Leu Ile Pro Phe Leu Cys Tyr Pro Ile Thr Lys
 2050 2055 2060

Lys Gly Ile Lys Thr Ser Leu Ser Lys Leu Lys Ser Val Val Ser Gly
 2065 2070 2075 2080

Asp Ile Leu Ser Tyr Ser Ile Ala Gly Arg Asn Glu Val Phe Ser Asn
 2085 2090 2095

Lys Leu Ile Asn His Lys His Met Asn Ile Leu Lys Trp Leu Asp His
 2100 2105 2110

Val Leu Asn Phe Arg Ser Ala Glu Leu Asn Tyr Asn His Leu Tyr Met
 2115 2120 2125

Ile Glu Ser Thr Tyr Pro Tyr Leu Ser Glu Leu Leu Asn Ser Leu Thr
 2130 2135 2140

Thr Asn Glu Leu Lys Lys Leu Ile Lys Ile Thr Gly Ser Val Leu Tyr
 2145 2150 2155 2160

Asn Leu Pro Asn Glu Gln
 2165

<210> 5

<211> 15219

<212> DNA

<213> respiratory syncytial virus

<400> 5

acgggaaaaa aatgcgtact acaaacttgc acattcgaaa aaaatggggc aaataagaac 60
 ttgataagtg ctatttaagt ctaacctttt caatcagaaa tggggtgcaa ttcactgagc 120
 atgataaagg ttagattaca aaattttatt gacaatgacg aagtagcatt gttaaaaata 180
 acatgttata ctgataaatt aattcttctg accaatgcat tagccaaagc agcaatacat 240
 acaattaaat taaacggcat agtttttata catgttataa caagcagtga agtgtgccct 300
 gataacaata ttgtagtga atctaacttt acaacaatgc caatactaca aaatggagga 360
 tacatatggg aattgattga gttgacacac tgctctcaat taaacgggtt aatggatgat 420
 aattgtgaaa tcaaattttc taaaagacta agtgactcag taatgactaa ttatatgaat 480
 caaatatctg acttacttgg gcttgatctc aattcatgaa ttatgtttag tctaattcaa 540
 tagacatgtg tttattacca ttttagttaa tataaaaact catcaaaggg aaatggggca 600
 aataaactca cctaatacat caaaccatga gcactacaaa tgacaacact actatgcaaa 660
 gattgatgat cacagacatg agaccctgt caatggattc aataataaca tctcttacca 720
 aagaaatcat cacacacaaa ttcataact tgataaacia tgaatgtatt gtaagaaaac 780
 ttgatgaaag acaagctaca tttacattct tagtcaatta tgagatgaag ctactgcaca 840
 aagtagggag taccaaatac aaaaaataca ctgaatataa tacaaaatat ggcactttcc 900
 ccatgcctat atttatcaat cacggcgggt ttctagaatg tattggcatt aagcctacaa 960

```

aacacactcc tataatatac aaatatgacc tcaacccgtg aattccaaca aaaaaaccaa 1020
cccaacccaaa ccaactatt cctcaaaca cagtgtctaa tagttaagaa ggagctaatac 1080
catttttagta attaaaaata aaagtaaagc caataacata aattggggca aatacaaaaga 1140
tggtctcttag caaagtcaag ttgaatgata cattaaataa ggatcagctg ctgtcatcca 1200
gcaaatcacac tattcaacgt agtacaggag ataatatga cactcccaat tatgatgtgc 1260
aaaaacacct aaacaaacta tgtggtatgc tattaatcac tgaagatgca aatcataaat 1320
tcacaggatt aataggtatg ttatatgcta tgtccagggt aggaaggga gacactataa 1380
agatacttaa agatgctgga tatcatgtta aagctaattg agtagatata acaacatatac 1440
gtcaagatat aaatggaaag gaaatgaaat tcgaagtatt aacattatca agcttgacat 1500
cagaaatata agtcaatatt gagatagaat ctagaaagtc ctacaaaaaa atgctaaaag 1560
agatgggaga agtgggtcca gaatataggc atgattctcc agactgtggg atgataatac 1620
tgtgtatagc tgcacttgtg ataaccaaat tagcagcagg agacagatca ggtcttacag 1680
cagtaattag gagggcaaac aatgtcttaa aaaacgaaat aaaacgatac aagggcctca 1740
taccaaagga tatagctaac agtttttatg aagtgtttga aaaacaccct catcttatag 1800
atgttttcgt gcactttggc attgcacaat catccacaag agggggtagt agagttgaag 1860
gaatctttgc aggattgttt atgaatgcct atgggttcagg gcaagtaatg ctaagatggg 1920
gagtttttagc caaatctgta aaaaatatca tgctaggaca tgctagtgtc caggcagaaa 1980
tgagagcaagt tgtggaagtc tatgagtatg cacagaagtt gggaggagaa gctggattct 2040
accatatatt gaacaatcca aaagcatcat tgctgtcatt aactcaattt cccaacttct 2100
caagtgtggt cctaggcaat gcagcaggtc taggcataat gggagagtat agaggtaacac 2160
caagaaacca ggatctttat gatgcagcta aagcatatgc agagcaactc aaagaaaatg 2220
gagtaataaa ctacagtgtt tttagactta cagcagaaga attggaagcc ataaagcatc 2280
aactcaacc caaagaagat gatgtagagc ttttaagttaa caaaaaatac ggggcaaata 2340
agtcaacatg gagaagtgtg cacctgaatt tcattggagaa gatgcaaata acaaagctac 2400
caaattccta gaatcaataa agggcaagtt cgcatcatcc aaagatccta agaagaaaga 2460
tagcataata tctgttaact caatagatat agaagtaact aaagagagcc cgataacatc 2520
tggcaccaac atcatcaatc caacaagtga agccgacagt accccagaaa caaaagccaa 2580
ctaccaaga aaacccttag taagcttcaa agaagatctc accccaagtg acaacccttt 2640
ttctaagttg tacaaggaaa caatagaaac atttgataac aatgaagaag aatctagcta 2700
ctcatatgaa gagataaatg atcaaacaaa tgacaacatt acagcaagac tagatagaat 2760
tgatgaaaaa ttaagtgaat tattaggaat gctccataca ttagtagttg caagtgcagg 2820
accacttca gctcgcgatg gaataagaga tgctatggtt ggtctaagag aagagatgat 2880
agaaaaata agagcggaag cattaatgac caatgatagg ttagaggcta tggcaagact 2940
taggaatgag gaaagcgaat aaatggcaaa agacacctca gatgaagtgt ctcttaatcc 3000
aacttccaaa aaattgagtg acttggttga agacaacgat agtgacaatg atctatcact 3060
tgatgatatt tgatcagcga tcaactcact cagcaatcaa caacatcaat aaaacagaca 3120
tcaatccatt gaatcaactg ccagaccgaa caaacaaacg tccatcagta gaaccaccaa 3180
ccaatcaatc aaccaattga tcaatcagca acccgacaaa attaacaata tagtaacaaa 3240
aaaagaacaa gatggggcaa atatggaaac atacgtgaac aagcttcacg aaggctccac 3300
atacacagca gctgttcagt acaatgttct agaaaaagat gatgatcctg catcactaac 3360
aatatgggtg cctatgttcc agtcattctg gccagcagac ttgctcataa aagaacttgc 3420
aagcatcaat atactagtga agcagatctc tacgcccacg ggaccttcac tacgagtcac 3480
gattaactca agaagtgtg tgctggctca aatgcctagt aatttcacat taagcgcaaa 3540
tgtatcatta gatgaaagaa gcaaattagc atatgatgta actacacctt gtgaaatcaa 3600
agcatgcagt ctaacatgct taaaagtaaa aagtatgtta actacagtca aagatcttac 3660
catgaagaca ttcaacccca ctcatgagat cattgctcta tgtgaatttg aaaatattat 3720
gacatcaaaa agagtaataa taccaacctc tctaagatca attagtgtca agaacaagga 3780
tctgaactca ctagaaaata tagcaaccac cgaattcaaa aatgctatca ccaatgcaaa 3840

```

aattattcct tatgcaggat tagtgtagt tatcacagtt actgacaata aaggagcatt 3900
caaatatatac aaaccacaga gtcaatttat agtagatctt ggtgcctacc tagaaaaaga 3960
gagcatatat tatgtgacta ctaattggaa gcatacagct acacgttttt caatcaaacc 4020
actagaggat taaacttaat tatcaacact gaatgacagg tccacatata tcctcaaact 4080
acacactata tccaaacatc ataaacatct acactacaca cttcatcaca caaaccaatc 4140
ccactcaaaa tccaaaatca ctaccagcca ctatccgcta gacctagagt gcgaataggc 4200
aaataaaaacc aaaatatggg gtaaatagac attagttaga gttcaatcaa tcttaacaac 4260
catttataacc gccaatcaa cacatatact ataaatctta aaatgggaaa tacatccatc 4320
acaatagaac tcacaagcaa attttggccc tattttacac taatacatat gatcttaact 4380
ctaattcttt tactaattat aatcactatc atgattgcaa cactaaataa gctaagtga 4440
cacaaagcat tctgcaacaa aactcttgaa ctaggacaga tgtaccaaat caacacacag 4500
agttccacca ttatgctgtg tcaaacata atcctgtata tacaacaaaa caaatccaat 4560
cctctcacag agtcacgggt tgcacaaaacc acgctaacca tcatggtagc atagagtagt 4620
tatttaaaaa ttaacataat gatgaattgt tagtatgaga tcaaaaaaaa cattggggca 4680
aatgcaacca tgtccaaaca caagaatcaa cgcactgcca ggactctaga aaagacctgg 4740
gatactctta atcatcta atgtaatatcc tcttgtttat acagattaaa tttaaaatct 4800
atagcacaaa tagcactatc agttttggca atgataatct caacctctct cataattgca 4860
gccataatat tcatcatctc tgccaatcac aaagttacac taacaacggt cacagttcaa 4920
acaataaaaa accacactga aaaaaacatc accacctacc ctactcaagt ctcaccagaa 4980
agggttagtt catccaagca acccacaacc acatcaccaa tccacacaag ttcagctaca 5040
acatcaccca atacaaaatc agaaacacac catacaacag cacaaacca aggcagaacc 5100
accacttcaa cacagaccaa caagccaagc acaaaaaccac gtccaaaaaa tccacaaaaa 5160
aaagatgatt accattttga agtggttcaac ttctgtccct gcagtatatg tggcaacaat 5220
caactttgca aatccatctg caaaacaata ccaagcaaca aaccaaagaa gaaaccaacc 5280
atcaaaccca caaacaaaacc aaccacaaaa accacaaaaca aaagagacct aaaaacacca 5340
gccaaaacga cgaaaaaaga aactaccacc aacccaacaa aaaaactaac cctcaagacc 5400
acagaaagag acaccagcac ctacacaatcc actgcactcg acacaaccac attaaaacac 5460
acagtccaac agcaatccct cctctcaacc acccccga aaacacacca ctccacacaa 5520
acaccacag catccgagcc ctccacacca aactccacc aaaaaaccca gccacatgct 5580
tagttattca aaaactacat cttagcagag aaccgtgatc tatcaagcaa gaacgaaatt 5640
aaacctgggg caaataacca tggagttgat gatccacaag tcaagtgcaa tcttcctaac 5700
tcttgctatt aatgcattgt acctcacctc aagtcagaac ataactgagg agttttacca 5760
atcgacatgt agtgcagtta gcagaggtta ttttagtgct ttaagaacag gttggtatac 5820
tagtgcata acaatagaat taagtaatat aaaagaaacc aaatgcaatg gaactgacac 5880
taaagtaaaa cttatgaaac aagaattaga taagtataag aatgcagtaa cagaattaca 5940
gctacttatg caaaacacac cagctgtcaa caaccgggccc agaagagaag caccacagta 6000
tatgaactac acaatcaata ccactaaaaa cctaaatgta tcaataagca agaagaggaa 6060
acgaagattt ctaggcttct tgttaggtgt gggatctgca atagcaagtg gtatagctgt 6120
atcaaaaagt ctacacctg aaggagaagt gaacaagatc aaaaatgctt tgttgctac 6180
aaacaaaagt gtagtcagt tatcaaatgg ggtcagtgt ttaaccagca aagtgttaga 6240
tctcaagaat tacataaata accaattatt acccatagta aatcaacaga gctgtcgcat 6300
ctccaacatt gaaacagtta tagaattcca gcagaagaac agcagattgt tggaaatcac 6360
cagagaattt agtgtaacag caggtgtaac aacaccttta agcacttaca tgttgacaaa 6420
cagtgaagtta ctatcattaa tcaatgatat gcctataaca aatgatcaga aaaaattaat 6480
gtcaagcaat gttcagatag taaggcaaca aagttattcc atcatgtcta taataaagga 6540
agaagtcctt gcataatgtg tacagctgcc tatctatggt gtaatagata caccttgctg 6600
gaaattgcac acatgcctc tatgcactac caacatcaaa gaaggatcaa atatttgtt 6660
aacaaggact gatagaggat ggtattgtga taatgcagga tcagtatcct tctttccaca 6720

ggctgacact tgtaaagtac agtccaatcg agtattttgt gacactatga acagtttgac 6780
 attaccaagt gaagtcagcc tttgtaacac tgacatatcc aattccaagt atgactgcaa 6840
 aattatgaca tcaaaaacag acataagcag ctcagtaatt acttctcttg gagctatagt 6900
 gtcagtctat ggtaaaacta aatgcactgc atccaacaaa aatcggtgga ttataaagac 6960
 attttctaatt ggttgtagct atgtgtcaaa caaaggagta gatactgtgt cagtgggcaa 7020
 cactttatac tatgtaaaca agctggaagg caagaacctt tatgtaaaag gggaacctat 7080
 aataaattac tatgaccctc tagtgtttcc ttctgatgag ttgatgcat caatatctca 7140
 agtcaatgaa aaaaatcaatc aaagttagc rttttatcgt aqatctgat aattactaca 7200
 taatgtaaat actggcaaat ctactacaaa tattatgata actacaatta ttatagtaat 7260
 cattgtagta ttgtatcat taatagctat tggtttactg ttgtattgta aagccaaaaa 7320
 cacaccagtt aactaagca aagaccaact aagtgggaatc aataatattg cattcagcaa 7380
 atagacaaaa aaccacctga tcatgtttca acaacaatct gctgaccacc aatcccaaat 7440
 caacttaca caaatatctc aacatcacag tacaggctga atcatttctc cacatcatgc 7500
 taccacata actaagctag atccttaact tatagttaca taaaaacctc aagtatcaca 7560
 atcaaccact aaatcaacac atcattcaca aaattaacag ctggggcaaa tatgtcgcga 7620
 agaaatcctt gtaaatttga gattagaggt cattgcttga atggtagaag atgtcactac 7680
 agtcataatt actttgaatg gcctcctcat gcattactag tgaggcaaaa cttcatgtta 7740
 aacaagatag tcaagtcaat ggacaaaagc atagacactt tgtctgaaat aagtggagct 7800
 gctgaactgg atagaacaga agaatatgct cttgggtatag ttggagtgtc agagagttac 7860
 ataggatcta taaacaacat aacaaaacaa tcagcatgtg ttgctatgag taaacttctt 7920
 attgagatca atagtgtgta cattaaaaag cttagagata atgaagaacc caattcacct 7980
 aagataagag tgtacaatca tgttatatca tacattgaga gcaatagaaa aaacaacaag 8040
 caaacatccc atctgtcaa gagactacca gcagacgtgc tgaagaagac aataaagaac 8100
 acattagata tccacaaaaa cataaccata agcaatccaa aagagtcaac tgtgaatgat 8160
 caaaatgacc aaaccaaaaa taatgatatt accggataaa tatccttgta gtatatcatc 8220
 catattgatc tcaagtgaag gcattggtgc tacattcaat cataaaaaa cattacaatt 8280
 taaccataac tatttgata accaccagcg tttattaaat catatatattg atgaaattca 8340
 ttggacacct aaaaacttat tagatgccac tcaacaattt ctccaacatc ttaacatccc 8400
 tgaagatata tatacagtat atatattagt gtcataatgc ttgaccataa cgactctatg 8460
 tcatccaacc ataaaactat tttgataagg ttatgggaca aaatggatcc cattattaat 8520
 ggaaactctg ctaatgtgta tctaactgat agttatttaa aagggtgtat ctctttttca 8580
 gagtgtaatg ctttagggag ttatcttttt aacggccctt atcttaaaaa tgattacacc 8640
 aacttaatta gtagacaaag cccactacta gagcatatga atcttaaaaa actaactata 8700
 acacagtcac taatatctag atatcataaa ggtgaactga aattagaaga accaacttat 8760
 ttccagtcac tacttatgac atataaaaagt atgtcctcgt ctgaacaaat tgctacaact 8820
 aacttactta aaaaaataat acgaagagcc atagaaataa gtgatgtaaa ggtgtacgcc 8880
 atcttgaata aactaggatt aaaggaaaag gacagagtta agcccaacaa taattcaggt 8940
 gatgaaaact cagtacttac aaccataatt aaagatgata tactttcggc tgtggaaaaa 9000
 aatcaatcat atacaaattc agacaaaagt cactcagtaa atcaaaatat cactatcaaa 9060
 acaacactct tgaaaaaatt gatgtgttca atgcaacatc ctccatcatg gttaatcac 9120
 tggttcaatt tatatacaaa attaaataac atattaacac aatatcgatc aaatgaggt 9180
 aaaagtcatg ggtttatatt aatagataat caaactttta gtgggttttca gtttatttta 9240
 aatcaatatg gttgtatcgt ttatcataaa ggactcaaaa aaatcacac tactacttac 9300
 aatcaatttt tgacatggaa agacatcagc cttagcagat taaatgtttg cttaattact 9360
 tggataagta attgtttaaa tacattaaac aaaagcttag ggctgagatg tggattcaat 9420
 aatgttgtgt tatcacaatt atttctttat ggagattgta tactgaaatt atttcataat 9480
 gaaggcttct acataataaa agaagtagag ggatttatta tgtctttaat tctaaacata 9540
 acagaagaag atcaatttaa gaaacgattt tataatagca tgctaaataa catcacagat 9600

gcagctatta aggcctcaaaa ggacctacta tcaagagtat gtcacacttt attagacaag 9660
acagtgtctg ataatatcat aaatggtaaa tggataatcc tattaagtaa atttcttaaa 9720
ttgattaagc ttgcagggtga taataatctc aataacttga gtgagctata ttttctcttc 9780
agaatccttg gacatccaat ggtcgatgaa agacaagcaa tggattctgt aagaattaac 9840
tgtaatgaaa ctaggttctta cttattaagt agtctaagta cattaagagg tgctttcatt 9900
tatagaatca taaaagggtt tgtaaatacc tacaacagat ggcccacctt aaggaatgct 9960
attgtcctac ctctaagatg gttaaactac tataaactta atacttatcc atctctactt 10020
yaaatcacag aaaaatgattt gattatctta tcaggatttc qtttctatcg tgagtttcat 10080
ctgcctaaaa aagtggatct tgaaatgata ataaatgaca aagccatttc acctccaaaa 10140
gatctaatat ggactagttt tcctagaaat tacatgccat cacatatata aaattatata 10200
gaacatgaaa agttgaagtt ctctgaaagc gacagatcga gaagagtact agagtattac 10260
ttgagagata ataaattcaa tgaatgcat ctatacaatt gtgtagtcaa tcaaagctat 10320
ctcaacaact ctaatcacgt ggtatcacta actggtaaaag aaagagagct cagtgtaggt 10380
agaatgtttg ctatgcaacc aggtatgttt agggcaaatcc aaatcttagc agagaaaaatg 10440
atagctgaaa atattttaca attcttccct gagagtgtga caagatatgg tgatctagag 10500
cttcaaaaga tattagaatt aaaagcagga ataagcaaca agtcaaatcg ttataatgat 10560
aactacaaca attatatcag taaatgttct atcattacag atcttagcaa attcaatcag 10620
gcatttagat atgaaacatc atgtatctgc agtgaatgat tagatgaact gcatggagta 10680
caatctctgt tctcttgggt gcatttaaca atacctcttg tcacaataat atgtacatat 10740
agacatgcac ctcccttcat aaaggatcat gttgttaatc ttaatgaggt tgatgaacaa 10800
agtggattat acagatatca tatgggtggt attgagggt ggtgtcaaaa actgtggacc 10860
attgaagcta tatcattatt agatctaata tctctcaaag ggaaattctc tatcacagct 10920
ctgataaatg gtgataatca gtcaattgat ataagcaaac cagttagact tatagagggt 10980
cagacccatg cacaagcaga ttatttgta gcattaaata gccttaaat gttatataaa 11040
gagtatgcag gtataggcca taagcttaag ggaacagaga cctatatatc ccgagatatg 11100
cagttcatga gcaaaacaat ccagcacaat ggagtgtact atccagccag tatcaaaaaa 11160
gtcctgagag taggtccatg gataaacacg atacttgatg attttaaagt tagtttagaa 11220
tctataggca gcttaacaca ggagttagaa tacagaggag aaagcttatt atgcagttta 11280
atatttagga acatttgggt atacaatcaa attgctttgc aactccgaaa tcatgcatta 11340
tgtaacaata agctatatat agatatattg aaagtattaa aacacttaaa aacttttttt 11400
aatcttgata gcattgatat ggctttatca ttgtatatga atttgcctat gctgtttggt 11460
gggtggtgat ctaatttgtt atatcgaaagc ttttatagga gaactccaga cttccttaca 11520
gaagctatag tacattcagt gtttgtgttg agctattata ctggtcacga tttacaagat 11580
aagctccagg atcttccaga tgatagactg aacaaattct tgacatgtgt catcacattt 11640
gataaaaaat ccaatgccga gtttgttaaca ttgatgagg atccacaggc tttagggtct 11700
gaaaggcaag ctaaaattac tagtgagatt aatagattag cagtaacaga agtcttaagt 11760
atagcccaa acaaaatatt ttctaaaagt gcacaacatt atactaccac tgagattgat 11820
ctaaatgaca ttatgcaaaa tatagaacca acttaccctc atggattaag agttgtttat 11880
gaaagtttac ctttttataa agcagaaaaa atagttaatc ttatatcagg aacaaaatcc 11940
ataactaata tacttgaaaa aacatcagca atagatacaa ctgatattaa tagggctact 12000
gatatgatga ggaaaaatat aactttactt ataaggatac ttccactaga ttgtaacaaa 12060
gacaaaagag agttattaag tttagaaaat cttagtataa ctgaattaag caagtatgta 12120
agagaaagat cttggtcatt atccaatata gtaggagtaa catcgccaag tattatgttc 12180
acaatgaaca ttaaataatc aactagcact atagccagtg gtataataat agaaaaatat 12240
aatgttaata gtttaactcg tggtgaaaga ggaccacca agccatgggt aggtcatcc 12300
acgcaggaga aaaaaacaat gccagtgtac aacagacaag ttttaacca aaagcaaaga 12360
gaccaaatag atttatttagc aaaattagac tgggtatatg catccataga caacaaagat 12420
gaattcatgg aagaactgag tactggaaca cttggactgt catatgaaaa agccaaaaag 12480


```

ttgtttccac aatatctaag tgtcaattat ttacaccgtt taacagtcag tagtagacca 12540
tgtgaattcc ctgcatcaat accagcttat agaacaacaa attatcattt tgatactagt 12600
cctatcaatc atgtattaac agaaaagtat ggagatgaag atatcgacat tgtgtttcaa 12660
aattgcataa gttttggtct tagcctgatg tcggttgtgg aacaattcac aaacatatgt 12720
cctaatagaa ttattctcat accgaagctg aatgagatac atttgatgaa acctcctata 12780
tttacaggag atgttgatat catcaagttg aagcaagtga tacaaaagca gcacatgttc 12840
ctaccagata aaataagttt aaccaatat gtagaattat tcttaagtaa caaagcactt 12900
aaatctggat ctccatcaaa ctctaattta atattaqtac ataaaatgtc tgattatttt 12960
cataatgctt atatttttaag tactaattta gctggacatt ggattctgat tattcaactt 13020
atgaaagatt caaaaggat ttttgaaaaa gattggggag aggggtacat aactgatcat 13080
atgttcatta atttgaatgt tttctttaat gcttataaga cttatttgct atgttttcat 13140
aaaggttatg gtaaagcaaa attagaatgt gatatgaaca cttcagatct tctttgtgtt 13200
ttggagttaa tagacagtag ctactggaaa tctatgtcta aagttttcct agaacaaaaa 13260
gtcataaaat acatagtcaa tcaagacaca agtttgcgta gaataaaagg ctgtcacagt 13320
tttaagttgt ggttttttaa acgccttaat aatgctaaat ttaccgtatg cccttgggtt 13380
gttaacatag attatcacc caccacacatg aaagctatat tatcttacat agatttagtt 13440
agaatggggt taataaatgt agataaatta accattaaaa ataaaaacaa attcaatgat 13500
gaattttaca catcaaatct cttttacatt agttataact tttcagacaa cactcatttg 13560
ctaacaaaac aaataagaat tgctaattca gaattagaag ataattataa caaactatat 13620
caccacacc cagaaacttt agaaaatatg tcattaaattc ctgttaaaag taataatagt 13680
aacaacaccta aattttgtat aagtggaaat accgaatcta tgatgatgtc aacattctct 13740
agtaaaaatgc atattaaatc ttccactgtt accacaagat tcaattatag caaacaagac 13800
tgttacaatt tattttccat tgttgtgata gacaagatta tagatcattc aggtaataca 13860
gcaaaatcta accaacttta caccaccact tcacatcaga catctttagt aagggaatagt 13920
gcatcacttt attgcatgct tccttggcat catgtcaata gatttaactt tgtatttagt 13980
tccacaggat gcaagatcag tatagagtat attttaaaag atcttaagat taaggacccc 14040
agttgtatag cattcatagg tgaaggagct ggtaacttat tattacgtac ggtagtagaa 14100
cttcatccag acataagata catttacaga agtttaaaag attgcaatga tcatagttta 14160
cctattgaat ttctaagggt atacaacggg catataaaca tagattatgg tgagaattta 14220
accattctctg ctacagatgc aactaataac attcattggt cttattttaca tataaaattt 14280
gcagaaccta ttagcatcct tgtctgcgat gctgaattac ctgttacagc caattggagt 14340
aaaattataa ttgaatggag taagcatgta agaaagtgca agtactgttc ttctgtaaat 14400
agatgcattt taattgcaaa atatcatgct caagatgaca ttgatttcaa attagataac 14460
attactatat taaaaactta cgtgtgccta ggtagcaagt taaaaggatc tgaagtttac 14520
ttaatcctta caataggccc tgcaaatata cttcctgttt ttgatgttgt acaaaatgct 14580
aaattgatac tttcaagaac taaaaatttc attatgccta aaaaaactga caaggaatct 14640
atcgtatgcaa atattaaaag cttaataacct ttctttgtt accctataac aaaaaagga 14700
attaagactt cattgtcaaa attgaagagt gtagttaatg gagatatatt atcatattct 14760
atagctggac gtaatgaagt attcagcaac aagcttataa accacaagca tatgaatata 14820
ctaaaatggc tagatcatgt tttaaatttt agatcagctg aacttaatta caatcattta 14880
tacatgatag agtccacata tccttactta agtgaattgt taaatagttt aacaaccaat 14940
gagctcaaga agctgattaa aataacaggt agtgtgctat acaaccttcc caacgaacag 15000
tagtttaaaa tatcattaac aagtttggtc aaatttagat gtaacacat cattatatta 15060
tagttattaa agaataata aacttttcaa taatttagca tattgattcc aaaattatca 15120
ttttagtctt aaggggttaa ataaaagtct aaaactaaca attatacatg tgcattcaca 15180
acacaacgag acattagttt ttgacacttt ttttctcgt 15219

```

<210> 6

<211> 2166

<212> PRT

<213> respiratory syncytial virus

<400> 6

Met Asp Pro Ile Ile Asn Gly Asn Ser Ala Asn Val Tyr Leu Thr Asp
 1 5 10 15

Ser Tyr Leu Lys Gly Val Ile Ser Phe Ser Glu Cys Asn Ala Leu Gly
 20 25 30

Ser Tyr Leu Phe Asn Gly Pro Tyr Leu Lys Asn Asp Tyr Thr Asn Leu
 35 40 45

Ile Ser Arg Gln Ser Pro Leu Leu Glu His Met Asn Leu Lys Lys Leu
 50 55 60

Thr Ile Thr Gln Ser Leu Ile Ser Arg Tyr His Lys Gly Glu Leu Lys
 65 70 75 80

Leu Glu Glu Pro Thr Tyr Phe Gln Ser Leu Leu Met Thr Tyr Lys Ser
 85 90 95

Met Ser Ser Ser Glu Gln Ile Ala Thr Thr Asn Leu Leu Lys Lys Ile
 100 105 110

Ile Arg Arg Ala Ile Glu Ile Ser Asp Val Lys Val Tyr Ala Ile Leu
 115 120 125

Asn Lys Leu Gly Leu Lys Glu Lys Asp Arg Val Lys Pro Asn Asn Asn
 130 135 140

Ser Gly Asp Glu Asn Ser Val Leu Thr Thr Ile Ile Lys Asp Asp Ile
 145 150 155 160

Leu Ser Ala Val Glu Asn Asn Gln Ser Tyr Thr Asn Ser Asp Lys Ser
 165 170 175

His Ser Val Asn Gln Asn Ile Thr Ile Lys Thr Thr Leu Leu Lys Lys
 180 185 190

Leu Met Cys Ser Met Gln His Pro Pro Ser Trp Leu Ile His Trp Phe
 195 200 205

Asn Leu Tyr Thr Lys Leu Asn Asn Ile Leu Thr Gln Tyr Arg Ser Asn
 210 215 220

Glu Val Lys Ser His Gly Phe Ile Leu Ile Asp Asn Gln Thr Leu Ser

225	230	235	240
Gly Phe Gln Phe Ile Leu Asn Gln Tyr Gly Cys Ile Val Tyr His Lys			
245	250	255	
Gly Leu Lys Lys Ile Thr Thr Thr Thr Tyr Asn Gln Phe Leu Thr Trp			
260	265	270	
Lys Asp Ile Ser Leu Ser Arg Leu Asn Val Cys Leu Ile Thr Trp Ile			
275	280	285	
Ser Asn Cys Leu Asn Thr Leu Asn Lys Ser Leu Gly Leu Arg Cys Gly			
290	295	300	
Phe Asn Asn Val Val Leu Ser Gln Leu Phe Leu Tyr Gly Asp Cys Ile			
305	310	315	320
Leu Lys Leu Phe His Asn Glu Gly Phe Tyr Ile Ile Lys Glu Val Glu			
325	330	335	
Gly Phe Ile Met Ser Leu Ile Leu Asn Ile Thr Glu Glu Asp Gln Phe			
340	345	350	
Lys Lys Arg Phe Tyr Asn Ser Met Leu Asn Asn Ile Thr Asp Ala Ala			
355	360	365	
Ile Lys Ala Gln Lys Asp Leu Leu Ser Arg Val Cys His Thr Leu Leu			
370	375	380	
Asp Lys Thr Val Ser Asp Asn Ile Ile Asn Gly Lys Trp Ile Ile Leu			
385	390	395	400
Leu Ser Lys Phe Leu Lys Leu Ile Lys Leu Ala Gly Asp Asn Asn Leu			
405	410	415	
Asn Asn Leu Ser Glu Leu Tyr Phe Leu Phe Arg Ile Phe Gly His Pro			
420	425	430	
Met Val Asp Glu Arg Gln Ala Met Asp Ser Val Arg Ile Asn Cys Asn			
435	440	445	
Glu Thr Arg Phe Tyr Leu Leu Ser Ser Leu Ser Thr Leu Arg Gly Ala			
450	455	460	
Phe Ile Tyr Arg Ile Ile Lys Gly Phe Val Asn Thr Tyr Asn Arg Trp			
465	470	475	480
Pro Thr Leu Arg Asn Ala Ile Val Leu Pro Leu Arg Trp Leu Asn Tyr			

485	490	495
Tyr Lys Leu Asn Thr Tyr Pro Ser Leu Leu Glu Ile Thr Glu Asn Asp		
500	505	510
Leu Ile Ile Leu Ser Gly Leu Arg Phe Tyr Arg Glu Phe His Leu Pro		
515	520	525
Lys Lys Val Asp Leu Glu Met Ile Ile Asn Asp Lys Ala Ile Ser Pro		
530	535	540
Pro Lys Asp Leu Ile Trp Thr Ser Phe Pro Arg Asn Tyr Met Pro Ser		
545	550	555
His Ile Gln Asn Tyr Ile Glu His Glu Lys Leu Lys Phe Ser Glu Ser		
565	570	575
Asp Arg Ser Arg Arg Val Leu Glu Tyr Tyr Leu Arg Asp Asn Lys Phe		
580	585	590
Asn Glu Cys Asp Leu Tyr Asn Cys Val Val Asn Gln Ser Tyr Leu Asn		
595	600	605
Asn Ser Asn His Val Val Ser Leu Thr Gly Lys Glu Arg Glu Leu Ser		
610	615	620
Val Gly Arg Met Phe Ala Met Gln Pro Gly Met Phe Arg Gln Ile Gln		
625	630	635
Ile Leu Ala Glu Lys Met Ile Ala Glu Asn Ile Leu Gln Phe Phe Pro		
645	650	655
Glu Ser Leu Thr Arg Tyr Gly Asp Leu Glu Leu Gln Lys Ile Leu Glu		
660	665	670
Leu Lys Ala Gly Ile Ser Asn Lys Ser Asn Arg Tyr Asn Asp Asn Tyr		
675	680	685
Asn Asn Tyr Ile Ser Lys Cys Ser Ile Ile Thr Asp Leu Ser Lys Phe		
690	695	700
Asn Gln Ala Phe Arg Tyr Glu Thr Ser Cys Ile Cys Ser Asp Val Leu		
705	710	715
Asp Glu Leu His Gly Val Gln Ser Leu Phe Ser Trp Leu His Leu Thr		
725	730	735
Ile Pro Leu Val Thr Ile Ile Cys Thr Tyr Arg His Ala Pro Pro Phe		

740	745	750
Ile Lys Asp His Val Val Asn Leu Asn Glu Val Asp Glu Gln Ser Gly		
755	760	765
Leu Tyr Arg Tyr His Met Gly Gly Ile Glu Gly Trp Cys Gln Lys Leu		
770	775	780
Trp Thr Ile Glu Ala Ile Ser Leu Leu Asp Leu Ile Ser Leu Lys Gly		
785	790	795
Lys Phe Ser Ile Thr Ala Leu Ile Asn Gly Asp Asn Gln Ser Ile Asp		
805	810	815
Ile Ser Lys Pro Val Arg Leu Ile Glu Gly Gln Thr His Ala Gln Ala		
820	825	830
Asp Tyr Leu Leu Ala Leu Asn Ser Leu Lys Leu Leu Tyr Lys Glu Tyr		
835	840	845
Ala Gly Ile Gly His Lys Leu Lys Gly Thr Glu Thr Tyr Ile Ser Arg		
850	855	860
Asp Met Gln Phe Met Ser Lys Thr Ile Gln His Asn Gly Val Tyr Tyr		
865	870	875
Pro Ala Ser Ile Lys Lys Val Leu Arg Val Gly Pro Trp Ile Asn Thr		
885	890	895
Ile Leu Asp Asp Phe Lys Val Ser Leu Glu Ser Ile Gly Ser Leu Thr		
900	905	910
Gln Glu Leu Glu Tyr Arg Gly Glu Ser Leu Leu Cys Ser Leu Ile Phe		
915	920	925
Arg Asn Ile Trp Leu Tyr Asn Gln Ile Ala Leu Gln Leu Arg Asn His		
930	935	940
Ala Leu Cys Asn Asn Lys Leu Tyr Leu Asp Ile Leu Lys Val Leu Lys		
945	950	955
His Leu Lys Thr Phe Phe Asn Leu Asp Ser Ile Asp Met Ala Leu Ser		
965	970	975
Leu Tyr Met Asn Leu Pro Met Leu Phe Gly Gly Gly Asp Pro Asn Leu		
980	985	990
Leu Tyr Arg Ser Phe Tyr Arg Arg Thr Pro Asp Phe Leu Thr Glu Ala		

995	1000	1005
Ile Val His Ser Val Phe Val Leu Ser Tyr Tyr Thr Gly His Asp Leu		
1010	1015	1020
Gln Asp Lys Leu Gln Asp Leu Pro Asp Asp Arg Leu Asn Lys Phe Leu		
1025	1030	1035 1040
Thr Cys Val Ile Thr Phe Asp Lys Asn Pro Asn Ala Glu Phe Val Thr		
1045	1050	1055
Leu Met Arg Asp Pro Gln Ala Leu Gly Ser Glu Arg Gln Ala Lys Ile		
1060	1065	1070
Thr Ser Glu Ile Asn Arg Leu Ala Val Thr Glu Val Leu Ser Ile Ala		
1075	1080	1085
Pro Asn Lys Ile Phe Ser Lys Ser Ala Gln His Tyr Thr Thr Thr Glu		
1090	1095	1100
Ile Asp Leu Asn Asp Ile Met Gln Asn Ile Glu Pro Thr Tyr Pro His		
1105	1110	1115 1120
Gly Leu Arg Val Val Tyr Glu Ser Leu Pro Phe Tyr Lys Ala Glu Lys		
1125	1130	1135
Ile Val Asn Leu Ile Ser Gly Thr Lys Ser Ile Thr Asn Ile Leu Glu		
1140	1145	1150
Lys Thr Ser Ala Ile Asp Thr Thr Asp Ile Asn Arg Ala Thr Asp Met		
1155	1160	1165
Met Arg Lys Asn Ile Thr Leu Leu Ile Arg Ile Leu Pro Leu Asp Cys		
1170	1175	1180
Asn Lys Asp Lys Arg Glu Leu Leu Ser Leu Glu Asn Leu Ser Ile Thr		
1185	1190	1195 1200
Glu Leu Ser Lys Tyr Val Arg Glu Arg Ser Trp Ser Leu Ser Asn Ile		
1205	1210	1215
Val Gly Val Thr Ser Pro Ser Ile Met Phe Thr Met Asn Ile Lys Tyr		
1220	1225	1230
Thr Thr Ser Thr Ile Ala Ser Gly Ile Ile Ile Glu Lys Tyr Asn Val		
1235	1240	1245
Asn Ser Leu Thr Arg Gly Glu Arg Gly Pro Thr Lys Pro Trp Val Gly		

1250	1255	1260
Ser Ser Thr Gln Glu Lys Lys Thr Met Pro Val Tyr Asn Arg Gln Val		
1265	1270	1275 1280
Leu Thr Lys Lys Gln Arg Asp Gln Ile Asp Leu Leu Ala Lys Leu Asp		
	1285	1290 1295
Trp Val Tyr Ala Ser Ile Asp Asn Lys Asp Glu Phe Met Glu Glu Leu		
	1300	1305 1310
Ser Thr Gly Thr Leu Gly Leu Ser Tyr Glu Lys Ala Lys Lys Leu Phe		
	1315	1320 1325
Pro Gln Tyr Leu Ser Val Asn Tyr Leu His Arg Leu Thr Val Ser Ser		
	1330	1335 1340
Arg Pro Cys Glu Phe Pro Ala Ser Ile Pro Ala Tyr Arg Thr Thr Asn		
1345	1350	1355 1360
Tyr His Phe Asp Thr Ser Pro Ile Asn His Val Leu Thr Glu Lys Tyr		
	1365	1370 1375
Gly Asp Glu Asp Ile Asp Ile Val Phe Gln Asn Cys Ile Ser Phe Gly		
	1380	1385 1390
Leu Ser Leu Met Ser Val Val Glu Gln Phe Thr Asn Ile Cys Pro Asn		
	1395	1400 1405
Arg Ile Ile Leu Ile Pro Lys Leu Asn Glu Ile His Leu Met Lys Pro		
	1410	1415 1420
Pro Ile Phe Thr Gly Asp Val Asp Ile Ile Lys Leu Lys Gln Val Ile		
1425	1430	1435 1440
Gln Lys Gln His Met Phe Leu Pro Asp Lys Ile Ser Leu Thr Gln Tyr		
	1445	1450 1455
Val Glu Leu Phe Leu Ser Asn Lys Ala Leu Lys Ser Gly Ser His Ile		
	1460	1465 1470
Asn Ser Asn Leu Ile Leu Val His Lys Met Ser Asp Tyr Phe His Asn		
	1475	1480 1485
Ala Tyr Ile Leu Ser Thr Asn Leu Ala Gly His Trp Ile Leu Ile Ile		
	1490	1495 1500
Gln Leu Met Lys Asp Ser Lys Gly Ile Phe Glu Lys Asp Trp Gly Glu		

1505	1510	1515	1520
Gly Tyr Ile Thr Asp His Met Phe Ile Asn Leu Asn Val Phe Phe Asn			
1525	1530	1535	
Ala Tyr Lys Thr Tyr Leu Leu Cys Phe His Lys Gly Tyr Gly Lys Ala			
1540	1545	1550	
Lys Leu Glu Cys Asp Met Asn Thr Ser Asp Leu Leu Cys Val Leu Glu			
1555	1560	1565	
Leu Ile Asp Ser Ser Tyr Trp Lys Ser Met Ser Lys Val Phe Leu Glu			
1570	1575	1580	
Gln Lys Val Ile Lys Tyr Ile Val Asn Gln Asp Thr Ser Leu Arg Arg			
1585	1590	1595	1600
Ile Lys Gly Cys His Ser Phe Lys Leu Trp Phe Leu Lys Arg Leu Asn			
1605	1610	1615	
Asn Ala Lys Phe Thr Val Cys Pro Trp Val Val Asn Ile Asp Tyr His			
1620	1625	1630	
Pro Thr His Met Lys Ala Ile Leu Ser Tyr Ile Asp Leu Val Arg Met			
1635	1640	1645	
Gly Leu Ile Asn Val Asp Lys Leu Thr Ile Lys Asn Lys Asn Lys Phe			
1650	1655	1660	
Asn Asp Glu Phe Tyr Thr Ser Asn Leu Phe Tyr Ile Ser Tyr Asn Phe			
1665	1670	1675	1680
Ser Asp Asn Thr His Leu Leu Thr Lys Gln Ile Arg Ile Ala Asn Ser			
1685	1690	1695	
Glu Leu Glu Asp Asn Tyr Asn Lys Leu Tyr His Pro Thr Pro Glu Thr			
1700	1705	1710	
Leu Glu Asn Met Ser Leu Ile Pro Val Lys Ser Asn Asn Ser Asn Lys			
1715	1720	1725	
Pro Lys Phe Cys Ile Ser Gly Asn Thr Glu Ser Met Met Met Ser Thr			
1730	1735	1740	
Phe Ser Ser Lys Met His Ile Lys Ser Ser Thr Val Thr Thr Arg Phe			
1745	1750	1755	1760
Asn Tyr Ser Lys Gln Asp Leu Tyr Asn Leu Phe Pro Ile Val Val Ile			

1765	1770	1775
Asp Lys Ile Ile Asp His Ser Gly Asn Thr Ala Lys Ser Asn Gln Leu		
1780	1785	1790
Tyr Thr Thr Thr Ser His Gln Thr Ser Leu Val Arg Asn Ser Ala Ser		
1795	1800	1805
Leu Tyr Cys Met Leu Pro Trp His His Val Asn Arg Phe Asn Phe Val		
1810	1815	1820
Phe Ser Ser Thr Gly Cys Lys Ile Ser Ile Glu Tyr Ile Leu Lys Asp		
1825	1830	1835
Leu Lys Ile Lys Asp Pro Ser Cys Ile Ala Phe Ile Gly Glu Gly Ala		
1845	1850	1855
Gly Asn Leu Leu Leu Arg Thr Val Val Glu Leu His Pro Asp Ile Arg		
1860	1865	1870
Tyr Ile Tyr Arg Ser Leu Lys Asp Cys Asn Asp His Ser Leu Pro Ile		
1875	1880	1885
Glu Phe Leu Arg Leu Tyr Asn Gly His Ile Asn Ile Asp Tyr Gly Glu		
1890	1895	1900
Asn Leu Thr Ile Pro Ala Thr Asp Ala Thr Asn Asn Ile His Trp Ser		
1905	1910	1915
Tyr Leu His Ile Lys Phe Ala Glu Pro Ile Ser Ile Phe Val Cys Asp		
1925	1930	1935
Ala Glu Leu Pro Val Thr Ala Asn Trp Ser Lys Ile Ile Ile Glu Trp		
1940	1945	1950
Ser Lys His Val Arg Lys Cys Lys Tyr Cys Ser Ser Val Asn Arg Cys		
1955	1960	1965
Ile Leu Ile Ala Lys Tyr His Ala Gln Asp Asp Ile Asp Phe Lys Leu		
1970	1975	1980
Asp Asn Ile Thr Ile Leu Lys Thr Tyr Val Cys Leu Gly Ser Lys Leu		
1985	1990	1995
Lys Gly Ser Glu Val Tyr Leu Ile Leu Thr Ile Gly Pro Ala Asn Ile		
2005	2010	2015
Leu Pro Val Phe Asp Val Val Gln Asn Ala Lys Leu Ile Leu Ser Arg		

2020	2025	2030
Thr Lys Asn Phe Ile Met Pro Lys Lys Thr Asp Lys Glu Ser Ile Asp 2035	2040	2045
Ala Asn Ile Lys Ser Leu Ile Pro Phe Leu Cys Tyr Pro Ile Thr Lys 2050	2055	2060
Lys Gly Ile Lys Thr Ser Leu Ser Lys Leu Lys Ser Val Val Asn Gly 2065	2070	2075 2080
Asp Ile Leu Ser Tyr Ser Ile Ala Gly Arg Asn Glu Val Phe Ser Asn 2085	2090	2095
Lys Leu Ile Asn His Lys His Met Asn Ile Leu Lys Trp Leu Asp His 2100	2105	2110
Val Leu Asn Phe Arg Ser Ala Glu Leu Asn Tyr Asn His Leu Tyr Met 2115	2120	2125
Ile Glu Ser Thr Tyr Pro Tyr Leu Ser Glu Leu Leu Asn Ser Leu Thr 2130	2135	2140
Thr Asn Glu Leu Lys Lys Leu Ile Lys Ile Thr Gly Ser Val Leu Tyr 2145	2150	2155 2160
Asn Leu Pro Asn Glu Gln 2165		

<210> 7
 <211> 15219
 <212> DNA
 <213> respiratory syncytial virus

<400> 7
 acgggaaaaa aatgcgtact acaaacttgc acattcgaaa aaaatggggc aaataagaac 60
 ttgataagtg ctatttaagt ctaacctttt caatcagaaa tggggtgcaa ttcactgagc 120
 atgataaagg ttagattaca aaattttatt gacaatgacg aagtagcatt gttaaaaaata 180
 acatgttata ctgataaatt aattcttctg accaatgcat tagccaaagc agcaatacat 240
 acaattaaat taaacggcat agtttttata catgttataa caagcagtga agtgtgccct 300
 gataacaata ttgtagtga atctaacttt acaacaatgc caatactaca aaatggagga 360
 tacatatggg aattgattga gttgacacac tgctctcaat taaacggttt aatggatgat 420
 aattgtgaaa tcaaattttc taaaagacta agtgactcag taatgactaa ttatatgaat 480
 caaatatctg acttacttgg gcttgatctc aattcatgaa ttatgttttag tctaattcaa 540
 tagacatgtg tttattacca ttttagttaa tataaaaact catcaaaggg aaatggggca 600
 aataaactca cctaataat caaacatga gcactacaaa tgacaacact actatgcaaa 660
 gattgatgat cacagacatg agaccctgt caatggattc aataataaca tctcttacca 720

aagaaatcat cacacacaaa ttcataact tgataaacia tgaatgtatt gtaagaaaac 780
ttgatgaaag acaagctaca tttacattct tagtcaatta tgagatgaag ctactgcaca 840
aagtagggag taccaaatat aaaaaataca ctgaatataa tacaaaatat ggcactttcc 900
ccatgcctat atttatcaat cacggcgggt ttctagaatg tattggcatt aagcctacaa 960
aacacactcc tataatatac aaatatgacc tcaaccctg aattccaaca aaaaaaccaa 1020
cccaaccaa ccaactatt cctcaaaaa cagtgtcaa tagttaagaa ggagctaatac 1080
catttttagta attaaaaata aaagtaaagc caataacata aattggggca aatacaaaaga 1140
lyyctcttag ccaagtcaag ttgaatgata caaaaataa ggatcagctc ctgtcatcca 1200
gcaaatcac tattcaacgt agtacaggag ataataatga cactcccaat tatgatgtgc 1260
aaaaacacct aaacaaacta tgtggtatgc tattaatcac tgaagatgca aatcataaat 1320
tcacaggatt aataggtatg ttatatgcta tgtccagggt aggaagggaa gacactataa 1380
agatacttaa agatgctgga tatcatgtta aagctaattg agtagatata acaacatatc 1440
gtcaagatat aaatggaaa gaaatgaaat tcaagatatt aacattatca agcttgacat 1500
cagaaatata agtcaatatt gagatagaat ctgaaaagtc ctacaaaaaa atgctaaaag 1560
agatgggaga agtggctcca gaatataggc atgattctcc agactgtggg atgataatac 1620
tgtgtatagc tgcacttgtg ataaccaaat tagcagcagg agacagatca ggtcttacag 1680
cagtaattag gagggcaaac aatgtcttaa aaaacgaaat aaaacgatac aagggcctca 1740
taccaaagga tatagctaac agtttttatg aagtgtttga aaaacaccct catcttatag 1800
atgttttctg gcactttggc attgcacaat catccacaag agggggtagt agagttgaag 1860
gaatctttgc aggattgttt atgaatgcct atgggtcagg gcaagtaatg ctaagatggg 1920
gagttttagc caaatctgta aaaaatatca tgctaggaca tgctagtgtc caggcagaaa 1980
tggagcaagt tgtggaagtc tatgagtatg cacagaagtt gggaggagaa gctggattct 2040
accatatatt gaacaatcca aaagcatcat tgctgtcatt aactcaattt cccaacttct 2100
caagtgtggt ctagggcaat gcagcagggt taggcataat gggagagtat agaggtacac 2160
caagaaacca ggatctttat gatgcagcta aagcatatgc agagcaactc aaagaaaatg 2220
gagtaataaa ctacagtgtg ttagacttaa cagcagaaga attggaagcc ataaagcatc 2280
aactcaaccc caaagaagat gatgtagagc tttaagttaa caaaaaatac ggggcaataa 2340
agtaacatg gagaagtttg cacctgaatt tcatggagaa gatgcaata acaaagctac 2400
caaattccta gaatcaataa agggcaagtt cgcacatcc aaagatccta agaagaaaga 2460
tagcataata tctgttaact caatagatat agaagtaact aaagagagcc cgataacatc 2520
tggcaccaac atcatcaatc caacaagtga agccgacagt accccagaaa caaaagccaa 2580
ctaccaaga aaacccttag taagcttcaa agaagatctc accccaagtg acaacccttt 2640
ttctaagttg tacaaggaaa caatagaaac atttgataac aatgaagaag aatctagcta 2700
ctcatatgaa gagataaatg atcaaacaaa tgacaacatt acagcaagac tagatagaat 2760
tgatgaaaaa ttaagtgaat tattaggaat gctccatata ttagtagttg caagtgcagg 2820
accacttca gctcgcatg gaataagaga tgctatggtt ggtctaagag aagagatgat 2880
agaaaaata agagcggag cattaatgac caatgatagg ttagaggcta tggcaagact 2940
taggaatgag gaaagcgaaa aaatggcaaa agacacctca gatgaagtgt ctcttaatcc 3000
aacttccaaa aaattgagt acttgttggg agacaacgat agtgacaatg atctatcact 3060
tgatgatttt tgatcagcga tcaactcact cagcaatcaa caacatcaat aaaacagaca 3120
tcaatccatt gaatcaactg ccagaccgaa caaacaacg tccatcagta gaaccaccaa 3180
ccaatcaatc aaccaattga tcaatcagca acccgacaaa attacaata tagtaacaaa 3240
aaaagaacaa gatggggcaa atatggaaac atacgtgaac aagcttcacg aaggtccac 3300
atacacagca gctgttcagt acaatgttct agaaaaagat gatgatcctg catcactaac 3360
aatatgggtg cctatgttcc agtcatctgt gccagcagac ttgctcataa aagaacttgc 3420
aagcatcaat atactagtga agcagatctc tacgccccaa ggaccttcac tacgagtcac 3480
gattaactca agaagtgtctg tgctggctca aatgcctagt aatttcatca taagcgcaaa 3540
tgtatcatta gatgaaagaa gcaaattagc atatgatgta actacacctt gtgaaatcaa 3600

```

agcatgcagct ctaacatgct taaaagtaaa agtatgtta actacagtca aagatcttac 3660
catgaagaca ttcaacccca ctcatgagat cattgctcta tgtgaatttg aaaatattat 3720
gacatcaaaa agagtaataa taccaacctt tctaagatca attagtgtca agaacaagga 3780
tctgaactca ctagaaaata tagcaaccac cgaattcaaa aatgctatca ccaatgcaaa 3840
aattattcct tatgcaggat tagtggttagt tatcacagtt actgacaata aaggagcatt 3900
caaatatatc aaaccacaga gtcaatttat agtagatctt ggtgcctacc tagaaaaaga 3960
gagcatatat tatgtgacta ctaattggaa gcatacagct acacgttttt caatcaaacc 4020
actagaggat taaacttaat tatcaaacat gaatgacagg tccacatata tcttcaaact 4080
acacactata tccaaacatc ataaacatct acactacaca cttcatcaca caaaccaatc 4140
ccactcaaaa tccaaaatca ctaccagcca ctatctgcta gacctagagt gcgaataggt 4200
aaataaaaacc aaaatatggg gtaaatagac attagttaga gttcaatcaa tcttaacaac 4260
catttatacc gccaattcaa cacatatact ataaatctta aaatgggaaa tacatccatc 4320
acaatagaat tcacaagcaa attttggccc tattttacac taatacatat gatcttaact 4380
ctaactcttt tactaattat aatcactatt atgattgcaa tactaaataa gctaagtga 4440
cataaagcat tctgtaacaa aactcttgaa ctaggacaga tgtatcaaat caacacatag 4500
agttctacca ttatgtgtg tcaaattata atcctgtata tataaacaaa caaatccaat 4560
cttctcacag agtcatggtg tcgcaaaacc acgctaacta tcatggtagc atagagtagt 4620
tatttaaaaa ttaacataat gatgaattgt tagtatgaga tcaaaaacaa cattggggca 4680
aatgcaacca tgtccaaaca caagaatcaa cgcactgcca ggactctaga aaagacctgg 4740
gatactctta atcatcta atgtaatatcc tcttgtttat acagattaaa tttaaaatct 4800
atgacacaaa tagcactatc agttttggca atgataatct caacctctct cataattgca 4860
gccataatat tcatcatctc tgccaatcac aaagtacac taacaacggt cacagttcaa 4920
acaataaaaa accacactga aaaaaacatc accacctacc ctactcaagt ctaccagaa 4980
agggtaggt catccaagca acccaaaccc acatcaccaa tccacacaag ttcagctaca 5040
acatcaccca atacaaaatc agaaacacac catacaacag cacaaccaa aggcagaacc 5100
accacttcaa cacagacca caagccaagc acaaaaccac gtccaaaaaa tccacaaaaa 5160
aaagatgatt accatttga agtgttcaac ttcgttcct gcagtatatg tggcaacaat 5220
caactttgca aatccatctg caaaacaata ccaagcaaca aaccaagaa gaaaccaacc 5280
atcaaaccca caaacaacc aaccacaaa acccaacaa aaagagacc aaaaacacca 5340
gccaaaacga cgaaaaaaga aactaccacc aaccacaaa aaaaaactaac cctcaagacc 5400
acagaaagag acaccagcac ctcaaatcc actgcaactg acacaaccac attaaaacac 5460
acagtccaac agcaatccct cctctcaacc acccccgaaa acacaccaa ctccacaaa 5520
acaccacag catccgagcc ctccacacca aactccaccc aaaaaaccca gccacatgct 5580
tagttattca aaaactacat cttagcagag aaccgtgatc tatcaagcaa gaacgaaatt 5640
aaacctgggg caaataacca tggagtgtgat gatccacaag tcaagtga tcttcctaac 5700
tcttgctatt aatgcattgt acctcacctc aagtcagaac ataactgagg agttttacca 5760
atcgacatgt agtgcagtta gcagaggtta ttttagtgct ttaagaacag gttggtatac 5820
tagtgtcata acaatagaat taagtaatat aaaagaaacc aaatgcaatg gaactgacac 5880
taaagtaaaa cttatgaaac aagaattaga taagtataag aatgcagtaa cagaattaca 5940
gctacttatg caaaacacac cagctgtcaa caaccgggcc agaagagaag caccacagta 6000
tatgaactac acaatcaata ccactaaaaa cctaaatgta tcaataagca agaagaggaa 6060
acgaagatth ctaggcttct tgttaggtgt gggatctgca atagcaagtgt gtatagctgt 6120
atcaaaagtt ctacaccttg aaggagaagt gaacaagatc aaaaatgctt tgttgtctac 6180
aaacaaagct gtagtcagtt tatcaaatgg ggtcagtggt ttaaccagca aagtgttaga 6240
tctcaagaat tacataaata accaattatt acccatagta aatcaacaga gctgtcgcat 6300
ctccaacatt gaaacagtta tagaattcca gcagaagaac agcagattgt tggaaatcac 6360
cagagaatth agtgtcaatg caggtgtaac aacaccttta agcacttaca tgttgacaaa 6420
cagtgagtt ctaacattaa tcaatgatat gcctataaca aatgatcaga aaaaattaat 6480

```

gtcaagcaat gttcagatag taaggcaaca aagttattcc atcatgtcta taataaagga 6540
 agaagtcctt gcataatgttg tacagctgcc tatctatggg gtaatagata caccttgctg 6600
 gaaattgcac acatcgcttc tatgcactac caacatcaaa gaaggatcaa atatttgttt 6660
 aacaaggact gatagaggat ggtattgtga taatgcagga tcagtatcct tctttccaca 6720
 ggctgacact tgtaaagtac agtccaatcg agtattttgt gacactatga acagtgtgac 6780
 attaccaagt gaagtcagcc tttgtaacac tgacatatc aattccaagt atgactgcaa 6840
 aattatgaca tcaaaaacag acataagcag ctacagtaatt acttctcttg gagctatagt 6900
 gtcattgctat ggtaaaaacta aatgcaacgc atccaacaaa aatccttqqa ttataaagac 6960
 atttttcta atgtgtgact atgtgtcaaa caaaggagta gatactgtgt cagtgggcaa 7020
 cactttatac tatgtaaaaca agctggaagg caagaacctt tatgtaaaag gggaacctat 7080
 aataaattac tatgacctc tagtgtttcc ttctgatgag tttgatgcat caatatctca 7140
 agtcaatgaa aaaatcaatc aaagtttagc ttttatctgt agatctgatg aattactaca 7200
 taatgtaaat actggcgaat ctactacaaa tattatgata actacaatta ttatagtaat 7260
 cattgtagta ttgttatcat taatagctat tggtttactg ttgtattgta aagccaaaaa 7320
 cacaccagtt acactaagca aagaccaact aagtgggaatc aataatattg cattcagcaa 7380
 atagacaaaa aaccacctga tcatgtttca acaacaatct gctgaccacc aatcccaaat 7440
 caacttaca caaatatttc aacatcacag tacaggctga atcatttcct cacatcatgc 7500
 taccacata actaagctag atccttaact tatagttaca taaaaacctc aagtatcaca 7560
 atcaaccact aaatcaacac atcattcaca aaattaacag ctggggcaca tatgtcgcga 7620
 agaaatcctt gtaaatttga gattagaggt cattgcttga atggtagaag atgtcactac 7680
 agtcataatt actttgaatg gcctcctcat gcattactag tgaggcaaaa ctctcatgta 7740
 aacaagatac tcaagtcaat ggacaaaagc atagacactt tgtctgaaat aagtggagct 7800
 gctgaactgg atagaacaga agaatatgct cttggtatag ttggagtgtc agagagttac 7860
 ataggatcta taaacaacat aacaaaacaa tcagcatgtg ttgctatgag taaacttctt 7920
 attgagatca atagtgtga cattaaaaag cttagagata atgaagaacc caattcacct 7980
 aagataagag tgtacaatac tgttatatca tacattgaga gcaatagaaa aaacaacaag 8040
 caaaccatcc tccacaaaag cataaccata agcaatccaa aagagtcaac tgtgaatgat 8100
 acattagata tccacaaaag cataaccata agcaatccaa aagagtcaac tgtgaatgat 8160
 caaaatgacc aaacaaaaaa taatgatatt accggataaa tatccttgta gtatatcatc 8220
 catattgatc tcaagtgaag gcattggtgc tacattcaat cataaaaaaca tattacaatt 8280
 taaccataac tatttggtga accaccagcg tttattaaat catatatttg atgaaattca 8340
 ttggacacct aaaaacttat tagatgccac tcaacaattt ctccaacatc ttaacatccc 8400
 tgaagatata tatacagtat atatatagtg gtcataatgc ttgaccataa cgactctatg 8460
 tcatccaacc ataaaactat tttgataagg ttatgggaca aaatggatcc cattattaat 8520
 ggaaactctg ctaatgtgta tctaactgat agttatttaa aagggtgttat ctctttttca 8580
 gagtgtaatg ctttagggag ttatcttttt aacggccctt atcttaaaaa tgattacacc 8640
 aacttaatta gtagacaaag cccactacta gagcatatga atcttaaaaa actaactata 8700
 acacagtcac taatatctag atatcataaa ggtgaactga aattagaaga accaacttat 8760
 ttccagtcac tacttatgac atataaaagt atgtcctcgt ctgaacaaat tgctacaaact 8820
 aacttactta aaaaaataat acgaagagcc atagaaaata gtgatgtaaa ggtgtacgcc 8880
 atcttgaata aactaggatt aaaggaaaag gacagagtta agcccaacaa taattcaggt 8940
 gatgaaaact cagtacttac aactataatt aaagatgata tactttcggc tgtggaaaac 9000
 aatcaatcat atacaaattc agacaaaagt cactcagtaa atcaaaatat cactatcaaa 9060
 acaacactct tgaaaaaatt gatgtgttca atgcaacatc ctccatcatg gttatacac 9120
 tggttcaatt tatatacaaa attaaataac atattaacac aatatcgatc aaatgaggta 9180
 aaaagtcagtg ggtttatatt aatagataat caaactttta gtgggttttca gtttatttta 9240
 aatcaatatg gttgtatcgt ttatcataaa ggactcaaaa aaatcacaac tactacttac 9300
 aatcaatttt tgacatggaa agacatcagc cttagcagat taaatgtttg cttaattact 9360

tggataagta attgtttaaa tacattaaac aaaagcttag ggctgagatg tggattcaat 9420
 aatgttgtgt tatcacaatt atttctttat ggagattgta tactgaaatt atttcataat 9480
 gaaggcttct acataataaa agaagtagag ggatttatta tgtctttaat tctaaacata 9540
 acagaagaag atcaatttag gaaacgattt tataatagca tgctaaataa catcacagat 9600
 gcagctatta aggctcaaaa ggacctacta tcaagagtat gtcacacttt attagacaag 9660
 acagtgtctg ataatatcat aaatggtaaa tggataatcc tattaagtaa atttcttaaa 9720
 ttgattaagc ttgcaggtga taataatctc aataacttga gtgagctata ttttctcttc 9780
 agaaicllty gacatccaat ggtcgatgaa agacaagcaa rggattctgt aagaattaac 9840
 tgtaatgaaa ctaagttcta cttattaagt agtctaagta cattaagagg tgctttcatt 9900
 tatagaatca taaaagggtt tgtaaatacc tacaacagat ggcccacctt aaggaaatgct 9960
 attgtcctac ctctaagatg gttaaaactac tataaaacta atacttatcc atctctactt 10020
 gaaatcacag aaaatgattt gattatttta tcaggattgc ggttctatcg tgagtttcat 10080
 ctgcctaaaa aagtggatct tgaaatgata ataaatgaca aagccatttc acctccaaaa 10140
 gatctaatat ggactagttt tcttagaaat tacatgccat cacatatata aaattatata 10200
 gaacatgaaa agttgaagtt ctctgaaagc gacagatcga gaagagtact agagtattac 10260
 ttgagagata ataaattcaa tgaatgcgat ctatacaatt gtgtagtcaa tcaaagctat 10320
 ctcaacaact ctaatcacgt ggtatcacta actggttaaag aaagagagct cagtgtaggt 10380
 agaatgtttg ctatgcaacc aggtatgttt aggc aaatcttagc agagaaaatg 10440
 atagctgaaa atattttaca attcttccct gagagtttga caagatatgg tgatctagag 10500
 cttcaaaaaga tattagaatt aaaagcagga ataagcaaca agtcaaactg ttataatgat 10560
 aactacaaca attatatcag taaatgttct atcattacag atcttagcaa attcaatcag 10620
 gcatttagat atgaaacatc atgtatctgc agtgatgtat tagatgaact gcatggagta 10680
 caatctctgt tctcttggtt gcatttaaca atacctcttg tcacaataat atgtacatat 10740
 agacatgcac ctcttttcat aaaggatcat gttgttaatc ttaatgaggt tgatgaacaa 10800
 agtggattat acagatatca tatgggtggt attgaggggt ggtgtcaaaa actgtggacc 10860
 attgaagcta tatcattatt agatctaata tctctcaaag ggaaattctc tatcacagct 10920
 ctgataaatg gtgataatca gtcaattgat ataaagcaaac cagttagact tatagagggt 10980
 cagacccatg cacaagcaga ttatttggtt gcattaaata gccttaaatt gttatataaa 11040
 gagtatgcag gtataggcca taagcttaag ggaacagaga cctatatatc ccgagatatg 11100
 cagttcatga gcaaaacaat ccagcacaat ggagtgtact atccagccag tatcaaaaaa 11160
 gtcctgagag taggtccatg gataaacacg atacttgatg attttaaagt tagtttagaa 11220
 tctataggca gcttaacaca ggagtttagaa tacagaggag aaagcttatt atgcagttta 11280
 atatttagga acatttggtt atacaatcaa attgctttgc aactccgaaa tcatgcatta 11340
 tgaacaata agctatattt agatatattg aaagtattaa aacacttaaa aacttttttt 11400
 aatcttgata gcattgatat ggctttatca ttgtatatga atttgcctat gctgtttggt 11460
 ggtggtgatc ctaatttggtt atatcgaagc ttttatagga gaactccaga cttccttaca 11520
 gaagctatag tacattcagt gtttgtgttg agctattata ctggtcacga tttacaagat 11580
 aagctccagg atcttccaga tgatagactg aacaaattct tgacatgtgt catcacattt 11640
 gataaaaatc ccaatgccga gtttgtaaca ttgatgaggg atccacaggc tttagggtct 11700
 gaaaggcaag ctaaaattac tagtgagatt aatagattag cagtaacaga agtcttaagt 11760
 atagcccaa acaaaatatt ttctaaaagt gcacaacatt atactaccac tgagattgat 11820
 ctaaatgaca ttatgcaaaa tatagaacca acttaccctc atggattaag agttgtttat 11880
 gaaagtttac ctttttataa agcagaaaaa atagttaatc ttatatcagg aacaaaatcc 11940
 ataactaata tacttgaaaa aacatcagca atagatacaa ctgatattaa tagggctact 12000
 gatatgatga ggaaaaatat aactttactt ataaggatac ttccactaga ttgtaacaaa 12060
 gacaaaagag agttattaag tttagaaaat cttagtataa ctgaattaa caagtatgta 12120
 agagaaagat cttggtcatt atccaatata gtaggagtaa catcgccaag tattatgttc 12180
 acaatggaca ttaaatatac aactagcact atagccagtg gtataataat agaaaaatat 12240

aatgttaata gtttaactcg tggtgaaaga ggaccaccca agccatgggt aggcctcatcc 12300
 acgcaggaga aaaaaacaat gccagtgtac aacagacaag ttttaaccaa aaagcaaaga 12360
 gaccaaatag atttattagc aaaattagac tgggtatatg catccataga caacaaagat 12420
 gaattcatgg aagaactgag tactggaaca cttggactgt catatgaaaa agccaaaaag 12480
 ttgtttccac aatatctaag tgtcaattat ttacaccgtt taacagtcag tagtagacca 12540
 tgtgaattcc ctgcatcaat accagcttat agaacaacaa attatcattt tgatactagt 12600
 cctatcaatc atgtattaac agaaaagtat ggagatgaag atatcgacat tgtgtttcaa 12660
 aattgrataa gttttgggtc tagcctgatg tcqqtqtqg aacaattcac aaacatatgt 12720
 cctaatagaa ttattctcat accgaagctg aatgagatac atttgatgaa acctcctata 12780
 tttacaggag atgttgatat catcaagttg aagcaagtga taaaaagca gcacatgttc 12840
 ctaccagata aaataagttt aacccaatat gtagaattat tcttaagtaa caaagcactt 12900
 aaatctggat ctacatcaa ctctaattta atattagtag ataaaatgtc tgattatttt 12960
 cataatgctt atatttttaag tactaattta gctggacatt ggattctgat tattcaactt 13020
 atgaaagatt caaaaggtag ttttgaaaaa gattggggag aggggtacat aactgatcat 13080
 atgttcatta atttgaatgt tttctttaat gcttataaga cttatttgct atgttttcat 13140
 aaaggttatg gtaaaacaaa attagaatgt gatatgaaca cttcagatct tctttgtgtt 13200
 ttggagttaa tagacagtag ctactggaaa tctatgtcta aagttttcct agaacaaaaa 13260
 gtcataaaat acatagtcaa tcaagacaca agtttgcgta gaataaaagg ctgtcacagt 13320
 ttttaagttg ggttttttaa acgccttaat aatgctaaat ttaccgtatg cccttgggtt 13380
 gttaacatag attatcaccc aacacacatg aaagctatat tatcttacat agatttagtt 13440
 agaatggggg taataaatgt agataaatta accattaaaa ataaaaacaa attcaatgat 13500
 gaattttaca catcaaatct cttttacatt agttataact tttcagacaa cactcatttg 13560
 ctaacaaaac aaataagaat tgctaattca gaattagaag ataattataa caaactatat 13620
 caccacaacc cagaaacttt agaaaatatg tcattaattc ctgttaaaag taataatagt 13680
 aacaaaccta aattttgtat aagtggaaat accgaatcta tgatgatgtc aacattctct 13740
 agtaaaatgc atattaaatc ttccactgtt accacaagat tcaattatag caaacaagac 13800
 ttgtacaatt tatttccaat tgtgtgata gacaagatta tagatcattc aggtaataca 13860
 gcaaaatcta accaacttta caccaccact tcacatcaga catcttagt aaggaaatagt 13920
 gcatcacttt attgcatgct tccttggcat catgtcaata gatttaactt tgtatttagt 13980
 tccacaggat gcaagatcag tatagagtat attttaaaag atcttaagat taaggacccc 14040
 agttgtatag cattcatagg tgaaggagct ggtaacttat tattacgtac ggtagtagaa 14100
 cttcatccag acataagata catttacaga agtttaaaag attgcaatga tcatagttta 14160
 cctattgaat ttctaagggt atacaacggg catataaaca tagattatgg tgagaattta 14220
 accattcctg ctacagatgc aactaataac attcattggt cttatttaca tataaaattt 14280
 gcagaacctt ttagcatctt tgtctgcat gctgaattac ctgttacagc caattggagt 14340
 aaaattataa ttgaatggag taagcatgta agaaagtga agtactgttc ttctgtaaat 14400
 agatgcattt taattgcaa atatcatgct caagatgaca ttgatttcaa attagataac 14460
 attactatat taaaaactta cgtgtgccta ggtagcaagt taaaaggatc tgaagtttac 14520
 ttaatcctta caataggccc tgcaaatata cttcctgttt ttgatgtgtt acaaaatgct 14580
 aaattgatac tttcaagaac taaaaatttc attatgccta aaaaaactga caaggaatct 14640
 atcgatgcag atattaaaag ctttaatactt ttctttgtt accctataac aaaaaaagga 14700
 attaagactt cattgtcaa attgaagagt gtagttaatg gagatatatt atcatattct 14760
 atagctggac gtaatgaagt attcagcaac aagcttataa accacaagca tatgaatatc 14820
 ctaaaatggc tagatcatgt tttaaatttt agatcagctg aacttaatta caatcattta 14880
 tacatgatag agtccacata tccttactta agtgaattgt taaatagttt aacaaccaat 14940
 gagctcaaga agctgattaa aataacaggt agtgtgctat acaaccttcc caacgaacag 15000
 tagtttaaaa tatcattaac aagtttggtc aaatttagat gctaacacat cattatatta 15060
 tagttattaa aaaatatata aacttttcaa taatttagca tattgattcc aaaattatca 15120

tttttagtctt aaggggttaa ataaaagtct aaaactaaca attatacatg tgcattcaca 15180
 acacaacgag acattagttt ttgacacttt ttttctcgt 15219

<210> 8

<211> 2166

<212> PRT

<213> respiratory syncytial virus

<400> 8

Met Asp Pro Ile Ile Asn Gly Asn Ser Ala Asn Val Tyr Leu Thr Asp
 1 5 10 15

Ser Tyr Leu Lys Gly Val Ile Ser Phe Ser Glu Cys Asn Ala Leu Gly
 20 25 30

Ser Tyr Leu Phe Asn Gly Pro Tyr Leu Lys Asn Asp Tyr Thr Asn Leu
 35 40 45

Ile Ser Arg Gln Ser Pro Leu Leu Glu His Met Asn Leu Lys Lys Leu
 50 55 60

Thr Ile Thr Gln Ser Leu Ile Ser Arg Tyr His Lys Gly Glu Leu Lys
 65 70 75 80

Leu Glu Glu Pro Thr Tyr Phe Gln Ser Leu Leu Met Thr Tyr Lys Ser
 85 90 95

Met Ser Ser Ser Glu Gln Ile Ala Thr Thr Asn Leu Leu Lys Lys Ile
 100 105 110

Ile Arg Arg Ala Ile Glu Ile Ser Asp Val Lys Val Tyr Ala Ile Leu
 115 120 125

Asn Lys Leu Gly Leu Lys Glu Lys Asp Arg Val Lys Pro Asn Asn Asn
 130 135 140

Ser Gly Asp Glu Asn Ser Val Leu Thr Thr Ile Ile Lys Asp Asp Ile
 145 150 155 160

Leu Ser Ala Val Glu Asn Asn Gln Ser Tyr Thr Asn Ser Asp Lys Ser
 165 170 175

His Ser Val Asn Gln Asn Ile Thr Ile Lys Thr Thr Leu Leu Lys Lys
 180 185 190

Leu Met Cys Ser Met Gln His Pro Pro Ser Trp Leu Ile His Trp Phe
 195 200 205

Asn Leu Tyr Thr Lys Leu Asn Asn Ile Leu Thr Gln Tyr Arg Ser Asn			
210	215	220	
Glu Val Lys Ser His Gly Phe Ile Leu Ile Asp Asn Gln Thr Leu Ser			
225	230	235	240
Gly Phe Gln Phe Ile Leu Asn Gln Tyr Gly Cys Ile Val Tyr His Lys			
	245	250	255
Gly Leu Lys Lys Ile Thr Thr Thr Thr Tyr Asn Gln Phe Leu Thr Trp			
	260	265	270
Lys Asp Ile Ser Leu Ser Arg Leu Asn Val Cys Leu Ile Thr Trp Ile			
	275	280	285
Ser Asn Cys Leu Asn Thr Leu Asn Lys Ser Leu Gly Leu Arg Cys Gly			
	290	295	300
Phe Asn Asn Val Val Leu Ser Gln Leu Phe Leu Tyr Gly Asp Cys Ile			
305	310	315	320
Leu Lys Leu Phe His Asn Glu Gly Phe Tyr Ile Ile Lys Glu Val Glu			
	325	330	335
Gly Phe Ile Met Ser Leu Ile Leu Asn Ile Thr Glu Glu Asp Gln Phe			
	340	345	350
Arg Lys Arg Phe Tyr Asn Ser Met Leu Asn Asn Ile Thr Asp Ala Ala			
	355	360	365
Ile Lys Ala Gln Lys Asp Leu Leu Ser Arg Val Cys His Thr Leu Leu			
	370	375	380
Asp Lys Thr Val Ser Asp Asn Ile Ile Asn Gly Lys Trp Ile Ile Leu			
385	390	395	400
Leu Ser Lys Phe Leu Lys Leu Ile Lys Leu Ala Gly Asp Asn Asn Leu			
	405	410	415
Asn Asn Leu Ser Glu Leu Tyr Phe Leu Phe Arg Ile Phe Gly His Pro			
	420	425	430
Met Val Asp Glu Arg Gln Ala Met Asp Ser Val Arg Ile Asn Cys Asn			
	435	440	445
Glu Thr Lys Phe Tyr Leu Leu Ser Ser Leu Ser Thr Leu Arg Gly Ala			
	450	455	460

Phe Ile Tyr Arg Ile Ile Lys Gly Phe Val Asn Thr Tyr Asn Arg Trp
 465 470 475 480
 Pro Thr Leu Arg Asn Ala Ile Val Leu Pro Leu Arg Trp Leu Asn Tyr
 485 490 495
 Tyr Lys Leu Asn Thr Tyr Pro Ser Leu Leu Glu Ile Thr Glu Asn Asp
 500 505 510
 Leu Ile Ile Leu Ser Gly Leu Arg Phe Tyr Arg Glu Phe His Leu Pro
 515 520 525
 Lys Lys Val Asp Leu Glu Met Ile Ile Asn Asp Lys Ala Ile Ser Pro
 530 535 540
 Pro Lys Asp Leu Ile Trp Thr Ser Phe Pro Arg Asn Tyr Met Pro Ser
 545 550 555 560
 His Ile Gln Asn Tyr Ile Glu His Glu Lys Leu Lys Phe Ser Glu Ser
 565 570 575
 Asp Arg Ser Arg Arg Val Leu Glu Tyr Tyr Leu Arg Asp Asn Lys Phe
 580 585 590
 Asn Glu Cys Asp Leu Tyr Asn Cys Val Val Asn Gln Ser Tyr Leu Asn
 595 600 605
 Asn Ser Asn His Val Val Ser Leu Thr Gly Lys Glu Arg Glu Leu Ser
 610 615 620
 Val Gly Arg Met Phe Ala Met Gln Pro Gly Met Phe Arg Gln Ile Gln
 625 630 635 640
 Ile Leu Ala Glu Lys Met Ile Ala Glu Asn Ile Leu Gln Phe Phe Pro
 645 650 655
 Glu Ser Leu Thr Arg Tyr Gly Asp Leu Glu Leu Gln Lys Ile Leu Glu
 660 665 670
 Leu Lys Ala Gly Ile Ser Asn Lys Ser Asn Arg Tyr Asn Asp Asn Tyr
 675 680 685
 Asn Asn Tyr Ile Ser Lys Cys Ser Ile Ile Thr Asp Leu Ser Lys Phe
 690 695 700
 Asn Gln Ala Phe Arg Tyr Glu Thr Ser Cys Ile Cys Ser Asp Val Leu
 705 710 715 720

Asp	Glu	Leu	His	Gly	Val	Gln	Ser	Leu	Phe	Ser	Trp	Leu	His	Leu	Thr
				725					730					735	
Ile	Pro	Leu	Val	Thr	Ile	Ile	Cys	Thr	Tyr	Arg	His	Ala	Pro	Pro	Phe
			740					745						750	
Ile	Lys	Asp	His	Val	Val	Asn	Leu	Asn	Glu	Val	Asp	Glu	Gln	Ser	Gly
		755						760						765	
Leu	Tyr	Arg	Tyr	His	Met	Gly	Gly	Ile	Glu	Gly	Trp	Cys	Gln	Lys	Leu
	770						775					780			
Trp	Thr	Ile	Glu	Ala	Ile	Ser	Leu	Leu	Asp	Leu	Ile	Ser	Leu	Lys	Gly
785						790				795					800
Lys	Phe	Ser	Ile	Thr	Ala	Leu	Ile	Asn	Gly	Asp	Asn	Gln	Ser	Ile	Asp
				805						810					815
Ile	Ser	Lys	Pro	Val	Arg	Leu	Ile	Glu	Gly	Gln	Thr	His	Ala	Gln	Ala
			820							825					830
Asp	Tyr	Leu	Leu	Ala	Leu	Asn	Ser	Leu	Lys	Leu	Leu	Tyr	Lys	Glu	Tyr
		835						840					845		
Ala	Gly	Ile	Gly	His	Lys	Leu	Lys	Gly	Thr	Glu	Thr	Tyr	Ile	Ser	Arg
		850					855					860			
Asp	Met	Gln	Phe	Met	Ser	Lys	Thr	Ile	Gln	His	Asn	Gly	Val	Tyr	Tyr
865						870					875				880
Pro	Ala	Ser	Ile	Lys	Lys	Val	Leu	Arg	Val	Gly	Pro	Trp	Ile	Asn	Thr
				885						890					895
Ile	Leu	Asp	Asp	Phe	Lys	Val	Ser	Leu	Glu	Ser	Ile	Gly	Ser	Leu	Thr
			900							905				910	
Gln	Glu	Leu	Glu	Tyr	Arg	Gly	Glu	Ser	Leu	Leu	Cys	Ser	Leu	Ile	Phe
			915					920					925		
Arg	Asn	Ile	Trp	Leu	Tyr	Asn	Gln	Ile	Ala	Leu	Gln	Leu	Arg	Asn	His
		930						935				940			
Ala	Leu	Cys	Asn	Asn	Lys	Leu	Tyr	Leu	Asp	Ile	Leu	Lys	Val	Leu	Lys
945						950					955				960
His	Leu	Lys	Thr	Phe	Phe	Asn	Leu	Asp	Ser	Ile	Asp	Met	Ala	Leu	Ser
						965					970				975

Leu Tyr Met Asn Leu Pro Met Leu Phe Gly Gly Gly Asp Pro Asn Leu
 980 985 990

Leu Tyr Arg Ser Phe Tyr Arg Arg Thr Pro Asp Phe Leu Thr Glu Ala
 995 1000 1005

Ile Val His Ser Val Phe Val Leu Ser Tyr Tyr Thr Gly His Asp Leu
 1010 1015 1020

Gln Asp Lys Leu Gln Asp Leu Pro Asp Asp Arg Leu Asn Lys Phe Leu
 1025 1030 1035 1040

Thr Cys Val Ile Thr Phe Asp Lys Asn Pro Asn Ala Glu Phe Val Thr
 1045 1050 1055

Leu Met Arg Asp Pro Gln Ala Leu Gly Ser Glu Arg Gln Ala Lys Ile
 1060 1065 1070

Thr Ser Glu Ile Asn Arg Leu Ala Val Thr Glu Val Leu Ser Ile Ala
 1075 1080 1085

Pro Asn Lys Ile Phe Ser Lys Ser Ala Gln His Tyr Thr Thr Thr Glu
 1090 1095 1100

Ile Asp Leu Asn Asp Ile Met Gln Asn Ile Glu Pro Thr Tyr Pro His
 1105 1110 1115 1120

Gly Leu Arg Val Val Tyr Glu Ser Leu Pro Phe Tyr Lys Ala Glu Lys
 1125 1130 1135

Ile Val Asn Leu Ile Ser Gly Thr Lys Ser Ile Thr Asn Ile Leu Glu
 1140 1145 1150

Lys Thr Ser Ala Ile Asp Thr Thr Asp Ile Asn Arg Ala Thr Asp Met
 1155 1160 1165

Met Arg Lys Asn Ile Thr Leu Leu Ile Arg Ile Leu Pro Leu Asp Cys
 1170 1175 1180

Asn Lys Asp Lys Arg Glu Leu Leu Ser Leu Glu Asn Leu Ser Ile Thr
 1185 1190 1195 1200

Glu Leu Ser Lys Tyr Val Arg Glu Arg Ser Trp Ser Leu Ser Asn Ile
 1205 1210 1215

Val Gly Val Thr Ser Pro Ser Ile Met Phe Thr Met Asp Ile Lys Tyr
 1220 1225 1230

Thr Thr Ser Thr Ile Ala Ser Gly Ile Ile Ile Glu Lys Tyr Asn Val			
1235	1240	1245	
Asn Ser Leu Thr Arg Gly Glu Arg Gly Pro Thr Lys Pro Trp Val Gly			
1250	1255	1260	
Ser Ser Thr Gln Glu Lys Lys Thr Met Pro Val Tyr Asn Arg Gln Val			
1265	1270	1275	1280
Leu Thr Lys Lys Gln Arg Asp Gln Ile Asp Leu Leu Ala Lys Leu Asp			
1285	1290	1295	
Trp Val Tyr Ala Ser Ile Asp Asn Lys Asp Glu Phe Met Glu Glu Leu			
1300	1305	1310	
Ser Thr Gly Thr Leu Gly Leu Ser Tyr Glu Lys Ala Lys Lys Leu Phe			
1315	1320	1325	
Pro Gln Tyr Leu Ser Val Asn Tyr Leu His Arg Leu Thr Val Ser Ser			
1330	1335	1340	
Arg Pro Cys Glu Phe Pro Ala Ser Ile Pro Ala Tyr Arg Thr Thr Asn			
1345	1350	1355	1360
Tyr His Phe Asp Thr Ser Pro Ile Asn His Val Leu Thr Glu Lys Tyr			
1365	1370	1375	
Gly Asp Glu Asp Ile Asp Ile Val Phe Gln Asn Cys Ile Ser Phe Gly			
1380	1385	1390	
Leu Ser Leu Met Ser Val Val Glu Gln Phe Thr Asn Ile Cys Pro Asn			
1395	1400	1405	
Arg Ile Ile Leu Ile Pro Lys Leu Asn Glu Ile His Leu Met Lys Pro			
1410	1415	1420	
Pro Ile Phe Thr Gly Asp Val Asp Ile Ile Lys Leu Lys Gln Val Ile			
1425	1430	1435	1440
Gln Lys Gln His Met Phe Leu Pro Asp Lys Ile Ser Leu Thr Gln Tyr			
1445	1450	1455	
Val Glu Leu Phe Leu Ser Asn Lys Ala Leu Lys Ser Gly Ser His Ile			
1460	1465	1470	
Asn Ser Asn Leu Ile Leu Val His Lys Met Ser Asp Tyr Phe His Asn			
1475	1480	1485	

Ala Tyr Ile Leu Ser Thr Asn Leu Ala Gly His Trp Ile Leu Ile Ile
 1490 1495 1500

Gln Leu Met Lys Asp Ser Lys Gly Ile Phe Glu Lys Asp Trp Gly Glu
 1505 1510 1515 1520

Gly Tyr Ile Thr Asp His Met Phe Ile Asn Leu Asn Val Phe Phe Asn
 1525 1530 1535

Ala Tyr Lys Thr Tyr Leu Leu Cys Phe His Lys Gly Tyr Gly Lys Ala
 1540 1545 1550

Lys Leu Glu Cys Asp Met Asn Thr Ser Asp Leu Leu Cys Val Leu Glu
 1555 1560 1565

Leu Ile Asp Ser Ser Tyr Trp Lys Ser Met Ser Lys Val Phe Leu Glu
 1570 1575 1580

Gln Lys Val Ile Lys Tyr Ile Val Asn Gln Asp Thr Ser Leu Arg Arg
 1585 1590 1595 1600

Ile Lys Gly Cys His Ser Phe Lys Leu Trp Phe Leu Lys Arg Leu Asn
 1605 1610 1615

Asn Ala Lys Phe Thr Val Cys Pro Trp Val Val Asn Ile Asp Tyr His
 1620 1625 1630

Pro Thr His Met Lys Ala Ile Leu Ser Tyr Ile Asp Leu Val Arg Met
 1635 1640 1645

Gly Leu Ile Asn Val Asp Lys Leu Thr Ile Lys Asn Lys Asn Lys Phe
 1650 1655 1660

Asn Asp Glu Phe Tyr Thr Ser Asn Leu Phe Tyr Ile Ser Tyr Asn Phe
 1665 1670 1675 1680

Ser Asp Asn Thr His Leu Leu Thr Lys Gln Ile Arg Ile Ala Asn Ser
 1685 1690 1695

Glu Leu Glu Asp Asn Tyr Asn Lys Leu Tyr His Pro Thr Pro Glu Thr
 1700 1705 1710

Leu Glu Asn Met Ser Leu Ile Pro Val Lys Ser Asn Asn Ser Asn Lys
 1715 1720 1725

Pro Lys Phe Cys Ile Ser Gly Asn Thr Glu Ser Met Met Met Ser Thr
 1730 1735 1740

Phe Ser Ser Lys Met His Ile Lys Ser Ser Thr Val Thr Thr Arg Phe
 1745 1750 1755 1760

Asn Tyr Ser Lys Gln Asp Leu Tyr Asn Leu Phe Pro Ile Val Val Ile
 1765 1770 1775

Asp Lys Ile Ile Asp His Ser Gly Asn Thr Ala Lys Ser Asn Gln Leu
 1780 1785 1790

Tyr Thr Thr Thr Ser His Gln Thr Ser Leu Val Arg Asn Ser Ala Ser
 1795 1800 1805

Leu Tyr Cys Met Leu Pro Trp His His Val Asn Arg Phe Asn Phe Val
 1810 1815 1820

Phe Ser Ser Thr Gly Cys Lys Ile Ser Ile Glu Tyr Ile Leu Lys Asp
 1825 1830 1835 1840

Leu Lys Ile Lys Asp Pro Ser Cys Ile Ala Phe Ile Gly Glu Gly Ala
 1845 1850 1855

Gly Asn Leu Leu Leu Arg Thr Val Val Glu Leu His Pro Asp Ile Arg
 1860 1865 1870

Tyr Ile Tyr Arg Ser Leu Lys Asp Cys Asn Asp His Ser Leu Pro Ile
 1875 1880 1885

Glu Phe Leu Arg Leu Tyr Asn Gly His Ile Asn Ile Asp Tyr Gly Glu
 1890 1895 1900

Asn Leu Thr Ile Pro Ala Thr Asp Ala Thr Asn Asn Ile His Trp Ser
 1905 1910 1915 1920

Tyr Leu His Ile Lys Phe Ala Glu Pro Ile Ser Ile Phe Val Cys Asp
 1925 1930 1935

Ala Glu Leu Pro Val Thr Ala Asn Trp Ser Lys Ile Ile Ile Glu Trp
 1940 1945 1950

Ser Lys His Val Arg Lys Cys Lys Tyr Cys Ser Ser Val Asn Arg Cys
 1955 1960 1965

Ile Leu Ile Ala Lys Tyr His Ala Gln Asp Asp Ile Asp Phe Lys Leu
 1970 1975 1980

Asp Asn Ile Thr Ile Leu Lys Thr Tyr Val Cys Leu Gly Ser Lys Leu
 1985 1990 1995 2000

Lys Gly Ser Glu Val Tyr Leu Ile Leu Thr Ile Gly Pro Ala Asn Ile
 2005 2010 2015

Leu Pro Val Phe Asp Val Val Gln Asn Ala Lys Leu Ile Leu Ser Arg
 2020 2025 2030

Thr Lys Asn Phe Ile Met Pro Lys Lys Thr Asp Lys Glu Ser Ile Asp
 2035 2040 2045

Ala Asp Ile Lys Ser Leu Ile Pro Phe Leu Cys Tyr Pro Ile Thr Lys
 2050 2055 2060

Lys Gly Ile Lys Thr Ser Leu Ser Lys Leu Lys Ser Val Val Asn Gly
 2065 2070 2075 2080

Asp Ile Leu Ser Tyr Ser Ile Ala Gly Arg Asn Glu Val Phe Ser Asn
 2085 2090 2095

Lys Leu Ile Asn His Lys His Met Asn Ile Leu Lys Trp Leu Asp His
 2100 2105 2110

Val Leu Asn Phe Arg Ser Ala Glu Leu Asn Tyr Asn His Leu Tyr Met
 2115 2120 2125

Ile Glu Ser Thr Tyr Pro Tyr Leu Ser Glu Leu Leu Asn Ser Leu Thr
 2130 2135 2140

Thr Asn Glu Leu Lys Lys Leu Ile Lys Ile Thr Gly Ser Val Leu Tyr
 2145 2150 2155 2160

Asn Leu Pro Asn Glu Gln
 2165

<210> 9

<211> 15219

<212> DNA

<213> respiratory syncytial virus

<400> 9

acgggaaaaa aatgcgtact acaaacttgc acattcgaaa aaaatggggc aaataagaac 60
 ttgataagtg ctatttaagt ctaacctttt caatcagaaa tgggggtgcaa ttcactgagc 120
 atgataaagg ttagattaca aaatttatgt gacaatgacg aagtagcatt gttaaaaaata 180
 acatgttata ctgataaatt aattcttctg accaatgcat tagccaaagc agcaatacat 240
 acaattaaat taaacggcat agtttttata catgtttata caagcagtga agtgtgccct 300
 gataacaata ttgtagtga atctaacttt acaacaatgc caatactaca aaatggagga 360
 tacatatggg aattgattga gttgacacac tgctctcaat taaacgggtt aatggatgat 420
 aattgtgaaa tcaaattttc taaaagacta agtgactcag taatgactaa ttatatgaat 480

caaatatctg acttacttgg gcttgatctc aattcatgaa ttatgttttag tctaattcaa 540
 tagacatgtg tttattacca ttttagttaa tataaaaact catcaaaggg aaatggggca 600
 aataaactca cctaatacat caaaccatga gactacaaa tgacaacact actatgcaaa 660
 gattgatgat cacagacatg agaccctgt caatggattc aataataaca tctcttacca 720
 aagaaatcat cacacacaaa ttcataact tgataaaca tgaatgtatt gtaagaaaac 780
 ttgatgaaag acaagctaca tttacattct tagtcaatta tgagatgaag ctactgcaca 840
 aagtagggag taccaaatac aaaaaataca ctgaatataa tacaaaatat ggcactttcc 900
 ccatgctat atttatcaat cacqccqqt ttctagaatg tattggcatt aagcctacaa 960
 aacacactcc tataatatac aaatatgacc tcaaccctg aattccaaca aaaaaacaa 1020
 cccaaccaa ccaactatt cctcaaaca cagtgtcaa tagttaagaa ggagctaata 1080
 catttttagta attaaaaata aaagtaaagc caataacata aattggggca aatacaaga 1140
 tggctcttag caaagtcaag ttgaatgata cattaataa ggatcagctg ctgtcatcca 1200
 gcaaatcac tattcaacgt agtacaggag ataatttga cactcccaat tatgatgtgc 1260
 aaaaacacct aaacaaacta tgtggtatgc tattaatcac tgaagatgca aatcataaat 1320
 tcacaggatt aataggtatg ttatatgcta tgtccaggtt aggaagggaa gacactataa 1380
 agatacttaa agatgctgga tatcatgtta aagctaattg agtagatata acaacatatc 1440
 gtcaagatat aaatggaaa gaaatgaaat tcgaagtatt aacattatca agcttgacat 1500
 cagaaatata agtcaatatt gagatagaat ctgaaaagtc ctacaaaaaa atgctaaaag 1560
 agatgggaga agtggctcca gaatataggc atgattctcc agactgtggg atgataatac 1620
 tgtgtatagc tgcacttgtg ataaccaaat tagcagcagg agacagatca ggtcttacag 1680
 cagtaattag gagggcaaac aatgtcttaa aaaacgaaat aaaacgatac aagggcctca 1740
 taccaaagga tatagctaac agtttttatg aagtgtttga aaaacaccct catcttatag 1800
 atgttttctg gcactttggc attgcacaat catccacaag agggggtagt agagttgaag 1860
 gaatcttttc aggattgttt atgaatgcct atgggttcagg gcaagtaatg ctaagatggg 1920
 gagtttttag caaatctgta aaaaatatca tgctaggaca tgctagtgtc caggcagaaa 1980
 tggagcaagt tgtggaagtc tatgagtatg cacagaagtt gggaggagaa gctggattct 2040
 accatatatt gaacaatcca aaagcatcat tgctgtcatt aactcaattt cccaacttct 2100
 caagtgtggt cctaggcaat gcagcaggtc taggcataat gggagagtat agaggtacac 2160
 caagaaacca ggatctttat gatgcagcta aagcatatgc agagcaactc aaagaaaatg 2220
 gagtaataaa ctacagtgtat ttagacttaa cagcagaaga attggaagcc ataaagcatc 2280
 aactcaacc caaagaagat gatgtagagc tttaagttaa caaaaaatac ggggcaata 2340
 agtcaacatg gagaagtttg cacctgaatt tcatggagaa gatgcaata acaaagctac 2400
 caaatcccta gaatcaataa agggcaagtt cgcacatcc aaagatccta agaagaaaga 2460
 tagcataata tctgttaact caatagatat agaagtaact aaagagagcc cgataacatc 2520
 tggcaccaac atcatcaatc caacaagtga agccgacagt accccagaaa caaaagccaa 2580
 ctaccaaga aaacccttag taagcttcaa agaagatctc accccaagtg acaacccttt 2640
 ttctaagtty tacaaggaaa caatagaaac atttgataac aatgaagaag aatctagcta 2700
 ctcatatgaa gagataaat atcaaacaaa tgacaacatt acagcaagac tagatagaat 2760
 tgatgaaaaa ttaagtgaat tattaggaat gctccatata ttagtagttg caagtgcagg 2820
 acccacttca gctcgcgatg gaataagaga tgctatgggt ggtctaagag aagagatgat 2880
 agaaaaata agagcggaag cattaatgac caatgatagg ttagaggcta tggcaagact 2940
 taggaatgag gaaagcgaaa aaatggcaaa agacacctca gatgaagtgt ctcttaatcc 3000
 aacttccaaa aaattgagtg acttgttgga agacaacgat agtgacaatg atctatcact 3060
 tgatgatttt tgatcagcga tcaactcact cagcaatcaa caacatcaat aaaacagaca 3120
 tcaatccatt gaatcaactg ccagaccgaa caaacaacg tccatcagta gaaccaccaa 3180
 ccaatcaatc aaccaattga tcaatcagca acccgacaaa attacaata tagtaacaaa 3240
 aaaagaacaa gatggggcaa atatggaaac atacgtgaac aagcttcacg aaggctccac 3300
 atacacagca gctgttcagt acaatgttct agaaaagat gatgatcctg catcactaac 3360

aatatgggtg cctatgttcc agtcatctgt gccagcagac ttgttcataa aagaacttgc 3420
aagcatcaat atactagtga agcagatctc tacgccccaa ggaccttcac tacgagtcac 3480
gattaactca agaagtgtgt tgctggctca aatgcctagt aatttcatca taagcgcaaa 3540
tgtatcatta gatgaaagaa gcaaattagc atatgatgta actacacctt gtgaaatcaa 3600
agcatgcagt ctaacatgct taaaagtata aagtatgtta actacagtca aagatcttac 3660
catgaagaca ttcaacccca ctcatgagat cattgtctta tgtgaatttg aaaatattat 3720
gacatcaaaa agagtaataa taccaacctt tctaagatca attagtgtca agaacaagga 3780
tctgaactca ctgaaaaata tagcaacac cgaattcaca aatqctatca ccaatgcaaa 3840
aattattcct tatgcaggat tagtggttagt tatcacagtt actgacaata aaggagcatt 3900
caaatatatc aaaccacaga gtcaatttat agtagatctt ggtgcctacc tagaaaaaga 3960
gagcatatat tatgtgacta ctaattggaa gcatacagct acacgttttt caatcaaacc 4020
actagaggat taaacttaat tatcaacact gaatgacagg tccacatata tcctcaaact 4080
acacactata tccaaacatc ataaacatct acactacaca cttcatcaca caaaccaatc 4140
ccactcaaaa tccaaaatca ctaccagcca ctatccgcta gacctagagt gcgaataggc 4200
aaataaaaacc aaaatatggg gttaaatagac attagttaga gttcaatcaa tcttaacaac 4260
catttatacc gccaatcaa cacatatact ataaatctta aaatgggaaa tacatccatc 4320
acaatagaac tcacaagcaa attttggccc tattttacac taatacatat gatcttaact 4380
ctaactcttt tactaattat aatcactatc atgattgcaa cactaaataa gctaagtga 4440
cacaagcat tctgcaacaa aactcttgaa ctaggacaga tgtaccaaat caacacacag 4500
agttccacca ttatgctgtg tcaaaccata atcctgtata tacaacaaa caaatccaat 4560
cctctcacag agtcacgggt tcgcaaaacc acgctaacca tcatggtagc atagagtagt 4620
tatttaaaaa ttaacataat gatgaattgt tagtatgaga tcaaaaacaa cattggggca 4680
aatgcaacca tgtccaaaca caagaatcaa cgcactgcca ggactctaga aaagacctgg 4740
gatactctta atcatctaat tgtaatatcc tcttgtttat acagattaaa tttaaaatct 4800
atagcacaac tagcactatc agttttggca atgataatct caacctctct cataattgca 4860
gccataatat tcatcatctc tgccaatcac aaagttagac taacaacggg cacagttcaa 4920
acaataaaaa accacactga aaaaaacatc accacctacc ctactcaagt ctcaccagaa 4980
agggttagtt catccaagca acccacaacc acatcaccaa tccacacaag ttcagctaca 5040
acatcaccca atacaaaatc agaaacacac catacaacag cacaaccaa aggcagaacc 5100
accacttcaa cacagaccaa caagccaagc acaaaaccac gtccaaaaaa tccacaaaaa 5160
aaagatgatt accattttga agtggtcaac ttcgttcctt gcagtatatg tggcaacaat 5220
caactttgca aatccatctg caaaaacata ccaagcaaca aaccaaagaa gaaaccaacc 5280
atcaaaccca caaacaacac aaccacaaa accacaaaac aaagagaccc aaaaacacca 5340
gccaaaacga cgaaaaaaga aactaccacc aaccacaaca aaaaactaac cctcaagacc 5400
acagaaaagag acaccagcac ctcaaatcc actgcactcg acacaaccac attaaaacac 5460
acagtccaac agcaatccct cctctcaacc acccccgaac acacacccaa ctccacacaa 5520
acaccacag catccgagcc ctccacacca aactccacc aaaaaacca gccacatgct 5580
tagttattca aaaactacat cttagcagag aacctgac tatcaagcaa gaacgaaatt 5640
aaacctgggg caaataacca tggagttgat gatccacaag tcaagtgaac tcttcctaac 5700
tcttgctatt aatgcattgt acctcacctc aagtcagaac ataactgagg agttttacca 5760
atcgacatgt agtgcagtta gcagaggtta ttttagtgct ttaagaacag gttggtatac 5820
tagtgtcata acaatagaat taagtaatat aaaagaaacc aaatgcaatg gaactgacac 5880
taaagtaaaa cttatgaac aagaattaga taagtataag aatgcagtaa cagaattaca 5940
gtactttatg caaaacacac cagctgtcaa caaccgggccc agaagagaag caccacagta 6000
tatgaactac acaatcaata ccactaaaaa cctaaatgta tcaataagca agaagaggaa 6060
acgaagattt ctaggcttct tgtaggtgt gggatctgca atagcaagtgt gtatagctgt 6120
atcaaaagtt ctacaccttg aaggagaagt gaacaagatc aaaaatgctt tgttgctac 6180
aaacaaagct gtagtcagtt tatcaaatgg ggtcagtggt ttaaccagca aagtgttaga 6240

tctcaagaat tacataaata accaattatt acccatagta aatcaacaga gctgtcgcat 6300
ctccaacatt gaaacagtta tagaattcca gcagaagaac agcagattgt tggaaatcac 6360
cagagaattt agtgtcaatg caggtgtaac aacaccttta agcacttaca tgttgacaaa 6420
cagtgagtta ctatcattaa tcaatgatat gcctataaca aatgatcaga aaaaattaat 6480
gtcaagcaat gttcagatag taaggcaaca aagttattcc atcatgtcta taataaagga 6540
agaagtccct gcataatgtg tacagctgcc tatctatggt gtaatagata caccttgctg 6600
gaaattgcac acatcgctc tatgcactac caacatcaaa gaaggatcaa atatttgttt 6660
aacaaggact galagaggat ggtattgtga taatgcaggga rragtarcct tctttccaca 6720
ggctgacact tgtaaagtac agtccaatcg agtattttgt gacactatga acagtttgac 6780
attaccaagt gaagtcagcc tttgtaacac tgacatattc aattccaagt atgactgcaa 6840
aattatgaca tcaaaaacag acataagcag ctacagtaatt acttctcttg gagctatagt 6900
gtcatgctat ggtaaaacta aatgcactgc atccaacaaa aatcggtgga ttataaagac 6960
atthttcta at ggtgtgact atgtgtcaaa caaaggagta gatactgtgt cagtgggcaa 7020
cactttatatac tatgtaaaca agctggaagg caagaacctt tatgtaaaag gggaacctat 7080
aataaattac tatgacctc tagtgtttcc ttctgatgag ttgatgcat caatatctca 7140
agtcaatgaa aaaatcaatc aaagtttagc ttttattcgt agatctgatg aattactaca 7200
taatgtaaat actggcaaat ctactacaaa tattatgata actacaatta ttatagtaat 7260
cattgtagta ttgttatcat taatagctat tggtttactg ttgtattgta aagccaaaaa 7320
cacaccagtt acactaagca aagaccaact aagtggaaac aataatattg cattcagcaa 7380
atagacaaaa aaccacctga tcatgtttca acaacaatct gctgaccacc aatcccaaat 7440
caacttaca caaatatttc aacatcacag tacaggtgta atcatttctt cacatcatgc 7500
taccacata actaagctag atccttaact tatagttaca taaaaacctc aagtatcaca 7560
atcaaccact aatcaaacac atcattcaca aaattaacag ctggggcaaa tatgtcgcgca 7620
agaaatcctt gtaaatgtga gattagaggt cattgcttga atggtagaag atgtcactac 7680
agtcataatt actttgaatg gcctcctcat gcattactag tgaggcaaaa ctctcatgta 7740
aacaagatac tcaagtcaat ggacaaaagc atagacactt tgtctgaaat aagtggagct 7800
gctgaactgg atagaacaga agaatatgct cttggtatag ttggagtgt agagagttac 7860
ataggatcta taaacaacat aacaaaaaca tcagcatgtg ttgctatgag taaacttctt 7920
attgagatca atagtgtatga cattaaaaag cttagagata atgaagaacc caattcacct 7980
aagataagag tgtacaatac tggttatatca tacattgaga gcaatagaaa aaacaacaag 8040
caaaccatcc atctgtctca gagactacca gcagacgtgc tgaagaagac aataaagaac 8100
acattagata tccacaaaag cataaccata agcaatccaa aagagtcaac tgtgaatgat 8160
caaatgacc aaacaaaaa taatgatatt accggataaa tatecttgta gtatatcatc 8220
catattgatc tcaagtgaat gcattggtgc tacattcaat cataaaaaa cattacaatt 8280
taaccataac tatttgata accaccagcg tttattaaat catatatattg atgaaattca 8340
ttggacacct aaaaacttat tagatgccac tcaacaattt ctccaacatc ttaacatccc 8400
tgaagatata tatacagtat atatataggt gtcataatgc ttgaccataa cgactctatg 8460
tcatccaacc ataaaactat tttgataagg ttatgggaca aaatggatcc cattattaat 8520
ggaaactctg ctaatgtgta tctaactgat agttatttaa aagggtgttat ctctttttca 8580
gagtgtaatg ctttagggag ttatcttttt aacggccctt atcttaaaaa tgattacacc 8640
aacttaatta gtagacaaaag cccactacta gagcatatga atcttaaaaa actaactata 8700
acacagtcatt taatatctag atatcataaa ggtgaactga aattagaaga accaacttat 8760
ttccagtcatt tacttatgac atataaaagt atgtcctcgt ctgaacaaat tgctacaact 8820
aacttactta aaaaaataat acgaagagcc atagaaataa gtgatgtaaa ggtgtacgcc 8880
atcttgaata aactaggatt aaaggaaaag gacagagtta agcccaacaa taattcaggt 8940
gatgaaaact cagtacttac aaccataaatt aaagatgata tactttcggc tgtggaaaac 9000
aatcaatcat atacaaattc agacaaaagt cactcagtaa atcaaaatat cactatcaaa 9060
acaacactct tgaaaaaatt gatgtgttca atgcaacatc ctccatcatg gttaatcac 9120

tggttcaatt tatatacaaa attaaataac atattaacac aatategatc aaatgaggta 9180
 aaaagtcacg ggtttatatt aatagataat caaactttta gtggttttca gtttatttta 9240
 aatcaatatg gttgtatcgt ttatcataaa ggactcaaaa aaatcacaaac tactacttac 9300
 aatcaatttt tgacatggaa agacatcagc cttagcagat taaatgtttg ctttaattact 9360
 tggataagta attgttttaa tacattaaac aaaagcttag ggctgagatg tggattcaat 9420
 aatgttgtgt tatcacaaatt atttctttat ggagattgta tactgaaatt atttcataat 9480
 gaaggcttct acataataaa agaagtagag ggatttatta tgtctttaat tctaaacata 9540
 acagaagaaag atcaatttaa gaaagatttt tataataqca tgctaaataa catcacagat 9600
 gcagctatta aggctcaaaa ggacctacta tcaagagtat gtcacacttt attagacaag 9660
 acagtgtctg ataatatcat aaatggtaaa tggataatcc tattaagtaa atttcttaaa 9720
 ttgattaagc ttgcaggtga taataatctc aataacttga gtgagctata ttttctcttc 9780
 agaactcttg gacatccaat ggctgatgaa agacaagcaa tggattctgt aagaattaac 9840
 tgtaatgaaa ctaagttcta cttattaagt agtctaagta cattaagagg tgctttcatt 9900
 tatagaatca taaaagggtt tgtaaatacc tacaacagat ggccacactt aaggaaatgct 9960
 attgtcctac ctctaagatg gttaaactac tataaactta atacttatcc atctctactt 10020
 gaaatcacag aaaatgattt gattatttta tcaggattgc ggttctatcg tgagtttcat 10080
 ctgcctaaaa aagtggatct tgaaatgata ataaatgaca aagccatttc acctccaaaa 10140
 gatctaatat ggactagttt tctagaaat tacatgccat cacatataca aaattatata 10200
 gaacatgaaa agttgaagtt ctctgaaagc gacagatcga gaagagtact agagtattac 10260
 ttgagagata ataaattcaa tgaatgcat ctatacaatt gtgtagtcaa tcaaagctat 10320
 ctcaacaact ctaatcacgt ggtatcacta actggttaaag aaagagagct cagtgtaggt 10380
 agaatgtttg ctatgcaacc aggtatgttt aggc aaatcttagc agagaaaaatg 10440
 atagctgaaa atattttaca attcttccct gagagtttga caagatatgg tgatctagag 10500
 cttcaaaaaga tattagaatt aaaagcagga ataagcaaca agtcaaactg ttataatgat 10560
 aactacaaca attatatcag taaatgttct atcattacag atcttagcaa attcaatcag 10620
 gcatttagat atgaaacatc atgtatctgc agtcatgtat tagatgaact gcatggagta 10680
 caatctctgt tctcttggtt gcatttaaca atacctcttg tcacaataat atgtacata 10740
 agacatgcac ctcttttcat aaaggatcat gttgttaatc ttaatgaggt tgatgaacaa 10800
 agtggattat acagatatca tatgggtggt attgagggct ggtgtcaaaa actgtggacc 10860
 attgaaagcta tatcattatt agatctaata tctctcaaag ggaaattctc tatcacagct 10920
 ctgataaatg gtgataatca gtcaattgat ataagcaaac cagttagact tatagagggt 10980
 cagacccatg cacaagcaga ttatttggtt gcattaaata gccttaaatt gttatataaa 11040
 gagtatgcag gtataggcca taagcttaag ggaacagaga cctatatatc ccgagatatg 11100
 cagttcatga gcaaaacaat ccagcacaat ggagtgtact atccagccag tatcaaaaaa 11160
 gtcctgagag taggtccatg gataaacacg atacttgatg attttaaagt tagtttagaa 11220
 tctataggca gcttaacaca ggagtttagaa tacagaggag aaagcttatt atgcagttta 11280
 atatttagga acatttggtt atacaatcaa attgctttgc aactccgaaa tcatgcatta 11340
 tgtaacaata agctatattt agatatattg aaagtattaa aacacttaaa aacttttttt 11400
 aatcttgata gcattgatat ggctttatca ttgtatatga atttgctat gctgtttggt 11460
 ggtggtgatc ctaatttggtt atatcgaagc ttttatagga gaactccaga cttccttaca 11520
 gaagctatag tacattcagt gtttgtgttg agctattata ctggtcacga tttacaagat 11580
 aagctccagg atcttccaga tgatagactg aacaaattct tgacatgtgt catcacattt 11640
 gataaaaatc ccaatgccga gtttgtaaca ttgatgaggg atccacaggc tttagggtct 11700
 gaaaggcaag ctaaaattac tagtgagatt aatagattag cagtaacaga agtcttaagt 11760
 atagcccaa acaaaatatt ttctaaaagt gcacaacatt atactaccac tgagattgat 11820
 ctaaatgaca ttatgcaaaa tatagaacca acttaccctc atggattaag agttgtttat 11880
 gaaagtttac ctttttataa agcagaaaaa atagttaatc ttatatcagg aacaaaatcc 11940
 ataactaata tacttgaaaa aacatcagca atagatacaa ctgatattaa tagggctact 12000

gatatgatga ggaaaaatat aactttactt ataaggatac ttccactaga ttgtaacaaa 12060
gacaaaagag agttattaag tttagaaaat cttagtataa ctgaattaag caagtatgta 12120
agagaaaagat cttgggtcatt atccaatata gtaggagtaa catcgccaag tattatgttc 12180
acaatgaaca ttaaatatac aactagcact atagccagtg gtataataat agaaaaatat 12240
aatgttaata gtttaactcg tgggtgaaaga ggccccacca agccatgggt aggtcatcc 12300
acgcaggaga aaaaaacaat gccagtgtac aacagacaag ttttaaccaa aaagcaaaga 12360
gaccaaataag atttattagc aaaattagac tgggtatatg catccataga caacaaagat 12420
gaailcatgg aggaactgag tactggaaca cttggactgt catatqaaaa agccaaaaag 12480
ttgtttccac aatatctaag tgtcaattat ttacaccgtt taacagtcag tagtagacca 12540
tgtgaattcc ctgcatcaat accagcttat agaacaacaa attatcattt tgatactagt 12600
cctatcaatc atgtattaac agaaaagtat ggagatgaag atatcgacat tgtgtttcaa 12660
aattgcataa gttttggtct tagcctgatg tgggtgtgg aacaattcac aaacatatgt 12720
cctaatagaa ttattctcat accgaagctg aatgagatac atttgatgaa acctcctata 12780
tttacaggag atgttgatat catcaagttg aagcaagtga taaaaagca gcacatgttc 12840
ctaccagata aaataagttt aaccaatat gtagaattat tcttaagtaa caaagcattt 12900
aaatctggat ctacatcaa ctctaattta atattagtac ataaaatgtc tgattatttt 12960
cataatgctt atattttaag tactaattta gctggacatt ggattctgat tattcaactt 13020
atgaaagatt caaaaggtat ttttgaaaaa gattggggag aggggtacat aactgatcat 13080
atgttcatta atttgaatgt tttctttaat gcttataaga cttatttgc tgttttcat 13140
aaaggttatg gtaaaagcaa attagaatgt gatatgaaca cttcagatct tctttgtgtt 13200
ttggagttaa tagacagtag ctactggaaa tctatgtcta aagttttcct agaacaaaaa 13260
gtcataaaat acatagtcaa tcaagacaca agtttgcgta gaataaaagg ctgtcacagt 13320
tttaagttgt ggttttttaa acgccttaat aatgctaaat ttaccgtatg cccttgggtt 13380
gttaacatag attatcaccc aacacacatg aaagctatat tatcttcat agatttagtt 13440
agaatggggt taataaatgt agataaatta accattaaaa ataaaaacaa attcaatgat 13500
gaattttaca catcaaactt cttttacatt agttataact tttcagacaa cactcatttg 13560
ctaacaaaac aaataagaat tgctaattca gaattagaag ataattataa caaactatat 13620
cacccaaccc cagaaacttt agaaaatatg tcattaattc ctgttaaaag taataatagt 13680
aacaaccta aattttgtat aagtggaaat accgaatcta tgatgatgtc aacattctct 13740
agtaaaatgc atattaaatc ttccactgtt accacaagat tcaattatag caaacaagac 13800
ttgtacaatt tatttccaat tgttgtgata gacaagatta tagatcattc aggtaatata 13860
gcaaaatcta accaacttta caccaccact tcacatcaga catctttagt aaggaatagt 13920
gcatcacttt attgcatgct tccttggcat catgtcaata gatttaactt tgtatttagt 13980
tccacaggat gcaagatcag tatagagtat attttaaaag atcttaagat taaggacccc 14040
agttgtatag cattcatagg tgaaggagct ggtaacttat tattacgtac ggtagtagaa 14100
cttcatccag acataagata catttacaga agtttaaaag attgcaatga tcatagttta 14160
cctattgaat ttctaagggt atacaacggg catataaaca tagattatgg tgagaattta 14220
accattcctg ctacagatgc aactaataac attcattggt cttatttaca tataaaattt 14280
gcagaacctt ttagcatctt tgtctgcgat gctgaattac ctgttacagc caattggagt 14340
aaaattataa ttgaatggag taagcatgta agaaagtgca agtactgttc ttctgtaaat 14400
agatgcattt taattgcaaa atatcatgct caagatgaca ttgatttcaa attagataac 14460
attactatat taaaaactta cgtgtgccta ggtagcaagt taaaaggatc tgaagtttac 14520
ttaatcctta caataggccc tgcaaatata ctctctgtt ttgatgttgt acaaaatgct 14580
aaattgatac tttaagaac taaaaatttc attatgccta aaaaaactga caaggaatct 14640
atcgatgcaa atattaaaag ctttaatacct ttcctttgtt accctataac aaaaaaagga 14700
attaagactt cattgtcaaa attgaagagt gtagttaatg gagatatatt atcatattct 14760
atagctggac gtaatgaagt attcagcaac aagcttataa accacaagca tatgaatata 14820
ctaaaaatggc tagatcatgt tttaaatttt agatcagctg aacttaatta caatcattta 14880

tacatgatag agtccacata tccttactta agtgaattgt taaatagttt aacaaccaat 14940
 gagctcaaga agctgattaa aataacaggt agtgtgctat acaaccttcc caacgaacag 15000
 tagtttaaaa tatcattaa aagtttggtc aaatttagat gctaacacat cattatatta 15060
 tagttattaa agaataata aacttttcaa taatttagca tattgattcc aaaattatca 15120
 ttttagtctt aaggggttaa ataaaagtct aaaactaaca attatacatg tgcattcaca 15180
 acacaacgag acattagttt ttgacacttt ttttctcgt 15219

<210> 10

<211> 2166

<212> PRT

<213> respiratory syncytial virus

<400> 10

Met Asp Pro Ile Ile Asn Gly Asn Ser Ala Asn Val Tyr Leu Thr Asp
 1 5 10 15

Ser Tyr Leu Lys Gly Val Ile Ser Phe Ser Glu Cys Asn Ala Leu Gly
 20 25 30

Ser Tyr Leu Phe Asn Gly Pro Tyr Leu Lys Asn Asp Tyr Thr Asn Leu
 35 40 45

Ile Ser Arg Gln Ser Pro Leu Leu Glu His Met Asn Leu Lys Lys Leu
 50 55 60

Thr Ile Thr Gln Ser Leu Ile Ser Arg Tyr His Lys Gly Glu Leu Lys
 65 70 75 80

Leu Glu Glu Pro Thr Tyr Phe Gln Ser Leu Leu Met Thr Tyr Lys Ser
 85 90 95

Met Ser Ser Ser Glu Gln Ile Ala Thr Thr Asn Leu Leu Lys Lys Ile
 100 105 110

Ile Arg Arg Ala Ile Glu Ile Ser Asp Val Lys Val Tyr Ala Ile Leu
 115 120 125

Asn Lys Leu Gly Leu Lys Glu Lys Asp Arg Val Lys Pro Asn Asn Asn
 130 135 140

Ser Gly Asp Glu Asn Ser Val Leu Thr Thr Ile Ile Lys Asp Asp Ile
 145 150 155 160

Leu Ser Ala Val Glu Asn Asn Gln Ser Tyr Thr Asn Ser Asp Lys Ser
 165 170 175

His Ser Val Asn Gln Asn Ile Thr Ile Lys Thr Thr Leu Leu Lys Lys
 180 185 190

Leu Met Cys Ser Met Gln His Pro Pro Ser Trp Leu Ile His Trp Phe
 195 200 205
 Asn Leu Tyr Thr Lys Leu Asn Asn Ile Leu Thr Gln Tyr Arg Ser Asn
 210 215 220
 Glu Val Lys Ser His Gly Phe Ile Leu Ile Asp Asn Gln Thr Leu Ser
 225 230 235 240
 Gly Phe Gln Phe Ile Leu Asn Gln Tyr Gly Cys Ile Val Tyr His Lys
 245 250 255
 Gly Leu Lys Lys Ile Thr Thr Thr Tyr Asn Gln Phe Leu Thr Trp
 260 265 270
 Lys Asp Ile Ser Leu Ser Arg Leu Asn Val Cys Leu Ile Thr Trp Ile
 275 280 285
 Ser Asn Cys Leu Asn Thr Leu Asn Lys Ser Leu Gly Leu Arg Cys Gly
 290 295 300
 Phe Asn Asn Val Val Leu Ser Gln Leu Phe Leu Tyr Gly Asp Cys Ile
 305 310 315 320
 Leu Lys Leu Phe His Asn Glu Gly Phe Tyr Ile Ile Lys Glu Val Glu
 325 330 335
 Gly Phe Ile Met Ser Leu Ile Leu Asn Ile Thr Glu Glu Asp Gln Phe
 340 345 350
 Lys Lys Arg Phe Tyr Asn Ser Met Leu Asn Asn Ile Thr Asp Ala Ala
 355 360 365
 Ile Lys Ala Gln Lys Asp Leu Leu Ser Arg Val Cys His Thr Leu Leu
 370 375 380
 Asp Lys Thr Val Ser Asp Asn Ile Ile Asn Gly Lys Trp Ile Ile Leu
 385 390 395 400
 Leu Ser Lys Phe Leu Lys Leu Ile Lys Leu Ala Gly Asp Asn Asn Leu
 405 410 415
 Asn Asn Leu Ser Glu Leu Tyr Phe Leu Phe Arg Ile Phe Gly His Pro
 420 425 430
 Met Val Asp Glu Arg Gln Ala Met Asp Ser Val Arg Ile Asn Cys Asn
 435 440 445

Glu Thr Lys Phe Tyr Leu Leu Ser Ser Leu Ser Thr Leu Arg Gly Ala
 450 455 460
 Phe Ile Tyr Arg Ile Ile Lys Gly Phe Val Asn Thr Tyr Asn Arg Trp
 465 470 475 480
 Pro Thr Leu Arg Asn Ala Ile Val Leu Pro Leu Arg Trp Leu Asn Tyr
 485 490 495
 Tyr Lys Leu Asn Thr Tyr Pro Ser Leu Leu Glu Ile Thr Glu Asn Asp
 500 505 510
 Leu Ile Ile Leu Ser Gly Leu Arg Phe Tyr Arg Glu Phe His Leu Pro
 515 520 525
 Lys Lys Val Asp Leu Glu Met Ile Ile Asn Asp Lys Ala Ile Ser Pro
 530 535 540
 Pro Lys Asp Leu Ile Trp Thr Ser Phe Pro Arg Asn Tyr Met Pro Ser
 545 550 555 560
 His Ile Gln Asn Tyr Ile Glu His Glu Lys Leu Lys Phe Ser Glu Ser
 565 570 575
 Asp Arg Ser Arg Arg Val Leu Glu Tyr Tyr Leu Arg Asp Asn Lys Phe
 580 585 590
 Asn Glu Cys Asp Leu Tyr Asn Cys Val Val Asn Gln Ser Tyr Leu Asn
 595 600 605
 Asn Ser Asn His Val Val Ser Leu Thr Gly Lys Glu Arg Glu Leu Ser
 610 615 620
 Val Gly Arg Met Phe Ala Met Gln Pro Gly Met Phe Arg Gln Ile Gln
 625 630 635 640
 Ile Leu Ala Glu Lys Met Ile Ala Glu Asn Ile Leu Gln Phe Phe Pro
 645 650 655
 Glu Ser Leu Thr Arg Tyr Gly Asp Leu Glu Leu Gln Lys Ile Leu Glu
 660 665 670
 Leu Lys Ala Gly Ile Ser Asn Lys Ser Asn Arg Tyr Asn Asp Asn Tyr
 675 680 685
 Asn Asn Tyr Ile Ser Lys Cys Ser Ile Ile Thr Asp Leu Ser Lys Phe
 690 695 700

Asn Gln Ala Phe Arg Tyr Glu Thr Ser Cys Ile Cys Ser Asp Val Leu
 705 710 715 720
 Asp Glu Leu His Gly Val Gln Ser Leu Phe Ser Trp Leu His Leu Thr
 725 730 735
 Ile Pro Leu Val Thr Ile Ile Cys Thr Tyr Arg His Ala Pro Pro Phe
 740 745 750
 Ile Lys Asp His Val Val Asn Leu Asn Glu Val Asp Glu Gln Ser Gly
 755 760 765
 Leu Tyr Arg Tyr His Met Gly Gly Ile Glu Gly Trp Cys Gln Lys Leu
 770 775 780
 Trp Thr Ile Glu Ala Ile Ser Leu Leu Asp Leu Ile Ser Leu Lys Gly
 785 790 795 800
 Lys Phe Ser Ile Thr Ala Leu Ile Asn Gly Asp Asn Gln Ser Ile Asp
 805 810 815
 Ile Ser Lys Pro Val Arg Leu Ile Glu Gly Gln Thr His Ala Gln Ala
 820 825 830
 Asp Tyr Leu Leu Ala Leu Asn Ser Leu Lys Leu Leu Tyr Lys Glu Tyr
 835 840 845
 Ala Gly Ile Gly His Lys Leu Lys Gly Thr Glu Thr Tyr Ile Ser Arg
 850 855 860
 Asp Met Gln Phe Met Ser Lys Thr Ile Gln His Asn Gly Val Tyr Tyr
 865 870 875 880
 Pro Ala Ser Ile Lys Lys Val Leu Arg Val Gly Pro Trp Ile Asn Thr
 885 890 895
 Ile Leu Asp Asp Phe Lys Val Ser Leu Glu Ser Ile Gly Ser Leu Thr
 900 905 910
 Gln Glu Leu Glu Tyr Arg Gly Glu Ser Leu Leu Cys Ser Leu Ile Phe
 915 920 925
 Arg Asn Ile Trp Leu Tyr Asn Gln Ile Ala Leu Gln Leu Arg Asn His
 930 935 940
 Ala Leu Cys Asn Asn Lys Leu Tyr Leu Asp Ile Leu Lys Val Leu Lys
 945 950 955 960

His Leu Lys Thr Phe Phe Asn Leu Asp Ser Ile Asp Met Ala Leu Ser
 965 970 975

Leu Tyr Met Asn Leu Pro Met Leu Phe Gly Gly Gly Asp Pro Asn Leu
 980 985 990

Leu Tyr Arg Ser Phe Tyr Arg Arg Thr Pro Asp Phe Leu Thr Glu Ala
 995 1000 1005

Ile Val His Ser Val Phe Val Leu Ser Tyr Tyr Thr Gly His Asp Leu
 1010 1015 1020

Gln Asp Lys Leu Gln Asp Leu Pro Asp Asp Arg Leu Asn Lys Phe Leu
 1025 1030 1035 1040

Thr Cys Val Ile Thr Phe Asp Lys Asn Pro Asn Ala Glu Phe Val Thr
 1045 1050 1055

Leu Met Arg Asp Pro Gln Ala Leu Gly Ser Glu Arg Gln Ala Lys Ile
 1060 1065 1070

Thr Ser Glu Ile Asn Arg Leu Ala Val Thr Glu Val Leu Ser Ile Ala
 1075 1080 1085

Pro Asn Lys Ile Phe Ser Lys Ser Ala Gln His Tyr Thr Thr Thr Glu
 1090 1095 1100

Ile Asp Leu Asn Asp Ile Met Gln Asn Ile Glu Pro Thr Tyr Pro His
 1105 1110 1115 1120

Gly Leu Arg Val Val Tyr Glu Ser Leu Pro Phe Tyr Lys Ala Glu Lys
 1125 1130 1135

Ile Val Asn Leu Ile Ser Gly Thr Lys Ser Ile Thr Asn Ile Leu Glu
 1140 1145 1150

Lys Thr Ser Ala Ile Asp Thr Thr Asp Ile Asn Arg Ala Thr Asp Met
 1155 1160 1165

Met Arg Lys Asn Ile Thr Leu Leu Ile Arg Ile Leu Pro Leu Asp Cys
 1170 1175 1180

Asn Lys Asp Lys Arg Glu Leu Leu Ser Leu Glu Asn Leu Ser Ile Thr
 1185 1190 1195 1200

Glu Leu Ser Lys Tyr Val Arg Glu Arg Ser Trp Ser Leu Ser Asn Ile
 1205 1210 1215

Val Gly Val Thr Ser Pro Ser Ile Met Phe Thr Met Asn Ile Lys Tyr
1220 1225 1230

Thr Thr Ser Thr Ile Ala Ser Gly Ile Ile Ile Glu Lys Tyr Asn Val
1235 1240 1245

Asn Ser Leu Thr Arg Gly Glu Arg Gly Pro Thr Lys Pro Trp Val Gly
1250 1255 1260

Ser Ser Thr Gln Glu Lys Lys Thr Met Pro Val Tyr Asn Arg Gln Val
1265 1270 1275 1280

Leu Thr Lys Lys Gln Arg Asp Gln Ile Asp Leu Leu Ala Lys Leu Asp
1285 1290 1295

Trp Val Tyr Ala Ser Ile Asp Asn Lys Asp Glu Phe Met Glu Glu Leu
1300 1305 1310

Ser Thr Gly Thr Leu Gly Leu Ser Tyr Glu Lys Ala Lys Lys Leu Phe
1315 1320 1325

Pro Gln Tyr Leu Ser Val Asn Tyr Leu His Arg Leu Thr Val Ser Ser
1330 1335 1340

Arg Pro Cys Glu Phe Pro Ala Ser Ile Pro Ala Tyr Arg Thr Thr Asn
1345 1350 1355 1360

Tyr His Phe Asp Thr Ser Pro Ile Asn His Val Leu Thr Glu Lys Tyr
1365 1370 1375

Gly Asp Glu Asp Ile Asp Ile Val Phe Gln Asn Cys Ile Ser Phe Gly
1380 1385 1390

Leu Ser Leu Met Ser Val Val Glu Gln Phe Thr Asn Ile Cys Pro Asn
1395 1400 1405

Arg Ile Ile Leu Ile Pro Lys Leu Asn Glu Ile His Leu Met Lys Pro
1410 1415 1420

Pro Ile Phe Thr Gly Asp Val Asp Ile Ile Lys Leu Lys Gln Val Ile
1425 1430 1435 1440

Gln Lys Gln His Met Phe Leu Pro Asp Lys Ile Ser Leu Thr Gln Tyr
1445 1450 1455

Val Glu Leu Phe Leu Ser Asn Lys Ala Leu Lys Ser Gly Ser His Ile
1460 1465 1470

Asn Ser Asn Leu Ile Leu Val His Lys Met Ser Asp Tyr Phe His Asn
 1475 1480 1485
 Ala Tyr Ile Leu Ser Thr Asn Leu Ala Gly His Trp Ile Leu Ile Ile
 1490 1495 1500
 Gln Leu Met Lys Asp Ser Lys Gly Ile Phe Glu Lys Asp Trp Gly Glu
 1505 1510 1515 1520
 Gly Tyr Ile Thr Asp His Met Phe Ile Asn Leu Asn Val Phe Phe Asn
 1525 1530 1535
 Ala Tyr Lys Thr Tyr Leu Leu Cys Phe His Lys Gly Tyr Gly Lys Ala
 1540 1545 1550
 Lys Leu Glu Cys Asp Met Asn Thr Ser Asp Leu Leu Cys Val Leu Glu
 1555 1560 1565
 Leu Ile Asp Ser Ser Tyr Trp Lys Ser Met Ser Lys Val Phe Leu Glu
 1570 1575 1580
 Gln Lys Val Ile Lys Tyr Ile Val Asn Gln Asp Thr Ser Leu Arg Arg
 1585 1590 1595 1600
 Ile Lys Gly Cys His Ser Phe Lys Leu Trp Phe Leu Lys Arg Leu Asn
 1605 1610 1615
 Asn Ala Lys Phe Thr Val Cys Pro Trp Val Val Asn Ile Asp Tyr His
 1620 1625 1630
 Pro Thr His Met Lys Ala Ile Leu Ser Tyr Ile Asp Leu Val Arg Met
 1635 1640 1645
 Gly Leu Ile Asn Val Asp Lys Leu Thr Ile Lys Asn Lys Asn Lys Phe
 1650 1655 1660
 Asn Asp Glu Phe Tyr Thr Ser Asn Leu Phe Tyr Ile Ser Tyr Asn Phe
 1665 1670 1675 1680
 Ser Asp Asn Thr His Leu Leu Thr Lys Gln Ile Arg Ile Ala Asn Ser
 1685 1690 1695
 Glu Leu Glu Asp Asn Tyr Asn Lys Leu Tyr His Pro Thr Pro Glu Thr
 1700 1705 1710
 Leu Glu Asn Met Ser Leu Ile Pro Val Lys Ser Asn Asn Ser Asn Lys
 1715 1720 1725

Pro Lys Phe Cys Ile Ser Gly Asn Thr Glu Ser Met Met Met Ser Thr
 1730 1735 1740

Phe Ser Ser Lys Met His Ile Lys Ser Ser Thr Val Thr Thr Arg Phe
 1745 1750 1755 1760

Asn Tyr Ser Lys Gln Asp Leu Tyr Asn Leu Phe Pro Ile Val Val Ile
 1765 1770 1775

Asp Lys Ile Ile Asp His Ser Gly Asn Thr Ala Lys Ser Asn Gln Leu
 1780 1785 1790

Tyr Thr Thr Thr Ser His Gln Thr Ser Leu Val Arg Asn Ser Ala Ser
 1795 1800 1805

Leu Tyr Cys Met Leu Pro Trp His His Val Asn Arg Phe Asn Phe Val
 1810 1815 1820

Phe Ser Ser Thr Gly Cys Lys Ile Ser Ile Glu Tyr Ile Leu Lys Asp
 1825 1830 1835 1840

Leu Lys Ile Lys Asp Pro Ser Cys Ile Ala Phe Ile Gly Glu Gly Ala
 1845 1850 1855

Gly Asn Leu Leu Leu Arg Thr Val Val Glu Leu His Pro Asp Ile Arg
 1860 1865 1870

Tyr Ile Tyr Arg Ser Leu Lys Asp Cys Asn Asp His Ser Leu Pro Ile
 1875 1880 1885

Glu Phe Leu Arg Leu Tyr Asn Gly His Ile Asn Ile Asp Tyr Gly Glu
 1890 1895 1900

Asn Leu Thr Ile Pro Ala Thr Asp Ala Thr Asn Asn Ile His Trp Ser
 1905 1910 1915 1920

Tyr Leu His Ile Lys Phe Ala Glu Pro Ile Ser Ile Phe Val Cys Asp
 1925 1930 1935

Ala Glu Leu Pro Val Thr Ala Asn Trp Ser Lys Ile Ile Ile Glu Trp
 1940 1945 1950

Ser Lys His Val Arg Lys Cys Lys Tyr Cys Ser Ser Val Asn Arg Cys
 1955 1960 1965

Ile Leu Ile Ala Lys Tyr His Ala Gln Asp Asp Ile Asp Phe Lys Leu
 1970 1975 1980

Asp Asn Ile Thr Ile Leu Lys Thr Tyr Val Cys Leu Gly Ser Lys Leu
 1985 1990 1995 2000

Lys Gly Ser Glu Val Tyr Leu Ile Leu Thr Ile Gly Pro Ala Asn Ile
 2005 2010 2015

Leu Pro Val Phe Asp Val Val Gln Asn Ala Lys Leu Ile Leu Ser Arg
 2020 2025 2030

Thr Lys Asn Phe Ile Met Pro Lys Lys Thr Asp Lys Glu Ser Ile Asp
 2035 2040 2045

Ala Asn Ile Lys Ser Leu Ile Pro Phe Leu Cys Tyr Pro Ile Thr Lys
 2050 2055 2060

Lys Gly Ile Lys Thr Ser Leu Ser Lys Leu Lys Ser Val Val Asn Gly
 2065 2070 2075 2080

Asp Ile Leu Ser Tyr Ser Ile Ala Gly Arg Asn Glu Val Phe Ser Asn
 2085 2090 2095

Lys Leu Ile Asn His Lys His Met Asn Ile Leu Lys Trp Leu Asp His
 2100 2105 2110

Val Leu Asn Phe Arg Ser Ala Glu Leu Asn Tyr Asn His Leu Tyr Met
 2115 2120 2125

Ile Glu Ser Thr Tyr Pro Tyr Leu Ser Glu Leu Leu Asn Ser Leu Thr
 2130 2135 2140

Thr Asn Glu Leu Lys Lys Leu Ile Lys Ile Thr Gly Ser Val Leu Tyr
 2145 2150 2155 2160

Asn Leu Pro Asn Glu Gln
 2165

<210> 11

<211> 15219

<212> DNA

<213> respiratory syncytial virus

<400> 11

acgggaaaaa aatgcgtact acaaacttgc acattcgaaa aaaatggggc aaataagaac 60
 ttgataagtg ctatttaagt ctaacctttt caatcagaaa tggggtgcaa ttcactgagc 120
 atgataaagg ttagattaca aaatttattt gacaatgacg aagtagcatt gttaaaaata 180
 acatgttata ctgataaatt aattcttctg accaatgcat tagccaaagc agcaatacat 240

```

acaattaaat taaacggcat agtttttata catgttataa caagcagtga agtgtgcctt 300
gataacaata ttgtagtgaa atctaacttt acaacaatgc caatactaca aaatggagga 360
tacatatggg aattgattga gttgacacac tgctctcaat taaacggttt aatggatgat 420
aattgtgaaa tcaaattttc taaaagacta agtgactcag taatgactaa ttatatgaat 480
caaatatctg acttacttgg gcttgatctc aattcatgaa ttatgttttag tctaattcaa 540
tagacatgtg tttattacca ttttagttaa tataaaaact catcaaaggg aaatggggca 600
aataaactca cctaatacat caaaccatga gcactacaaa tgacaacact actatgcaaa 660
gar.tgatgat cacaqacatg agaccctgt caatggattc aataataaca tctcttacca 720
aagaaatcat cacacacaaa ttcataact tgataaaca tgaatgtatt gtaagaaaac 780
ttgatgaaag acaagctaca tttacattct tagtcaatta tgagatgaag ctactgcaca 840
aagtagggag taccaaatac aaaaaatata ctgaatataa taaaaaatat ggcactttcc 900
ccatgcctat atttatcaat cacggcgggt ttctagaatg tattggcatt aagcctacaa 960
aacacactcc tataatatac aaatatgacc tcaaccctg aattccaaca aaaaaaccaa 1020
cccaacacaa ccaactatt cctcaaaca cagtgtctca tagttaagaa ggagctaata 1080
catttttagta attaaaaata aaagtaaagc caataacata aattggggca aatacaaga 1140
tggtctcttag caaagtcaag ttgaatgata cattaaataa ggatcagctg ctgtcatcca 1200
gcaaatacac tattcaacgt agtacaggag ataattattga cactcccaat tatgatgtgc 1260
aaaaacacct aaacaaacta tgtggtatgc tattaatcac tgaagatgca aatcataaat 1320
tcacaggatt aataggtatg ttatatgcta tgtccagggt aggaagggaa gacactataa 1380
agatacttaa agatgctgga tatcatgtta agctaattgg agtagatata acaacatata 1440
gtcaagatat aaatggaaag gaaatgaaat tcgaagtatt aacattatca agcttgacat 1500
cagaaatata agtcaatatt gagatagaat ctgaaagtc ctacaaaaaa atgctaaaag 1560
agatgggaga agtggctcca gaatataggc atgattctcc agactgtggg atgataatac 1620
tgtgtatagc tgcacttggt ataaccaaat tagcagcagg agacagatca ggtcttacag 1680
cagtaattag gagggcaaac aatgtcttaa aaaacgaaat aaaacgatac aagggcctca 1740
taccaaagga tatagctaac agtttttatg aagtgtttga aaaacaccct catcttatag 1800
atgttttcgt gcactttggc attgcacaat catccacaag agggggtagt agagttgaag 1860
gaatctttgc aggattgttt atgaatgcct atggttcagg gcaagtaatg ctaagatggg 1920
gagttttagc caaatctgta aaaaatatca tgctaggaca tgctagtgtc caggcagaaa 1980
tgagcaagt tgtggaagtc tatgagtatg cacagaagtt gggaggagaa gctggattct 2040
accatatatt gaacaatcca aaagcatcat tgctgtcatt aactcaattt cccaacttct 2100
caagtgtggt ctaggcaat gcagcaggtc taggcataat gggagagtat agaggtagac 2160
caagaaacca ggatctttat gatgcagcta aagcatatgc agagcaactc aaagaaaatg 2220
gagtaataaa ctacagtgtt tttagactta cagcagaaga attggaagcc ataaagcatc 2280
aactcaacc caaagaagat gatgtagagc ttttagttaa caaaaaatac ggggcaata 2340
agtcaacatg gagaagtttg cacctgaatt tcatggagaa gatgcaata acaaagctac 2400
caaattccta gaatcaataa agggcaagtt cgcatcatcc aaagatccta agaagaaaga 2460
tagcataata tctgttaact caatagatat agaagtaact aaagagagcc cgataacatc 2520
tgccaccaac atcatcaatc caacaagtga agccgacagt accccagaaa caaaagccaa 2580
ctaccaaga aaaccctag taagcttcaa agaagatctc accccaagtg acaacccttt 2640
ttctaagttg tacaaggaaa caatagaaac atttgataac aatgaagaag aatctagcta 2700
ctcatatgaa gagataaatg atcaaacaaa tgacaacatt acagcaagac tagatagaat 2760
tgatgaaaaa ttaagtgaag tattaggaat gctccataca ttagtagttg caagtgcagg 2820
accacttca gctcgcgatg gaataagaga tgctatgggt ggtctaagag aagagatgat 2880
agaaaaata agagcggaag cattaatgac caatgatagg ttagaggcta tggcaagact 2940
taggaatgag gaaagcgaaa aaatggcaaa agacacctca gatgaagtgt ctcttaatcc 3000
aacttccaaa aaattgagtg acttgttgga agacaacgat agtgacaatg atctatcact 3060
tgatgatttt tgatcagcga tcaactcact cagcaatcaa caacatcaat aaaacagaca 3120

```

tcaatccatt gaatcaactg ccagaccgaa caaacaacg tccatcagta gaaccaccaa 3180
ccaatcaatc aaccaattga tcaatcagca acccgacaaa attaacaata tagtaacaaa 3240
aaaagaacaa gatggggcaa atatggaaac atacgtgaac aagcttcacg aaggctccac 3300
atacacagca gctgttcagt acaatgttct agaaaaagat gatgatcctg catcactaac 3360
aatatgggtg cctatgttcc agtcattctgt gccagcagac ttgtcctataa aagaacttgc 3420
aagcatcaat atactagtga agcagatctc tacgcccacaa ggaccttcac tacgagtcac 3480
gattaactca agaagtgtg tgctggctca aatgcctagt aatttcattca taagcgcaaa 3540
tgtatcatta gatgaagaa gcaaattagc atatqatqta actacacctt gtgaaatcaa 3600
agcatgcagt ctaacatgct taaaagtaaa aagtatgtta actacagtca aagatcttac 3660
catgaagaca ttcaacccca ctcatgagat cattgtctta tgtgaatttg aaaatattat 3720
gacatcaaaa agagtaataa taccaacctt tctaagatca attagtgtca agaacaagga 3780
tctgaactca ctagaaaata tagcaaccac cgaattcaaa aatgctatca ccaatgcaaa 3840
aattattcct tatgaggat tagtggtagt tatcacagtt actgacaata aaggagcatt 3900
caaatatatc aaaccacaga gtcaatttat agtagatctt ggtgcctacc tagaaaaaga 3960
gagcatatat tatgtgacta ctaattggaa gcatacagct acacgttttt caatcaaac 4020
actagaggat taaacttaat tatcaacact gaatgacagg tccacatata tcctcaaac 4080
acacactata tccaaacatc ataaacatct acactacaca ctctatcaca caaaccaatc 4140
ccactcaaaa tccaaatca ctaccagcca ctatctgcta gacctagagt gcgaataggt 4200
aaataaaacc aaaatattgg gtaaatagac attagttaga gttcaatcaa tcttaacaac 4260
catttatacc gccaatcaa cacatatact ataaatctta aaatgggaaa tacatccatc 4320
acaatagaat tcacaagcaa attttgccc tattttacac taatacatat gatcttaact 4380
ctaactcttt tactaattat aatcactatt atgattgcaa tactaaataa gctaagtga 4440
cataaagcat tctgtaacaa aactcttgaa ctaggacaga tgtatcaaat caacacatag 4500
agttctacca ttatgtgtg tcaaatata atcctgtata tataaacaaa caaatccaat 4560
cttctcacag agtcgtgtg tcgcaaac accgtaacta tcatggtagc atagagtagt 4620
tatttaaaaa ttaacataat gatgaattgt tagtatgaga tcaaaaacaa cattggggca 4680
aatgcaacca tgtccaaaca caagaatcaa cgcactgcca ggactctaga aaagacctgg 4740
gatactctta atcatcta atgtaatatcc tcttggttat acagattaaa tttaaaatct 4800
atagcaca aa tagcactatc agttttggca atgataatct caacctctct cataattgca 4860
gccataatat tcatcatctc tgccaatcac aaagttagac taacaacggc cacagttcaa 4920
acaataaaaa accacactga aaaaaacatc accacctacc ctactcaagt ctcaccagaa 4980
agggttagtt catccaagca acccacaacc acatcaccaa tccacacaag ttcagctaca 5040
acatcaccca atacaaaatc agaaacacac catacaacag cacaaaccaa aggcagaaacc 5100
accacttcaa cacagaccaa caagccaagc acaaaaccac gtccaaaaaa tccaccacaa 5160
aaagatgatt accattttga agtggttaac ttctgtccct gcagtatatg tggcaacaat 5220
caactttgca aatccatctg caaaacaata ccaagcaaca aaccaagaa gaaaccaacc 5280
atcaaacc caaacaac aaccacaaa accacaaa aaagagaccc aaaaacacca 5340
gccaaaacga cgaaaaaaga aactaccacc aaccacaaa aaaaactaac cctcaagacc 5400
acagaaagag acaccagcac ctccaatcc actgactcg acacaaccac attaaaacac 5460
acagtcacac agcaatccct cctctcaacc accccgaaa acacaccaa ctccacacaa 5520
acaccacag catccgagcc ctccacacca aactccacc aaaaaacca gccacatgct 5580
tagttattca aaaactacat cttagcagag aaccgtgatc tatcaagcaa gaacgaaatt 5640
aaacctgggg caaataacca tggagttgat gatccacaag tcaagtga tcttcctaac 5700
tcttgctatt aatgcattgt acctcacctc aagtcagaac ataactgagg agttttacca 5760
atcgacatgt agtgcagtta gcagaggtta ttttagtgct ttaagaacag gttggtatc 5820
tagtgctata acaatagaat taagtaatat aaaagaaacc aaatgcaatg gaactgacac 5880
taaagtaaaa cttatgaaac aagaattaga taagtataag aatgcagtaa cagaattaca 5940
gtacttatg caaaacacac cagctgtcaa caaccgggc agaagagaag caccacagta 6000

tatgaactac acaatcaata ccactaaaaa cctaaatgta tcaataagca agaagaggaa 6060
 acgaagattt ctaggcttct tgtaggtgt gggatctgca atagcaagt gtatagctgt 6120
 atcaaaagtt ctacaccttg aaggagaagt gaacaagatc aaaaatgctt tgttgtctac 6180
 aaacaaagct gtagtcagtt tatcaaatgg ggtcagtggt ttaaccagca aagtgttaga 6240
 tctcaagaat tacataaata accaattatt acccatagta aatcaacaga gctgtcgcac 6300
 ctccaacatt gaaacagtta tagaattcca gcagaagaac agcagattgt tggaaatcac 6360
 cagagaattt agtgtcaatg caggtgtaac aacaccttta agcacttaca tgttgacaaa 6420
 cagrgagtta ctatcattaa tcaatqatat gcctataaca aatgatcaga aaaaattaat 6480
 gtcaagcaat gttcagatag taaggcaaca aagttattcc atcatgtcta taataaagga 6540
 agaagtcctt gcatatgttg tacagctgcc tatctatggt gtaatagata caccttgctg 6600
 gaaattgcac acatgcctc tatgcactac caacatcaaa gaaggatcaa atatttgttt 6660
 aacaaggact gatagaggat ggtattgtga taatgcagga tcagtatcct tctttccaca 6720
 ggtgacact tgtaaagtac agtccaatcg agtattttgt gacactatga acagtttgac 6780
 attaccaagt gaagtcagcc tttgtaacac tgacatatc aattccaagt atgactgcaa 6840
 aattatgaca tcaaaaacag acataagcag ctacagtaatt acttctcttg gagctatagt 6900
 gtcagtctat ggtaaaacta aatgcactgc atccaacaaa aatcgtggga ttataaagac 6960
 atttttcta atgtgtgact atgtgtcaaa caaaggagta gatactgtgt cagtgggcaa 7020
 cactttatatac tatgtaaaaca agctggaagg caagaacctt tatgtaaaag gggaacctat 7080
 aataaaattac tatgacctc tagtgtttcc ttctgatgag tttgatgcat caatatctca 7140
 agtcaatgaa aaaatcaatc aaagtttagc ttttattcgt agatctgatg aattactaca 7200
 taatgtaaat actggcaaat ctactacaaa tattatgata actacaatta ttatagtaat 7260
 cattgtagta ttgttatcat taatagctat tggtttactg ttgtattgta aagccaaaaa 7320
 cacaccagtt acactaagca aagaccaact aagtgggaatc aataatattg cattcagcaa 7380
 atagacaaaa aaccacctga tcatgtttca acaacaatct gctgaccacc aatcccaaat 7440
 caacttacaa caaatatttc aacatcacag tacaggctga atcatttcct cacatcatgc 7500
 taccacata actaagctag atccttaact tatagttaca taaaaacctc aagtatcaca 7560
 atcaaccact aaatcaacac atcattcaca aaattaacag ctggggcaaa tatgtcgcga 7620
 agaaatcctt gtaaatgtga gattagaggt cattgcttga atggtagaag atgtcactac 7680
 agtcataatt actttgaatg gcctcctcat gcattactag tgaggcaaaa ctcatgtta 7740
 aacaagatac tcaagtcaat ggacaaaagc atagacactt tgtctgaaat aagtggagct 7800
 gctgaactgg atagaacaga agaatatgct cttgggtatag ttggagtgc agagagttac 7860
 ataggatcta taaacaacat aacaaaacaa tcagcatgtg ttgctatgag taaacttctt 7920
 attgagatca atagtgtga cattaaaaag cttagagata atgaagaacc caattcacct 7980
 aagataagag tgtacaatac tgttatatca tacattgaga gcaatagaaa aaacaacaag 8040
 caaacctacc atctgctcaa gagactacca gcagacgtgc tgaagaagac aataaagaac 8100
 acattagata tccacaaaag cataaccata agcaatccaa aagagtcaac tgtgaatgat 8160
 caaaatgacc aaacaaaaa taatgatatt accggataaa tatccttgta gtatatcatc 8220
 catattgatc tcaagtgaat gcattggttc tacattcaat cataaaaaa cattacaatt 8280
 taaccataac tatttgata accaccagc tttattaaat catatatttg atgaaattca 8340
 ttggacacct aaaaacttat tagatgccac tcaacaattt ctccaacatc ttaacatccc 8400
 tgaagatata tatacagtat atatatagat gtcataatgc ttgaccataa cgactctatg 8460
 tcatccaacc ataaaactat tttgataagg ttatgggaca aaatggatcc cattattaat 8520
 ggaaactctg ctaatgtgta tctaactgat agttatttaa aaggtgttat ctctttttca 8580
 gagtgtaatg ctttagggag ttatcttttt aacggccctt atcttaaaaa tgattacacc 8640
 aacttaatta gtagacaaag cccactacta gagcatatga atcttaaaaa actaactata 8700
 acacagtcac taatatctag atatcataaa ggtgaactga aattagaaga accaacttat 8760
 ttccagtcac tacttatgac atataaaagt atgtcctcgt ctgaacaaat tgctacaact 8820
 aacttactta aaaaaataat acgaagagcc atagaataa gtgatgtaaa ggtgtacgcc 8880

atcttgaata aactaggatt aaaggaaaag gacagagtta agcccaacaa taattcaggt 8940
 gatgaaaact cagtacttac aactataatt aaagatgata tactttcggc tgtggaaaac 9000
 aatcaatcat atacaaattc agacaaaagt cactcagtaa atcaaaatat cactatcaaa 9060
 acaacactct tgaaaaaatt gatgtgttca atgcaacatc ctccatcatg gttaatcacac 9120
 tggttcaatt tatatacaaa attaaataac atattaacac aatatcgatc aaatgaggta 9180
 aaaagtcagtg ggtttatatt aatagataat caaactttaa gtggttttca gtttatttta 9240
 aatcaatatg gttgtatcgt ttatcataaa ggactcaaaa aaatcacacac tactacttac 9300
 aatcaatttt tgacatggaa agacatcagc cttagcagat taaatgtttg ctttaattact 9360
 tggataagta attgtttaaa tacattaaac aaaagcttag ggctgagatg tggattcaat 9420
 aatgttgtgt tatcacaatt atttctttat ggagattgta tactgaaatt atttcataat 9480
 gaaggcttct acataataaa agaagtagag ggatttatta tgtctttaat tctaacata 9540
 acagaagaag atcaatttag gaaacgattt tataatagca tgctaaataa catcacagat 9600
 gcagctatta aggtcaaaa ggacctacta tcaagagtat gtcacacttt attagacaag 9660
 acagtgtctg ataatatcat aaatggtaaa tggataatcc tattaagtaa atttcttaaa 9720
 ttgattaagc ttgcaggtga taataatctc aataacttga gtgagctata ttttctcttc 9780
 agaatctttg gacatccaat ggtcgatgaa agacaagcaa tggattctgt aagaattaac 9840
 tgtaatgaaa ctaagttcta cttattaagt agtctaagta cattaagagg tgctttcatt 9900
 tatagaatca taaaagggtt tgtaaatacc tacaacagat ggcccacctt aaggaatgct 9960
 attgtcttac ctctaagatg gttaaactac tataaactta atacttatcc atctctactt 10020
 gaaatcacag aaaatgattt gattatttta tcaggattgc ggttctatcg tgagtttcat 10080
 ctgcctaaaa aagtggatct tgaaatgata ataaatgaca aagccatttc acctccaaaa 10140
 gatctaatat ggactagttt tcttagaaat tacatgccat cacatataca aaattatata 10200
 gaacatgaaa agttgaagtt ctctgaaagc gacagatcga gaagagtact agagtattac 10260
 ttgagagata ataaattcaa tgaatgcgat ctatacaatt gtgtagtcaa tcaaagctat 10320
 ctcaacaact ctaatcacgt ggtatcacta actggtaaaag aaagagagct cagtgtaggt 10380
 agaatgtttg ctatgcaacc aggtatgttt aggcaaatcc aaatcttagc agagaaaatg 10440
 atagctgaaa atattttaca attcttccct gagagtttga caagatatgg tgatctagag 10500
 cttcaaaaga tattagaatt aaaagcagga ataagcaaca agtcaaactc ttataatgat 10560
 aactacaaca attatatcag taaatgttct atcattacag atcttagcaa attcaatcag 10620
 gcatttagat atgaaacatc atgtatctgc agtgatgtat tagatgaact gcatggagta 10680
 caatctctgt tctcttggtt gcatttaaca atacctcttg tcacaataat atgtacatat 10740
 agacatgcac ctcccttcat aaaggatcat gttgttaatc ttaatgaggt tgatgaacaa 10800
 agtggattat acagatatca tatgggtggt attgagggct ggtgtcaaaa actgtggacc 10860
 attgaagcta tatcattatt agatctaata tctctcaaag ggaaattctc tatcacagct 10920
 ctgataaatg gtgataatca gtcaattgat ataagcaaac cagtttagact tatagagggt 10980
 cagacccatg cacaagcaga ttatttggtt gcattaaata gccttaaatt gttatataaa 11040
 gagtatgcag gtataggcca taagcttaag ggaacagaga cctatatatc ccgagatatg 11100
 cagttcatga gcaaaacaat ccagcacaaat ggagtgtact atccagccag tatcaaaaaa 11160
 gtctgagag taggtccatg gataaacacg atacttgatg attttaaagt tagtttagaa 11220
 tctataggca gcttaacaca ggagttagaa tacagaggag aaagcttatt atgcagttta 11280
 atatttagga acatttggtt atacaatcaa attgctttgc aactccgaaa tcatgcatta 11340
 tgtaacaata agctatatatt agatatattg aaagtattaa aacacttaaa aacttttttt 11400
 aatcttgata gcattgatat ggctttatca ttgtatatga atttgcctat gctgtttggt 11460
 ggtggtgatc ctaatttggtt atatcgaaagc ttttatagga gaactccaga cttccttaca 11520
 gaagctatag tacattcagt gtttgtgttg agctattata ctggtcacga tttacaagat 11580
 aagctccagg atcttcaga tgatagactg aacaaattct tgacatgtgt catcacattt 11640
 gataaaaaatc ccaatgccga gtttgtaaca ttgatgaggg atccacaggc tttagggtct 11700
 gaaaggcaag ctaaaattac tagtgagatt aatagattag cagtaacaga agtcttaagt 11760

atagcccccac acaaaatatt ttctaaaagt gcacaacatt atactaccac tgagattgat 11820
 ctaaatgaca ttatgcaaaa tatagaacca acttacccctc atggattaag agttgtttat 11880
 gaaagtttac ctttttataa agcagaaaaa atagttaatc ttatatcagg aacaaaatcc 11940
 ataactaata tacttgaaaa aacatcagca atagatacaa ctgatattaa tagggctact 12000
 gatattgatga ggaaaaatat aactttactt ataaggatac ttccactaga ttgtaacaaa 12060
 gacaaaagag agttattaag tttagaaaaat cttagtataa ctgaattaag caagtatgta 12120
 agagaaagat cttggtcatt atccaatata gtaggagtaa catcgccaag tattatgttc 12180
 acaatggaca ttaaatatac aactaqcact atagccagtg gtataataat agaaaaatat 12240
 aatgttaata gtttaactcg tggtgaaaga ggaccacca agccatgggt aggtcatcc 12300
 acgcaggaga aaaaaacaat gccagtgtac aacagacaag ttttaacca aaagcaaaga 12360
 gaccaaatac atttattagc aaaattagac tgggtatatg catccataga caacaaagat 12420
 gaattcatgg aagaactgag tactggaaca cttggactgt catatgaaaa agccaaaaag 12480
 ttgtttccac aatatctaag tgtcaattat ttacaccgtt taacagtcag tagtagacca 12540
 tgtgaattcc ctgcatcaat accagcttat agaacaacaa attatcattt tgatactagt 12600
 cctatcaatc atgtattaac agaaaagtat ggagatgaag atatcgacat tgtgtttcaa 12660
 aattgcataa gttttggctc tagcctgatg tcggttggtg aacaattcac aaacatatgt 12720
 cctaatagaa ttattctcat accgaagctg aatgagatac atttgatgaa acctcctata 12780
 tttacaggag atgttgatat catcaagttg aagcaagtga tacaaaagca gcacatgttc 12840
 ctaccagata aaataagttt aacccaatat gtagaattat tcttaagtaa caaagcactt 12900
 aaatctggat ctcacatcaa ctctaattta atattagtac ataaaatgtc tgattatattt 12960
 cataatgctt atattttaag tactaattta gctggacatt ggattctgat tattcaactt 13020
 atgaaagatt caaaaggat ttttgaaaaa gattggggag aggggtacat aactgatcat 13080
 atgttcatta atttgaatgt tttctttaat gcttataaga cttatttgct atgttttcat 13140
 aaagggtatg gtaaaagcaaa attagaatgt gatatgaaca cttcagatct tctttgtgtt 13200
 ttggagttaa tagacagtag ctactggaaa tctatgtcta aagttttcct agaacaaaaa 13260
 gtcataaaat acatagtcaa tcaagacaca agtttgcgta gaataaaagg ctgtcacagt 13320
 ttttaagtgt ggttttttaa acgccttgat aatgctaaat ttaccgtatg cccttgggtt 13380
 gttaacatag attatcacc aacacacatg aaagctatat tatcttacat agatttagtt 13440
 agaatggggt taataaatgt agataaatta accattaaaa ataaaaacaa attcaatgat 13500
 gaattttaca catcaaatct cttttacatt agttataact tttcagacaa cactcatttg 13560
 ctaacaaaac aaataagaat tgctaattca gaattagaag ataattataa caaactatat 13620
 caccacccc cagaaacttt agaaaatatg tcattaatc ctgttaaaag taataatagt 13680
 aacaaaccta aattttgtat aagtggaaat accgaatcta tgatgatgtc aacattctct 13740
 agtaaaatgc atattaaatc ttccactgtt accacaagat tcaattatag caaacaagac 13800
 ttgtacaatt tattttccat tgttgtgata gacaagatta tagatcattc aggtaatata 13860
 gcaaaatcta accaacttta caccaccact tcacatcaga catctttagt aaggaaatagt 13920
 gcatcacttt attgcatgct tccttggcat catgtcaata gatttaactt tgtatttagt 13980
 tccacaggat gcaagatcag tatagagtat attttaaaag atcttaagat taaggacccc 14040
 agttgtatag cattcatagg tgaaggagct ggtaacttat tattacgtac ggtagtagaa 14100
 cttcatccag acataagata catttacaga agtttaaaag attgcaatga tcatagttta 14160
 cctattgaat ttctaagggt atacaacggg catataaaca tagattatgg tgagaattta 14220
 accattcctg ctacagatgc aactaataac attcattggt cttatttaca tataaaattt 14280
 gcagaaccta ttagcatctt tgtctgcgat gctgaattac ctgttacagc caattggagt 14340
 aaaattataa ttgaatggag taagcatgta agaaagtga agtactgtc ttctgtaaat 14400
 agatgcattt taattgcaaa atatcatgct caagatgaca ttgatttcaa attagataac 14460
 attactatat taaaaactta cgtgtgccta ggtagcaagt taaaaggatc tgaagtttac 14520
 ttaatcctta caataggccc tgcaaatata cttcctgttt ttgatgttgt acaaaatgct 14580
 aaattgatc tttcaagaac taaaatttc attatgccta aaaaaactga caaggaatct 14640

atcgatgcag ttattaaaag cttaatacct ttcctttgtt accctataac aaaaaaagga 14700
 attaagactt cattgtcaaa attgaagagt gtagttaatg gagatatatt atcatattct 14760
 atagctggac gtaatgaagt attcagcaac aagcttataa accacaagca tatgaatatc 14820
 ctaaaatggc tagatcatgt tttaaatttt agatcagctg aacttaatta caatcattta 14880
 tacatgatag agtccacata tccttactta agtgaattgt taaatagttt aacaaccaat 14940
 gagctcaaga agctgattaa aataacaggt agtgtgctat acaaccttcc caacgaacag 15000
 tagtttaaaa tatkattaac aagtttggtc aaatttagat gctaacacat cattatatta 15060
 tagttttrraa aaaatataca aacttttcaa taatttagca tattgattcc aaaattatca 15120
 ttttagtctt aaggggttaa ataaaagtct aaaactaaca attatacatg tgcattcaca 15180
 acacaacgag acattagttt ttgacacttt ttttctcgt 15219

<210> 12

<211> 2166

<212> PRT

<213> respiratory syncytial virus

<400> 12

Met Asp Pro Ile Ile Asn Gly Asn Ser Ala Asn Val Tyr Leu Thr Asp
 1 5 10 15

Ser Tyr Leu Lys Gly Val Ile Ser Phe Ser Glu Cys Asn Ala Leu Gly
 20 25 30

Ser Tyr Leu Phe Asn Gly Pro Tyr Leu Lys Asn Asp Tyr Thr Asn Leu
 35 40 45

Ile Ser Arg Gln Ser Pro Leu Leu Glu His Met Asn Leu Lys Lys Leu
 50 55 60

Thr Ile Thr Gln Ser Leu Ile Ser Arg Tyr His Lys Gly Glu Leu Lys
 65 70 75 80

Leu Glu Glu Pro Thr Tyr Phe Gln Ser Leu Leu Met Thr Tyr Lys Ser
 85 90 95

Met Ser Ser Ser Glu Gln Ile Ala Thr Thr Asn Leu Leu Lys Lys Ile
 100 105 110

Ile Arg Arg Ala Ile Glu Ile Ser Asp Val Lys Val Tyr Ala Ile Leu
 115 120 125

Asn Lys Leu Gly Leu Lys Glu Lys Asp Arg Val Lys Pro Asn Asn Asn
 130 135 140

Ser Gly Asp Glu Asn Ser Val Leu Thr Thr Ile Ile Lys Asp Asp Ile
 145 150 155 160

Leu Ser Ala Val Glu Asn Asn Gln Ser Tyr Thr Asn Ser Asp Lys Ser

	165		170		175
His Ser Val Asn Gln Asn Ile Thr Ile Lys Thr Thr Leu Leu Lys Lys					
	180		185		190
Leu Met Cys Ser Met Gln His Pro Pro Ser Trp Leu Ile His Trp Phe					
	195		200		205
Asn Leu Tyr Thr Lys Leu Asn Asn Ile Leu Thr Gln Tyr Arg Ser Asn					
	210		215		220
Glu Val Lys Ser His Gly Phe Ile Leu Ile Asp Asn Gln Thr Leu Ser					
	225		230		235
Gly Phe Gln Phe Ile Leu Asn Gln Tyr Gly Cys Ile Val Tyr His Lys					
		245		250	255
Gly Leu Lys Lys Ile Thr Thr Thr Thr Tyr Asn Gln Phe Leu Thr Trp					
	260		265		270
Lys Asp Ile Ser Leu Ser Arg Leu Asn Val Cys Leu Ile Thr Trp Ile					
	275		280		285
Ser Asn Cys Leu Asn Thr Leu Asn Lys Ser Leu Gly Leu Arg Cys Gly					
	290		295		300
Phe Asn Asn Val Val Leu Ser Gln Leu Phe Leu Tyr Gly Asp Cys Ile					
	305		310		315
Leu Lys Leu Phe His Asn Glu Gly Phe Tyr Ile Ile Lys Glu Val Glu					
		325		330	335
Gly Phe Ile Met Ser Leu Ile Leu Asn Ile Thr Glu Glu Asp Gln Phe					
	340		345		350
Arg Lys Arg Phe Tyr Asn Ser Met Leu Asn Asn Ile Thr Asp Ala Ala					
	355		360		365
Ile Lys Ala Gln Lys Asp Leu Leu Ser Arg Val Cys His Thr Leu Leu					
	370		375		380
Asp Lys Thr Val Ser Asp Asn Ile Ile Asn Gly Lys Trp Ile Ile Leu					
	385		390		395
Leu Ser Lys Phe Leu Lys Leu Ile Lys Leu Ala Gly Asp Asn Asn Leu					
		405		410	415
Asn Asn Leu Ser Glu Leu Tyr Phe Leu Phe Arg Ile Phe Gly His Pro					

420	425	430
Met Val Asp Glu Arg Gln Ala Met Asp Ser Val Arg Ile Asn Cys Asn		
435	440	445
Glu Thr Lys Phe Tyr Leu Leu Ser Ser Leu Ser Thr Leu Arg Gly Ala		
450	455	460
Phe Ile Tyr Arg Ile Ile Lys Gly Phe Val Asn Thr Tyr Asn Arg Trp		
465	470	475 480
Pro Thr Leu Arg Asn Ala Ile Val Leu Pro Leu Arg Trp Leu Asn Tyr		
485	490	495
Tyr Lys Leu Asn Thr Tyr Pro Ser Leu Leu Glu Ile Thr Glu Asn Asp		
500	505	510
Leu Ile Ile Leu Ser Gly Leu Arg Phe Tyr Arg Glu Phe His Leu Pro		
515	520	525
Lys Lys Val Asp Leu Glu Met Ile Ile Asn Asp Lys Ala Ile Ser Pro		
530	535	540
Pro Lys Asp Leu Ile Trp Thr Ser Phe Pro Arg Asn Tyr Met Pro Ser		
545	550	555 560
His Ile Gln Asn Tyr Ile Glu His Glu Lys Leu Lys Phe Ser Glu Ser		
565	570	575
Asp Arg Ser Arg Arg Val Leu Glu Tyr Tyr Leu Arg Asp Asn Lys Phe		
580	585	590
Asn Glu Cys Asp Leu Tyr Asn Cys Val Val Asn Gln Ser Tyr Leu Asn		
595	600	605
Asn Ser Asn His Val Val Ser Leu Thr Gly Lys Glu Arg Glu Leu Ser		
610	615	620
Val Gly Arg Met Phe Ala Met Gln Pro Gly Met Phe Arg Gln Ile Gln		
625	630	635 640
Ile Leu Ala Glu Lys Met Ile Ala Glu Asn Ile Leu Gln Phe Phe Pro		
645	650	655
Glu Ser Leu Thr Arg Tyr Gly Asp Leu Glu Leu Gln Lys Ile Leu Glu		
660	665	670
Leu Lys Ala Gly Ile Ser Asn Lys Ser Asn Arg Tyr Asn Asp Asn Tyr		

675

680

685

Asn Asn Tyr Ile Ser Lys Cys Ser Ile Ile Thr Asp Leu Ser Lys Phe
 690 695 700

Asn Gln Ala Phe Arg Tyr Glu Thr Ser Cys Ile Cys Ser Asp Val Leu
 705 710 715 720

Asp Glu Leu His Gly Val Gln Ser Leu Phe Ser Trp Leu His Leu Thr
 725 730 735

Ile Pro Leu Val Thr Ile Ile Cys Thr Tyr Arg His Ala Pro Pro Phe
 740 745 750

Ile Lys Asp His Val Val Asn Leu Asn Glu Val Asp Glu Gln Ser Gly
 755 760 765

Leu Tyr Arg Tyr His Met Gly Gly Ile Glu Gly Trp Cys Gln Lys Leu
 770 775 780

Trp Thr Ile Glu Ala Ile Ser Leu Leu Asp Leu Ile Ser Leu Lys Gly
 785 790 795 800

Lys Phe Ser Ile Thr Ala Leu Ile Asn Gly Asp Asn Gln Ser Ile Asp
 805 810 815

Ile Ser Lys Pro Val Arg Leu Ile Glu Gly Gln Thr His Ala Gln Ala
 820 825 830

Asp Tyr Leu Leu Ala Leu Asn Ser Leu Lys Leu Leu Tyr Lys Glu Tyr
 835 840 845

Ala Gly Ile Gly His Lys Leu Lys Gly Thr Glu Thr Tyr Ile Ser Arg
 850 855 860

Asp Met Gln Phe Met Ser Lys Thr Ile Gln His Asn Gly Val Tyr Tyr
 865 870 875 880

Pro Ala Ser Ile Lys Lys Val Leu Arg Val Gly Pro Trp Ile Asn Thr
 885 890 895

Ile Leu Asp Asp Phe Lys Val Ser Leu Glu Ser Ile Gly Ser Leu Thr
 900 905 910

Gln Glu Leu Glu Tyr Arg Gly Glu Ser Leu Leu Cys Ser Leu Ile Phe
 915 920 925

Arg Asn Ile Trp Leu Tyr Asn Gln Ile Ala Leu Gln Leu Arg Asn His

930	935	940
Ala Leu Cys Asn Asn Lys Leu Tyr Leu Asp Ile Leu Lys Val Leu Lys		
945	950	955 960
His Leu Lys Thr Phe Phe Asn Leu Asp Ser Ile Asp Met Ala Leu Ser		
	965	970 975
Leu Tyr Met Asn Leu Pro Met Leu Phe Gly Gly Gly Asp Pro Asn Leu		
	980	985 990
Leu Tyr Arg Ser Phe Tyr Arg Arg Thr Pro Asp Phe Leu Thr Glu Ala		
	995	1000 1005
Ile Val His Ser Val Phe Val Leu Ser Tyr Tyr Thr Gly His Asp Leu		
	1010	1015 1020
Gln Asp Lys Leu Gln Asp Leu Pro Asp Asp Arg Leu Asn Lys Phe Leu		
	1025	1030 1035 1040
Thr Cys Val Ile Thr Phe Asp Lys Asn Pro Asn Ala Glu Phe Val Thr		
	1045	1050 1055
Leu Met Arg Asp Pro Gln Ala Leu Gly Ser Glu Arg Gln Ala Lys Ile		
	1060	1065 1070
Thr Ser Glu Ile Asn Arg Leu Ala Val Thr Glu Val Leu Ser Ile Ala		
	1075	1080 1085
Pro Asn Lys Ile Phe Ser Lys Ser Ala Gln His Tyr Thr Thr Thr Glu		
	1090	1095 1100
Ile Asp Leu Asn Asp Ile Met Gln Asn Ile Glu Pro Thr Tyr Pro His		
	1105	1110 1115 1120
Gly Leu Arg Val Val Tyr Glu Ser Leu Pro Phe Tyr Lys Ala Glu Lys		
	1125	1130 1135
Ile Val Asn Leu Ile Ser Gly Thr Lys Ser Ile Thr Asn Ile Leu Glu		
	1140	1145 1150
Lys Thr Ser Ala Ile Asp Thr Thr Asp Ile Asn Arg Ala Thr Asp Met		
	1155	1160 1165
Met Arg Lys Asn Ile Thr Leu Leu Ile Arg Ile Leu Pro Leu Asp Cys		
	1170	1175 1180
Asn Lys Asp Lys Arg Glu Leu Leu Ser Leu Glu Asn Leu Ser Ile Thr		

1185	1190	1195	1200
Glu Leu Ser Lys Tyr Val Arg Glu Arg Ser Trp Ser Leu Ser Asn Ile			
1205	1210	1215	
Val Gly Val Thr Ser Pro Ser Ile Met Phe Thr Met Asp Ile Lys Tyr			
1220	1225	1230	
Thr Thr Ser Thr Ile Ala Ser Gly Ile Ile Ile Glu Lys Tyr Asn Val			
1235	1240	1245	
Asn Ser Leu Thr Arg Gly Glu Arg Gly Pro Thr Lys Pro Trp Val Gly			
1250	1255	1260	
Ser Ser Thr Gln Glu Lys Lys Thr Met Pro Val Tyr Asn Arg Gln Val			
1265	1270	1275	1280
Leu Thr Lys Lys Gln Arg Asp Gln Ile Asp Leu Leu Ala Lys Leu Asp			
1285	1290	1295	
Trp Val Tyr Ala Ser Ile Asp Asn Lys Asp Glu Phe Met Glu Glu Leu			
1300	1305	1310	
Ser Thr Gly Thr Leu Gly Leu Ser Tyr Glu Lys Ala Lys Lys Leu Phe			
1315	1320	1325	
Pro Gln Tyr Leu Ser Val Asn Tyr Leu His Arg Leu Thr Val Ser Ser			
1330	1335	1340	
Arg Pro Cys Glu Phe Pro Ala Ser Ile Pro Ala Tyr Arg Thr Thr Asn			
1345	1350	1355	1360
Tyr His Phe Asp Thr Ser Pro Ile Asn His Val Leu Thr Glu Lys Tyr			
1365	1370	1375	
Gly Asp Glu Asp Ile Asp Ile Val Phe Gln Asn Cys Ile Ser Phe Gly			
1380	1385	1390	
Leu Ser Leu Met Ser Val Val Glu Gln Phe Thr Asn Ile Cys Pro Asn			
1395	1400	1405	
Arg Ile Ile Leu Ile Pro Lys Leu Asn Glu Ile His Leu Met Lys Pro			
1410	1415	1420	
Pro Ile Phe Thr Gly Asp Val Asp Ile Ile Lys Leu Lys Gln Val Ile			
1425	1430	1435	1440
Gln Lys Gln His Met Phe Leu Pro Asp Lys Ile Ser Leu Thr Gln Tyr			

1445	1450	1455
Val Glu Leu Phe Leu Ser Asn Lys Ala Leu Lys Ser Gly Ser His Ile		
1460	1465	1470
Asn Ser Asn Leu Ile Leu Val His Lys Met Ser Asp Tyr Phe His Asn		
1475	1480	1485
Ala Tyr Ile Leu Ser Thr Asn Leu Ala Gly His Trp Ile Leu Ile Ile		
1490	1495	1500
Gln Leu Met Lys Asp Ser Lys Gly Ile Phe Glu Lys Asp Trp Gly Glu		
1505	1510	1515
Gly Tyr Ile Thr Asp His Met Phe Ile Asn Leu Asn Val Phe Phe Asn		
1525	1530	1535
Ala Tyr Lys Thr Tyr Leu Leu Cys Phe His Lys Gly Tyr Gly Lys Ala		
1540	1545	1550
Lys Leu Glu Cys Asp Met Asn Thr Ser Asp Leu Leu Cys Val Leu Glu		
1555	1560	1565
Leu Ile Asp Ser Ser Tyr Trp Lys Ser Met Ser Lys Val Phe Leu Glu		
1570	1575	1580
Gln Lys Val Ile Lys Tyr Ile Val Asn Gln Asp Thr Ser Leu Arg Arg		
1585	1590	1595
Ile Lys Gly Cys His Ser Phe Lys Leu Trp Phe Leu Lys Arg Leu Asp		
1605	1610	1615
Asn Ala Lys Phe Thr Val Cys Pro Trp Val Val Asn Ile Asp Tyr His		
1620	1625	1630
Pro Thr His Met Lys Ala Ile Leu Ser Tyr Ile Asp Leu Val Arg Met		
1635	1640	1645
Gly Leu Ile Asn Val Asp Lys Leu Thr Ile Lys Asn Lys Asn Lys Phe		
1650	1655	1660
Asn Asp Glu Phe Tyr Thr Ser Asn Leu Phe Tyr Ile Ser Tyr Asn Phe		
1665	1670	1675
Ser Asp Asn Thr His Leu Leu Thr Lys Gln Ile Arg Ile Ala Asn Ser		
1685	1690	1695
Glu Leu Glu Asp Asn Tyr Asn Lys Leu Tyr His Pro Thr Pro Glu Thr		

1700	1705	1710
Leu Glu Asn Met Ser Leu Ile Pro Val Lys Ser Asn Asn Ser Asn Lys		
1715	1720	1725
Pro Lys Phe Cys Ile Ser Gly Asn Thr Glu Ser Met Met Met Ser Thr		
1730	1735	1740
Phe Ser Ser Lys Met His Ile Lys Ser Ser Thr Val Thr Thr Arg Phe		
1745	1750	1755 1760
Asn Tyr Ser Lys Gln Asp Leu Tyr Asn Leu Phe Pro Ile Val Val Ile		
1765	1770	1775
Asp Lys Ile Ile Asp His Ser Gly Asn Thr Ala Lys Ser Asn Gln Leu		
1780	1785	1790
Tyr Thr Thr Thr Ser His Gln Thr Ser Leu Val Arg Asn Ser Ala Ser		
1795	1800	1805
Leu Tyr Cys Met Leu Pro Trp His His Val Asn Arg Phe Asn Phe Val		
1810	1815	1820
Phe Ser Ser Thr Gly Cys Lys Ile Ser Ile Glu Tyr Ile Leu Lys Asp		
1825	1830	1835 1840
Leu Lys Ile Lys Asp Pro Ser Cys Ile Ala Phe Ile Gly Glu Gly Ala		
1845	1850	1855
Gly Asn Leu Leu Leu Arg Thr Val Val Glu Leu His Pro Asp Ile Arg		
1860	1865	1870
Tyr Ile Tyr Arg Ser Leu Lys Asp Cys Asn Asp His Ser Leu Pro Ile		
1875	1880	1885
Glu Phe Leu Arg Leu Tyr Asn Gly His Ile Asn Ile Asp Tyr Gly Glu		
1890	1895	1900
Asn Leu Thr Ile Pro Ala Thr Asp Ala Thr Asn Asn Ile His Trp Ser		
1905	1910	1915 1920
Tyr Leu His Ile Lys Phe Ala Glu Pro Ile Ser Ile Phe Val Cys Asp		
1925	1930	1935
Ala Glu Leu Pro Val Thr Ala Asn Trp Ser Lys Ile Ile Ile Glu Trp		
1940	1945	1950
Ser Lys His Val Arg Lys Cys Lys Tyr Cys Ser Ser Val Asn Arg Cys		

1955	1960	1965			
Ile Leu Ile Ala Lys Tyr His Ala Gln Asp Asp Ile Asp Phe Lys Leu					
1970	1975	1980			
Asp Asn Ile Thr Ile Leu Lys Thr Tyr Val Cys Leu Gly Ser Lys Leu					
1985	1990	1995		2000	
Lys Gly Ser Glu Val Tyr Leu Ile Leu Thr Ile Gly Pro Ala Asn Ile					
	2005	2010		2015	
Leu Pro Val Phe Asp Val Val Gln Asn Ala Lys Leu Ile Leu Ser Arg					
	2020	2025		2030	
Thr Lys Asn Phe Ile Met Pro Lys Lys Thr Asp Lys Glu Ser Ile Asp					
	2035	2040		2045	
Ala Val Ile Lys Ser Leu Ile Pro Phe Leu Cys Tyr Pro Ile Thr Lys					
	2050	2055		2060	
Lys Gly Ile Lys Thr Ser Leu Ser Lys Leu Lys Ser Val Val Asn Gly					
	2065	2070		2075	2080
Asp Ile Leu Ser Tyr Ser Ile Ala Gly Arg Asn Glu Val Phe Ser Asn					
	2085	2090		2095	
Lys Leu Ile Asn His Lys His Met Asn Ile Leu Lys Trp Leu Asp His					
	2100	2105		2110	
Val Leu Asn Phe Arg Ser Ala Glu Leu Asn Tyr Asn His Leu Tyr Met					
	2115	2120		2125	
Ile Glu Ser Thr Tyr Pro Tyr Leu Ser Glu Leu Leu Asn Ser Leu Thr					
	2130	2135		2140	
Thr Asn Glu Leu Lys Lys Leu Ile Lys Ile Thr Gly Ser Val Leu Tyr					
	2145	2150		2155	2160
Asn Leu Pro Asn Glu Gln					
	2165				

INTERNATIONAL SEARCH REPORT

In International Application No

PCT/US 98/19145

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/45 C07K14/135 C12N7/08 A61K39/155

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X, L	WO 98 13501 A (UDEM S A ET AL.) 2 April 1998 (L: Priority) see page 62 - page 75; claims 12,13,22,23,38,39,45,46 ---	1-11
X	EP 0 567 100 A (AMERICAN CYANAMID COMPANY) 27 October 1993 see the whole document ---	1,3,5
P, X	WO 97 38138 A (UNIVERSITY OF MICHIGAN ;HERLOCHER M LOUISE; MAASSAB HUNEIN F) 16 October 1997 see claims 1-10 --- -/--	1,3,5



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 January 1999

Date of mailing of the international search report

14/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cupido, M

INTERNATIONAL SEARCH REPORT

In tional Application No
PCT/US 98/19145

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 98 02530 A (US DEPARTMENT OF HEALTH; WHITEHEAD STEPHEN S ; COLLINS PETER L; JUHASZ) 22 January 1998 see claims 1,2,62 -----	1,3,5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/19145

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 5 and 6
are directed to a method of treatment of the human or animal
body, the search has been carried out and based on the alleged
effects of the vaccine.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 98/19145

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9813501 A	02-04-1998	AU 4427897 A	17-04-1998
EP 0567100 A	27-10-1993	AU 3705793 A	28-10-1993
		CA 2094464 A	22-10-1993
		JP 6022756 A	01-02-1994
		NZ 247444 A	22-12-1994
		ZA 9302763 A	08-02-1994
WO 9738138 A	16-10-1997	AU 2438597 A	29-10-1997
WO 9802530 A	22-01-1998	AU 3799797 A	09-02-1998